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Opium poppy, Papaver somniferum, is the sole source of the analgesic alkaloids morphine 
and codeine as well as thebaine, a precursor for semi-synthetic opiates. T6ODM (thebaine 6-
O-demethylase) and CODM (codeine O-demethylase) are dioxygenases involved in morphine 
biosynthesis and represent promising targets for metabolic engineering of the morphinan 
alkaloid pathway through reverse genetic screening. An EMS (ethyl methanesulfonate)-
mutagenised population of a morphine accumulating cultivar (>4000 plants) was screened 
for mutations in CODM and T6ODM. Although nonsense mutations were found in both, 
complete metabolic blocks and codeine and thebaine were not observed owing to the 
presence of multiple copies of these genes in the genome. Crosses and further mutagenesis 
were attempted to produce new cultivars of opium poppy with increased yields of codeine 
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Chapter 1- Introduction 
1.1 The opium poppy, Papaver somniferum L. 
Papaver somniferum is an annual herb of the Papaveraceae family belonging to the basal 
eudicots (Linné and Salvius, 1753). Mature plants can reach heights of up to 1.5 m. Lengths of 
the semi-erect leaves shorten towards the top of the stem which is solid and may have hairs. 
The four petals of the flower vary in colour from red to white and in Tasmanian varieties 
flowers are a pale pink with a darker purple dot at their base. A multi-rayed stigma occupies 
the centre of the flower and multiple stamens surround it. The fruit is a porous capsule. After 
fertilisation, the petals drop off and the seed capsule swells and takes on a distinctive shape 
i.e. spherical with a star-shaped flattened top. The top lifts up as the capsule dries out to aid 
in dispersal of seed. The entire growth cycle takes approximately 120 days.  
 
Figure 1. Opium poppies growing in the field in Tasmania. Plants are at different stages of 
development. These include the characteristic hook stage prior to flowering. The pale pink petals of 
flowering plants are also seen with a darker purple dots towards the base. When these petals fall the seed 
capsule swells and the top flattens. Photo credit: Carol Walker 
Papaver somniferum has a chromosome number of eleven (Kaul et al., 1979; Lavania and 
Srivastava, 1999; Wakhlu and Bajwa, 1987). Its genome has an estimated size of 3724 Mb 
(Bennett and Smith, 1976) but it has yet to be sequenced. Plants are mainly self-pollinating 
but are able to outcross to generate variation (Bhandari, 1990; Kumar and Patra, 2010; Patra 
et al., 1992).  
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Opium poppy produces latex in highly specialised cells called laticifers. The latex contains 
a range of benzylisoquinolines alkaloids (BIAs) many of which have analgesic and sleep-
inducing properties. Morphine is perhaps the most well known example of a BIA from opium 
poppy. These characteristics led Carl Linnaeus to name the plant somniferum, which means 
sleep-inducing in Latin. The fact that there are no real wild opium poppy varieties points to 
the close interaction between the plant and humans over the last few millennia. It is still one 
of the most important medicinal plants in use today. 
1.2 Historical importance of opium poppy 
Opium poppy has been used for the medicinal properties conferred by some of its 
alkaloids for many thousands of years. Sumerian artefacts from 4000BC bear images of 
opium poppies. It was known as hul gil, the plant of joy (Brownstein, 1993). Opium was 
widely used by the Minoans for cult rituals or healing purposes since at least the 5th century 
BC (Askitopoulou et al., 2002). Images of poppies are depicted in Egyptian pictography and 
Roman sculptures. Egyptian priests promoted the use of opium preparations called 
thebacium, named after the city of Thebes where the poppies were cultivated (Tibi, 2003). 
Seeds were widely used as food before the Greeks recognised the sleep-inducing effects of the 
capsules and latex. Opium comes from the Greek word opus meaning latex. By the 8th century 
AD, opium use had spread to Arabia, India and China and the Arabs had organised its trade. 
Ignition and smoking of opium to obtain a more powerful medicinal effect began in Islamic 
culture. The Chinese also smoked opium, often in combination with tobacco. Indians 
ordinarily ingested opium. The pain relieving properties of opium in surgery were recognised 
by the Greeks and Romans, while Arab culture developed the preparations still further, 
frequently using opium for the treatment of diarrhoea (Aragon-Poce et al., 2002), coughs and 
colds and ocular remedies (Tibi, 2003) 
Medicinal use of opium became more widespread in the 16th century after the Swiss-
German alchemist Paracelsus discovered that the alkaloids in opium are more soluble in 
alcohol than in water. A tincture of opium or laudanum had use in pain relief (van Ree et al., 
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1999). Various preparations of laudanum were later used in combination with everything 
from saffron and sugar to mercury and whiskey for the treatment of practically every ailment 
known to man. By the 18th century the British East India Company controlled prime poppy 
growing areas of India and dominated the trade controlling supply and setting prices. 
Importation and recreational use of opium in China was banned by the Imperial Chinese 
Court, but efforts to enforce this were stepped up in 1839 by the Emperor Tao Kwang. This 
led to the First Opium War, when the British Empire responded with force. Defeated China 
was forced to sign the Treaty of Nanjing in 1842 allowing the opium trade to expand with the 
opening of five new ports. Hong Kong was also ceded to the British. In 1856 the Second 
Opium War broke out over demands that the trade be expanded even further. Again, China 
was defeated and forced to sign the Treaty of Tientsin in 1858, formally legalising opium 
imports to China. By the end of the century, it is estimated that over a quarter of all Chinese 
males were addicted to opium. These events in history point to the potential abuse of the 
plant. Nevertheless, use of the plant for its medicinal properties also flourished at this time 
and efforts were being made to identify the active ingredients.  
Although laudanum use continued to flourish, there were often problems with purity and 
its precise content in active ingredients could not be measured. A milestone in pharmacy was 
reached when morphine was first isolated by Friedrich Sertürner (Sertürner, 1806). He 
named it after Morpheus, the Greek god of sleep. Morphine was the first ever medicinal 
alkaloid isolated in pure form from a plant (Luch, 2009). This is testimony to the medicinal 
importance of opium poppy in the history of mankind. The discovery ushered in modern 
pharmacology, because for the first time it was possible to precisely measure the dose-effect 
relationship of a drug. Furthermore, the pharmaceutical industry developed as some 
pharmacists realised specialising in the extraction and supply of specific alkaloids to other 
pharmacists could be a profitable enterprise. Merck started marketing morphine 
commercially in 1827. In the wake of the isolation of morphine, additional alkaloids with 
medicinal applications were isolated from the opium poppy plant, including the analgesic and 
antitussive codeine (Robiquet, 1832), the non-opiate alkaloid noscapine (Robiquet, 1817) 
 
22  
and the smooth muscle relaxant papaverine (Merck, 1848). By the 1850s pure alkaloids 
rather than crude opium preparations were being used for the relief of pain, cough and 
diarrhoea. Use expanded after the invention of the hypodermic syringe in 1857.  
Besides the use of its alkaloids for pharmaceutical applications, its seeds are a source for 
poppy seed oil, which has established uses as cooking oil, lamp oil and varnish and is also 
used to make paints and soaps. More recently, pharmaceutical and medicinal diagnostic 
applications as an adjuvant add to its importance as a high quality edible oil (Krist et al., 
2005). Poppy seeds are also used by the bakery and confectionery industries.  
However, the primary reason opium poppy is cultivated today is for its alkaloids. It is the 
sole commercial source of the analgesics morphine and codeine. It is also the only source for 
thebaine and oripavine, which are used as precursors for a range of semisynthetic opiates 
(Berenyi et al., 2009). 
Morphine is easily converted to O,O-diacetylmorphine, otherwise known as heroin, which 
is more potent and is used as a recreational drug for the intense euphoria it induces. 
Tolerance soon develops and users require larger doses to achieve the same effect. Heroin 
was first made from morphine in England in 1874 by CR Wright but it was some time later in 
1898 when Bayer marketed the substance as a highly effective drug for the treatment of 
coughs, asthma, bronchitis and the discomfort associated with tuberculosis (Munsey, 2005). 
Employees of Bayer reported feeling ‘heroic’ after consuming the drug which led to its brand 
name ‘Heroin’. By 1913 Bayer had stopped selling it as it became clear that, contrary to initial 
claims, it was addictive and a culture of recreational use had developed. Today, illicit 
cultivation of opium poppy remains a major problem. Much of the heroin consumed in the 
world originates in politically unstable Afghanistan. Illicit cultivation has also been 
documented in countries such as Iran, Pakistan, Thailand, Burma and Mexico. Continued use 
of heroin leads to dependence and associated social problems and this highlights the 
potential abuse of medicinal products from Papaver somniferum. The International Council 
for Security and Development has proposed that Afghanistan be afforded a preferred supplier 
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status in a bid to break its reliance on the opium trade and boost the supply of opiate based 
medicines. This proposal would imply that global production of morphine and thebaine is 
inadequate to satisfy demand. However, the International Narcotics Control Board (INCB), 
which is charged with monitoring the implementation of United Nations drug control 
conventions, has stated that production and stocks of morphine and thebaine are in excess of 
demand and notes that producing countries actually have plans to increase poppy production 
(INCB, 2010).  
1.3 Benzylisoquinoline alkaloids 
Benzylisoquinoline alkaloids (BIAs) are a large and structurally diverse group of alkaloids 
with approximately 2500 members (Facchini et al., 2007; Hagel and Facchini, 2013). They are 
secondary metabolites generally thought to play roles in plant defence against herbivores 
and pathogens. Much of the research on BIAs has focussed on their pharmacology in humans 
rather than their physiological roles in the plant. However, there are some reports of BIA 
roles as antifeedants to insects (Krug and Proksch, 1993; Park et al., 2000; Sellier et al., 2011; 
Shields et al., 2008) and inhibitors to the propagation of bacteria and viruses (Schmeller et al., 
1997). The occurrence of BIAs is thought to have a monophyletic origin (Liscombe et al., 
2005). These alkaloids are most common among the order Ranunculales, specifically the 
Papaveraceae, Ranunculaceae, Berberidaceae and Menispermaceae families (Ziegler and 
Facchini, 2008). Protoberberine (e.g. (S)-Scoulerine), benzophenanthridine (e.g. 
sanguinarine) and 1-benzylisoquinoline alkaloids have a broad distribution and have even 
been described in a gymnosperm, Gnetum parvifolium (Xu and Lin, 1999). In opium poppy 
(Papaver somniferum; Papaveraceae) sieve elements and specialised laticifers of the phloem 
are the sites of synthesis and storage of BIAs (Bird et al., 2003; Samanani et al., 2006) In 
contrast phloem tissues are not involved in BIA synthesis in meadow rue (Thalictrum flavum; 






The term alkaloid was introduced by Carl Friedrich Wilhelm Meißner in 1819 and it is 
derived from the Latin word alkali which in turn came from Arabic al qali or “ashes of plants” 
(Meißner, 1819). Alkaloids are a diverse group of nitrogen-containing plant secondary 
metabolites present in approximately 20% of plants (Facchini et al., 2007). Many of the 
approximately 12,000 known plant alkaloids have been exploited since the start of 
civilisation for their potent biological activities as potions, medicines, and poisons.  
Pharmacological properties of alkaloids useful to mankind include antimalarial (quinine), 
antiasthma (ephedrine), anticancer (vincristine, vinblastine), vasodilatory (papaverine), 
muscle relaxant ((+)-tubocurarine), analgesic (morphine), antihyperglycemic (piperine) and 
antibacterial (sanguinarine). Many are used in traditional or modern medicine, or as starting 
points for drug discovery. Alkaloids are also used as stimulants (caffeine, nicotine, cocaine), 
narcotics and poisons (aconitine, tubocurarine).  
Specialised plant secondary metabolites such as alkaloids are a reflection of adaptation of 
plants to their environment as many are thought to provide protection against various biotic 
and abiotic stresses. Alkaloids are thought to have important ecochemical functions in the 
defence of the plant against pathogenic organisms and herbivores or, as in the case of 
pyrrolizidine alkaloids, as pro-toxins for insects, which further modify the alkaloids and then 
incorporate them into their own defence secretions (Hartmann, 1999; Hartmann and Ober, 
2000; Ober and Hartmann, 2000).   
Chemical synthesis of many alkaloids is difficult due to their complex structures which 
often contain multiple asymmetric centres. For example, the structure of morphine, which 
has five such asymmetric centres, was not solved (Gates and Tschudi, 1952) until 146 years 
after it was first isolated. Since the 1950s, advances in technology have enabled researchers 
to study alkaloid biosynthesis in greater detail, and enzymes involved in the biosynthesis of 
indole, isoquinoline, tropane, pyrrolizidine, and purine classes of alkaloids have been 
identified and characterised (Kutchan, 1995). Tools such as feeding of plants with 
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radiolabelled precursors, analysis with nuclear magnetic resonance spectroscopy and plant 
cell culture techniques have aided our understanding of alkaloid biosynthesis. Plants are still 
largely superior chemists and we rely on alkaloid extraction from plants rather than difficult 
and uneconomical chemical synthesis of complex structures such as the morphinans 
(morphine, codeine, thebaine) from Papaver somniferum and anticancer agents (vinblastine 
and vincristine) from Catharanthus roseus. 
1.3.2 Society’s use of BIAs 
Prominent members of the BIA family include emetine (an antiprotozal from the ipecac 
root, Carapichea ipecacuanha), colchicine (a microtubule disrupter used to treat gout from 
the autumn crocus, Colchicum autumnale) and berberine (used as an antimicrobial in eye 
drops and also in the treatment of intestinal disorders, cancer, HIV and diabetes).  
Benzophenanthridine alkaloids, a subclass of the BIAs, are produced by a number of 
species within the Papaveraceae. These include bloodroot (Sanguinaria canadensis), opium 
poppy (Papaver somniferum), and California poppy (Eschscholtzia californica). Bloodroot 
extracts rich in the intensely red benzophenanthridine alkaloid sanguinarine are used in oral 
hygiene products because of its antiplaque properties. Berberine and sanguinarine have been 
considered as anticancer drugs (Bessi et al., 2012). Benzophenanthridine alkaloids have been 
shown to accumulate in cell cultures of E. californica in response to various fungal elicitors 
(Schumacher et al., 1987).  
The 1-benzylisoquinoline papaverine has use as for treatments of cerebral vasospasm 
(Kassell et al., 1992) and erectile dysfunction (Dinsmore, 2005). Dimers of 1-
benzylisoquinolines, known as bisbenzylisoquinolines often have use as pharmaceuticals e.g. 
dauricine found in Chinese herbal preparations of Moonseed (Menispermum dauricum) has 
use as an antiarrhythmic agent (Qian, 2002) and (+)-tubocurarine is used as a neuromuscular 
blocking agent in anesthesia (Wenningmann and Dilger, 2001) .  
Morphinan and promorphinan alkaloids are produced by certain genera of the 
Papaveraceae, Menispermaceae and Berberidaceae (Liscombe et al., 2005) and include 
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valuable pharmaceuticals such as the narcotic analgesics codeine and morphine. Thebaine is 
not itself used as an analgesic, but it is converted into a wide range of semi-synthetic opiates 
such as oxycodone, oxymorphone, etorphine and burprenorphine (Berenyi et al., 2009). 
Thebaine is also used to manufacture a range of opiate antagonists including naltrexone, 
methylnaltrexone, nalmefene as well as naloxone. 
Phthalideisoquinoline alkaloids are found in Eschscholzia, Papaver, Dicentra and Glaucium 
within the Papaveraceae, and Cocculus within the Menispermaceae (Liscombe et al., 2005). 
Noscapine is present in the latex of certain opium poppy chemotypes and other Papaver 
species (Sariyar, 2002) and has antitussive and anticancer properties (Barken et al., 2008; 
Mahmoudian and Rahimi-Moghaddam, 2009). The ability of opium poppy chemotypes to 
synthesise noscapine is conferred by the presence of a complex gene cluster encoding many 
of the enzymes required for its synthesis (Winzer et al., 2012).  
Pavine, isopavine, rhoeadine and cularine alkaloids are smaller BIA subgroups found in 
most Papaveraceae genera and certain members of the Menispermaceae and Ranunculaceae, 
such as meadow rue (Thalictrum flavum) (Gözler et al., 1983; Liscombe et al., 2005; 
Montgomery et al., 1983).  
1.3.3 Roles of BIAs in the plant 
Various studies have offered potential roles for BIAs in plant defence. Berberine, for 
example, has antiherbivore properties towards a variety of insects (Park et al., 2000; Sellier 
et al., 2011; Shields et al., 2008). Sanguinarine and chelerythrine (a benzophenanthridine 
present in the greater celandine, Chelidonium majus and the plume poppy, Macleaya cordata) 
demonstrated activities against economically important pathogentic fungi (Liu et al., 2009). 
Similarly, antifungal and antimicrobial activities were attributed to aporphine (Zhang et al., 
2012) and protopine alkaloids (Singh et al., 2009). Studies have also suggested BIA roles in 
the deterrence of larger pests such as the South American primate Callithrix flaviceps (Simas 
et al., 2001) and pocket gophers (Watts et al., 2011).  A defensive ecophysiological role for 
morphine has been suggested since it was shown that, when opium poppy plants are 
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wounded, morphine is rapidly metabolised to two forms of bismorphine, which are 
incorporated into the cell wall to increase resistance to pectinase hydrolysis (Morimoto et al., 
2003, 2001). Production of bismorphine is catalyzed by a bismorphine-forming peroxidase 
(BFP) that pre-exists in the capsules and leaves, allowing this defence system to be rapidly 
induced in response to mechanical damage. BFP does not accept codeine and thebaine as 
substrates and it was also demonstrated to be unable to catalyse the oxidation of various 
phenolics. Therefore, it appears to be a unique peroxidase with restricted substrate 
specificities as opposed to other plant peroxidases which catalyse a range of substrates. 
In response to a fungal elicitor, sanguinarine production in opium poppy cell cultures was 
shown by microarray and RNA blot experiments to involve not only an increase in all known 
sanguinarine biosynthetic gene transcripts, but also an increases in the abundance of 
metabolic enzymes in primary metabolism such as sugar catabolism, the shikimate pathway, 
and aromatic amino acid metabolism (Zulak et al., 2006). The most abundant transcripts in 
response to the elicitor were for defence related proteins and enzymes involved in S-
adenosylmethionine (SAM), alkaloid, and phenylpropanoid biosynthesis. A later study, which 
involved pyrosequencing elicitor treated opium poppy cell cultures, counted transcripts of 
proteins involved in metabolism, defence, signalling, transport and cellular structure as most 
abundant (Desgagné-Penix et al., 2010). The defence related transcripts encoded chitinase, β-
lactamase, polyphenol oxidase, zyloglucanase inhibitor, peroxidase, and pathogenesis-related 
(PR) proteins. These were similar to results generated with an opium poppy seedling cDNA 
library in terms of ESTs associated with plant stress/defence and metabolism (Ziegler et al., 
2005). While evidence for specific roles of BIAs is scarce, the available results indicate roles 
in plant defence against herbivores, insects and pathogens.  
1.4 Biosynthesis of BIAs in opium poppy 
Synthesis of specific alkaloids is under developmental control. Sanguinarine and 
dihydrosanguinarine are reported to be the most abundant root alkaloids (Frick et al., 2005) 
whereas noscapine and papaverine accumulate only in aerial organs (Facchini and De Luca, 
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1995). Although morphine and codeine are predominant in the aerial organs, they have also 
been found in roots. 
1.4.1 Structural diversity from a common origin 
All BIAs share a common precursor in (S)-norcoclaurine, which is formed by 
condensation of two derivatives of tyrosine, namely, dopamine and 4-
hydroxyphenylacetaldehyde (4-HPAA) (Stadler et al., 1989, 1987)(Figure 2).  
 
Figure 2. Condensation reaction leading to the common precursor of all plant benzylisoquinolines, 
(S)-norcoclaurine. The reaction is catalysed by norcoclaurine synthase (NCS). 
The reaction is catalysed by norcoclaurine synthase (NCS), a member of the 
pathogenesis-related (PR10) and Bet v 1 protein families (DeLoache et al., 2015; Lee and 
Facchini, 2010; Liscombe et al., 2005; Samanani et al., 2004). NCS is a promiscuous enzyme 
that can also cyclise dopamine with a wide variety of acetaldehydes yielding various 
substituted tetrahydroisoquinoline alkaloids (Ruff et al., 2012). Subsequent 6-O-methylation 
of (S)-norcoclaurine followed by N-methylation, cytochrome P450 dependent 3’-
hydroxylation, and 4’-O-methylation results in the formation of the central branch point 
intermediate, (S)-reticuline (Frenzel and Zenk, 1990; Pauli and Kutchan, 1998; Sato et al., 
1993). 
Various C-C or C-O coupling reactions involving one or two 1-benzylisoquinoline units 
yield the core backbone structures of other BIA subgroups (Figure 3). These backbones can 
then undergo modifications such as aromatic ring hydroxylation, or N-methylation 
generating a tertiary or quaternary amine, to yield the diversity of compounds. Hydroxyl 
















Figure 3. Representative benzylisoquinolines alkaloid subclasses with diverse backbone structures 
produced from the 1-benzylisoquinoline intermediate. 
1.4.2 Benzophenanthridine and protoberberine biosynthesis 
The first step in benzophenanthridine and protoberberine alkaloid biosynthesis is the 
conversion of (S)-reticuline to (S)-scoulerine catalysed by the berberine bridge enzyme (BBE) 
(Facchini et al., 1996b). Progress from (S)-scoulerine to sanguinarine is achieved by six 
enzymes including three CYPs (CheSyn, StySyn, P6H; Díaz Chávez et al., 2011; Ikezawa et al., 
2007; Takemura et al., 2013), an N-methyltransferase (TMNT, Liscombe and Facchini, 2007) 
and a flavoprotein oxidase (MSH, Beaudoin and Facchini, 2013). The final oxidation of 
dihydrosanguinarine to sanguinarine is catalysed by dihydrobenzophenanthridine oxidase 
(DBOX, Hagel et al., 2012). The reverse reaction is catalysed by sanguinarine reductase 
(SanR), which may reduce the cytotoxic effects of sanguinarine within the cytoplasm (Weiss 
et al., 2006). 
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1.4.3 Phthalideisoquinoline biosynthesis 
Alternatively, in poppy chemotypes that accumulate the phtalideisoquinoline noscapine, 
(S)-scoulerine undergoes 9-O-methylation by (S)-scoulerine O-methyltransferase (SOMT) to 
yield (S)-tetrahydocolumbamine (Takeshita et al., 1995). The introduction of a 
methylenedioxy bridge by canadine synthase (CanSyn; Ikezawa et al., 2003) and addition of a 
methyl group by tetrahydroprotoberberine-cis-N-methyltransferase (TNMT; Liscombe and 
Facchini, 2007) produce N-methylcanadine, a precursor of noscapine. Nine of the ten genes 
resident on the noscapine gene cluster participate in the synthesis of noscapine from N-
methylcanadine (Winzer et al., 2012).  
1.4.4 Promorphinan and morphinan biosynthesis 
Morphine biosynthesis begins with the epimerisation of (S)-reticuline to (R)-reticuline 
(Farrow et al., 2015; Winzer et al., 2015). The reaction is catalysed by a P450-oxidoreductase 
fusion protein called STORR ((S)-to-(R)-reticuline). The P450 module catalyses the 
conversion of (S)-reticuline to a 1,2-dehydroreticuline intermediate which is then converted 
to (R)-reticuline by the oxidoreductase module.  
Salutaridine synthase (SalSyn; Gesell et al., 2009) catalyses the conversion of (R)-
reticuline to salutaridine, which is subsequently reduced to salutaridinol by salutaridine 
reductase (SalR; Ziegler et al., 2006). O-acetylation by salutaridine-7-O-acetyltransferase 
(SalAT; Grothe et al., 2001) is followed by with pH-dependent spontaneous rearrangement to 




Figure 4. Biosynthesis of the major benzylisoquinoline alkaloids from derivatives of tyrosine 
dopamine and 4-Hydroxyphenylacetaldehyde. The major subclasses formed from the central branchpoint 
intermediate (S)-Reticuline are highlighted. Colours for the commercially valuable alkaloids noscapine, 
thebaine, oripavine, codeine and morphine will be maintained throughout the thesis. Acronyms for the 





Although the pathway is bifurcated at this point, the major route to morphine from 
thebaine (Figure 4) is thought to occur via codeinone (Nielson et al., 1983). The minor route 
involves the intermediates oripavine and morphinone (Brochmann-Hanssen, 1984). 
Codeinone reductase (COR) reduces codeinone to codeine in the penultimate step of the 
major pathway (Unterlinner et al., 1999). COR also reduces morphinone to morphine in the 
final step of the minor pathway. The recent identification of codeine-O-demethylase (CODM) 
and thebaine 6-O-demethylase (T6ODM) which catalyse unique O-demethylation steps of 
morphine biosynthesis completed the biochemical pathway (Hagel and Facchini, 2010a). 
Kinetic data using recombinant enzymes suggested the biosynthetic pathway through 
codeine is preferred. Virus Induced Gene Silencing (VIGS) showed large increases in the 
accumulation of thebaine and codeine upon silencing of T6ODM and CODM, respectively. 
Thus these genes are excellent targets for mutagenesis to obtain alleles with impaired 
functions. These alleles may provide stable and heritable alkaloid phenotypes and eventually 
lead to novel bespoke varieties of opium poppy. 
1.4.5 Enzymes involved in BIA metabolism 
A limited number of enzyme families are involved in BIA metabolism. The most 
prominent enzyme classes are the CYPs and S-adenosylmethionine-dependent O- and N-
methyltransferases (Hagel and Facchini, 2013; Ziegler and Facchini, 2008). NCS, already 
mentioned above, is a member of the pathogenesis-related (PR10) and Bet v 1 protein 
families. FAD-linked oxidoreductases, and 2-oxoglutarate/Fe2+-dependent dioxygenases and 
NADPH-dependent short-chain dehydrogenase/reductases are the other enzyme families 
with more than one participant in BIA metabolism. Codeinone reductase (COR) is a NADPH-
dependent aldo-keto reductase involved in the final steps of morphine biosynthesis 
(Unterlinner et al., 1999). Finally, an acetyl-CoA dependent acetyltransferase called 
salutaridine 7-O-acetyltransferase (SalAT) is involved in the formation of thebaine. Figure 4 
shows the array of BIAs that can be formed after the initial synthesis of (S)-norcoclaurine 
using this limited number of enzyme families.  
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1.4.6 Sites of BIA biosynthesis and storage 
All members of the genus Papaver produce latex containing BIAs. Latex is the cytoplasm 
of specialised elongated secretory cells called laticifers (Hagel et al., 2008b). Latex has a 
positive turgor and exudes when tissues are damaged e.g. by a herbivore. Laticifers in 
Papaver somniferum have an articulated (i.e. composed of a series of cells joined together as 
seen in opium poppy) morphology (Nessler and Mahlberg, 1977). They are found adjacent to 
or proximal to the sieve elements of the phloem in all organs and contain vesicles into which 
alkaloids are sequestered (Hagel et al., 2008b; Nessler and Mahlberg, 1979). Vesicles are 
thought to derive from dilations of the endoplasmic reticulum (Alcantara et al., 2005). 
Compartmentalisation may provide protection from potentially toxic intermediates and 
confer controls over metabolic regulation. Laticifers contain low molecular mass major latex 
proteins (MLPs) in the cytosol whose precise function remains to be discovered (Nessler et 
al., 1985). 
Results from experiments with in situ labelling of mRNA and proteins in opium poppy 
suggest pathway enzymes are assembled in companion cells and translocated to sieve 
elements where BIAs are synthesised (Bird et al., 2003; Samanani et al., 2006). Another study 
localised four BIA biosynthetic enzymes to phloem parenchyma rather than sieve elements 
and codeineone reducatase (COR) to laticifers (Weid et al., 2004). This discrepancy may have 
been due to differences in experimental design between the two groups i.e. differences in 
specificity of antibodies or differences in plant growth conditions.  
A shotgun proteomics approach was recently used to determine the relative abundance of 
proteins in isolated latex and whole stem (including latex) (Onoyovwe et al., 2013). The 
results demonstrated that nine morphine biosynthetic enzymes were represented in the 
whole stem, whereas only four of the final five pathway enzymes were detected in the latex. 
This suggests that the genes catalysing the final steps of morphine biosynthesis, T6ODM, COR 
and CODM, are primarily located in laticifers. Noscapine synthase (NOS)(Chen and Facchini, 
2014) and 7-OMT (Onoyovwe et al., 2013) are also abundant in laticifers, suggesting that 
synthesis of noscapine and methylated derivatives of reticuline such as laudanosine also 
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occurs in the latex. Upstream enzymes are spatially separated. They are made in companion 
cells and transported to sieve elements to catalyse reactions modifying the 
benzylisioquinoline backbone. It is thought that thebaine and narcotinehemiacetal are the 
substrates transported into laticifers from sieve elements for the final steps of the morphine 
and noscapine biosynthesis pathways, respectively.  
Spatial regulation of pathway enzymes at the subcellular and cellular levels may be a way 
of optimising production by providing optimal microenvironments for reactions or reducing 
interactions with competing pathways. Elicitor treated opium poppy cell cultures produce 
sanguinarine rather than morphine. Transcripts for enzymes involved in sanguinarine 
biosynthesis were detected, but some of the enzymes involved in morphine biosynthesis 
were absent, which offers a transcriptional basis for the lack of morphine production in 
dedifferentiated cells (Desgagné-Penix et al., 2010).  
Following their synthesis, BIAs are ultimately transported to adjacent or proximal 
laticifers for storage. It is not yet clear whether BIA transport is symplastic involving 
plasmodesmata or apoplastic implicating as yet unknown transporters or channels. One 
study has demonstrated a role for an ATP-binding cassette (ABC) transporter in berberine 
transport from the root to the rhizome in Japanese goldthread (Coptis japonica) (Shitan et al., 
2003). ABC transporters are involved in the transport of other plant secondary metabolites 
such as terpenoids and phenolics (Yazaki, 2006, 2005). Additionally, an N-methyltransferase 
catalysing the first step in tropane alkaloid metabolism and a homolog of BBE from Nicotiana 
benthamiana were independently fused to GFP, and shown to localise at mesophyll 
plasmodesmata (Escobar et al., 2003). This result would indicate that alkaloid biosynthetic 
enzymes may possess targeting information which could facilitate symplastic transport. 
There has been suggestions that BIA biosynthetic enzymes may be organised into complexes 
or metabolic channels (Allen et al., 2004). This was offered as an explanation for why RNAi 
blockage of COR, in opium poppy resulted in elevated levels of (S)-reticuline and not 
codeinone. The loss of COR through RNAi was postulated to disrupt the normal multienzyme 
complex and prevent metabolic flux to morphine. It now appears than RNAi silencing was 
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non-specific and the closely related STORR gene, involved in the epimerization of reticuline, 
may also have been silenced (Winzer et al., 2015).  
1.5 CODM and T6ODM are 2-ODDs involved in O-demethylation in alkaloid 
metabolism 
T6ODM is a 2-oxoglutarate/Fe(II) dependent dioxygenase (2-ODD) identified by 
differential expression in a morphine and codeine free mutant (T). The morphinan pathway 
in this mutant was blocked at thebaine (Hagel et al., 2008a). An opium poppy 23,000-element 
microarray was used to compare the stem transcriptomes of this mutant and three 
morphine-accumulating varieties (L, 11 and 40). T6ODM, a 2-ODD, had lower transcript 
levels in T compared to the morphine-accumulating varieties. CODM, which is specific for the 
3-O-methyl group of thebaine and codeine, was identified after querying an opium poppy 
expressed sequence tag (EST) database with T6ODM. Upstream oxidative reactions such as 
ring hydroxylation and C-C phenol coupling steps are catalysed by P450 family members and 
so the involvement of 2-ODDs in morphine biosynthesis was unexpected (Hagel and Facchini, 
2010a). Demethylation of thebaine and codeine in humans is achieved with cytochrome P450 
enzymes (Kramlinger et al., 2015; Zhu, 2008). The demonstration that poppy achieves these 
reactions with 2-ODDs was interesting because application of the acylcyclohexanedione 
trinexapac-ethyl (Moddus) increases thebaine content in crops at the expense of morphine 
(Cotterill, 2010). This chemical also inhibits dioxygenases involved in the synthesis of 
gibberellin hormones, and so these observations may hint at a possible mechanism of action 
of Moddus with regard to increasing thebaine content of poppy crops.  
T6ODM and CODM are the only members of the 2-ODDs capable of catalysing O-
demethylation reactions (Hagel and Facchini, 2010b). This class of enzymes require 2-
oxoglutarate and molecular oxygen as substrates and iron Fe(II) as a cofactor to catalyse the 
oxidation of a substrate along with decarboxylation of 2-oxoglutarate forming succinate and 
carbon dioxide. Other members of the 2-ODDs are known to catalyse N-demethylation 
reactions. These include AlkB-type proteins, which catalyse the removal of N-linked methyl 
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groups of purine and pyrimidine bases in ribonucleic acids (Yi et al., 2009), and histone N-
demethylases with Jumonji C domains (Mosammaparast and Shi, 2010). These 2-ODDs 
achieve demethylation by hydroxylation of the O- or N-linked methyl groups, leading to the 
departure of formaldehyde (Hagel and Facchini, 2010b; Loenarz and Schofield, 2008).  
Kinetic analysis of recombinant T6ODM showed oripavine is actually the preferred 
substrate of T6ODM, followed by thebaine, while codeine is not accepted as a substrate. 
Recombinant CODM displayed a stronger preference for codeine than thebaine (Hagel and 
Facchini, 2010a). 
1.5.1 O-demethylation in plant metabolism 
Demethylases play a role in a number of biological processes such as epigenetic 
regulation, DNA repair, toxin degradation and the biosynthesis of specialised metabolites. 
These activities are achieved by members of enzyme families such as the cytochrome P450s, 
flavin adenine dinucleotide (FAD)-dependent oxidases, 2-ODDs and Rieske-domain proteins. 
T6ODM and CODM are examples in a small group of plant enzymes with the ability to catalyse 
O-demethylation reactions (Hagel and Facchini, 2010b). By contrast there are many examples 
of plant O-methyltransferases known to be involved in the biosynthesis of secondary 
metabolites (Lam et al., 2007). 
1.5.2 2-ODDs are involved in both primary and secondary metabolism in plants 
In plant primary metabolism, 2-ODDs are known to be involved in posttranslational 
modification by proline hydroxylations (P4H) (Gorres and Raines, 2010), DNA repair by the 
removal of deleterious methyl lesions from plant genomes (ALKBH2) (Meza et al., 2012), 
histone demethylation by the “Jumonji” enzymes (Takeuchi et al., 2006) and plant hormone 
synthesis and catabolism. They catalyse several steps in synthesis gibberellins (Yamaguchi, 
2008), plant growth regulators that play roles in all stages of plant development such as 
germination, stem elongation, leaf expansion, flower and fruit development and seed set 
(Phillips, 1998). Ethylene, a plant growth regulator with roles in senescence and fruit 
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ripening, similarly has a 2-ODD (ACCO) involved in its synthesis (Nakajima et al., 1990; 
Straeten et al., 1990). Recently, a 2-ODD (DAO) was shown to be involved in indole-3-acetic 
acid (IAA) catabolism in rice (DeLoache et al., 2015; Lee and Facchini, 2010; Liscombe et al., 
2005; Samanani et al., 2004). Salicylic acid (SA) is involved in plant defence, stress responses 
and senescence. An enzyme called S3H in Arabidopsis thaliana was shown to be involved in 
SA inactivation (Zhang et al., 2013). 
2-ODDs have also been shown to have roles in the biosynthesis of numerous plant 
secondary metabolites. Several facilitate the formation of different classes of flavonoids such 
as flavone synthase (FNS I), flavanone 3 β-hydroxylase (F3H) and flavonol synthase (FLS) and 
anthocyanidin synthase (ANS), also known as leucoanthocyanidin dioxygenase (LDOX) 
(Cheng et al., 2014; Gebhardt et al., 2005). The 2-ODDs AOP2, AOP3 and GSL-OH are involved 
in the biosynthesis of glucosinolates in the Brassicales, compounds responsible for bitter 
flavour (Hansen et al., 2008; Kliebenstein et al., 2001). Hyoscyamine 6β-hydroxylase (H6H) is 
a 2-ODD involved in hallucinogenic and toxic tropane alkaloid biosynthesis in members of the 
Solonaceae family (Hashimoto and Yamada, 1986). Desacetoxyvindoline-4-hydroxylase 
(D4H) is a 2-ODD involved in the biosynthesis of the monoterpene indole alkaloid vindoline 
in Catharanthus roseus (Vazquez-Flota et al., 1997). BX6 is a member of a gene cluster 
encoding the enzymes necessary for the production of DIBOA and DIMBOA benzoxazinoid 
defense molecules in the Poaceae family (Jonczyk et al., 2008). The coumarins are another 
class of defence compounds that have 2-ODDs involved in their synthesis in Arabidopsis (Kai 
et al., 2008), sweet potato (Matsumoto et al., 2012) and common rue (Vialart et al., 2012). 
Finally, a gene cluster in solanaceous food plants which encodes the enzymes necessary for 
the production of antinutritional steroidal glycoalkaloids contains a 2-ODD (Itkin et al., 
2013). 
Crystal structure analysis of leucoanthocyanidin synthase (LDOX) and 1-
aminocyclopropane-1-carboxylic acid oxidase (ACCO) have demonstrated components of the 
active site (Wilmouth et al., 2002; Zhang et al., 2004)-a double-stranded beta helix fold with a 
conserved sequence motif, HX(D/E)XnH, that is essential for binding Fe(II) (Clifton et al., 
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2006). 2-oxoglutarate-binding residues are less well conserved and may be characteristic of 
different subfamilies, whereas residues linked to substrate binding are variable and may 
involve mobile elements surrounding the active site (Loenarz and Schofield, 2008).  
Until recently, three 2-ODDs were known in opium poppy- T6ODM, CODM and a 
dioxygenase initially called DIOX2 but later renamed protopine O-dealkylase (PODA) when 
its function was determined (Farrow and Facchini, 2013). A fourth, papaverine 7-O-
demethylase (P7ODM), was shown to be involved in the biosynthesis of pacodine from the 
vasodilator papaverine (Farrow and Facchini, 2015). Sequence comparisons of known plant 
2-ODDs indicated a monophyletic origin of the opium poppy members (Hagel and Facchini, 
2010b). The phylogenetic analysis supports different origins of these enzymes and other 2-
ODDs involved in monoterpene indole alkaloid biosynthesis (D4H) and tropane alkaloid 
biosynthesis (H6H). A more recent ancestral link was suggested between these enzymes and 
a noroclaurine synthase (NCS) involved in BIA metabolism from Coptis japonica (Minami et 
al., 2007). 2-ODDs involved in glucosinolate and flavonoid metabolism indicated a low degree 
of sequence conservation and suggest these are a highly diversified enzyme classes which 
evolved to meet the needs of the particular plant in which they are found (Hagel and Facchini, 
2010b; Kawai et al., 2014). In contrast, 2-ODDs involved in primary metabolism were found 
to be conserved, indicating their important roles in core metabolism (Kawai et al., 2014). 
Figure 5 shows a multiple sequence alignment of opium poppy 2-ODDs, and Petunia hybrida 


















CLUSTAL O(1.2.1) multiple sequence alignment   
        
PhACCO       ------------------------------------------------------MENFPI  
AtLDOX       -----------MVAVERVESLAKSGIISIPKEYIRPKEELESINDVFLEEKKEDGPQVPT  
PsCODM       METPILIKLGNGLSIPSVQELAKLTLAEIPSRYTCTGESPLNNI---GASVT-DDETVPV  
PsPODA       METAKLMKLGNGMSIPSVQELAKLTLAEIPSRYICTVENLQLPV---GASVIDDHETVPV  
PsT6ODM      MEKAKLMKLGNGMEIPSVQELAKLTLAEIPSRYVCANENLLLPM---GASVINDHETIPV  
 
PhACCO       ISLDKV---NGVERAATMEMIKDACENWGFFELVNHGIPREVMDTVEKMTKGHYKKCMEQ  
AtLDOX       IDLKNIESDDEKIRENCIEELKKASLDWGVMHLINHGIPADLMERVKKAGEEFFSLSVEE  
PsCODM       IDLQNLLSPEPVVGKLELDKLHSACKEWGFFQLVNHGVDALLMDNIKSEIKGFFNLPMNE  
PsPODA       IDIENLISSEPVTEKLELDRLHSACKEWGFFQVVNHGVDTSLVDNVKSDIQGFFNLSMNE  
PsT6ODM      IDIENLLSPEPIIGKLELDRLHFACKEWGFFQVVNHGVDASLVDSVKSEIQGFFNLSMDE  
 
PhACCO       RFKEL--VASKALEG-----VQAEVTDMDWESTFFLKHLPIS--NISEVPDLDEEYREVM  
AtLDOX       KEKYANDQATGKIQGYGSKLANNASGQLEWEDYFFHLAYPEEKRDLSIWPKTPSDYIEAT  
PsCODM       KTKYG--QQDGDFEGFGQPYIESEDQRLDWTEVFSMLSLPLHLRKPHLFPELPLPFRETL  
PsPODA       KIKYG--QKDGDVEGFGQAFVASEDQTLDWADIFMILTLPLHLRKPHLFSKLPLPLRETI  
PsT6ODM      KTKYE--QEDGDVEGFGQGFIESEDQTLDWADIFMMFTLPLHLRKPHLFSKLPVPLRETI  
 
PhACCO       RDFAKRLEKLAEELLDLLCENLGLEKGYLKNAFYGSKGPNFGTKVSNYPPCPKPDLIKGL  
AtLDOX       SEYAKCLRLLATKVFKALSVGLGLEPDRLEKEVGGLEELLLQMKINYYPKCPQPELALGV  
PsCODM       ESYLSKMKKLSTVVFEMLEKSLQ--LVEIKGMTDLFEDGLQTMRMNYYPPCPRPELVLGL  
PsPODA       ESYSSEMKKLSMVLFEKMEKALQVQAVEIKEISEVFKDMTQVMRMNYYPPCPQPELAIGL  
PsT6ODM      ESYSSEMKKLSMVLFNKMEKALQVQAAEIKGMSEVFIDGTQAMRMNYYPPCPQPNLAIGL  
                
PhACCO       RAHTDAGGIILLFQDDKVSGLQLLKDGQWIDVPPMRHSIVVNLGDQLEVITNGKYKSVMH  
AtLDOX       EAHTDVSALTFIL-HNMVPGLQLFYEGKWVTAKCVPDSIVMHIGDTLEILSNGKYKSILH  
PsCODM       TSHSDFSGLTILLQLNEVEGLQIRKEERWISIKPLPDAFIVNVGDILEIMTNGIYRSVEH  
PsPODA       TPHSDFGGLTILLQLNEVEGLQIKNEGRWISVKPLPNAFVVNVGDVLEIMTNGMYRSVDH  
PsT6ODM      TSHSDFGGLTILLQINEVEGLQIKREGTWISVKPLPNAFVVNVGDILEIMTNGIYHSVDH  
                      * * 
PhACCO       RVIAQKDGARMSLASFYNPGSD-AVIYPAPALVEKEAEENKQVYPKFVFDD--YMKLYAG  
AtLDOX       RGLVNKEKVRISWAVFCEPPKDKIVLKPLPEMVSVESPAK---FPPRTFAQHIEHKLFGK  
PsCODM       RAVVNSTKERLSIATFHDSKLE-SEIGPISSLVTPETPAL---FKRGR---------YED  
PsPODA       RAVVNSTKERLSIATFHDPNLE-SEIGPISSLITPNTPAL---FRSGST--------YGE  
PsT6ODM      RAVVNSTNERLSIATFHDPSLE-SVIGPISSLITPETPAL---FKSGST--------YGD  
                         
PhACCO       LKFQAKEPRFEAMKAMETDVKMDPIATV  
AtLDOX       EQEELVSEKND-----------------  
PsCODM       ILKENLSRKLDG-KSFLDYMRM------  
PsPODA       LVEEFHSRKLDG-KSFLDSMRM------  
PsT6ODM      LVEECKTRKLDG-KSFLDSMRI------  
                                 
Figure 5. Multiple sequence alignment of opium poppy 2-oxoglutarate/Fe(II)-dependent dioxygenases 
and 2-oxoglutarate/Fe(II)-dependent dioxygenases from Petunia hybrida and Arabidopsis thaliana for 
which crystal structures have been determined. PhACCO, Petunia hybrida 1-aminocyclopropane-1-
carboxylic acid oxidase (Q08506); AtLDOX, Arabidopsis thaliana leucoanthocyanidin dioxygenase 
(Q96323), PsCODM, Papaver somniferum codeine O-demethylase (ADD85331), PsPODA, Papaver 
somniferum protopine O-dealkylase (ADD85330), PsT6ODM, Papaver somniferum thebaine 6-O-
demethylase (ADD85329). Diamonds indicate the conserved catalytic triad motif essential for binding 
Fe(II). Asterisks indicate residues thought to be involved in 2-oxoglutarate binding. Clustal Omega at 





1.5.3 Broader roles of T6ODM, CODM and PODA in opium poppy 
The three opium poppy 2-ODDs were recently shown to differentially accept various non-
morphinan BIA substrates (from a pool of 26) (Farrow and Facchini, 2013). In particular 
certain protopine and protoberberine alkaloids were effective substrates for catalysis. CODM 
and PODA were also shown to catalyse the O,O-demethylation of methylenedioxy bridges on 
protopine alkaloids. Protopines are intermediates in the synthesis of benzophenanthridine 
and rhoeadine alkaloids. PODA can also catalyse O,O-demethylation on protoberberine 
alkaloids. The metabolic roles of 2-ODDs in the O-demethylation and O,O-demethylation of 
protopine compounds and downstream derivatives such as sanguinarine and rhoeadine 
alkaloids (N-methylporphyroxine and glaudine) was demonstrated with virus induced gene 
silencing (VIGS). PODA expression was not detected in the cultivar of opium poppy used in 
the experiment so VIGS was targeted to T6ODM, CODM and both genes simultaneously 
(Farrow and Facchini, 2013). CODM displayed greater affinity to some of these substrates 
than towards thebaine and codeine, pointing to the possible origin of recruitment of these 
genes into the morphinan-branch pathway.  
Silencing of T6ODM alone, or both genes together, resulted in a substantial increase in the 
accumulation of thebaine at the expense of morphine and codeine. By contrast, suppression 
of CODM transcript levels resulted in a significant increase in the accumulation of codeine 
and lower levels of morphine. This confirms earlier results showing roles for CODM and 
T6ODM in morphine biosynthesis (Hagel and Facchini, 2010a; Wijekoon and Facchini, 2012). 
Sanguinarine in the roots was down in plants with reduced levels of T6ODM and/or CODM 
transcripts while levels of the protopine alkaloids cryptopine, protopine and allocryptopine 
increased significantly (Farrow and Facchini, 2013). O-demethylcryptopine increased in 
abundance in CODM-silenced plants. Similarly, accumulation of the protoberberines N-
methylstylopine and N-methylcanadine were increased in T6ODM and/or CODM-silenced 
plants.  
PODA performs an O,O-demethylation on the isoquinoline moiety of the protopine or 
protoberberine backbone. In contrast CODM targets methylenedioxy bridges on the 
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isoquinoline or benzyl moieties of protopine alkaloids only. The accumulation of protopine 
alkaloids in plants with reduced CODM transcript levels was generally in agreement with the 
catalytic functions and substrate range of recombinant CODM, which displayed high relative 
activities against protopines. Recombinant T6ODM, however, displayed only trace activities 
towards protopines and so the accumulation of these compounds in response to T6ODM 
silencing was unexpected. O,O-demethylated BIAs were not detected in planta, suggesting 
their rapid recycling or redistribution into other products.  
T6ODM and PODA share 85% amino acid sequence identity, yet PODA displays only trace 
levels of 6-O-demethylase activity with thebaine and oripavine (Farrow and Facchini, 2013). 
Remarkably, the enzymes catalyse different reactions on the same substrate. (R,S)-canadine 
and allocryptopine were O-demethylated by T6ODM but O,O-demethylated by PODA. These 
results may offer an insight into the origins of CODM and T6ODM. Morphine biosynthesis in 
opium poppy may have arisen from duplication and neofunctionalisation of ODDs involved in 
the formation of protopine, protoberberine, benzophenanthridine and rhoeadine alkaloids. 
The effects of minor amino acid changes on the substrate specificities and activities of opium 
poppy ODDs was demonstrated when a four amino acid substitution of CODM resulted in an 
enzyme capable of O-demethylating codeine, but not thebaine (Runguphan et al., 2012). The 
mutations are thought to change a region of alpha helix in the wild type CODM to a random 
coil in the codeine-specific mutant. This change appears to prevent the productive binding of 
thebaine without altering the efficiency of codeine O-demethylation.  
Certain chemotypes of Papaver somniferum have a 10-gene cluster enabling diversion of 
(S)-reticuline away from morphine biosynthesis and towards the synthesis of the anticancer 
alkaloid noscapine (Winzer et al., 2012). It was therefore reasonable to suggest the plant also 
contains a similar cluster for the synthesis of morphine. Clusters of genes in plants are 
thought to arise through gene duplication followed by neo-and sub-functionalisation or 
translocation (Boycheva et al., 2014). Clustering could lead to improved functionality and 
heredity. Coordinate regulation or the avoidance of the build up of toxic intermediates may 
be reasons why clustered genes operate more efficiently. Coinheritance of an entire pathway 
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leading to an important defence molecule against pathogens, e.g. avenacin in oat (Qi et al., 
2004) or herbivores e.g benzoxaxinoids in grasses (Sue et al., 2011), can confer a selective 
advantage.  
1.5.4 Regulation of CODM and T6ODM 
Treatment of opium poppy with trinexapac-ethyl (a acylcyclohexanedione inhibitor of 
dioxygenases involved in the synthesis of gibberellin hormones) increases thebaine and 
codeine content at the expense of morphine (Cotterill, 2010). However, 
acyclcyclohexanediones did not inhibit enzyme activities of T6ODM and CODM in vitro, 
suggesting an as yet unknown indirect mode of action (Hagel and Facchini, 2010a). Yields of 
morphine have been suggested to increase in response to treatment of gibberellic acid (Khan 
et al., 2007). The developmental and phytohormonal control of BIA biosynthesis in opium 
poppy is an area that needs more attention (Beaudoin and Facchini, 2014). 
WRKY and bBLH transcriptional regulators have been shown to be involved in BIA 
biosynthesis in Coptis japonica (Kato et al., 2007; Yamada et al., 2011). In opium poppy 
transcriptional regulation of BIA biosynthetic genes in response to wounding showed a 
possible role for WRKY transcription factors (Mishra et al., 2013). WRKY elements also 
appear in the promoter regions of components of the noscapine gene cluster (Winzer et al., 
2012) and a latex specific dioxygenase (CODM; Raymond, 2004), suggesting a wider role for 
WRKY transcription factors in the regulation of BIA biosynthesis. 
1.6 Supply of opiates 
The medicinal properties of Papaver somniferum have long been recognised due to its 
unique ability to synthesize the analgesic morphinans morphine, codeine and thebaine. 
Opium poppy also produces a variety of perhaps less well known biologically active BIAs 
such as the antispasmodic 1-benzylisoquinoline papaverine, the antimicrobial 




1.6.1 Controlled substances 
The poppy industry is highly regulated under international law. The INCB implements the 
United Nations Single Convention on Narcotic Drugs 1961 (the Convention), as amended by 
the Protocol Amending the Single Convention 1972. It determines quotas for the growing of 
narcotic plants based on estimates of worldwide demand. In 1972, Australia restricted the 
growing of opium poppies to the state of Tasmania. However, in recent years permission has 
been granted to start growing poppies in Victoria and the Northern Territory (Safi, 2014). 
Cultivation, possession or refining of opium poppies are all offences in Tasmania unless in the 
possession of a licence which is granted annually.  
1.6.2 Tasmania 
Tasmania in Australia is the world’s largest producer of opium alkaloids for the 
pharmaceutical market. GlaxoSmithKline in Latrobe and Tasmanian Alkaloids in Westbury 
together produce half of the world’s concentrate of poppy straw (CPS) from approximately 
10% of the production area (Dicker, n.d.). CPS is the concentrated near pure alkaloid powder 
produced from the chemical extraction of poppy straw (husk). CPS-morphine, CPS-codeine, 
CPS-thebaine and CPS-oripavine are all produced in Australia. Tasmanian Alkaloids 
commenced operations in 1975 and it is now owned by Johnson & Johnson. A third producer 
began operations in the state in 2004. TPI Enterprises is Australian owned and it also has 
operations in Victoria, the Northern Territory and Portugal.  
The poppy industry in Tasmania began in the 1960s after a subsidiary of the 
multinational Glaxo sought out a replacement for an unreliable British climate. Trials were 
undertaken in New South Wales, Southern Australia, Western Australia and New Zealand. 
The combination of a suitable climate (spring rains, lots of sunshine and hot dry summers) 
and fertile soils (high organic matter and suitable pH) ensured Tasmania remained the 
location of choice.  Today the three producers provide seed to farmers with which 20,000-
30,000 hectares of opium poppy are grown each year. The industry is a major contributor to 
the economy of the state. It uses the extraction of dried poppy straw, based on that first 
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developed by Janos Kabay in Hungary in 1925, with modified bespoke extraction 
technologies. The capsules are left to dry in the summer sun and then crushed to straw. 
Excess seed can go on to be used by the food or poppy oil industries. The remaining husk is 
used to extract alkaloids by chemical treatment.  In Tasmania, Macquarie Oils extracts poppy 
seed oil from seed collected from thebaine crops. The poppy meal that remains after the oil 
has been extracted has use as an agricultural fertiliser. The oil is used in bio-diesel. The 
alkaloid industry grosses in excess of AUD 100m (£52m) annually and farm gate returns to 
growers are typically AUD 70-90m (£36-47m) (Tasmanian Government, 2012). Tasmania’s 
geographical isolation and climate together with the expertise and best practices developed 
by both farmers and processors over the past 40 years have ensured that Tasmania is the 
largest producer of opiate based analgesics in the world.  
1.6.3 Other producers 
Turkey, Hungary, France and Spain also produce CPS products. India, by contrast, 
produces traditional opium by making incisions in the epidermal wall of the capsules of 
unripe plants. When the latex that exudes dries it is called opium. The US and UK are the 
largest markets for CPS, while the US is the largest importer of opium (Fist, 2001). However, 
the US has an “80-20” rule whereby it imports 80% of its narcotic raw materials from the 
traditional producers, India and Turkey. Imports of thebaine are not restricted with the “80-
20 rule” and so in recent years Australia has exported much of the thebaine obtained from 
high thebaine varieties to the US.  
1.6.4 Potential alternative BIA production systems 
BIAs made by opium poppy are structurally complex and chemical synthesis is not 
economical.  Only sanguinarine has been found in significant levels in opium poppy cell 
cultures (after treatment with a fungal elicitor) (Alcantara et al., 2005; Facchini and Bird, 
1998; Zulak et al., 2006). Specialised lacticifer cells are required for synthesis of morphinans 
in the plant. Inactivation of developmentally regulated genes or spatial segregation of 
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pathway intermediates from enzymes involved in morphine biosynthesis may account for the 
failure of dedifferentiated cell cultures to produce morphinans.  
Many groups are working towards reconstituting BIA biosynthesis in microbial systems 
to provide an alternative to metabolic engineering in the native host, opium poppy (Glenn et 
al., 2013). Recently, a complex ten gene pathway introduced to yeast resulted in the 
formation of dihydrosanguinarine and its oxidised derivative sanguinarine from (R,S)-
norlaudanosine (Fossati et al., 2014). Commercial production of sanguinarine is achieved 
with the bloodroot (Sanguinaria canadensis L.). Similarly, the ability of engineered yeast to 
convert simple sugars to an intermediate in BIA biosynthesis, salutaridine, was demonstrated 
(Hawkins and Smolke, 2008). Recently, a seven enzyme pathway introduced to yeast was 
shown to enable conversion of L-tyrosine to (S)-reticuline (DeLoache et al., 2015). A second 
recent paper described how the second half of the pathway to morphinans was introduced to 
yeast (Fossati et al., 2015) leaving all except one of the chemical reactions required to convert 
sugar to morphinans achievable in yeast. The last remaining enzyme involved, STORR ((S)-to-
(R)-reticuline), was recently discovered (Farrow et al., 2015; Winzer et al., 2015), opening up 
the prospect of commercial production of morphinans in yeast. Manufacture of the 
antimalarial terpenoid artemisinin, originally derived from Artemisia annua, is an example 
where a pathway to a plant based medicinal product can be viably produced in yeast (Paddon 
et al., 2013). Semi synthetic production of artemisinin can be achieved whereby the steps up 
to artemisinic acid are produced in yeast leaving the final steps involving introduction of the 
endoperoxide bridge to be performed by an expensive photooxidative process. This final step 
adds significantly to the overall cost of production of artemisinin by genetic engineering.  
Poppy BIA production, however, is a much more challenging proposition with a complex 
multistep biosynthetic pathway. The yields of morphinans produced by engineered yeast to 
date are very low, and, until the process is just as efficient and cost effective, commercial 
production of alkaloids is likely to remain in plant based systems in the short to medium 
term. Thebaine yields in excess of 70 kg/ha can be achieved in Tasmania and so the target for 
microbial based production systems is very high. The need increased efficiency of these 
 
46  
systems was recognised in another recent paper describing the production of thebaine in 
yeast by expressing 21 enzymes from a variety of sources (Galanie et al., 2015). However, one 
advantage the approach may have is in the production of alkaloids that would not accumulate 
in planta. The limitations of plant metabolic engineering may be overcome with microbes and 
allow exploration of the potential structural diversity of natural product derivatives. Yeast 
expressing poppy and Pseudomonas putida M10 genes were shown to convert thebaine to 
valuable final products such as hydrocodone and oxycodone (Galanie et al., 2015; Thodey et 
al., 2014).  
1.7 Poppy Breeding 
Opium poppy has been bred for thousands of years. Although there are many species 
under the genus Papaver which produce alkaloids, only Papaver somniferum L and Papaver 
setigerum DC produce morphine in significant quantities (Panicker et al., 2007). In the past 
two decades global consumption of opiates and opioids, as measured by the INCB, has tripled 
(Figure 6a; INCB, 2015). ‘Opiates’ is the term used to describe drugs derived from opium 
poppy and their derivatives, such as the semi-synthetic alkaloids. ‘Opioids’ is a more general 
term for both natural and synthetic drugs with morphine-like properties. They are mainly 
used for their analgesic properties to treat severe pain (fentanyl, hydromorphone, 
methadone, morphine, pethidine), moderate to severe pain (buprenorphine and oxycodone) 
and mild to moderate pain (codeine, dihydrocodeine, dextropropoxyphene) as well as in 
anaesthesia (fentanyl and its analogues such as anfeltanil). They are also used to treat cough 
(codeine, dihydrocodeine), diarrhoea (codeine and diphenoxylate) and addiction 
(buprenorphine and methadone). Innovation in poppy breeding is required to keep pace with 
demand for morphine but also to develop varieties with increased levels of key intermediates 
that have valuable uses in the preparation of pharmaceuticals. Increases in the numbers of 
defined daily doses for statistical purposes (S-DDD) are correlated with landmark growths in 
the use of oxycodone and hydrocodone in 2000-2001 and buprenorphine in 2005. These 




1.7.1 Requirement for varieties with high yields of codeine 
Codeine is an opiate used for its analgesic, antitussive and antidiarrheal properties 
(American Society of Health-System Pharmacists, 2015.). It is on the WHO Model List of 
Essential Medicines, a list of the most important medicines required for a basic health system 
(WHO, 2013). It is a natural alkaloid of the opium poppy plant Papaver somniferum L., but 
normally constitutes only a minor fraction of the total alkaloids. Codeine comes from the 
Greek word “kodeia” which means “poppy head” (Van Hout et al., 2014). Codeine is now the 
most widely used opiate in the world and is regarded as an effective analgesic with a wide 
safety margin. Its strength ranges from 8-12% of morphine in most people. This reduced 
potency means codeine is a more versatile drug. In our bodies codeine is converted into 
morphine and codeine-6-glucoronide (Vree et al., 2000). In fact over 80% of a dose of codeine 
is conjugated to glucuronic acid to codeine-6-glucoronide and this is the primary route to 
analgesia from codeine.  
The majority of the global codeine is consumed as codeine phosphate with small amounts 
as codeine hydrochloride and codeine base. These salts are then used to manufacture 
medications for the relief of pain (analgesics) and cough (antitussives). Codeine is often used 
in the treatment of diarrhoea. Codeine has also been used as the starting material and 
prototype of a large class of mainly mild to moderately strong opioids such as 
dihydrocodeine, hydrocodone (Vicodin when combined with acetaminophen) and oxycodone 
(OxyContin). These opioids are generally made from thebaine in recent times. Codeine is 
marketed as both a single-ingredient drug and in combination with paracetamol (co-codamol 
e.g. Panadeine), aspirin (co-codaprin) or ibuprofen (Nurofen Plus). Codeine is also sold in 
cough syrups in combination with a range of other active ingredients.  
Worldwide demand for codeine far exceeds the available supply produced in plants. 
Therefore most (85-90%; Fist et al., 2010) of the codeine currently being manufactured is 
obtained from morphine through the process of O-methylation, with the result that the major 
part of the world's licit morphine production is to support the manufacture of codeine 
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Figure 6. International Narcotics Control Board estimated (dotted lines) world requirements for 
2015. a) Increasing consumption of opiates and opioids across the world in the last two decades. To allow 
for aggregation of data for drugs with different potencies consumption levels are expressed in billions of 
defined daily doses for statistical purposes (S-DDD). b) Consumption of opiates manufactured from 
morphine, in tonnes of morphine equivalent, 2010-2013. c) Expected rise in demand for opiate raw 
materials rich in morphine. d) Expected rise in demand for opiate raw materials rich in thebaine. Source: 
INCB, 2015. 
Quaternary ammonium methylating agents in the presence of various bases are used to 
methylate morphine at the phenolic hydroxyl group at position 3 (Fist et al., 2010). However 
this approach generates N,N-dimethylaniline (DMA),  a particularly odiferous and toxic 
byproduct which must be completely removed from the product. This imposes waste 
disposal, safety and environmental concerns. Solvents such as toluene or xylene are also 
required in the process, which creates further safety, environmental and cost burdens. 
Industrial-scale morphine methylations may suffer from yield losses from undermethylation, 
leaving too much unreacted morphine, or on the other hand overmethylation, leading to 
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formation of codeine-O (6)-methyl ether ('methylcodeine'). Impurities such as methylcodeine 
and dimethylpseudomorphine are difficult to remove and can result in significant yield 
losses.  
The first reported commercial codeine crops were reported in Australia in 2009 and 
France in 2013. Global utilisation of codeine CPS amounted to 24.6 tonnes in 2013, which is 
still a fraction of the amount of morphine used (INCB, 2015). Over 350 tonnes of codeine are 
produced worldwide each year, with France and the UK being the biggest producers 
(approximately 20% each). India is by far the biggest importer of codeine with over 40 
tonnes imported and consumed in 2013 (INCB, 2015). Global demand by manufacturers for 
opiate raw materials rich in morphine is increasing modestly (Figure 6c) and is expected to 
be above 400 tonnes this year. Much of this is to support the manufacture of codeine. On the 
whole industrial-scale methylation of morphine for the production of codeine is an expensive 
and time consuming process, one that could be reduced or avoided with the development of a 
variety in which the morphinan pathway was blocked at codeine. 
1.7.2 Requirement for varieties with high yields of thebaine and oripavine 
Demand for thebaine-based opiates is concentrated mainly in the United States and has 
increased sharply since the late 1990s (for oxycodone in particular). Thebaine reached a 
production peak of 158 tonnes in 2012 (INCB, 2015). Among the biggest producers the US 
uses much of its thebaine internally and so Australia and Spain are the main exporters to the 
rest of the world. The UK is the largest importer of thebaine (25.9 tonnes in 2013). Thebaine 
and oripavine are themselves not used therapeutically but are used for the synthesis of 
powerful drugs such as oxycodone (OxyContin), buprenorphine (Subutex) and naloxone 
(Narcan) which are used as analgesics and in the treatment of addiction (Berenyi et al., 2009). 
Ethorphine is another semi-synthetic analgesic that is 8000 times more potent than 
morphine and is used to immobilise large game animals.  
Oripavine is an intermediate in the alternative pathway from thebaine to morphine 
(Brochmann-Hanssen, 1984). In 2013 oripavine was produced by the US (14.9 tonnes), 
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Australia (2.7 tonnes) and Switzerland (0.8 tonnes) (INCB, 2015). However, the US and Swiss 
figures actually refer to imported oripavine from Australia. Oripavine is used to make 
naloxone, naltrexone, methylnaltrexone, hydromorphone and oxymorphone. 
Global trends point to continuing increases in demand for thebaine and oripavine (Figure 
6d) and so there is a genuine requirement to develop new varieties with increased yields of 
these important alkaloids. Oripavine, in particular, is in demand, and development of lines 
with high yields of this alkaloid is a priority. The reason is that the above listed derivatives 
require O-demethylation using expensive and toxic reagents with concurrent yield loss. 
Development of varieties with metabolic blocks at thebaine or oripavine would increase 
yields and therefore lower production costs of both of these valuable opiates.  
1.7.3 GSK Australia’s opiates division 
The poppy industry in Tasmania was set up by GSK in the 1960s and the company still 
produces about 25% of the world’s opiates supply on the island. It does not grow commercial 
crops itself but rather contracts out the growing to farmers in the fertile areas of the northern 
coast and central plains. Farmers are paid in terms of yield of specific alkaloid in the 
harvested crops. Prices are negotiated with the Tasmanian Poppy Growers Association prior 
the planting period (July-October). Prices fluctuate based on global demand for specific 
alkaloids and levels of stocks held in vaults. A GSK field officer would then provide written 
recommendations to the farmer concerning, for example, weed and pest control. Typically, 
poppies are grown in a field once every 3-4 years as part of a rotation with other crops such 
as onion or potato. The plants flower in December and are ready to harvest from January to 
March. Harvesting of dried poppy straw and capsules is automated. Harvested material is 
initially brought to GSK’s site at Latrobe, Tasmania for initial processing. The seed cleaning 
facility removes the seed for export to the food industry around the world. This accounts for 
approximately 5% of sales. However, the main value in the crop is in the alkaloids it produces 
and so the remaining straw and dust is pelleted before being loaded on trucks bound for the 
ferry across the Bass Strait to Melbourne. Extraction of opiates takes place at GSK’s Port 
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Fairy, Victoria site. The company also has a number of sites in Tasmania for field trials to 
develop new varieties for future production. The research programme broadly aims to 
increase the yield of alkaloid per hectare, improve crop reliability and reduce the cost of 
production. In 2015 GSK Australia’s opiates division was acquired by Mumbai based Sun 
Pharmaceutical Industries (SunPharma).  
1.7.4 Chemical sprays used by the poppy industry  
The costs of spraying crops are the borne by the grower. As well as regular spraying for 
herbicides and fungicides, the grower may apply specific chemicals for altering 
characteristics of the crop. Application of Moddus decreases the proportion of morphine in 
the capsules of poppy plants and increases proportions of thebaine and oripavine (Cotterill, 
2010). Ultimate has the effect of reducing seed weight by up to 30% while increasing stem 
weight by the same proportion (personal communication). Sumagic is a plant growth 
regulator which is used for reducing plant height (Dean, 2011). It is thought to achieve this by 
affecting gibberellin production in sprayed plants. Breeding these desired characteristics into 
poppy would reduce the cost for both the grower and GSK, while also reducing the amount of 
chemicals released into the environment for the purpose of crop production.  
1.8 Sources of genetic variation for breeding 
During crop evolution there has been a continuous reduction in genetic diversity as 
breeders focussed on “elite” cultivars. This genetic erosion can become a bottleneck. 
Collection and characterisation of diverse germplasm from distinct geographic regions can be 
a good starting point for breeding. This is largely the conventional approach to breeding with 
opium poppy whereby variability and useful traits can be introduced by hybridisation. 
Alternatives are genetic modification and the artificial increase in variation though (random) 
mutagenesis. The latter aims to provide maximum genomic variation with a minimum 
decrease in viability of the plant. It has been successfully applied in recent decades to 
introduce much needed variation in commercial crops. Records maintained by the joint FAO-
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IAEA Division show that 3218 crop cultivars, with useful traits introduced by mutagenesis, 
have been released (FAO-IAEA, 2015). 
1.8.1 Genetically engineered opium poppy 
Metabolic engineering often involves the transfer of desired genes into the genome of a 
plant cell, followed by regeneration of a transgenic plant from undifferentiated tissue. 
Transformation of poppy has been reported with plants (Chitty et al., 2003; Frick et al., 2004; 
Park and Facchini, 2000a; Pathak et al., 2012), root cultures (Facchini et al., 2008; Flem-
Bonhomme et al., 2004; Park and Facchini, 2000b) and cell suspension cultures (Belny et al., 
1997).  However, it remains a difficult and inefficient procedure due primarily to recalcitrant 
regeneration. 
To date, poppy transformation protocols have been used to upregulate or silence specific 
genes for research purposes. Genetically engineered poppy plants expressing antisense-BBE 
have altered latex profiles compared to wild type plants (Frick et al., 2004). RNAi mediated 
silencing of members of the COR gene family resulted in the accumulation of the non-narcotic 
(S)-reticuline rather than morphine (Allen et al., 2004). This may have resulted in concurrent 
silencing of the STORR locus involved in the epimerisation of reticuline (Winzer et al., 2015). 
Genetically engineered opium poppy crops are not in use commercially. Furthermore, in 
Tasmania, where over half of the world’s opiate based medicines are produced, a moratorium 
on genetically modified organisms has been in place. There are increasing calls to lift this 
moratorium from both industry (“GMO Review Submission No. 158 - GSK Australia - 
Department of Primary Industries, Parks, Water and Environment,” 2013) and growers 
(Williams, 2013). Traditional mutagenesis approaches avoid the hurdles of regulation in the 
meantime.  
1.8.2 Chemical mutagenesis 
Chemical mutagenesis with alkylating agents such as ethylmethane sulfonate (EMS) 
causes a high density of irreversible point mutations (Henikoff and Comai, 2003).  Guanine is 
 
53  
alkylated leading to a transition of the original G/C base pair, resulting in the formation of an 
A/T pair (Greene et al., 2003). In Arabidopsis, it was estimated that 5% of EMS-generated 
mutations lead to premature termination of the gene product or disruptions in splicing 
whereas 50% cause missense mutations (Greene et al., 2003; Martín et al., 2009). N-methyl-
N-nitrosourea (MNU) treatment of rice and soybean produced primarily G/C to A/T 
transitions (similar to EMS) but a combination of MNU and sodium azide resulted in 20% A/T 
to G/C changes (Cooper et al., 2008; Suzuki et al., 2007; Till et al., 2007).  
Chemical mutagenesis can result in four types of mutation: 
 Silent: in an intron or non-coding sequence 
 Neutral: nucleotide substitution but new codon encodes the same amino acid 
 Nonsense: introduction of premature stop codon 
 Missense: change of amino acid 
Nonsense and missense mutations can render the protein non-functional or they can alter the 
original function in some way.  
A forward genetics approach involves the application of chemical mutagen to wild type 
seeds to acquire plants with desired phenotypes. These treatments cause either nucleotide 
substitutions or deletions and are transmitted to future generations. Forward screens of 
poppy mutants may identify a novel phenotype. However, locating the gene (and mutation) 
responsible would prove difficult due to the absence of genetic maps and genomic sequence 
information for opium poppy, resources which have been used in a process of chromosome 
walking in other species. Alternatively, microarray analysis and comparative EST profiling 
could be used to link a gene with a phenotype.  
Alternatively, a reverse genetics approach requires mutant populations for the detection 
of plants with specific genotypes rather than phenotypes. Technologies such as TILLING 
(Targeting Induced Local Lesions in Genomes; Comai and Henikoff, 2006; Kurowska et al., 
2011; Till et al., 2003) are deployed to identify point mutations in genes of interest. Once 
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mutations are stabilised, any changes in phenotype may be attributed to the induced 
mutation.  
1.8.2.1 Previous mutagenesis of opium poppy 
Various groups have used chemical mutagens and ionising radiation on opium poppy in 
the past (Chauhan and Patra, 1993; Floria and Ghiorghita, 1980; Sharma et al., 1999). This 
approach led to the production of non-narcotic opium-free ‘Sujata’ from a narcotic crop 
(Sharma et al., 1999).  It had use as a food crop seeds rich in protein and unsaturated oil. 
Indian researchers also identified a high thebaine variant in a mutant population and 
discussed the possibility of using it in tissue culture systems for the production of thebaine 
(Chaterjee et al., 2010). 
Australian researchers found that EMS mutagenesis of opium poppy resulted in plants 
with increased yields of thebaine and oripavine (Fist et al., 2000; Millgate et al., 2004). M1 
plants were selfed and the resulting M2 seed was sown. The latex of 18,000 M2 plants was 
screened for alkaloid content. One M2 plant, designated “Norman”, was identified which was 
free of morphine and codeine and accumulated increased levels of thebaine and oripavine. 
The resulting top1 (meaning thebaine, oripavine poppy 1) poppy mutant caused a change in 
the industry in Tasmania whereby thebaine and oripavine could be efficiently produced from 
morphine-free crops. The segregation of 375 F2 individuals was Mendelian and consistent 
with the involvement of a single gene (Millgate et al., 2004). A 17,000 element microarray 
was queried for changes in gene expression in the mutant. Ten transcripts were differentially 
suppressed in top1. However, none of the corresponding genes appeared to be involved in 
morphine biosynthesis. The top1 phenotype may be caused by an alteration of an as yet 
unidentified transport or structural component, preventing the correct inter- or intra-cellular 
compartmentalisation of thebaine and oripavine. 
Another Canadian group used EMS mutagenesis on poppy seeds and from 10,000 M1 
plants grown to maturity two interesting mutant phenotypes were identified-one 
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accumulating reticuline and the second curiously accumulating the antimicrobial 
sanguinarine in the latex (Desgagne-Penix et al., 2009).  
Fast neutron mutagenesis (FNM) of thebaine/oripavine TOP1 material has been used to 
produce 21 thebaine only plants after a screen of approximately 35,000 M2 plants (Fist et al., 
2013). Fifty-two high thebaine selections (including 9 of the 21 having substantially no 
oripavine, morphine or codeine) were cross-pollinated with 3 different morphine-containing 
poppy lines. The F2 generation of plants from these crosses were then tested, and many were 
found to contain high levels of codeine, variable levels of thebaine and substantially no 
oripavine or morphine.  
They also produced plants having codeine as the predominant alkaloid and substantially 
no oripavine, morphine or thebaine. These plants resulted from crossing the thebaine only 
plant with plants containing morphine. It is unclear why the new plants accumulate codeine, 
but the authors postulate that the step between codeine and morphine (CODM) has been 
substantially blocked. 
They suggest that the gene controlling the step between thebaine and oripavine (T6ODM) 
that appears to have been blocked in high thebaine poppy is also responsible for the 
conversion of codeine to morphine (CODM). Therefore, when the gene responsible for 
producing thebaine-only poppies in conjunction with the TOP1 or Norman mutation is 
introduced into plants lacking that mutation, a codeine phenotype is produced.  
There is no evidence that TILLING (for detection of SNPs introduced by EMS) or de-
TILLING (for detection of deletions caused by FNM) approaches were subsequently used to 
identify the molecular basis of these phenotypes. However, their characteristic phenotypes 
have been patented by Tasmanian Alkaloids and have led to their commercial thebaine and 




1.9 Targeting Induced Local Lesions in Genomes (TILLING) 
TILLING is a reverse genetics technique originally developed as a service to the 
Arabidopsis community whereby allelic series of EMS-induced point mutations could be 
ordered by researchers (Arabidopsis TILLING project; ATP; Till et al., 2003). At its simplest, 
TILLING allows for high throughput screening of pooled gDNA of mutagenised populations to 
identify mutations in genes of interest. Originally, the TILLING method relied upon 
denaturing HPLC to detect mutations (McCallum et al., 2000). The identification of single-
strand-specific endonucleases that cleave DNA at the site of mismatched nucleotides in 
otherwise double stranded DNA allowed for much higher throughput and the eventual 
proliferation of TILLING as a reverse genetics tool (Colbert et al., 2001). Mismatches form a 
heteroduplex ‘bubble’ or ‘bulge’ that is recognised by these enzymes and nicked. The 
endonuclease CEL1, extracted from celery (Apium graveolens), was used in the method 
published by the ATP (Colbert et al., 2001; Till et al., 2003). In fact celery juice extract (CJE) 
was often successfully used in place of relatively expensive purified CEL1 enzyme (Till et al., 
2004).  Figure 9 in Chapter 2 provides an overview of the process used in this project. 
1.9.1 Choice of TILLING platforms 
CEL1 cleaves at the sites of induced mutations in heteroduplexes formed after PCR with 
fluorescently labelled primers. For many years, LI-COR DNA analysers were the platform of 
choice for separating out DNA fragments of 96 pools in a single run (i.e. 384 plants or 768 
plants if pooled 4 fold or 8 fold respectively). The forward and reverse primers are labelled 
with fluorescent dyes that are detected at 700 nm and 800 nm, respectively. Two electronic 
images files are produced per gel run-one from each of the 700 nm and 800 nm channels (Till 
et al., 2006). Mutation detection is carried out using a programme called GelBuddy (Zerr and 
Henikoff, 2005).  
Researchers undertaking TILLING with Medicago truncatula offered an alternative 
mutation detection platform when they demonstrated separation of CJE-cut PCR fragments 
with the Applied Biosystems™ 3730xl (Le Signor et al., 2009). The method also relies on the 
use of fluorescently labelled primers in PCR. This method was adopted for the RevGenUK 
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TILLING service offered to the Medicago truncatula, Brassica rapa and Lotus japonica 
communities (Stephenson et al., 2010).  
Avoiding the use of expensive labelled PCR primers, a modified TILLING approach was 
demonstrated in wheat using non-denaturing polyacrylamide gels with ethidium bromide 
staining for mutation detection rather than LI-COR systems (Uauy et al., 2009). Low budget 
TILLING of a rice mutant population was demonstrated with unlabelled PCR primers and a 
simple agarose gel based detection assay (Raghavan et al., 2007). 
Changes in melting temperatures of PCR fragments conferred by induced mutations can 
be detected using high-resolution melting (HRM;Botticella et al., 2011; Dong et al., 2009; 
Gady et al., 2009; Li et al., 2010; Ririe et al., 1997; Zhou et al., 2005). The technique is limited 
to small amplicons of less than 400bp but it can be useful to target specific exons for example.  
In recent years, with the advent of more affordable next generation sequencing platforms, 
TILLING-by-sequencing has been demonstrated successfully. Illumina™ sequencing of target 
genes amplified from multidimensionally pooled DNA templates allowed the identification of 
mutants in mutant populations of rice and wheat (Tsai et al., 2011). Pools of PCR products are 
given molecular barcodes with the addition of DNA adapters allowing for multiple target 
genes or even amplicons from different species in a single next generation sequencing run. 
Sophisticated bioinformatics pipelines deconvolute samples after sequencing based on the 
barcodes (Missirian et al., 2011). Mutations are identified by comparison to a wild type 
reference. Tilling by sequencing could be advantageous in polyploid crops such as Brassica 
napus where it is often difficult to design primers to amplify specific orthologues (Wells et al., 
2013). Conventional TILLING approaches with polyploid crops are often complicated by 
mixed amplicons. This results in CEL1 cleavage of every mismatch position throughout the 
amplicon making it more difficult to detect induced mutations. Like HRM, the technique is 
limited to relatively small amplicons i.e. typical sequence read lengths of the next generation 
sequencing platform used. Conventional TILLING with gel-based separation allows for 
analysis for much larger amplicons (~1.5 kb on LI-COR DNA analysers).  
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1.9.2 Applications of TILLING outside of model plants 
TILLING is appropriate to many crop species especially in Europe where work with 
genetically engineered crops is restricted and in parts of the world without the regulatory 
infrastructure for work on such crops. Interesting mutant alleles detected by TILLING can be 
introgressed into different backgrounds. In recent years there has been various examples of 
the utilisation of TILLING as a breeding tool for agronomically important crops. In bread 
wheat, Triticum aestivum, for example, TILLING mutants of the starch branching enzyme II 
(SbeIIa) genes resulted in higher amylose content (Botticella et al., 2011; Slade et al., 2012). 
TILLING mutants of Δ12 and Δ15 desaturase genes of hemp, Cannabis sativa, produced major 
alterations in seed fatty acids. One mutant produces particularly high levels of high oleic 
hemp oil (Bielecka et al., 2014). A TILLING mutant of the waxy gene of potato, Solanum 
tuberosum, was used to establish elite lines lacking granule-bound starch synthase I activity 
and producing high-amylopectin starch (Muth et al., 2008). TILLING has also been 
successfully applied to tomato, Solanum lycopersicum, where mutants of an ethylene receptor 
gene, Sletr1, resulted in delayed fruit ripening and a longer shelf life (Okabe et al., 2011), and, 
mutants of the DET1 gene resulted in elevated levels of both carotenoid and phenylpropanoid 
phytonutrients in ripe fruit (Jones et al., 2012). 
1.10 Summary and aims 
Morphine, codeine and thebaine are part of a large and diverse group of 
benzylisoquinoline alkaloids made by Papaver somniferum. Opiates from this plant are used 
to manufacture a range of medicines for use in pain relief, vasodilation, antimicrobials, 
anticancer agents, antitussives and the treatment of addiction. Morphine represents the 
largest output from the poppy industry but much of morphine produced each year is 
converted back to codeine, which is less potent and so has more versatile uses. BIA 
biosynthesis begins with a condensation reaction between two derivatives of the amino acid 
tyrosine yielding (S)-norcoclaurine. Subsequent 6-O-methylation, N-methylation, 3’-
hydroxylation, and 4’-O-methylation results in the formation of the central branch point 
intermediate, (S)-reticuline. Biosynthesis of morphine proceeds from here via epimerisation 
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to (R)-reticuline catalysed by STORR (Winzer et al., 2015). Within the morphinan subgroup 
two 2-ODDs and a codeinone reductase are involved in the conversion of thebaine to 
morphine in a bifurcated pathway.  
Prior to the commencement of this PhD project chemical mutagenesis had been carried 
out on high morphine commercial poppy variety, designated HM2 (Winzer et al., 2015). The 
mutant population was generated by colleagues. The chemical mutagen, ethyl 
methanesulfonate (EMS), was used to induce random point mutations. M1 plants were sown 
and selfed in York and M2 plants were screened for desirable alkaloid profiles in field trials in 
Tasmania with the help of our industrial collaborators GSK Australia. However, a potential 
problem with the forward genetic approach is that mutations in key genes in a heterozygous 
state will not result in phenotypes in the M2 if mutant alleles are recessive. A reverse genetic 
approach, that identifies individuals with mutations in key genes involved in alkaloid 
biosynthesis, could overcome this problem, since mutations could be brought to 
homozygosity in subsequent generations and assessed for changes in alkaloid profiles. Hence, 
a reverse genetic approach was adopted as the main strategy in this thesis work. The first 
target gene would be CODM, with the aim of identifying mutations that would contribute to a 
high codeine phenotype. The second target would be T6ODM, with the aim of creating high 
thebaine/oripavine lines. The existing mutant population described above would be screened 
for CODM and T6ODM mutations. Any mutants found would be assessed for changes in their 
alkaloid profiles i.e. a reduction in morphine content and increases in codeine, thebaine and 
oripavine. Any new varieties with desirable alkaloid profiles may reduce the need for 
chemical processing of opiates and spraying of poppy crops. The approach would also 




Figure 7. Final steps in the biosynthesis of morphine from thebaine catalysed by the T6ODM, CODM 
and COR enzymes. 
GSK is the largest producer of morphine in the world. However, each year the majority of 
the morphine crop goes to support the manufacture of codeine (O-methylation of morphine). 
CODM was selected as a candidate gene for reverse genetics with the aim of developing an 
improved Papaver somniferum line with higher yields of codeine. This gene is involved in the 
final step of morphine biosynthesis (Figure 7) and silencing of CODM by VIGS has been shown 
to increase the yields of codeine to morphine (Farrow and Facchini, 2013; Hagel and Facchini, 
2010a; Wijekoon and Facchini, 2012). Plants with compromised CODM activity would allow 
codeine to be produced without the need to grow morphine poppies and the expensive and 
time-consuming industrial-scale methylation of the resulting morphine. Codeine is more 
soluble than morphine and easier to purify. Therefore, the yield, quality and cost of natural 
codeine obtained from a codeine poppy would all be improved relative to synthetic codeine 
obtained from morphine. Of course this would depend on the ability of the CODM mutant 
plant to accumulate codeine to levels at least as high as current morphine lines.  
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Likewise, in the past 15 years there has been increasing worldwide demands for two 
other precursors of morphine, namely thebaine and oripavine. T6ODM was selected as a 
candidate gene for reverse genetics with the aim of developing an improved Papaver 
somniferum line with higher yields of thebaine and oripavine. This gene is involved in the 
final steps of morphine biosynthesis and silencing of T6ODM by VIGS has been shown to 
increase the yields of thebaine (Farrow and Facchini, 2013; Hagel and Facchini, 2010a; 
Wijekoon and Facchini, 2012). 
The availability of the gene sequences of CODM and T6ODM (Hagel and Facchini, 2010a) 
provided an opportunity for a reverse genetics approach to try and identify alleles which 
would result in similar phenotypes which could be stably transmitted. The initial aim of this 
project then was to screen the already existing HM2 mutant population for mutations in the 
genes for these 2-ODDs. The starting HM2 seed produces plants which accumulate 
predominantly morphine in their capsules and only approximately 3% (of total alkaloids) of 
each of codeine and thebaine. DNA from a subpopulation (~4000 M2 plants) of the larger 
mutant population grown in Tasmania was available for the reverse genetic screen. Any 
mutants identified would then be assessed for altered yields of the highly valuable opiates 
codeine, thebaine and oripavine. Identification of mutations which would terminate 
biosynthesis of morphine at a valuable precursor would be an ideal output. Morphine-free 
single alkaloid crops would also lead to more straightforward extractions from raw material 
and remove the need for several hazardous steps in the chemical processing of opiates. A 
thebaine-oripavine only variety with high yields would avoid the need to spray commercial 
crops with chemicals for the enhancement of thebaine production. Bespoke varieties created 
by reverse genetics would have the associated molecular markers that could be used in 
future molecular breeding programmes.
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Chapter 2- Methods 
2.1 Characterisation of gene targets 
Complementary DNA sequences for opium poppy CODM (GenBank accession: GQ500141), 
T6ODM (GenBank accession: GQ500139) and PODA/DIOX2 (GenBank accession: GQ500140) 
provided the starting point for a characterisation of these genes in GSK commercial lines 
(Hagel and Facchini, 2010a). Previous work in our group involved 454 pyrosequencing on 
complementary DNA libraries derived from stem and capsule tissue from two morphine 
accumulating cultivars, HM2 and HM1, a noscapine accumulating cultivar, HN1, and a 
thebaine accumulating cultivar, HT1. The resulting expressed sequence tag (EST) database 
was queried with the cDNA sequences of CODM and T6ODM. Matching ESTs and the 
published cDNA sequences of CODM and T6ODM were aligned and used to design primers in 
an effort to obtain the genomic DNA sequence for both T6ODM and CODM. This information 
would be fundamental for the design of appropriate primers for a reverse genetic screen for 
mutants.  
At the beginning of the project probes for T6ODM and CODM were prepared to screen the 
same bacterial artificial chromosome (BAC) library in which the noscapine gene cluster was 
identified and characterised (Winzer et al., 2012). They successfully pulled out a number of 
CODM- and T6ODM-containing BACs. There was no overlap i.e. probes for each target did not 
have hits with any one BAC. Sequencing of CODM and T6ODM containing BACs was 
attempted at GSK and Amplicon Express (a company that offers BAC library preparation and 
sequencing services; Pullman, WA) using various next generation sequencing platforms. The 
assembly of short sequence reads into useful contigs was complicated due to the presence of 
repetitive DNA. While these efforts were ongoing, attempts were made to amplify and clone 
the genes from gDNA of opium poppy (Chapter 3). Sequencing of inserts would reveal the 




2.1.1 Cloning of full length PCR products and sequencing 
PCR products generated with PfuUltraII HS DNA polymerase (Aglient, 600670) were 
cloned with the StrataClone Blunt PCR Cloning Kit (Aglient, 240207) according to the 
manufacturer’s instructions. Briefly, the Strataclone blunt PCR cloning vector mix contains 
two blunt-ended DNA arms, each charged with topoisomerase I on one end and containing a 
loxP recognition sequence on the other end. Blunt-ended PCR products are efficiently ligated 
to these vector arms in a 5min ligation reaction by topoisomerase I-mediated strand ligation. 
The resulting linear molecule is then transformed into a competent cell line engineered to 
transiently express Cre recombinase. Cre-mediated recombination between the vector loxP 
sites creates a circular DNA molecule that is proficient for replication in cells growing on 
media containing ampicillin or kanamycin.  
PCR products generated with GoTaq Flexi DNA polymerase (Promega, M8305) were 
cloned with the StrataClone PCR Cloning Kit (Aglient, 240205) according to the 
manufacturer’s instructions because of the 3’-A overhangs generated using PCR. The PCR 
cloning kit is similar to the Blunt PCR cloning kit except that the topisomerase-charged ends 
have a modified uridine (U*) overhang. Taq amplified PCR products, which contain 3’-
adenosine overhangs, are efficiently ligated to these vector arms in the 5min ligation reaction, 
through A-U* base-pairing followed by topoisomerase I-mediated strand ligation. 
Transformation proceeds in the same manner as the Blunt PCR kit. 
M13 colony PCR was performed by preparing 20 µl of mastermix in wells of a 96 well 
plate. A sterile toothpick was used to take up a colony of bacteria from a petri dish and it was 
placed in the appropriate well of the 96 well plate (containing PCR mastermix). The toothpick 
was agitated to remove the bacterial cells. Once all samples were loaded on the plate, PCR 





20 µl mastermix for each colony contained: 
0.125 μl GoTaq Flexi DNA polymerase (Promega, M8305) 
1.2 μl MgCl2 (25 mM) 
4 μl 5x GoTaq Flexi green buffer 
2 μl dNTPs (2 mM) (New England Biolabs, N0447) 
1 μl of each M13 primer (10μM) 
10.675 μl HyClone molecular biology grade water (Thermo Scientific, SH3053801).  
 
M13 PCR conditions were as follows: 
95°C 2 min,  
30 cycles of (95°C for 30 sec, 55°C 30 sec, 72°C 3 min) 
72°C 5 min. 
 
PCR products were visualised on a 1.5% w/v agarose gel. Selected colonies were 
inoculated in 5 ml of fresh LB medium containing kanamycin (50 mg/L) and incubated 
overnight before plasmid extraction. 
2.1.2 Plasmid extraction 
Cloned plasmids were extracted using the QIAprep Spin Miniprep Kit (Qiagen, 27104) 
according to the manufacturer’s instructions. Briefly the kit is based on alkaline lysis of 
bacterial cells followed by adsorption of DNA onto silica in the presence of high salt. Washing 
and elution steps result in high yields of plasmid DNA. Recovered plasmids were quantified 
with the nanodrop (Thermo Scientific) and sequencing reactions were set up using the 
procedure indicated below.  
2.1.3 PCR product purification 
PCR products were purified using the QiaQuick PCR purification kit (Qiagen, 28104) 
according to the manufacturer’s instructions. Briefly, the kit makes use of spin column 
technology for the purification of PCR products. DNA adsorbs to the silica membrane in the 
presence of high concentrations of salt while contaminants pass through the column. 
Impurities are efficiently washed away and DNA is eluted with water. 30 µl PCR product was 
added to 150 µl of buffer PB as a starting point and purified PCR products were eluted with 
30 µl of HyClone molecular biology grade water (Thermo Scientific) by adding the water to 
the centre of the Qiaquick membrane, letting the column stand for 1min, and then 
centrifuging at 13,000 rpm for 1 min.  
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2.1.4 Preparation of samples for sequencing 
2.1.4.1 University of York sequencing service 
1µl primer (3.2µM) and purified PCR product were deposited premixed in a volume of 
7.2µl for Sanger sequencing. Enzyme and buffer were added by the Genomics lab to take the 
final volume to 10µl. The quantity of template required was calculated using the following 
guidelines: 
PCR product  Final concentration per reaction 
500-1000 bp  10-20 ng 
1000bp-2000 bp 20-40 ng 
>2000 bp  30-50 ng 
Plasmids  200-300 ng 
 
Samples were submitted in 0.2 ml domed capped PCR tubes (Axygen, PCR-02D-C) or 
alternatively in 96-well plate format (Starlabs, I1402-9800). 
2.1.4.2 Eurofins sequencing service 
17 µl of premix was prepared containing 2 µl of 10 µM primer and 15 µl of purified PCR 
products. If PCR products were between 300-1000 bp 75 ng of DNA was added to premix. For 
PCR products between 1000-3000bp 150 ng of DNA was added to premix.   
2.1.5 BAC isolation 
Primer sequences were passed to Amplicon Express  to allow screening of a bacterial 
artificial chromosome (BAC) library made from a GSK noscapine variety, HN1, for CODM and 
T6ODM containing BACs. Two of the hits were chosen for further study here-namely 
PS_158A11 and PS_33D07 (both hits for CODM). A tip was placed in the appropriate wells of 
the 384 well plates and streaked across a LB agar plate containing 12.5 µg/ml 
chloramphenicol. Plates were incubated at 37°C overnight. One colony was picked and 
streaked across another plate and incubated overnight again at 37°C. A single colony was 
then placed in a starter culture of 2.5 ml LB medium (12.5 µg/ml) chloramphenicol) and 
incubated for 16 h at 37°C at 300 rpm. Cells were harvested at 6000 x g for 15 min at 4°C. The 
Qiagen large construct kit (Qiagen, 12462) was then used for BAC isolation according to the 
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manufacturer’s instructions. The ATP required for the exonuclease digestion step was 
obtained from Sigma (A3377). BAC DNA was quantified with the nanodrop. 
The work displayed in Figure 15 and Appendix J took place with BAC DNA isolated by 
Amplicon Express. 
2.1.6 LongAmp PCR 
The LongAmp Taq PCR kit (New England Biolabs, E5200S) was used to investigate 
whether DIOX genes were physically linked to one another. Successful long range PCR 
between primers designed with different DIOX cDNA sequences would indicate linkage 
between the genes and an estimation of how close they are.  
50 µl LongAmp PCR reactions were set up as follows:  
20 µl HM2 gDNA template (10 ng/µl)  
10 µl 5x LongAmp Buffer  
1.5 µl dNTPs 
2 µl LongAmp Taq  
12.5 µl dH2O  
2 µl forward primer (10 µM)  
2 µl reverse primer (10 µM).  
 
The PCR programme used was 94°C 30 sec, 30 cycles of (94°C 30 sec, 65°C 13 min 30 
sec), 65°C 10 min. PCR products were visualised on 0.6% agarose gel run at 100 V for 3 h 30 
min.  
2.1.7 RNA extraction 
Each frozen stem sample was ground under liquid nitrogen in a mortar.  Approximately 
200 mg of powderised material was collected in a 2 ml eppendorf and weighed. RNA was 
extracted according to a method developed for extracting RNA from pine trees with slight 
modifications (Chang et al., 1993). 
Extraction buffer consisted of: 
2% CTAB (hexadecyltrimethylammonium bromide) (Sigma, M52365) 
2% PVP (polyvinylpyrrolidinone K30) (VWR, A2259) 
100 mM Tris-HCl (pH 8.0) (Sigma, 93363) 
25 mM EDTA (Sigma, E8008) 
2.0 M NaCl 
0.5 g/l spermidine (Sigma, 49761) 




450 μl of extraction buffer and 9 μl of 2% beta-mercaptoethanol (Sigma, M3148) was 
prepared for each 100 mg of sample and heated to 65°C. 450 μl was added to each 100 mg of 
sample and vortexed to fully homogenise. Samples were then incubated at 65°C for 10 min. 
The first extraction occurred with equal volumes of chloroform:isoamyl alcohol (24:1; 
CHCl3:IAA). After it was added the samples were vortexed for 2 min to mix and then spun at 
10,000 rpm/10 min/RT. The supernatant was transferred to a fresh 2 ml Eppendorf and 
extracted with equal volumes CHCl3:IAA at 10,000 rpm/10 min/RT. This was repeated for a 
third time before 600-640 μl of supernatant was collected. One quarter volume of 10 M LiCl 
was added and it was precipitated overnight at -20°C.  
Following LiCl precipitation RNA was centrifuged at 12,000 rpm/20 min/4°C and the 
supernatant was discarded. The pellet was dissolved in 500 μl warmed SSTE. SSTE was made 
from 1.0 M NaCl, 0.5% SDS, 10 mM Tris-HCl (pH 8.0) and 1 mM EDTA (pH 8.0). 
After another extraction with one volume of 500 μl CHCl3:IAA the supernatant was 
transferred to a fresh 1.5 ml Eppendorf tube and two volumes of 100% ethanol was added 
and mixed gently. The RNA precipitated at -20°C for 2 h.  
To harvest the precipitated RNA, the sample was spun at 10,000 rpm/20 min/4°C. The 
supernatant was carefully and completely removed, the pellet washed with 75% ethanol and 
then air dried for 2-3 min at RT. The pellet was then dissolved in 50 μl of nuclease-free dH2O 
and tapped gently for 5 min. It was then incubated at 65°C for 5 min. Crude RNA was then 
quantified with a nanodrop (Thermo Scientific).  
RNA was further purified with the RNeasy Plus Micro Kit (Qiagen, 74034). 45 μl of crude 
RNA was added to 5 μl of water and 350 µl Buffer RLT plus and mixed well by pipetting. The 
sample is then passed through a gDNA Eliminator spin column. This, together with the high-
salt buffer, ensures removal of gDNA. Ethanol is added to the flow-through to provide 
appropriate binding conditions for RNA, and the sample is then applied to the RNeasy 
MinElute spin column, where total RNA binds to the membrane and contaminants are 
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efficiently washed away. With this procedure RNA molecules larger than 200 nucleotides are 
purified. Purified RNA was then quantified on the nanodrop (Thermo Scientific). 
2.1.8 cDNA preparation 
RNA was reverse transcribed with the Quantitect Reverse Transcription Kit (Qiagen, 
205310) according to the manufacturer’s instructions. Briefly, the Quantitect Reverse 
Transcriptase is a blend of omniscript and sensiscript Reverse Transcriptases, which has a 
high affinity for RNA and is capable of cDNA synthesis from a wide range of RNA amounts in 
20min. Purified RNA is added to a master mix prepared from Quantitect Reverse 
Transcriptase, Quantitect RT buffer and RT Primer Mix. RT Primer Mix ensures cDNA 
synthesis from all regions of RNA transcripts, even from 5’ regions. The reaction takes place 
at 42°C and is inactivated at 95°C. 
2.2 Sample tracking  
 
Figure 8. Overview of the sample tracking process used in the project. Seed batches are assigned an S 
number. The resulting seedlings are given Sd numbers. At 4 weeks old, a small section of leaf is placed into 
a well of a PM collection plate. DNA is extracted and placed into the corresponding well of a D plate. 
Mature capsules split open. The seed is assigned an S number for the next generation and the remaining 
capsule material is ground into a fine powder and approximately 10mg is placed in a PM plate for alkaloid 
extraction. Running plates for UPLC analysis are given an R number. Links at each stage are tracked using 
apps on a barcode reading PDA.  
Figure 8 provides a graphical overview of the sample tracking procedures in the project. 
For the HM2 TILLING population each M2 seedling had the same “Sd” number as the M2 seed 
batch from which it was derived i.e. any mutation identified in Sd-123456 could be recovered 
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by sowing siblings from seed batch id S-123456. For subsequent generations “S” numbers 
were assigned to collected seed in an unordered fashion but tracked in a database. 
2.3 Reverse Genetic Screen 
The original EMS mutagenesis of HM2 seed and extraction of DNA from the M2 seedlings 
was carried out by Thilo Winzer, Marcelo Kern and Lynda Sainty. During the project the 
method was used again to mutagenise seed derived from one of the M2s in the original 
TILLING population which carried a CODM Q254* knockout mutation.  
2.3.1 Ethyl methanesulfonate (EMS) mutagenesis 
Seeds for mutagenesis were weighed out. As a guide 1000 Australian Blue seeds were 
taken to weigh approximately 0.5325 g. Seeds were soaked in 0.1% (w/v) potassium chloride 
solution (Sigma, 60131) for 24 h on a rocking platform using a 10ml universal tube for 1000 
seeds and a 50 ml Falcon tube for 2000 or more seeds. The moving solution ensured all seeds 
in the tube were agitated.  
On the day of mutagenesis, the potassium chloride was poured off from the soaking seeds. 
A disposable fine pipette was used to remove the last of the liquid. In the fume hood 105 µl of 
EMS (Sigma, M0880) and 500 µl of DMSO (Sigma, 276855) were added to 5 ml of 0.2M 
NaH2PO4.2H2O (Sigma, 71505, pH to 5.0 with NaOH) and 4.395 ml of H2O to produce the 10 
ml 100mM solution needed for every 1000 seeds. This could be adjusted for different total 
volumes and/or concentrations of EMS. The mixture was shaken well to form an emulsion. It 
was added to the seeds using a disposable pipette which was then placed with any other solid 
waste in a container containing 2 l of deactivating solution (10% sodium thiosulphate; Sigma 
72049). A control mixture lacking EMS was also prepared. Tubes were placed on the rocking 
platform to be agitated by the moving solution thus ensuring adequate EMS treatment. 
Enough sodium thiosulphate to produce a 10% solution with all the liquid waste that 
would be produced was weighed out and placed in a large conical flask. After EMS treatment, 
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the EMS solution was poured off into the waste flask. A disposable fine pipette was used to 
remove the last of the liquid from around the seeds.  
The seeds were washed twice in deactivating 100mM sodium thiosulphate solution by 
placing the tubes back on the rocking platform for 15 min. The seeds were then washed twice 
with distilled water in the same manner before drying them overnight on 3 mm paper in 
large Petri dishes.  
2.3.2 TILLING populations 
 The letters assigned to TILLING subpopulations refer to the dose of and length of 
exposure to EMS: B=3 h, 200 mM EMS and C=5 h, 200 mM EMS. HM2 received the B and C 
treatments by group members prior to the commencement of this PhD. The lowest 
germination rates and M1 survival rates were observed in the C subpopulations due to the 
longer exposure time to EMS. M1 seedlings were sown in the glasshouse in York. All M2 
seedlings were grown in the field in Tasmania (forward screen) and a subsection of the B and 
C populations (~4000) were grown in the glasshouse in York which allowed extraction of M2 
DNA (Table 1). These M2 seedlings were sacrificed after DNA sampling. Resowing and 
identifying the mutation in siblings would recover any mutations identified. 
Each M2 seed family was assigned a unique S number and the same Sd number was 
assigned to the resulting seedling from which DNA was extracted. DNA was normalized to 10 
ng/μl for all 45 DNA plates. DNA was pooled fourfold for PCR by mixing equal amounts of 
four DNA samples in new pool plates. The pooling strategy is outlined in Appendix A.  
M5 CODMb Q254* mutant seed also received the B and C treatments. M1 seedlings were 
grown in the glasshouse in York. M2 seedlings were grown in the field in Tasmania (forward 
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Table 1. Subpopulations of the original HM2 mutant population that were screened for mutations by 
TILLING 
Population 
M1 pop size 
(% germination freq.) 
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Table 2. Subpopulations of the new CODMb Q254* mutant population. M2s were assessed in a forward 
screen in Tasmania in the 2014/2015 growing season. 
2.3.3 Plant growth conditions 
Following EMS treatment dried seeds were sown immediately on poppy mix (John Innes 
no 2 compost, vermiculite and perlite (4:2:1)) in Maxi (Fleet) RootrainersTM (Haxnicks, Mere, 
UK) and then covered with a thin layer of compost. Seeds were kept moist by covering the 
trays with a lid with the vents open. The lid was removed once shoots appeared. Plants were 
grown under glass in 16 h days at the University of York horticulture facilities.  
For analysis of subsequent generations and crosses plants were grown under glass using 
the same Rootrainers and conditions described above for M2 seedling emergence. Plant lines 
assessed in field trials was grown at the GlaxoSmithKline Australia field-trial site, Latrobe, 
Tasmania from September 2014 to February 2015. 
2.3.4 DNA extraction 
Plant material for DNA extraction was taken from young leaves (approximately 4 weeks). 
30-50 mg was placed in the bottom of a collection microtubule (Qiagen, 19560). Samples 
were stored at -20C until processing. DNA was extracted in a 96-well plate format using the 
Qiagen Biosprint 96 Plant kit (Qiagen, 941558) and the Tissue Lyser (Qiagen). Briefly, with 
this automated system DNA is extracted from lysate and transferred between wash plates by 
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means of magnetic DNA-binding beads. In the elution plate, DNA dissociates from the beads 
and dissolves in TE.   
One 3 mm tungsten-carbide bead was added to each well of the microtubule collection 
plate containing plant material. 300 µl of buffer RLT (lysis buffer) was added and the tubes 
were sealed with collection microtube caps (Qiagen, 19566). Each rack of collection 
microtubules was placed between the adapter plates and fixed in to the Tissue Lyser clamps. 
Samples were homogenised for 90 sec at 25 Hz, allowed to rest for 60 sec, then homogenised 
again for 90sec. The adapter set was then disassembled before reversing rotating the rack 
180 and reassembling. The adapter sets were placed back into the Tissue Lyser for two more 
homogenisations. Each rack was then centrifuged at 4350 rpm for 15 min while the wash, 
elution and lysate plates were prepared.  
Wash 1  Buffer RPW (reconstituted)    500 µl  
Wash 2  100% ethanol      500 µl 
Wash 3  100% ethanol      500 µl 
Wash 4  0.02% Tween 20     500 µl 
Elution  TE       200 µl 
Lysate  100% isopropanol + MagAttract Suspension G 200 µl + 20 µl  
        respectively 
 
200 µl of lysate from each sample was transferred to the S-block containing isopropanol 
and magnetic beads taking care not to carry over any plant material. The 96 well format and 
sample order was retained during all procedures and transfers. All plates were loaded on to 
the Biosprint 96 machine for DNA extraction. The BS96 DNA plant protocol was used. The 
elution plate was covered with a self-adhesive film after processing. 
DNA from the material grown in Tasmanian field trials in the 2014/2015 growing season 
was extracted by the Australian Genome Research Facility in Adelaide, SA.  
2.3.5 Normalisation of DNA plates 
Following DNA quantification on the nanodrop (Thermo Scientific) DNA samples were 
normalised to 10 ng/μl concentration using HyClone molecular biology grade water (Thermo 
Scientific, SH3053801).  
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The DNA extractions for the original HM2 mutagenised population was carried out by 
group members prior to the commencement of this PhD. However, twelve new pool plates 
were created from the DNA storage plates prior to TILLING CODM and T6ODM. Normalised 
DNA plates were pooled 4 fold for PCR amplification. Refer to Appendix A for the pooling 
strategy.  
DNA from plants in subsequent generations was also normalised to 10 ng/μl prior to 
genotyping. DNA concentrations of samples from the Tasmanian field trials were quantified 
at the Australian Genome Research Facility. Working DNA plates with 10 ng/μl 
concentrations of each sample were prepared in York prior to genotyping.  
2.3.6 Primer design for TILLING 
Primers for TILLING were designed using web-based Primer 3 Plus (Untergasser et al., 
2007) making use of intron sequences and identified polymorphic sites obtained in initial 
sequencing work to target specific copies of CODM and T6ODM. Optimum annealing 
temperatures for each primer pair were identified in temperature gradient PCR. Touchdown 
PCR was used to ensure specificity. 
For CODM it was decided to screen exons 2, 3 and 4 in all three identified copies of CODM 
simultaneously using primer pair F9/R5 (Figure 16). For T6ODM, where more numerous 
copies were detected, information obtained from sequencing was used to exploit a 
polymorphic site to design primers (F14/R27) that would specifically amplify the copy of 







2.3.7 Targeting Induced Local Lesions IN Genomes (TILLING) method  
 
Figure 9. Overview of the TILLING method. Wild type seed is mutagenized with EMS. M1 plants are 
allowed to self. DNA is collected from M2 seedlings and pooled four fold for PCR with primers for the 
target gene. PCR products are heated to separate fragments and left to reanneal with any complementary 
strand in the sample i.e. to form heteroduplexes. Differences in gene sequence between members of the 
pool would result in heteroduplex bubbles at the point of the mismatch. The sample is then treated with 
an enzyme that recognises and cleaves at the sites of heteroduplexes resulting in two fragments the sum of 
the sizes of which is equal to the size of the full length PCR product. Separation of fragments out on an 
agarose gel enables mutation detection. Prospective mutations are confirmed by sequencing after steps 
are taken to identify the individual in the pool of 4 that is carrying the mutation. The final step is to assess 
whether the mutation has the desired effect on the phenotype. 
2.3.7.1 Amplification and heteroduplex formation of BBE PCR products for validation of 
Fragment Analyser as a mutation detection platform 
BBE was amplified from gDNA pools in nested PCR using the primers listed in Appendix 
K. In the first round 10 μl PCR reactions were set up with 0.1 μl GoTaq Flexi DNA polymerase 
(Promega, M8305), 0.6 μl MgCl2 (25 mM), 2 μl GoTaq Flexi colourless buffer, 0.1 μl dNTPs (20 
mM; New England Biolabs, N0447), 0.2 μl of each primer (10 μM), 4.3 μl HyClone molecular 
biology grade water (Thermo Scientific, SH3053801) and 2.5 μl (25ng) of template DNA.  PCR 
conditions were as follows:  
94°C 2 min,  
20 cycles of (94°C for 20 sec, Tann of 65°C (-0.5°C per cycle) 30 sec , 72°C 2 min) 
15 cycles of (94°C for 20 sec, 55°C 30 sec , 72°C 2 min 




20 l of was added to HyClone molecular biology grade water was added to each PCR 
product and 1 l was used for the second round of PCR set up with 0.1 μl GoTaq Flexi DNA 
polymerase (Promega, M8305), 0.6 μl MgCl2 (25 mM), 2 μl GoTaq Flexi colourless buffer, 0.1 
μl dNTPs (20 mM; New England Biolabs, N0447), 0.2 μl of each primer (10 μM), 5.8 μl 
HyClone molecular biology grade water (Thermo Scientific, SH3053801). 
PCR conditions were as follows:  
94°C 1 min,  
20 cycles of (94°C for 20 sec, 55°C 40 sec, 72°C 2 min) 
72°C 7min 
 
This was immediately followed by heteroduplex formation: 
95°C for 3 min 
Ramp to 55°C at 0.1°C/sec 
55°C 20 min 
Ramp to 25°C at 0.1°C/sec 
 
2.3.7.2 Amplification of CODM and T6ODM for TILLING 
CODM and T6ODMa were amplified from pool plates using CODM F9/R5 and T6ODM 
F14/R27, respectively. 10 μl PCR reactions were set up in wells of a semi skirted PCR plate 
(Starlabs, I1402-9800) with 0.1 μl GoTaq Flexi DNA polymerase (Promega, M8305), 0.6 μl 
MgCl2 (25 mM), 2 μl GoTaq Flexi colourless buffer, 0.2 μl dNTPs (New England Biolabs, 
N0447), 0.5 μl of each primer (10 μM), 4.1 μl HyClone molecular biology grade water 
(Thermo Scientific, SH3053801) and 2 μl (20 ng) of template DNA.  
CODM PCR conditions were as follows:  
95°C 2 min,  
10 cycles of (94°C for 20 sec, Tann of 67-62°C (-0.5°C per cycle) 30 sec , 72°C 75sec) 
37 cycles of (94°C for 20 sec, 62°C 30 sec , 72°C 75 sec 
72°C 5 min. 
 
(T6ODM F14/R27 temperature gradient was 73-68°C, with a final Tann of 68°C) 
This was followed immediately by heteroduplex formation: 
99°C 10 min 
70°C 20 sec (-0.3°C per cycle) x 70 
hold at 4°C 
 
PCR products were diluted 1_in_5 with sterile dH2O. 2 μl of this diluted PCR product was 
treated with 2 μl of working concentration dsDNA Cleavage Enzyme (AATI, FS-CLKENZ) in 
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the heteroduplex digestion reaction. In brief, an intercalating dye in the gel binds to dsDNA 
and allows detection of fragments of DNA as the run through the gel. The system allows the 
separation of fragments between 35 bp and 5000 bp in 80 min and will accurately measure 
the length of (cleaved) PCR products. Mutations were detected using the Mutation Discovery 
Kit (AATI, DNF-920-K0500T) on the Fragment Analyser machine (AATI) according to the 
manufacturer’s instructions for the Mutation Detection Kit. The machine was fitted with a 96-
Capillary Array Cartridge (Fluorescence), 55 cm effective/80 cm total length, 50 µm ID (AATI, 
A2300-9650-5580). Running conditions were as follows: 
Full condition 
Prerun: 12 kV 30sec 
Marker voltage injection (35 bp and 5000 bp): 7.5 kV 15 sec 
Sample voltage injection: 7.5 kV 45 sec 
Separation: 12 kV 75 min 
 
A mutation in a pool resulted in heteroduplex formation following PCR and subsequent 
cleavage. Mutations were detected if two small fragments of DNA whose total sizes 
corresponded to the full length PCR product size were observed in a lane.  
2.3.7.3 ‘EcoTILLING’ for detection of CODM and T6ODM alleles from other sources 
1µl of a 10ng/µl DNA from new varieties was combined with 1 µl of 10 ng/µl HM2 gDNA 
and amplified as before with the CODM F9/R5 primer combination. Heteroduplexes were 
allowed to form in each well and treatment with the cleavage enzyme precluded 
polymorphism detection on the Fragment Analyser. If there were differences in sequence 
unique bands would be observed on the TILLING gel. 
2.3.7.4 Validation of Fragment Analyser based mutation detection  
Previously the group used LICOR DNA analysers to screen for the HM2 TILLING 
population for mutations. Advanced Analytical’s Fragment Analyser is a high-throughput 
capillary electrophoresis system that counts TILLING as one of its applications. Advantages 
over the LICOR system include automatic sample loading from a 96 well plate and the fact 
that expensive fluorescently labelled primers are not required. Instead a dye in the 
separation gel gives a signal in the presence of dsDNA. The TILLING kit provided includes an 
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endonuclease for the recognition and nicking of heteroduplexes.  Previously the group 
identified mutations in the gene for the berberine bridge enzyme (BBE) which catalyses the 
conversion of (S)-reticuline to (S)-scoulerine. BBE mutants were found in wells B2, B4, D5, A8, 
C8 and F12 of pool plate 2. BBE was amplified from these six pools once more and the 
Fragment Analyser system was used to detect these positive controls. In addition, BBE PCR 
products were digested with Surveyor, the endonuclease previously used for heteroduplex 
cleavage, and also the dsDNA cleavage enzyme supplied with the Fragment Analyzer TILLING 
kit. The new enzyme proved just as efficient as Surveyor (data not shown). Furthermore, four 
different heteroduplex formation methods were tested in the validation (Table 3).  
Both enzymes worked equally well cleaving heteroduplexes caused by the presence of 
BBE mutations in the pools analysed. It was decided to use the AATI enzyme supplied with 
the Fragment Analyser kit in future experiments rather than purchase additional Surveyor.  
Method Description References 
1 95°C 3 min 
Ramp to 55°C at 0.1°C per sec 
55°C 20 min 
Ramp to 25°C at 0.1°C per sec 
25°C 1 sec 
Previously used in the 




2 99°C 10 min 
70°C 20 sec x 70 cycles (-0.3°C per cycle) 
(Le Signor et al., 2009) 
3 Plate placed in waterbath at 95°C for 10 min.  
Waterbath switched off and allowed to cool 
overnight.  
Novel 
4 96°C 10 min 
Ramp -0.5°C per sec to 85°C 
85°C 20 sec x 150 (-0.3°C per cycle) 
(Suzuki et al., 2007) 
Table 3. Heteroduplex formation methods trialled in Fragment Analyser validation experiment 
Likewise all four heteroduplex formation methods worked well. Mutations most easily 
stood out from background fluorescence when method 2 was used. In addition diluting PCR 
products by a factor of five prior to digestion with cleavage enzyme ensured the mutations 
were most easily observed (data not shown). Following this experiment cleavage of diluted 
PCR product subjected to hetroduplex formation method 2 with the AATI enzyme was chosen 
as the optimum method for screening. This was the combination in which mutations were 
most easily determined.  Figure 10 shows an example of the peaks in flouresence generated 
by dsDNA running through the gel (a dye in the running gel binds to dsDNA and excites a 
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detector which provides a measurement in RFU). A mutation in BBE in one of the four plants 
in the pool caused the 977 bp PCR product to be cut into two fragments of 446 bp and 564 bp.  
 
Figure 10. Example of peaks generated by AATI enzyme cleavage of 977 bp BBE PCR product. These 
peak sizes correspond to those observed on the Licor system where the mutation was originally 
discovered. 
Figure 11 shows the ‘gel image’ from the Fragment Analyser depicting recovery of known 
BBE mutations with method 2 and dsDNA cleavage enzyme. In each case the ~980 bp BBE 
PCR product was cut into two fragments by the cleavage enzyme. The expected fragment 
sizes (based on Licor measurements) were from left to right- well B2 (431 bp & 551 bp), well 
B4 (422 bp & 556 bp), D5 (360 bp & 623 bp), A8 (233 bp & 753 bp), C8 (288 bp & 705 bp), 
F12 (343 bp & 644 bp). 
 
Figure 11. Recovery of six known BBE mutations on the Fragment Analyser. The brightest bands are 
for the 35 bp and 5000 bp markers and the full length PCR product (~980 bp). Pairs of bands with 
combined sizes of ~980 bp indicate the presence of a BBE mutation in the pool. 
The results demonstrate the sensitivity and reproducibility of the system. It was decided 
to use the Fragment Analyser with these sample preparation criteria for the detection of 
CODM and T6ODM mutations in the HM2 TILLING population.  One advantage of the Licor 
system is that mutation detection with labeled primers indicates where to look for the 
mutation in subsequent sequencing i.e. if a 300 bp fragment was observed with one 
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particular dye you know the mutation is approximately 300 bp from that end of the PCR 
product. With the Fragment Analyser the mutation could be 300 bp from either end of the 
PCR product. The entire PCR product was sequenced to ensure coverage of both ends. 
However, the superior size estimations of the Fragment Analyser meant locating the base 
affected by the mutation was easily accomplished i.e. it would be close to 300 bp from one of 
ends. 
2.3.8 Rescreen & mutation confirmation 
De novo DNA plates containing pooled DNA samples in which mutations were identified 
and the four individuals which made up the pool were created with concentrations of 10 
ng/µl. These were used as template in PCR and TILLING to validate the mutation signals 
previously observed and identify which of the four individuals in the pool carried the 
mutation.  
For T6ODM mutation rescreens, PCR reactions involving individuals needed to be spiked 
with wild type HM2 DNA to ensure heteroduplex formation and mutation detection e.g. PCR 
was set up with 1 µl individual DNA + 1 µl wild type DNA + 8 µl mastermix. This was not 
required for CODM mutation rescreens as multiple copies of CODM were amplified in PCR 
ensuring heteroduplex formation even in the presence of homozygous mutations in a specific 
copy. Once the individual plant carrying the mutation was identified the relevant gene(s) 
were amplified by PCR, purified and sequenced as described above.  
2.4 Breeding using identified CODM and T6ODM polymorphisms 
In order to track mutations in crosses, allele specific primers were designed to 
distinguish mutant from wild type alleles in PCR. The mutations were then used as molecular 
markers in a marker assisted breeding programme. 
2.4.1 Set up of crosses 
Sowing of forward screen lines, TILLING mutants and GSK commercial lines was 
staggered over a number of weeks to ensure enough parent plants flowered together to 
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enable crosses to be carried out. The high codeine forward screen plants in particular were 
known to be shorter and to flower quite early relative to controls. Each week 20 plants from 
each seed batch were sown.  
Preferably, TILLING mutants were used as males in a cross with commercial lines. This 
would enable concurrent selfing of the mutant with the remaining pollen and the production 
of seed for the next generation if required. At the hook stage, would be female plants were 
emasculated and bagged. Two days after emasculation, pollen was transferred to the stigma 
from a suitable male plant with tweezers. The bag was replaced to ensure fertilisation by the 
transferred pollen only.  
2.4.2 Design of primers for Allele-specific PCR (AS-PCR) 
The online tools WebSNAPER (Drenkard et al., 2000) and WASP (Wangkumhang et al., 
2007) were used to design primers for allele specific PCR (AS-PCR). The WASP system makes 
use of different destabilising effects by introducing one deliberate 'mismatch' at the 
penultimate base of the AS primers to improve the specificity of the resulting AS primers. The 
tools returned a number of possible primer pairs for each SNP. Primer pairs were assessed to 
determine the optimum annealing temperatures and to ensure specificity. Positive controls 
were M2 and M3 DNA samples with which mutations were detected by TILLING while 
negative controls were siblings that lacked the relevant mutation and wild type HM2 DNA. 
WebSNAPER and WASP outputs together with the primers ultimately used are detailed in the 
Appendix D.  
2.4.3 AS-PCR 
10 μl AS-PCR reactions were set up in wells of a 96 well PCR plate (Starlabs, I1402-9800) 
with 0.1 μl GoTaq Flexi DNA polymerase (Promega, M8305), 0.6 μl MgCl2 (25mM), 2 μl GoTaq 
Flexi colourless buffer, 0.2 μl dNTPs (New England Biolabs, N0447), 0.5 μl of each primer (10 
μM), 4.1 μl HyClone molecular biology grade water (Thermo Scientific, SH3053801) and 2 μl 




PCR conditions were as follows: 
95°C 2 min,  
35 cycles of (95°C 30 sec, optimum Tann 30 sec , 72°C 30 sec) 
72°C 5 min. 
 
PCR products were visualised on 1.5% w/v agarose gel. Alternatively, if large numbers of 
samples were to be screened for different mutations PCR products generated with different 
AS-PCR primers were pooled four fold before loading on the Fragment Analyser i.e. 2.5 μl of 
PCR product from each mutation screen plate were pooled together to create 10 μl in each 
well of a new PCR product pool plate. If an AS-PCR was not performed for a certain well 
(because it was not relevant) or there was no DNA target in a certain well, 2.5 μl of sterile 
dH2O was added instead to ensure the total volume in each well was 10 μl. The PCR product 
pool plate was vortexed to mix and spun down briefly. 4 μl was added to 20 μl of Dilution 
Buffer 1X TE (AATI, DNF-495-0125). 
Mutations were detected using agarose gel electrophoresis or the dsDNA Reagent Kit 
(AATI, DNF-900-K0500T) on the Fragment Analyser machine (AATI) according to the 
manufacturer’s instructions. In brief, an intercalating dye in the gel binds to dsDNA and 
allows detection of fragments of DNA as the run through the gel. The system allows the 
separation of fragments between 35 bp and 500 bp and will accurately measure the length of 
PCR products. The machine was fitted with a 96-Capillary Array Cartridge (Fluorescence), 
55cm effective/80cm total length, 50 µm ID (AATI, A2300-9650-5580).  
Running conditions were as follows: 
Full condition 
Prerun: 8 kV 30 sec 
Marker voltage injection (35 bp+500 bp): 7.5 kV 10 sec 
Sample voltage injection: 7.5 kV 10 sec 
Separation: 8 kV 80 min 
 
2.5 Phenotyping 
Both latex and capsules were analysed for alkaloid content using protocols established 
previously in the group. These procedures are detailed below. Material assessed in field trials 
in Tasmania in the final year were phenotyped at GSK’s facilities in Port Fairy, Victoria.  
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2.5.1 Capsule harvest and seed cleaning 
In the greenhouse, capsules were removed from mature dry plants together with the “Sd” 
number and placed in a medium sized negative bag. (If the plant carried more than one seed 
capsule and all the capsules stem from self-pollination events they were put into the same 
bag. If the plant was used as a mother in a cross and contained more than one capsule, the 
capsule used in the cross was put in a separate bag). 
In the lab, the stigmatic disc was removed with a scissors and the seed was poured on to a 
piece of filter paper. Any large pieces of debris were removed with a forceps. The seed was 
then poured in to a pre labelled seed bag. The seed was assigned a seed batch id at this point 
by using the PDA to scan the new “S” number and the “Sd” numbers of the parent(s) used to 
create the seed (Figure 8). The “Sd” label of the mother plant was stored with the capsule. 
2.5.2 Alkaloid extraction from latex 
This method was adapted from an opium poppy mutant screening method (Fist et al., 
2005). Latex was typically sampled from plants between the 10-leaf stage and the “running-
up” stage (about 15 cm high). 500 µl of 10% acetic acid (Sigma, 695092) was distributed into 
each collection microtube (Qiagen, 19560). The Qiagen 96 well rack of collection microtubes 
was assigned a “PM” number and a Waters plate (Waters, 186002481) was assigned a 
corresponding “M” number. The Qiagen rack was taken to the glasshouse for sampling. A leaf 
was detached from the plant and approximately 0.5 µl of latex was collected from the wound 
using a 200 µl yellow pipette tip (Starlabs, S1111-0706). The yellow tip with latex was mixed 
in the tube until most of the latex was suspended in the acetic acid solution. The PDA was 
then used to link the position on the “PM” plate to the seedling (“Sd”) id.  The tip was left in 
the collection microtube while the other samples were collected. This process was repeated 
until all samples were collected. Tips were then removed from the tubes by tapping gently 
against the sides to ensure that no latex is left on the tip. The tubes were sealed with 
collection microtube caps (Qiagen, 19566), the rack cover was replaced and the rack was 
vortexed vigorously for one minute. The rack was then centrifuged at 4000 x g for 2 min. 50 
µl of supernatant was transferred to the “M” plate containing 450 µl 1% acetic acid. The “M” 
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plate was then sealed (Waters, 186002789) with a Combi Thermo-Sealer (Waters, SP-
0669/240). The extraction plate was stored for up to 2 weeks at 4C for short term storage (-
80C for long term storage). 
2.5.3 Alkaloid extraction from capsules 
Capsules were thoroughly dry before processing. Safelock 2 ml microcentrifuge tubes 
(VWR, 211-2165) were assigned “Sd” numbers. Each capsule was placed in a stainless steel 
grinding jar (Qiagen, 69985) together with a steel bead and the jar was closed. A Tissue Lyser 
bead mill (Qiagen) was used to grind the capsules using a frequency of 25 Hz for a duration of 
50 sec. The jars were allowed to stand for one minute before opening to allow the powder to 
settle. Powder from the grinding jar was transferred to an Eppendorf using a plastic funnel 
(Simport, F490-3). Each sample had its own funnel and funnels were placed in a beaker of 
warm water while the other samples were processed. Using the PDA the eppendorf tube ids 
(“Sd”) were linked to the actual plant ids (“Sd”).  
A single microtubule was placed in a 10 ml glass beaker. Approximately 10 mg of powder 
(one levelled scoop of a micro-spatula scoop/round end (Corning, 3013) was weighed out in 
the microtube. Up to 88 samples could be weighed out and placed on each “PM” plate. Column 
12 was reserved for standards-morphine, codeine, oripavine, noscapine, thebaine, blank and 
10% acetic acid. Standards for morphine, codeine, oripavine and thebaine were gifts from the 
Bruce group (CNAP, University of York). Noscapine was obtained from Sigma (363960). 
Extractions were performed on the same day as UPLC runs by specialist staff at CNAP 
(University of York). 500 µl of 10% acetic acid was pipetted over each powdered sample. The 
tubes were closed with plastic caps and the rack cover replaced. The rack was then vortexed 
thoroughly. It was then shaken using the bead mill at 5 Hz for 10 min before centrifugation at 
4000 x g for 2 min. 450 µl of 1% acetic acid was placed in each well of a Waters plate (Waters, 
186002481) and then 50 µl of the was added to each well taking care not to disturb the pellet. 
The extraction plate was stored for no longer than 2 weeks at 4°C (-80°C for longer storage). 
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2.5.4 UPLC-MS analysis of major alkaloids 
This work was carried out by specialist staff at CNAP (University of York). Running plates 
(“R” number) were Waters 1 ml round well collection plate (Waters, 186002481). 50 µl of 
extract from the extraction plate (“M” number) was added to 450 µl 1% acetic acid in the 
running plate, respecting the plate layout. The running plate was then heat sealed.  Samples 
were run on the UPLC with the Waters Acquity BEH C18 100x2.1 mm column maintained at 
60C. Mobile phase A was 10 mM ammonium bicarbonate, pH 10.2, with ammonium 
hydroxide. Mobile phase B was methanol. The weak wash solvent was 1% acetic acid (2000 
µl) and the strong wash solvent was ethanol (2000 µl). The seal wash solvent was methanol. 
Injection loop size was 2 µl (with a 15 µl metal needle) and the injection mode was full loop 
with load ahead at 0.1 min.  
UPLC settings: Waters Acquity, Gradient program: 0-0.2 min hold at 98% A 2% B, 0.2-0.5 
min linear to 60% A 40% B, 0.5-4.0 min linear to 20%A 80%B, 4.0-4.5 min hold at to 20%A 
80%B, 4.5-4.6 min linear to 98%A 2%B, 4.6-5.0 min hold at 98%A 2%B. 
Mass spectrometer settings: LTQ-Orbitrap with APCI source. Source conditions: source 5 
µA, vaporizer temperature 250C, capillary temperature 250C, capillary voltage 9 V, tube 
lens voltage 60 V, sheath flow (N2) 40 units, aux flow (N2) 20 units.  
LTQ-Orbitrap conditions: positive ion mode, scan range 150-900 m/z, resolution 7500 
FWHM @ 400, 1 µscan, max ion time 100 ms, injection waveforms on.  
2.6 Analysis of the impact of detected mutations on alkaloid accumulation 
in roots and shoots  
To assess the impact of CODM and T6ODM mutations on the accumulation of alkaloids in 
the plant an experiment was set up whereby plants from five mutant lines and wild type HM2 




2.6.1 Growth conditions 
Seeds were sown on a 50:50 mix of silica sand (Sibelco Minerals and Chemicals, MS 01 
0001) and Terragreen to allow the efficient collection of roots for sampled plants. It was 
anticipated that this would be easier to wash off than soil and allow the collection of 
minimally damaged root material for analysis. The mix was placed in root trainers (LBS 
Worldwide, RTTR117 & RTTR105) and was treated once with Intercept 70WG 
(Levington Horticulture Ltd). The plants were fed once a week with Phostrogen beginning 
two weeks after germination. The feeding increased to twice a week once the plants were 
well established (before the plants had started to show flower buds). Feeding continued 
through to harvesting of mature dried capsules.  
For each of the lines used in the experiment (Table 18) stem and root material was 
collected from early seedlings (es), plants at the hook stage prior to flowering (hk), flowering 
plants (flw) and maturing plants 10-14 days post flowering after petal fall (mat). The dates at 
which each plant flowered was recorded to enable sampling of mat material.  
2.6.2 Sampling of stem and root material  
On the day plants were sampled, the vermiculite was washed off the roots under a running 
tap. The roots were then dried thoroughly with a paper towel. A small section of root was 
(50-100 mg) set aside for RNA extraction by placing it in a 2 ml eppendorf. Both the roots for 
metabolite analysis and RNA extraction were flash frozen in liquid nitrogen before storage at 
-80°C. When all the required roots for metabolite analysis were collected they were 
lyophilised for 48 h and ground up for metabolite profiling in the same manner that mature 
capsules are processed (see section 2.5.3).  
A section of stem (approximately 1 inch in length) was taken immediately below the 
flower/capsule was used for RNA extraction. Exudated latex was also taken for metabolite 
analysis. Because sampling involved sacrificing a plant, results for different growth stages are 
for siblings rather than a timecourse of a single plant. Latex from each plant was stored in 
wells of a 96 well collection plate containing 10% acetic acid. When latex was collected from 
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all samples the latex was analysed for alkaloids using the method described previously 
(section 2.5.2).  
Sampling at each stage was done in triplicate i.e. three HM2 plants each of es, hk, flw and 
mat stages. The dried capsule, latex and root metabolite results displayed are the average of 
three technical replicates.  
2.6.3 RNA extraction and cDNA synthesis 
Both root and stem tissue was ground in liquid nitrogen and weighed. RNA was extracted 
with the RNeasy Plant Mini Kit (Qiagen, 74904) according to the manufacturer’s instructions. 
No more than 100 mg of frozen tissue was used in each extraction. Briefly, the tissue was 
ground thoroughly in liquid nitrogen with a mortar and pestle and the powder was decanted 
into a pre-cooled 2 ml eppendorf. A lysis buffer (RLT) was then added before the lysate was 
run through a QIAshredder spin column to remove the cell debris. After a number of cleaning 
steps with an RNeasy spin column a 30 l volume of RNA from each sample was recovered by 
elution with RNase-free water.  
Crude RNA was further cleaned up and concentrated using the RNeasy Plus Micro Kit 
(Qiagen, 74034). This ensured effective removal of contaminants, such as genomic DNA 
(gDNA) and phenol, which can interfere with transcript quantification. The procedure 
outlined in appendix C of the handbook was followed. Briefly, 350 l of Buffer RLT Plus was 
added to the crude RNA and mixed well. The sample was run through a gDNA Eliminator spin 
column and transferred to an RNeasy MiniElute Spin column for a series of washes. RNase-
free waster was used to elute the RNA (final volume of 12 l).  
RNA concentration was determined with the nanodrop (Thermo Scientific) and purity 
was assessed with the 2200 TapeStation System (Aglient) with an RNA ScreenTape (Aglient, 
5067-5576).  
First strand cDNA was synthesised from total RNA using Superscript II reverse 
transcriptase (Invitrogen, 18064-022) as described previously (Wijekoon and Facchini, 
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2012). Briefly, an initial 13 l reaction was set up (to have final volume of 20 l) with 1 l 
(100-400 ng) of total RNA, 2.5 mM anchored oligo dT primer (Thermo Scientific, AB-1247), 
0.5 mM dNTPs (New England Biolabs, N0447) and HyClone molecular biology grade water 
(Thermo Scientific, SH3053801). The mixture was heated to 65C for 5 min followed by a 
quick chill on ice. Superscript II kit components, 1x RT buffer and 5 mM DTT were added 
before incubation at 42C for 2 min. Finally 1 l (200 units) of the reverse transcriptase was 
added and the reaction was incubated at 42C for 50 min followed by an inactivation step of 
70C for 15 min. 
2.6.4 QPCR 
Real time quantitative PCR (RT-qPCR) was carried out with SYBR Green detection on 
triplicate technical and triplicate biological replicates for each tissue sampled representing 
different development points in the 6 lines sown for the experiment. 0.5 l of cDNA was 
added to 8.3 l HyClone molecular biology grade water (Thermo Scientific, SH3053801), 1.2 
l of 300nM primer mix and 10 l of 2x Fast SYBR Green Master Mix (Applied Biosystems, 
4385612). The StepOne™ Plus Real Time PCR system (Applied Biosystems) was used for real-
time quantitative detection of target nucleic acid sequences. Primers for the relative 
quantification of target genes were used previously (Hagel and Facchini, 2010a; Wijekoon 
and Facchini, 2012). PCR conditions were 95C 20 sec, followed by 40 cycles of 95C 3 sec, 
60C 30 sec. Fluorescent signal intensities were recorded and analysed using the system 
software. The threshold (Ct) value for each gene was normalised against the Ct for -actin, 
which was used as the constitutive reference transcript. Relative levels of morphinan gene 
transcripts were compared using the 2-T method (Livak and Schmittgen, 2001).
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Chapter 3- Reverse genetic screens 
3.1 HM2 mutant population 
A mutagenised population of 10000 lines has been established from the GSK morphine 
variety HM2. The mutagenised population has been used both for the isolation of mutants in 
specific target genes (reverse genetics) in York and for field based screening for altered 
alkaloid content in Tasmania (forward genetics). The B2, C1 and B3 subpopulations make up 
the TILLING population (Table 1) with 4146 members.  
3.2 Multiple copies of CODM in the opium poppy genome 
3.2.1 Sequencing of CODM from genomic DNA template 
The cDNA sequence for CODM (GenBank accession: GQ500141) was used to probe our in 
house EST database for contigs with similar sequence. ps1bContig1267, an EST built from 
HM2 ESTs, was used to design primer CODM_F1f. Situated before the transcription initiation 
site, this primer in conjunction with primer CODM_R1, situated downstream of the 
termination site, would allow amplification of a large portion of the CODM gene from a HM2 
gDNA pool. The resulting ~2kb PCR products were cloned with the Strataclone Blunt PCR 
cloning kit. Colony PCR confirmed the presence of the ~2 kb inserts (Figure 12). 
 
Figure 12. M13 colony PCR with ten positive CODM transformations. Lane 11 contained the control 
insert supplied with the cloning kit. 
 
Plasmids from 6 of these colonies were purified and sequenced. This led to the 
identification of three introns in CODM when the cDNA and gDNA sequences were compared 
in a sequence alignment (Figure 16).  
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3.2.2 Polymorphic sites identified in CODM sequence 
Closer examination of the alignment revealed the presence of two sites of conflict. The 
first is a silent single nucleotide polymorphism in exon 4. TCG and TCT both encode serine. A 
SNP was also noted 16bp downstream of the stop site in the 3’UTR. A ‘C’ or a ‘T’ is possible at 
this site. One clone was an exact match to the published cDNA sequence (GQ500141) with a 
‘G’ at the exon 4 site and a ‘T’ at the 3’UTR site (Table 6). PCR clones containing the containing 
the alternative combinations of bases at the two polymorphic sites were also sequenced.  
Matches for CODM in the EST database were probed for the occurrence of these 
polymorphic sites to determine if this observation was merely the consequence of different 
alleles of CODM in HN1 or if it may point to the expression of multiple copies of CODM in GSK 
commercial cultivars. CODM contigs from the different cultivars (HM2, HM1, HN1 and HT1) 
often were built up using sequence reads with different bases at the exon 4 and 3’UTR sites 
(Table 4). For example, ps1bContig1872 is a CODM contig made from HM2 ESTs and at the 
exon 4 site 6 of the 9 EST reads have a ‘G’, while the remainder have a ‘T’ (Figure 13). The 
ESTs in this contig support the role of multiple copies of CODM in HM2. This is likely 











Exon 4 SNP           
'G'  'T' 
GQ500141  
ps1bContig1872* (6of9 EST reads) ps1bContig1872* (3of9 EST reads) 
ps1cContig5406* (1of2 EST reads) ps1cContig5406* (1of2 EST reads) 
ps2aContig1105 (3of5 EST reads) ps2aContig1105 (2of5 EST reads) 
ps3cContig12033 (all) ps3bContig7406 (3of5 EST reads) 
ps3dContig9594 (1of2 EST reads) ps3dContig9594 (1of2 EST reads) 
ps4aContig4210 (all) ps4cFQURZIE02KUPOU 
HM2     HM1     HN1     HT1      
 
3’UTR SNP           
'T' 'C'  
GQ500141  
ps1bContig1872* (4of6 ESTs) ps1bContig1872* (2of6 ESTs) 
ps1cContig5406* (4of7 ESTs) ps1cContig5406* (3of7 ESTs) 
ps2aContig1105 (7of8 ESTs) ps2aContig1105 (1of8 ESTs) 
ps2bContig6192, ps2cContig2179, (all)  
ps3aContig10572 (2of4 ESTs) ps3aContig10572 (2of4 ESTs) 
ps3bContig7406 (4of8 ESTs) ps3bContig7406 (4of8 ESTs) 
ps3cContig12033 (1of4 ESTs) ps3cContig12033 (3of4 ESTs) 
ps3dContig9594 (2of 3 ESTs) ps3dContig9594 (1of3 ESTs) 
ps4aContig4210, ps4bContig6687, ps4cContig1507  
HM2     HM1     HN1     HT1      
Table 4. Recording the presence of different bases at two polymorphic sites in CODM ESTs. ps1 to ps4 
contigs were built from morphine cultivars HM2 & HM1, noscapine cultivar HN1 and thebaine cultivar 
HT1, respectively. GQ500141 is the published CODM cDNA sequence (Hagel and Facchini, 2010a). *The 
EST assemblies for contigs ps1bContig1872 and ps1cContig5406 are displayed in Figure 13 showing the 
number of times each bases was observed at the two polymorphic sites e.g. at site 1 in ps1bContig1872 6 





















Exon 4 variation 
ps1bFPZG94Y02LD5LU+   TAGGCCCAA--TTTCG-AGCTTGGTCAC                                 
ps1bFPZG94Y01ASC5R+   TAGGCCCAA--TTTCG-AGCTTGGTCAC                                 
ps1bFPZG94Y02LBBVH+   TAGGACCAA--TAGCG-AGCTTGATCACACC-AGAGACACCTG---CTTTGTTCAAAAG  
ps1bFPZG94Y02NWZ57+   TAGGCCCAA--TTTCT-AGCTTGGTCACACC-AGAGACACCTG---CTTTGTTCAAAAGA 
ps1bFPZG94Y01EFH8P+   TAGGCCCAA--TTTCG-AGCTTGGTCACACC-AGAGACACCTG---CTTTGTTCAGAAGA 
ps1bFPZG94Y02KRRRF+   TAGGCCCAA--TTTCT-AGCTTGGTCACACC-AGAGACACCTG---CTTTGTTCAAAAGA 
ps1bFPZG94Y01AE996+   TAGGCCCCAATTTTCTTAGCTTGGTCACACCCAGAGACACCTG---CTTTGTTC       
ps1bFPZG94Y02O21TK+   TAGGCCCAA--TTTCT-AGCTTGGTCACACC-AGAGACACCTG---CTTTGTTCAAAAGA 
ps1bFPZG94Y02LVTVN+   TAGGCCCAA--TTTCG-AGCTTGGTCACACC-AGAGACACCTG---CTTTGTTCAAAAGA 
ps1bFPZG94Y01DR7IC+      GCCCAA--TTTCG-AGCTTGGTCACACC-AGAGACACCTG---CTTTGTTCAAAAGA 
ps1bFPZG94Y02M2MJD+                            CACACC-AGAGACACCTGTTTCTTTGTTCAAAAGA 
                  ____________________________________________________________ 
consensus             TAGGCCCAA--TTTCG-AGCTTGGTCACACC-AGAGACACCTG---CTTTGTTCAAAAGA 
 
3’UTR variation 
ps1bFPZG94Y01EFH8P+   TTTCTCGACTAC                                                 
ps1bFPZG94Y02KRRRF+   TTTCTCGACTACATGAGGATGTGAGAAAGTGTG-AACA                       
ps1bFPZG94Y02O21TK+   TTTCTCGACTACATGAGGATGTGAGAAAGTGTGTAACATATATTATACTCCACATTGTGT 
ps1bFPZG94Y02LVTVN+   TTTCTCGACTACATGAGGATGTGAGAAAGTGTG-AACATATATTATACTCCACATTGTGT 
ps1bFPZG94Y01DR7IC+   TTTCTCGACTACATGAGGATGTGAGAAAGTGTG-AACATACATTATACTCCACATTGTGT 
ps1bFPZG94Y02M2MJD+   TTTCTCGACTACATGAGGATGTGAGAAAGTGTGAACCATATATTATACTCCACATTGTGT 
ps1bFPZG94Y02NEY0J+   TTTCTCGACTACATGAGGATGTGAGAAAGTGTG-AACATACATTATACTCCACATTGTGT 
ps1bFPZG94Y01CKEMT+   TTTCTCGACTACATGAGGATGTGAGAAAGTGTG-AACATATATTATACTCCACATTGTGT 
ps1bFPZG94Y01DDA1Y-                                                    CCACATTGTGT 
ps1bFPZG94Y02NOC71+                                                              T 
                      ____________________________________________________________ 
consensus             TTTCTCGACTACATGAGGATGTGAGAAAGTGTG-AACATATATTATACTCCACATTGTGT 
 
ps1cContig5406 
Exon 4 variation 
ps1cFPZG94Y02K61LC+   TCAATCGCGACATTTCATGACTCTAAACTAGAGTCAGAAATAGGCCCAATTTCGAGCTTG 
ps1cFPZG94Y01EU29I-                                     CAGAAATAGGCCCAATTTCTAGCTTG 
                      ____________________________________________________________ 
consensus             TCAATCGCGACATTTCATGACTCTAAACTAGAGTCAGAAATAGGCCCAATTTCGAGCTTG 
 
3’UTR variation 
ps1cFPZG94Y01EU29I-   TGTGAACATATATTATACTCCACATTGTGTTTAATATATGATGAAATAAGTTGCTTTTGA 
ps1cFPZG94Y01C510H+   TGTGAACATACATTATACTCCACATTGTGTTTAATATATGATGAATTAAGTTGCTTTTGA 
ps1cFPZG94Y01D1274+   TGTGAACATACATTATACCCCACATTGTGTTTAATATATGATGAAATAAGTTGCTTTTGA 
ps1cFPZG94Y01C0QQS+   TGTGAACATACATTATACTCCACATTGTGTTTAATATATGATGAAATAAGTTGCTTTTGA 
ps1cFPZG94Y02LKF2D+   TGTGAACATATATTATACTCCACATTGTGTTTAATATATGATGAAATAAGTTGCTTTTGA 
ps1cFPZG94Y02OJVTU+    GTGAACATATATTATACTCCACATTGTGTTTAATATATGATGAAATAAGTTGCTTTTGA 
ps1cFPZG94Y02LTH3C+    GTGAACATATATTATACTCCACATTGTGTTTAATATATGATGAAATAAGTTGCTTTTGA 
                      ____________________________________________________________ 
consensus             TGTGAACATATATTATACTCCACATTGTGTTTAATATATGATGAAATAAGTTGCTTTTGA 
Figure 13. Alignment around the sites of CODM sequence variation in two HM2 EST contigs. The 
polymorphic sites are highlighted.  
In order to determine whether the different copies of CODM are present in all plants or 
represent alleles of CODM in the lines analysed, DNA from an M2 plant (derived from EMS 
mutagenesis of HM2) was taken together with the DNA of numerous M3 plants derived from 
the seed collected from the self-pollinated M2 plant (Sd-110071). CODM was amplified from 
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each DNA sample. PCR products were purified and sequenced. Double peaks were observed 
in the chromatograms for the M2 and all M3 plants indicating at least two, if not all three, 
versions of CODM are in each plant (Table 5). 
Description Seedling_id Exon 4 3'UTR 
M2 Sd-110071 G/T C/T 
M3 Sd-110994 G/T C/T 
M3 Sd-110996 G/T C/T 
M3 Sd-110997 G/T C/T 
M3 Sd-110998 G/T C/T 
M3 Sd-110999 G/T C/T 
M3 Sd-111000 G/T C/T 
M3 Sd-111001 G/T C/T 
M3 Sd-111003 G/T C/T 
M3 Sd-111004 G/T C/T 
M3 Sd-111006 G/T C/T 
M3 Sd-111008 G/T C/T 
M3 Sd-111012 G/T C/T 
M3 Sd-111013 G/T C/T 
Table 5. Signals observed in the chromatograms at the two CODM polymorphic sites in an M2 
individual and M3 plants derived from selfed seed of the M2 plant.  
If the M2 plant, Sd-110071, was heterozygous for CODM, and the versions observed were 
alleles of CODM, a quarter of M3s would have a ‘C’ at the 3’UTR polymorphic site, half would 
have ‘C/T’ and the remaining quarter would have ‘T’.  However, all M3 plants were genotyped 
‘C/T’ (Table 5). Likewise all M3 plants were genotyped ‘G/C’ at the exon 4 polymorphic site. 
Therefore, these do not represent alleles of CODM. Rather, multiple copies of CODM are 
present in each plant. These contain nucleic acid differences at two polymorphic sites but the 
amino acid sequence of the encoded CODM would remain unchanged.  
3.2.3 Three copies of CODM in the genome of opium poppy 
Further cloning and sequencing of CODM from HN1 gDNA and cDNA templates revealed 
the presence of three copies of CODM which we designate CODMa, CODMb and CODMc (Table 
6). CODMa is identical to the characterised gene (GenBank accession: GQ500141; Hagel and 
Facchini, 2010a).  
 Exon 4 site 3’UTR site 
CODMa G T 
CODMb T T 
CODMc G C 
Table 6. Nucleotides at the exon 4 and 3'UTR polymorphic sites in copies of CODM 
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Large cultures of two of the BACs which the CODM probe pulled out of the library, 
PS_33D07 and PS_158A11, were prepared for BAC purification. CODM was amplified using 
each of these purified BACs as template in PCR. Products were again cloned and sequenced as 













Table 7. Bases occurring at the CODM polymorphic sites in CODM clones obtained when using BAC 
DNA as a template in PCR. 
Table 7 shows the nucleic acids at the exon 4 and 3’ UTR polymorphic sites detected in 
each CODM clone sequenced. CODMb was cloned and sequenced seven times from the 
PS_33D07 template, suggesting that only CODMb resides on this BAC. By contrast CODMa and 
CODMc were cloned and sequenced using PS_158A11 as a template. The results suggest close 
linkage of copies of CODM in the genome. BACs typically contain 150-350 kb of sequence and 
BACs containing CODMa and CODMc were shown to be within this range. PCRs for T6ODM 
and other genes involved in morphine biosynthesis such as BBE, 7-OMT, COR, SalAT and SalR 
failed so CODM is unlikely to form part of a morphinan gene cluster if such a cluster does 
exist. If all three copies of CODM detected are functional then mutations in all would have to 








Copy of CODM 
33D07_CODM F9/R5 (3) T T CODMb 
33D07_CODM F9/R5 (6) T T CODMb 
33D07_CODM F9/R5 (7) T T CODMb 
33D07_CODM F1f/R1 (2) T T CODMb 
33D07_CODM F1f/R1 (5) T T CODMb 
33D07_CODM F1f/R1 (6) T T CODMb 
33D07_CODM F1f/R1 (7) T T CODMb 
158A11_CODM F9/R5 (6) G C CODMc 
158A11_CODM F9/R5 (8) G T CODMa 
158A11_CODM F9/R5 (9) G T CODMa 
158A11_CODM F1f/R1 (2) G C CODMc 
158A11_CODM F1f/R1 (3) G T CODMa 
158A11_CODM F1f/R1 (4) G C CODMc 
158A11_CODM F1f/R1 (5) G T CODMa 
158A11_CODM F1f/R1 (6) G C CODMc 
158A11_CODM F1f/R1 (7) G C CODMc 
158A11_CODM F1f/R1 (10) G T CODMa 
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3.2.4 Two copies of CODMc are within ~150 kb of each other 
Amplicon Express sequenced a selection of the CODM-containing BACs with the HiSeq 
(sequencing-by synthesis; Illumina) and PacBio (single molecule real time sequencing; Pacific 
Biosciences) sequencing platforms. Assembly of the sequence reads into contigs was carried 
out by Yi Li.  Assembly was a challenge due to repetitive sequence. Scaffolds were assembled 
from HiSeq data of 48 x 2 paired end (PE) libraries from each BAC and four size (500, 800, 
2000 and 5000 bp) mate pair (MP) libraries from all BACs.  
PacBio contigs for 8 BAC clones were then compared with the scaffolds. The most reliable 
contigs/scaffolds built were generated from PacBio sequencing of two BACs-89C05 and 
109:H06. CODM is highlighted in the sequences of the three largest contigs in Appendix J.  
BAC:Contig Length (kb) Gene copy present 
PS_109H06:000063 54 CODMb 
PS_89C05:000086 41 CODMc 
PS_89C05:000087 11.5 CODMc 
Table 8. Copies of CODM detected on the three largest CODM containing contigs generated using the 
sequencing results obtained from Amplicon Express. 
89C05 contains two copies of CODMc and 109H06 contains CODMb (Table 8, Figure 14). 
BACs typically have a capacity of 150 kb. Even though the two copies of CODMc were not on 
the same contig, the contigs were generated with the same template DNA and must be within 
150 kb of one another.  
DNA from seven of the BACs in which the CODM probe hybridised was used in PCR in an 
attempt to amplify CODMa/c and CODMb. Reverse primers exploiting the variation at the 
exon 4 polymorphic site (Figure 13) would enable specific amplification of CODMa/c or 
CODMb. If independent PCR products were obtained using both reverse primers, it would 




Figure 14. Schematic showing copies of CODM sequenced and their source. CODMa/b/c were 
originally detected in ESTs (Figure 13) and from gDNA sources (Table 5 and data not shown). Sequencing 
of two BACs detected with a CODM probe confirmed the presence of copies of CODM. Two copies of CODMc 
were observed on BAC 89C05. Although they were observed in one continuous contig the fact that they 
reside on the same insert in this BAC means the two copies of CODM must reside within a range in line 
with the capacity of a BAC. Overall the results point to the presence of a multigene family possibly 
originating from duplications.  
PCR products were visualised on an agarose gel (Appendix J). The results indicate that 
89C05 may contain a copy of CODMb as well as two copies of CODMc described above. 
CODMb was found to be present on all the BACs tested. CODMb is the only version present on 
109H06 (Appendix J).  
3.2.5 Sequence analysis of contigs from 89C05 and 109H06 
The large 54 kb contig obtained using sequence data from BAC 109H06 contains CODMb. 
The promoter region agrees almost exactly with a CODM promoter sequenced and 
characterised by US researchers over a decade ago (Raymond, 2004). There are only 3 
conflicts in a 2.5 kb overlap. This validates the PacBio sequencing and contig assembly and 
means a full length promoter, coding regions, introns and downstream region is available for 
CODMb on BAC 109:H06. 
The 2.5 kb promoter sequence also assembles with the two contigs generated from 
89C05 sequencing- PS_89C05:000086 (41 kb) and PS_89C05:000087 (11.5 kb). However, this 
can only happen gaps in the alignment are allowed. The results suggest that a series of 
duplications of both coding and promoter regions has taken place. 
 Primers F14/R10 span a potential duplicated of the CODM promoter in 
PS_89C05:000086. A tandem duplication of 348 bp was spotted in the assembly and primers 
spanning this site were designed. Amplification with F14/R10 from the region represented 
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by PS_89C05:000086 would create a 1099 bp product. In contrast, amplification from the 
region represented by PS_89C05:00087 would create a 751 bp product. PCR using BAC 
89C05 as a template yielded both products (Figure 14). Although the larger product was 
likely outcompeted in the early rounds of PCR there is a faint band for a 1099 bp PCR product 
as well as the 751 bp product. This verifies the presence of two copies of CODMc on the 
region of the poppy genome carried by BAC 89CO5. Furthermore, although the coding 
sequence of CODMc is unchanged, there are a number of duplicated regions both upstream 
and downstream.  
 
Figure 15. Overview of the duplications in the alignment of contigs generated from PacBio sequencing 
of BAC 89C05. The blue lines represent sequence upstream and downstream of CODMc. Red lines indicate 
areas of sequence that have been duplicated e.g. a section of 348 bp upstream of CODMc has been 
tandemly duplicated in contig PS_89C05:000086. A gap in the other contig is thus present in the 
alignment. Primers (F14/R10) spanning this site were designed to verify the existence of the duplication 
in 89C05:000086 by PCR. Different sized PCR products were generated using template represented by 
contigs 000086 and 000087.  
In addition, PS_89C05:000087 contains an 154 bp duplication immediately prior to the 
CODM coding region out of which 110 bp is an exact match to the beginning of the CODM 
coding sequence It is not clear yet whether the duplications alter the ability of the genes to be 
transcribed or if they contain cis elements that might alter the circumstances under which 
different copies of CODM are expressed. There are also further duplications (3 kb and 3.6 kb 
downstream of CODM) in PS_89C05:000087. Apart from the duplications the sequences of 
PS_89C05:000086 and PS_89C05:000087 are remarkably similar suggesting a duplication 
even of the genomic regions containing CODMc. 
3.2.6 ORF Prediction 
FGENESH (Solovyev et al., 2006) and NCBI’s ORF Finder (available at 
http://www.ncbi.nlm.nih.gov/projects/gorf/; Marchler-Bauer et al., 2011) were used to 
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identify potential open reading frames in the two largest contigs PS_89C05:000086 and 
PS_109H06:000063. Apart from CODM, most of the ORFs identified contained conserved 
domains for retrotransposons related genes such as retropepsin, gag protein, reverse 
transcriptase, RNase H1 and RVE integrase. No other genes involved in morphine 
biosynthesis were found. However, a DIOX_N conserved domain was identified on 
PS_89C05000086 within 7 kb of CODMc. Other ORFs identified on this contig were for a 
protein with 60-70% identities to predicted nucleobase-ascorbate transporter from Vitis 
vinifera and Phoenix canariensis and a protein with 60% identity to a predicted transcription 
factor, DPB-like from Fragaria resca. Predicted ORFs on PS_109H06:000063 had identities to 
peptidase, M14-carboxypeptidases and chromosome partition protein, Smc. 
3.2.7 CENSOR analysis for repeats 
A common feature of plant gene clusters is the presence of neighbouring transposable 
elements and retrotransposons such as those described in Arabidopsis thaliana, Lotus 
japonica and Papaver somniferum (Field et al., 2011; Krokida et al., 2013; Winzer et al., 2012).  
The CENSOR programme was used to scan the two largest contigs for repeat elements 
(Kohany et al., 2006).  
Most of the repetitive DNA on both contigs (Table 9) is due to Long Terminal Repeat 
(LTR) Retrotransposons, specifically of the Ty3/Gypsy family. These elements are similar to 
retroviruses but lack an ORF for an envelope (ENV) proteins required for intercellular 
transmission of retroviruses. 
LTR and non-LTR retrotransposons (Class I transposable elements) operate via a “copy-
and-paste” mechanism whereby mRNA transcribed from the element by RNA polymerase II 
undergoes reverse transcription and then integrates into a new position in the genome by an 
integrase (Lisch, 2013). hAT and CACTA are class II elements which operate via a “cut-and-
paste” mechanism in which the elements are physically excised from the chromosome and 
reintegrated at a new location by a transposase enzyme. Helitrons are the third class of 
transposable elements found in plant genomes and these are thought to transpose via a 
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“rolling circle” mechanism. Nicking at the Helitron terminus is followed by DNA synthesis, 
strand displacement and resolution of a heteroduplex by DNA replication. Many Helitrons 
have short sequences at their termini and “filler” sequences composed of fragments of 
captured genes.  
PS_89C05:000086 
Repeat Class Fragments Length 
Integrated Virus 1 91 
    Caulimoviridae 1 91 
Transposable Element 34 5161 
    DNA transposon 13 1565 
       Helitron 2 144 
       MuDR 4 774 
       hAT 3 173 
    LTR Retrotransposon 21 3596 
       Copia 5 611 
       Gypsy 15 2927 
Total 35 5252 
 
PS_109H06:000063 
Repeat Class Fragments Length 
Transposable Element 44 9332 
    DNA transposon 15 1688 
       EnSpm/CACTA 4 437 
       Helitron 4 336 
       Mariner/Tc1 1 181 
       MuDR 3 355 
       hAT 2 239 
    LTR Retrotransposon 28 7587 
       Copia 4 317 
       Gypsy 24 7270 
    Non-LTR 
Retrotransposon 
1 57 
Total 44 9332 
Table 9. Summary of repeats identified on the two largest CODM containing contigs 
3.2.8 Section summary 
Cloning and sequencing of CODM from genomic DNA of GSK commercial lines of opium 
poppy has revealed that there are multiple copies. Initial efforts determined differences 
between copies at just two polymorphic sites. Three different versions of CODM were 
detected, differing only with the bases at these two sites. The differences do not lead to amino 
acid changes. Subsequent sequencing of BAC 89C05 showed that two copies of CODMc are 
physically linked to each other. Therefore, there are at least four copies of CODM in the 
genome. BAC derived sequence information will enable further study of these copies. It is 
likely that they arose due to gene duplications. No other genes involved in the morphinan 
pathway were observed on the CODM containing BACs but the genes were in a context of 
much LTR Retrotransposon sequence.  
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3.3 TILLING for induced mutations in CODM 
3.3.1 Design of appropriate primers to maximise mutation recovery 
Using the sequence information obtained from sequencing clones of CODM the Primer 3 
Plus webtool (Untergasser et al., 2007) was used to design primers for TILLING. At this stage 
it was known that there were multiple copies of CODM in the genome and although CODM-
containing BACs were not yet sequenced the decision was made to screen all copies of CODM 
simultaneously using primer pair F9/R5 (Figure 15). PCR with this primer pair would 
generate a PCR fragment of 1335 bp allowing mutation detection in exons 2, 3 and 4. The 
‘window’ to be screened also spanned numerous splice sites which could be interrupted by 
mutations introduced by EMS. Mutations at these sites could lead to aberrant RNA splicing 
and the subsequent translation of altered or truncated proteins. If deemed necessary in 
future, mutations in exon 1 could be detected with primer pair F10/R6.  
 
Figure 16. Regions of CODM amplified using different CODM primer combinations. Primer pair F9/R5 was 
used for TILLING. Primer pairs F12/R7 and F12/R8 were used to amplify CODMa/c and CODM, 
respectively. 
Differences between CODM copies towards the 3’ end of the genes were anticipated to 
result in common banding patterns on TILLING gels across all samples i.e. heteroduplex 
bubbles would form at these points in all samples and result in cleavage (Figure 17). Cleavage 
at these sites would generate four fragments with sizes of 1227 bp, 1091 bp, 244 bp and 108 
bp.  
Primers R7 and R8 make use of the polymorphism in exon 4 in that utilisation of primer 
R7 results in amplification of CODMa and CODMc. Primer R8, in contrast, was designed to 
selectively amplify CODMb. These primers would be useful for amplifying CODM for 
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sequencing reactions in order to determine which copy of CODM any detected mutation 
resides on.  
3.3.2 Mutation screen 
 
Figure 17a shows the Fragment Analyser gel when digested pool plate 2 CODM PCR 
products were loaded. Due to differences among copies of CODM in the genome there are 
common bands in the TILLING gel as expected. The task is to identify any unique pairs of 
fragments. An example of a CODM mutation is present in Lane 34 (well C10). Figure 17b 
displays the fluorescent signals observed in Lane 34. The software estimated the sizes of the 
cut fragments unique to this lane to be 456 bp and 841 bp. The sum of the sizes of these 
fragments is the roughly the size of the full length PCR product. Figure 17c shows the 
rescreen of well C10 of pool plate 2 plus the four individual DNA samples that made up the 
pool. These DNA samples were located using the information in Appendix A. The same 
fragments were seen in the pooled DNA sample and the third individual (Sd-100571). This 
individual is the carrier of the CODM mutation. 
 This process was repeated for all twelve pool plates (Appendix B). Typically when 
doing TILLING with individuals the DNA would be spiked with wild type DNA. This would 
allow for heteroduplexes to form after PCR between wild type and mutant alleles. For CODM, 
multiple copies were amplified in the PCR and so heteroduplexes formed between mutant 
alleles and wild type alleles from an additional copy. In many cases only one unique band was 
observed in a lane in a TILLING gel. Nevertheless this was brought forward for rescreen to 
















b)                                                                                                                               c)     
  
 
Figure 17. Identification of a CODM mutation (using primer pair F9/R5 for PCR). a) Fragment Analyser 
gel image for pool plate 2 CODM PCR products after digestion with the AATI enzyme. Lanes 1-12 = Wells 
A1-A12, Lanes 13-24=Wells B1-B12 etc. A CODM mutation is present in well C10 (Lane 34)-unique bands 
are indicated with arrows. b) Fluorescent signals detected in well C10. Unique 456 bp and 841 bp 
fragments indicate a CODM mutation. c) Rerun of (from left to right) well C10 and the four components of 
the pool. The mutation is in the third individual.  
3.3.2.1 Determining which copy of CODM affected by EMS induced mutation 
When all individuals carrying CODM were identified, DNA from these individuals was 
once again used in PCR to amplify CODMa/c and CODMb. It was not possible using the 
sequence information available at the time to design primers to distinguish between CODMa 
and CODMc. Both CODMa/c and CODMb PCR products were purified and sequenced and the 
fragment sizes observed on the TILLING gels were used to inform where the mutations could 
potentially be.  
3.3.2.2 Summary of CODM mutations detected in reverse genetic screen 
Table 10 provides a summary of the CODM mutations found in the reverse genetic screen 
of 4146 M2 plants. Appendix B has the full record of the fragments detected in the initial 
screen and the follow up rescreen as well as the actual TILLING gel images. In total 44 
mutations in CODM were confirmed in 42 plants. Five were silent i.e. the nucleotide change 
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will not cause an amino acid substitution. Many of the mutations identified were in introns 2 
(16) and 3 (12). This left 9 missense mutations in the coding region of CODM (Figure 18). 
Most importantly, 2 nonsense mutations were identified-W261* in CODMa/c and Q254* in 
CODMb.  
 
Figure 18. Locations of mutations identified in CODMa/c and CODMb. The region of the genes 




Well Screening Rescreening Plant Sd numbers in pool 









Fragment 1 (bp) Fragment 2 (bp) Fragment 1 (bp) Fragment 2 (bp) 
One 
A8 315 - 881 - 100057 100058 100059 100060 D-10001 A8-D8 Intron 2 - - - 
C4 390 914 386 911 100105 100106 100107 100108 D-10002 A4-D4 Intron 3 - - - 
Two 
B4 778 - 795 - 100429 100430 100431 101234 D-10005 E4-H4 Y177Y silent - - - 
C10 456 841 462 849 100569 100570 100571 100572 D-10006 A10-D10 Intron 2 - - - 
Three 
D8 383 941 373 919 101195 100942 100943 100944 D-10010 E8-H8 Intron 3 - - - 
Four 
E10 912 - 406 896 101712 101714 101720 101721 D-10015 A10-D10 Intron 2 - - - 
F3 364 966 349 940 101493 101494 101495 101497 D-10015 E3-H3 T283I CODMb S-101497 B2 
H7 446 849 442 844 101626 101627 101628 101629 D-10016 E7-H7 Intron 2 - - - 
Five 
F2 802 - 528 786 101981 101982 101983 101984 D-10019 E2-H2 S176F CODMb S-101983 B2 





101946 101947 101948 101949 D-10020 E1-H1 
Intron 2, a 
Intron 3,b - - - 
Six 
G7 530 788 536 784 102571 102572 102573 102574 D-10024 A7-D7 W261* CODMa/c S-102574 B2 
H3 785 - 535 783 102503 102504 102505 102506 D-10024 E3-H3 Y177Y silent - - - 
Seven 
G11 495 813 500 807 103225 103226 103227 103228 D-10028 A11-D11 F271L CODMb S-103228 C1 
Eight 
B8 336 - 426 878 103059 103060 103061 103062 D-10029 E8-H8 Intron 2 - - - 







E6 372 955 336 957 103279 103282 103283 103284 D-10031 A6-D6 T283I CODMa/c S-103284 C1 





103248a 103249 103250b 103251 D-10031 E2-H2 
 
Intron 3,b - - - 
F9 337 -  386 935 103312 103314 103315 103316 D-10031 E9-H9 Intron 3 - - - 
G2 523 847 505 813 103357 103358 103359 103360 D-10032 A2-D2 Intron 2 - - - 
G3 385 984 373 933 103366 103367 103369 103370 D-10032 A3-D3 Intron 3 - - - 
G4 554 814 528 769 103378 103379 103381 103382 D-10032 A4-D4 S176S silent - - - 
G8 467 904 452 863 103419 103420 103421 103422 D-10032 A8-D8 Intron 2 - - - 
G12 556 823 533 785 103456 103458 103459 103460 D-10032 A12-D12 I262V CODMb S-103458 C1 





103361 103362 103364 103365 D-10032 E2-H2 
Intron 2, a 
Not found, b - - - 






Plant Sd numbers 





Seed batch number 
of mutant 
Population 
Fragment 1 (bp) Fragment 2 (bp) Fragment 1 (bp) Fragment 2 (bp) 
Nine 
A1 444 - 422 900 103466 103467 103468 103469 D-10033 A1-D1 Intron 3 - - - 
A7 537 817 520 786 103529 103530 103532 103534 D-10033 A7-D7 P266S CODMb S-103534 C1 
B12 192 1166 506 816 103647 103648 103626 103627 D-10033 E12-H12 Intron 2 - - - 
C3 450 902 436 873 103583 103584 103585 103586 D-10034 A3-D3 Intron 2 - - - 
C6 424 934 400 875 103618 103619 103620 103621 D-10034 A6-D6 Intron 3 - - - 
Ten 
B4 467 876 454 840 103781 103784 103785 103789 D-10035 E4-H4 Intron 2 - - - 
C5 222 - 422 859 103891 103892 103893 103894 D-10036 A5-D5 Intron 3 - - - 
F4 425 935 417 881 103934 103935 103936 103937 D-10037 E4-H4 Intron 3 - - - 
G11 644 731 622 705 104359 104281 104282 104283 D-10038 A11-D11 L232F CODMb  S-104281 B3 
H9 400 936 383 889 104331 104340 104321 104322 D-10038 E9-H9 Intron 3 - - - 
Eleven 
A1 483 849 472 821 104191 104192 104193 104194 D-10039 A1-D1 Intron 2 - - - 
A10 573 787 548 754 104529 104530 104531 104532 D-10039 A10-D10 Q254* CODMb S-104530 B3 
A12 370 971 362 939 104549 104550 104551 104553 D-10039 A12-D12 Intron 2 - - - 
B12 434 919 421 884 104554 104555 104556 104557 D-10039 E12-H12 Intron 2 - - - 
F2 393 971 378 930 104737 104738 104739 104741 D-10041 E2-H2 Intron 3 - - - 
F6 404 - 346 952 104665 104666 104667 104668 D-10041 E6-H6 G285G silent - - - 
Twelve 
C5 467 895 451 863 105065 105066 105068 105069 D-10044 A5-D5 Intron 2 - - - 
Table 10. Summary of identified CODM mutations in the HM2 EMS mutagenised population. Individuals in the pool of four carrying the mutation are shaded. The nature of each 
mutation and the copy of CODM in which it resides are documented. The shaded mutations were prioritised for further work.
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3.3.2.3 Selection of best candidates for producing heritable phenotypic changes 
An online tool called PARSESNP (Project Aligned Related Sequences and Evaluate SNPs) 
was used to assess the potential impact of the CODM mutations obtained (Table 11). 
Mutation severity was predicted using the PARSESNP, SIFT and SNAP programmes 
(Bromberg and Rost, 2007; Ng and Henikoff, 2003; Taylor and Greene, 2003). The two 
nonsense mutants are predicted to be deleterious as the resulting protein would miss 
approximately 100 amino acids from its C terminus including residues important for 
substrate recognition and 2-oxoglutarate binding (Hagel and Facchini, 2010a; Runguphan et 
al., 2012). Appendix B contains shows the nucleotides affected and the corresponding change 
in amino acid (in the case of missense mutations). The analysis predicts that the T283I 
mutations, obtained in each copy of CODM (Table 10; Pool plate 4 F3 & Pool plate 8 E6), 
would have a severe effect on function. The E301K mutation returned borderline PSSM and 
SIFT scores but it was interesting in that it lies next to an arginine involved in 2-oxoglutarate 
binding (Hagel and Facchini, 2010a; Runguphan et al., 2012). These two missense mutations 
as well the two nonsense mutations (Q254* and W261*) were chosen to be the focus of 














C1428T S176F CODMb   Neutral (69%) 
C1595T L232F CODMb   Neutral (89%) 
A1685G I262V CODMb   Neutral (94%) 
C1697T P266S CODMb   Neutral (78%) 
C1714G F271L CODMb 6.8 0.42 Neutral (85%) 
C1858T T283I CODMa/c 17.0 0.00 Non-neutral (63%) 
C1858T T283I CODMb 17.0 0.00 Non-neutral (63%) 
G1911A E301K CODMa/c 10.5 0.16 Non-neutral (58%) 
Table 11. Predicted severity of discovered CODM missense mutations. Mutation severity is predicted 
using the PARSESNP and SIFT programmes (Ng and Henikoff, 2003; Taylor and Greene, 2003). Mutations 
are predicted to have a severe effect on protein function if PSSM scores are >10 and the SIFT scores are 
<0.05. SNAP is a neural-network based method that uses in silico derived protein information (e.g. 
secondary structure, conservation, solvent accessibility, etc.) in order to make predictions regarding 
functionality of mutated proteins (Bromberg and Rost, 2007). SNAP outputs indicate whether SNPs are 
either "neutral" in the sense that the resulting point-mutated protein is not functionally discernible from 





3.3.3 Detection of alleles from other sources 
3.3.3.1 Alleles with slight differences to HM2 CODM are present in other opium poppy 
varieties 
A 96 well DNA plate with 3 replicates of DNA from 32 different poppy lines was created. 






GSK morphine lines Externally sourced 
lines 
HN1 HT1 HM1 “Afghan Princess” 
HN2 HT2 HM2 “Venus” 
HN3 HT3 HM3 “Double Raspberry” 
 HT5 HM5 “Applegreen” 
  additional four historic 
lines 
“Burgundy Frills” 
   “Violetta Blush” 
   “Shyama” 
   “The Giant” 
   “White” 
Table 12. Lines used in EcoTILLING experiments for mining of additional CODM and T6ODM alleles. 
Noscapine lines possess the noscapine gene cluster. The thebaine lines have not been genetically 
characterised and any key polymorphisms leading to the thebaine phenotype are not known.  
Sample DNA from additional varieties was mixed with HM2 DNA and amplified as before 
with the CODM F9/R5 primer combination. Heteroduplexes were allowed to form in each 
well and treatment with the cleavage enzyme precluded polymorphism detection on the 
Fragment Analyser. If there were differences in sequence unique bands would be observed 
on the TILLING gel (Figure 19). This approach, whereby the objective is to  identify alleles in 
different varieties as opposed to mutant populations is often referred to as ‘EcoTILLING’. 





Figure 19. EcoTILLING gel to identify additional CODM alleles. Lanes 1-12 = A1-A12, 13-24 = B1-B12 
etc. Unique bands of ~400 bp and ~700 bp were observed in some lanes. Those in the first three lanes are 
indicated with arrows. 
Two polymorphic sites were found when analysing the sequencing results. They are only 
two bases apart which explains why only one pair of unique bands were seen on the gel in 
those lines that have both. Both polymorphisms would result in amino acid changes (first 
letter is amino acid in HM2 at this position). 
Variety  Differences from HM2 CODM 
Violetta Blush F271L 
HT3 F271L  
HT1 F271L 
HT5 F271L (one individual) 
Giant F271L 
Applegreen F271L & I272T 
Double Raspberry F271L & I272T 
Venus F271L & I272T 
Shyama  F271L & I272T 
Afghan Princess F271L & I272T 
White F271L & I272T 
Table 13. Differences in CODM sequence detected among certain varieties used and HM2. 
CODM in noscapine lines and other morphine lines was identical to HM2.  However the 
thebaine lines contained an F271L polymorphism that was also present in some of the new 
externally sourced lines analysed (Table 12). Interestingly, HT2 (the oldest thebaine line 
analysed) did not have the F271L polymorphism. The fact that it is present in other lines 
suggests it is a natural allele of CODM in opium poppy. Curiously, the polymorphism was also 
introduced to HM2 during EMS mutagenesis (Table 10; Pool plate 7 G11, Sd-103228) but it is 





3.3.3.2 Two alleles of CODM are common to all high codeine forward screen lines 
The same EcoTILLING strategy used previously (Figure 19) was employed to check 
whether there are any differences in the nucleotide sequence of CODM in five high codeine 
forward screen lines and WT HM2 from which they were derived. These five lines had 
undergone numerous rounds of selfing in the field in Tasmania. Capsules of these lines 
accumulate substantially more codeine and thebaine than HM2- codeine comprises typically 
30% of the total alkaloid content. The five seed batches were sent to York for DNA extraction 
and analysis. DNA from the resulting seedlings was spiked with equal amounts of HM2 wild 
type DNA prior to PCR. Differences in sequence between wild type and mutant CODM would 
result in heteroduplexes and cleavage. Figure 20 shows the discovery of two new CODM 
polymorphisms in three of the high codeine lines S-122066 (MAS 1983 C), S-122067 (MAS 
1833 B) and S-122068 (MAS 1835 D). Sequencing CODMa/c and CODMb in these and 
individuals of S-114247 (MAS 2235 D) and S-114248 (MAS 2237 D) revealed the nature of 
these polymorphisms to be an E193K substitution in CODMa/c and R158K substitution in 
CODMb (Figure 20). In addition there is also a silent substitution in CODMb-S321S. The 
E193K mutation was predicted to be non-neutral by the SNAP programme (Bromberg and 
Rost, 2007). The three nucleotide substitutions are G/C to A/T transitions and so it is likely 
that they were EMS induced (Greene et al., 2003). All individuals genotyped were 
homozygous for each of the polymorphisms, indicating that they are fixed and likely 
contribute to the high codeine phenotype. The two remaining high codeine forward screen 
lines, S-114247 (MAS 2235 D) and S-114248 (MAS 2237 C), were subsequently shown to 
possess both of the CODM polymorphisms by AS-PCR rather than TILLING and sequencing 
(Appendix B). The five high codeine lines had similar phenotypes in the glasshouse in York as 





Figure 20. 'EcoTILLING' high codeine lines for CODM polymorphisms. Two pairs of fragments are visible in 
various lanes-200 bp +1200 bp & 600 bp +800 bp. In addition a single band of 700 bp is visible. These 
were caused by CODM E193K, R158K and S321S polymorphisms present in all five high codeine forward 
screen lines. These polymorphisms may be associated with the high codeine phenotypes (expressed as a 
percentage of total alkaloids in mature capsules) observed both in the field in Tasmania and in the 
glasshouse in York.  
3.3.3.3 All five high codeine lines are derived from the same M2 plant  
All five high codeine lines derived from the same original M2 seed batch, S-103234 of the 
highly mutagenised C1 subpopulation. This seed batch was actually included in the reverse 
genetic screen but there was a PCR failure with well E1 of pool plate 8 which contained DNA 
from Sd-103234 (Appendix B; Pool plate 8, lane 49).  
Carol Walker of GSK kindly provided genealogy records for the five high codeine forward 
screen lines demonstrating how they all derived from the M2 seed batch S-103234. The 
records show a doubling in the codeine content of capsules between C1M3 RMUUS 314 and 
C1M4 MUVS 107 (Figure 21; Appendix B). The CODM polymorphisms may have been in 
segregating in RMUUS 314. Seed was then collected from RMUUS 314 E which gave rise to a 
number of MUV 107 plants homozygous for the CODM polymorphisms including MUVS 107 
A, whose codeine content was four times higher than the mean codeine content of plants in 






MAS 1983 C 
        
S-122066 
          
popn season old ID seed ID 
 
plot no M C O T 
 
    
OP row HM2 3.1117 
    
C1M2 07_08 25c S-103234 OP row MUT 437 2.9664 0.2557 0.0150 0.2019 
 
    
SP caps MUTS 437 G 4.4067 0.5943 0.0060 0.0769 
 




   
 
      
          
C1M3 08_09 
  
OP row HM3 3.67 
    
    
OP row RMUU 314 3.7286 0.6138 0.0011 0.2387 
 
    
SP caps RMUUS 314 E 4.2614 0.6006 0.0136 0.0813 
 




    
 
      
          
C1M4 09_10 
  
OP row HM1 2.918 0.332 0.027 0.121 
 
    
OP row MUV 107 2.352 1.391 0.051 1.105 
 
    
SP caps MUVS 107 A 2.315 2.316 0.024 1.209 
 
C1M5 2010 
Seed from MUVS 107 A sent to Tom Davies to grow over Australian winter. Seed harvested and returned labelled UKMUVS 
107 A 
 






   
Seed sown into 5 replicated rows in TAS 
   
          
 
     
M+pM C O T M 
C1M6 10_11 REP 4/5  
 
OP row HM4 2.569 0.144 0.015 0.105 2.352 
  
ex ukmuvs 107a 
 




OP row MUWT 1964 2.356 0.709 0.017 0.429 2.073 
    
SP caps MUWTS 1964 C 2.266 2.001 0.059 0.696 2.154 






   
      
          
          
C1M7 11_12 
    




ex muwts 1964 C 
 




OP row HT5 1.001 0.189 0.709 2.473 4.372 
    
OP row MA 1983 3.005 1.691 0.040 1.316 6.052 
    
SP caps MAS 1983 C 3.766 2.089 0.076 1.379 7.309 
Figure 21. Development of the high codeine forward screen line S-122066 (MAS 1983 C) from S-103234. In 
each season the phenotypes are compared to the current morphine (HMx) and thebaine (HTx) lines. OP= 
open pollinated. SP= self pollinated. Phenotypes expressed as percentage dry weight of morphine (M), 
codeine (C), oripavine (O), thebaine (T) and pseudomorphine (pM). The best individuals in each row are 
highlighted. The genealogies for the four other high codeine lines are in Appendix B. They all share the 
same origin in S-103234.  
3.3.4 Section summary 
Although it was clear that there were multiple copies of CODM in the genome it was 
decided to screen all copies simultaneously for EMS-induced mutations. PCR amplification 
and sequencing would then determine whether any detected mutation would reside on 
CODMa/c or CODMb. Nonsense mutations were found in the TILLING screen which became 
the focus of efforts to recover mutations among M2 siblings. Furthermore, two CODM 
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polymorphisms were detected in high codeine forward screen lines. These may cause or be 
linked to the cause of the high codeine phenotype. 






 c)     d)     e)
 
Figure 22. Recovery of CODM mutations 
a) Q254*, W261* and T283I mutation recovery plate. Common fragments were produced due to 
differences between copies of CODM. However sets of fragments in a number of lanes indicate the 
presence of mutations. 
b) E301K mutation recovery plate.  
c) Example of W261* mutation detection in well C4 (lane 28 on gel a). The W261* mutation generated 
fragments of 783 bp and 351 bp.  
d) Example of Q254* mutation detection in well A6 (lane 6 on gel a). The Q254* mutation generated 
fragments of 761 bp and 333 bp.  
e) Example of E301K mutation detection in well A5 (lane 5 on gel b). The E301K mutation generated 
fragments of 960 bp and 289 bp.  
 
The M2 seed for each missense and nonsense mutant was located and sown. DNA was 
extracted from 4-week-old seedlings derived from each seed batch. These DNA samples were 
then screened for the CODM mutations initially found in their M2 sibling. The W261* and 
Q254* mutations were recovered (Figure 21a,c,d). The seed from the CODMb and CODMa/c 
T283I mutants gave rise to just 2 and 18 plants, respectively. Unfortunately, the mutation 
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was not detected in any of these M2 siblings (Figure 21a). For this reason, DNA from siblings 
of the next most interesting CODMa mutant, E301K, was extracted and screened. The E301K 
mutation was recovered in 5 seedlings (lanes 5, 17, 40, 63 and 76) of the 34 screened (Figure 
21b,e).  
3.4.1 Sequencing to confirm W261* and E301K CODMa/c mutations  
a) 
   
Sd-828044 example of WT  Sd-828047 example of ‘carrier’ 
b) 
 
    
Sd-828062 example of WT  Sd-828068 example of ‘carrier’  
 
Figure 23. Sequencing CODM in CODMa/c mutants 
a) Examples of sequencing traces of the codons affected by the W261* mutation. WT CODM has TGG 
encoding tryptophan. The mutant has TAG stop codon. 
b) Examples of the sequencing traces of the codons affected by the E301K mutation. WT CODM was a 
GAG encoding glutamic acid. The mutant has a AAG encoding lysine.  
S-102574 seed was sown and 38 seedlings were screened for the W261* mutation. 9 
carriers were found. It is not appropriate to designate them heterozygotes as in each case 
there are not two equally sized peaks in the chromatogram at the mutation position (Figure 
23a). In fact the green peak (A) is always a quarter of the size of the black peak (G). This 
results from amplification of both CODMa and CODMc in PCR with primers F12/R7. This 
mixed PCR product was the template in the sequencing reaction. In a heterozygote there was 
one mutant template for every three wild type templates. It is likely that these 9 plants are 
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heterozygous mutants of either CODMa or CODMc. Likewise S-103127 seed was sown and 34 
seedlings were screened for the E301K mutation. 5 carriers were recovered (Figure 23b). 
3.4.2 Sequencing to determine zygosity of carriers of the Q254* mutation in 
CODMb 
S-104530 seed was sown and 32 seedlings were screened for the Q254* mutation. 8 
homozygotes and 8 heterozygotes were found.  
 
Figure 24 shows examples of the sequencing traces from a wild type plant, a heterozygote 
and a homozygote. In this case only CODMb was amplified in PCR (using primer pair F12/R8) 
prior to sequencing. Heterozygotes had WT and mutant signals of equal magnitude at the 
position of the mutation. Homozygotes displayed a complete change of base from C to T at 
this position. This confirms that the primers used selectively amplifies CODMb and indicates 
that there is only one copy of CODMb in the genome.  
     
Sd-828227 example of WT          Sd-828202 example    Sd-828201 example 
of heterozygote   of homozygote 
 
Figure 24. Sequencing CODM in CODMb mutants. Examples of sequencing traces of the codons affected 
by the Q254* mutation. WT CODM has CAA encoding glutamine. The mutant has a TAA stop codon. 
3.4.3 Analysis of M2 capsules-CODMb Q254* mutants in particular have elevated 
codeine levels 
 Capsules of M2 siblings were ground and their alkaloid contents were analysed by UPLC. 
All capsules analysed had morphine as the predominant alkaloid, much like the wild type 
HM2 from which the mutant population was derived. Introduction of CODM mutations, 
therefore, did not result in a complete block of metabolism at codeine. This is not surprising 
since even with one copy knocked out, having two remaining functional copies of CODM 
appears to be sufficient to demethylate codeine to morphine at levels similar to that of HM2. 
The mean (±SD) codeine yields among CODMa/c W261* carriers (homo & het) and CODMb 
Q254* homozygotes were 4.0± 1.6 and 3.0+2.1 μg/mg dw, respectively. This compares with a 
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HM2 average of 1.5±0.8 μg/mg dw. In terms of percentage of total alkaloids, the capsules of 
CODMa/c W261* carriers (homo & het) and CODMb Q254* homozygotes had 6.4% and 6.7% 
codeine, respectively, while those of HM2 had 2.8%. Likewise, thebaine yields in CODMa/c 
W261* carriers (homo & het) and CODMb Q254* homozygotes were 3.1± 3.0 and 1.7+2.6 
μg/mg dw, respectively, while that of HM2 was 1.0±0.6 μg/mg. The high standard deviations 
are likely to reflect the variety of background mutations among siblings. Nevertheless, the 
codeine (Figure 25) contents of CODMa/c W261* mutants and codeine and thebaine contents 
in the CODMb Q254* mutants suggested partial blocks of metabolism due to the induced 
mutations. M3 seed collected from the capsules prior to phenotypic analysis was sown for 
further analysis. Crosses to combine CODM mutations would be attempted with the resulting 
M3 plants. Double or triple mutants would be required to produce lines that accumulate 
much higher levels of codeine. 
 
Figure 25. Mean codeine content (±SD) of the capsules of M2 siblings and wild type HM2. 
3.4.4 Analysis of M3 capsules-Q254* mutants 3 fold more codeine than HM2 
M3 seedlings were genotyped using allele specific PCR to determine whether the plants 
carried a CODM mutation prior to being used as a parent in a cross (section 3.5.5 below). 
CODMa/c W261* and E301K mutations were still segregating in M3 as the M2 parents were 
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homozygotes, heterozygotes and wild types were represented among siblings derived from 
seed batches S-114020, S-114037 and S-114110 (Figure 26).  
The two M3 CODMb Q254* seed batches sown were produced by M2s known to be 
homozygous for the mutation. Therefore, all M3s were also homozygous. In M3 plants 
derived from S-114055, the mean codeine content of the capsules (5.8±0.6 μg/mg; 10.5% of 
total alkaloids) was up to three times (Figure 26 and Appendix B) higher than wild type HM2 
(1.8±1.1 μg/mg; 3.6% of total alkaloids).  Likewise, thebaine content in the capsules (6.2±3.5 
μg/mg; 11.2% of total alkaloids) was up to four times (Appendix B) higher than wild type 
HM2 (1.5±1.4 μg/mg; 3.0% of total alkaloids). Full alkaloid profiles for each line are displayed 
in Appendix B.  
 
Figure 26. Mean codeine content (±SD) of the capsules in M3 CODM mutants and wild type HM2. 
W261* and E301K mutations were still segregating among M3s. 25% would be expected to be 
homozygous, 50% heterozygous and the remaining 25% WT. All Q254* M3s were homozygous for the 
CODMb mutation.  
3.4.5 Attempts to create CODM double mutants to further impact on disrupting 
O-demethylation to morphine 
T6ODMa and PODA display no activity against codeine (Hagel and Facchini, 2010a). 
Therefore, disrupting all copies of CODM in a plant should be sufficient to block metabolism 
at codeine. Crosses were set up to combine the CODM mutant alleles identified in the various 
copies in the TILLING screen. A CODM double or triple mutant may be enough to achieve a 
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Figure 27. Possible scenarios involved with the recovery of CODM double mutants. a) Copies of CODM 
are unlinked i.e. on different chromosomes and 1 in every 16 F2s should be homozygous for two CODM 
mutations. b) Copies of CODM are linked and the recovery of a double mutant will be dependent on a 
crossing over event. The frequency with which this will occur is dependent on the distance between copies 
of CODM.  
There is evidence from our BAC library to suggest that at least two copies of CODMc are 
linked in sequence held on BAC 89C05 (Figure 15). Furthermore, CODMa and CODMc were 
cloned and sequenced from BAC 158A11 (Table 7). If copies of CODM were in fact linked, 
crosses among M3s with different CODM mutations would produce a uniform heterozygous 
population, with each plant containing one CODM-containing chromosome from each parent. 
During meiosis the homologous chromosomes may or may not ‘cross over’ and form 
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recombinants (Figure 27b). The closer the copies are to each other the less chance that 
recombination bringing two different CODM mutations together will occur. If copies of CODM 
are unlinked the strategy would involve following the crosses through to the F2 generation 
and identifying double homozygotes (1 in every 16 F2s; Figure 27a). 
Eight E301K x W261*, three E301K x Q254* and five W261* x Q254* crosses were 
successfully carried out. F1 seed was sown and ten F1 individuals from each seed batch was 
sown for genotyping to confirm transmission of the CODM mutant alleles (Appendix B). F1 
plants confirmed to possess two CODM mutations were prioritised for selfing to produce F2 
seed (Appendix B). 
Five F2 seed batches resulting from W261* x Q254* crosses: S-123066, S-123067, S-
123072, S-123079 and S-123086 were sown. S-123028 represented an F2 from a W261* x 
E301K cross and S-123055 was the F2 seed sown which resulted from a E301K x Q254* 
cross. 40 F2s from each of the 7 seed batches were genotyped by AS-PCR and sequencing 
(Appendix B). No double mutants were recovered. The vast majority of F2s were 
heterozygous for each CODM mutation introduced by the parents in the original cross. In the 
small number of cases where an F2 individual was homozygous for one CODM mutation, it 
lost the other one. This suggests that the CODMa/c and CODMb copies are closely linked. 
These conclusions were confirmed by sequencing results at the time where copies of CODMa 
and CODMc were amplified and cloned from BAC 158A11 (Table 7) and later PacBio 
sequencing of BAC 89C05 where two copies of CODMc were found to reside on the same BAC 
(Figure 15). A BAC typically has a size of about 150 kb and so at least two copies of CODM 
must be within this range of each other.  
Overall, the results suggest that multiple copies of CODM reside in a relatively small 
region of the poppy genome. However, knocking out just one copy of those identified 
produced already elevated levels of codeine. Crosses between CODM mutants may be difficult 
due to close linkage. It is worth stating that the BAC sequencing results were not available at 
the time the crosses were being set up (Chapter 5) and so efforts to combine CODM 
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mutations were initiated. As an alternative strategy to crosses, seed from the CODMb Q254* 
mutant was bulked up for further EMS mutagenesis. Perhaps multiple rounds of mutagenesis 
will eventually be required to identify knockouts in all copies or at least those copies which 
are expressed and most active.  
3.4.6 Section summary 
The CODM nonsense mutations (W261* and Q254*) and the E301K polymorphism were 
recovered in M2 siblings. Alkaloid content of M2 and M3 capsules were assessed which 
indicated partial increases in codeine content compared to HM2. In an effort to increase the 
yield of codeine further, crosses were attempted to produce plants with multiple mutated 
copies of CODM. However, F2s homozygous for two CODM mutations were not identified 
suggesting close linkage between copies of CODM in the genome. 
3.5 Numerous copies of T6ODM in the opium poppy genome 
3.5.1 Sequencing of T6ODM from genomic DNA template 
The NEB LongAmp PCR kit was used initially to amplify T6ODM from HM2 gDNA using 
primers designed with the published cDNA sequence (GenBank accession: GQ500139) and 
matching contigs in the EST database. A ~2 kb PCR product was generated with primers LA 
F1/R2. This PCR product was purified and sequenced. The results indicated the presence of 
three introns, similar to CODM. However, intron 2 was much longer than intron 2 in CODM. 
The sequence information obtained was used to design additional primers for T6ODM 
amplification. 
Primer pairs F2/R2 and LA F4/R3 produced similarly large PCR products with HM2 
gDNA. F2/R2 would amplify the 5’ region of the gene while LA F4/R3 would amplify the 3’ 
end including the third intron and exon 4. PCR products generated with these primer pairs 
were then cloned and sequenced with the Strataclone Blunt PCR cloning kit. Colony PCR 




       T6ODM F2/R2   T6ODM LA F4/R3 
Figure 28. M13 colony PCRs with positive T6ODM F2/R2 and LA F4/R3 transformations. Lane 11 in each 
case contained the control insert supplied with the Strataclone Blunt PCR cloning kit. 
Plasmids from 5 each of the F2/R2 and LA F4/R3-containing colonies were purified and 
sequenced. This led to the confirmation of three introns in T6ODM when the cDNA and gDNA 
sequences were compared in a sequence alignment (Table 14, Figure 31). Furthermore, there 
were numerous polymorphisms between each of the clones and the published T6ODM cDNA 
sequence, indicating that the primers may have amplified members of a multi gene family. In 
addition to SNPs there were small differences in the sizes of introns i.e. insertions or 
deletions evident in the alignment of cloned T6ODM sequence.  
Amplification of full length CODM, T6ODM and DIOX2/PODA gene sequence from HN1 
gDNA template proved difficult with Phusion polymerase. These difficulties were overcome 
with GoTaq polymerase. Although this enzyme has a higher reported error rate than Phusion 
it was decided to use it to amplify as large a portion of these 2-ODD genes as possible. 
Multiple clones for each would be sequenced so any variation would have to be observed 
more than once in order to be considered a genuine SNP and distinguish it from possible 
errors introduced by GoTaq polymerase. T6ODM primer pair F1/R4 generated a 1374 bp PCR 
product with HN1 cDNA template as expected and a >2kb product with HN1 gDNA template. 
These PCR products were cloned with the Strataclone PCR cloning kit. Twelve colonies were 
analysed by colony PCRs (generated from cDNA and gDNA templates) for presence of the 





       HN1 gDNA template    HN1 cDNA template 
Figure 29. M13 colony PCR with positive T6ODM F1/R4 transformations. 
3.5.2 Numerous copies of T6ODM reside in the genome of opium poppy 
The sequences of different clones generated to date were compared 
-  10 with HM2 gDNA as template 
- 6 with HN1 gDNA as template 
- 6 with HN1 cDNA as template 
-  published T6ODM cDNA sequence 
Table 14 lists the bases observed in consensus sequences of clones of T6ODM gDNA and 
cDNA. Patterns of SNPs allowed grouping together of different clones. The results indicate 
that there are at least seven different copies of T6ODM in the genome. To date, however, 
there is only evidence of expression of two of these (cDNA sequences only in the green and 
blue groups). These are the copies that are expressed. The others appear not to be expressed 
as suggested by the lack of cDNA and ESTs and in two cases mutations have accumulated at 
different sites that introduce premature stop codons. If these were expressed they would not 
be functional.  The green group of sequences is an exact match for the published T6ODM 
cDNA sequence (GenBank accession: GQ500139) so it has been assigned T6ODMa. The blue 
set is to be called T6ODMb. PODA/DIOX2 (GenBank accession: GQ500140) was not among 






Table 14. Record of bases observed at different polymorphic sites in sequence alignment of cloned T6ODM sequences.  The numbers in the columns represent the positions of conflict 
in the sequence. This table enabled grouping together of clones. The green group is an 100% match at the nucleotide level to the published T6ODM cDNA sequence. Different primer 
pairs were used in the initial PCRs. A ‘-‘  at the ends indicates portions of the gene not amplified and sequenced. Interior ‘-‘ indicate gaps in the alignment due to insertions/deletions at 



































































































































































































































































































































































































































































































published cDNA G A A A T - - G A - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - G G T G T C G T T - - - - - T G G C T T
HN1_cDNA(12) G A A A T - - G A - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - G G T G T C G G T - - - - - T G G C T T
HN1_cDNA(4) G A A A T - - G A - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - G G T G T C G G T - - - - - T G G C T T
HN1_cDNA(8) G A A A T - - G A - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - G G T G T C G G T - G T G C T G G C T T
HN1_gDNA(11) G A A A T G A G A T A G G C T G A C T C C C T G A C T A - C C A G C T G A C T A - C C A G C G C C G A T C C T T G C T T A T T G G T G T C G G T - G T G C T G G C T T
HN1_gDNA(3) G A A A T G A G A T A G G C T G A C T C C C T G A C T A - C C A G C T G A C T A - C C A G C G C C G A T C C T T G C T T A T T G G T G T C G G T - G T G C T G G C T T
HM2_gDNA(6) G A A A T G A G A T A G G C T G A C T C C C T G A C T A - C C A G C T G A C T A - C C A G C G C C G A T C C T T G C T T A T T G G T - - - - - - - - - - - - - - - - -
HN1_cDNA(2) A C G G C - - A C - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - G G C G A C G T T - - - - - C A G C T G
HN1_cDNA(6) A C G G C - - A C - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - G G C G A C G T T - - - - - C A G C T G
HN1_cDNA(10) A C G G C - - A C - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - G G C G A C G T T - - - - - C A G C T G
HM2_LA_gDNA_(4) - - - - - - - A C C A G A C C G C C T T C C C G G C C G - T T G G C C G G C C G - T T G G C G C A G G C A C T T G T C G A C T G G C G A C G T T G C T G C C A G C T G
HN1_gDNA(7) A C G G C G C A C C A G A C C G C C T T C C C G G C C G - T T G G C C G G C C G - T T G G C G C A G G C A C T T G T C G A T T G G C G A C G T T G C T G C C A G C T G
HM2_gDNA(8) A C G G C G C A C C A G A C C G C C T T C C C G G C C G - T T G G C C G G C C G - T T G G C G C A G G C A C T T G T C G A C T G G C - - - - - - - - - - - - - - - - -
HM2_gDNA(10) A C G G C G C A C C A G A C C G C C T T C C C G G C C G - T T G G C C G G C C G - T T G G C G C A G G C A C T T G T C G A C T G G C - - - - - - - - - - - - - - - - -
HM2_LA_gDNA_(8) - - - - - - - A C C A G A C C G C C T T C C C G G C C G - T T G G C C G G C C G - T T G G C G C A G G C A C T T G T C G A C T G G C G A C G T T G C T G C T G G C T T
HM2_LA_gDNA_(1) - - - - - - - A C C A G A C C G C C T T C C C G G C C G - T T G G C C G G C C G - T T G G C G C A G G C A C T T G T C G A C T G G T G T C G G T - G T G C T G G C T T
HM2_LA_gDNA_(7) - - - - - - - A C C A G A C C G C C T T C C C G G C C G - T T G G C C G G C C G - T T G G C G C A G G C A C T T G T C G A C T G G C G A C T T T - C C T C C G T A A G
HN1_gDNA(1) A C A G C T C G C T C A A A T T C C A C T T T A G A T A - T C A A C T A G A T A - T C A A C T T A A A T - T C G G T C T A T T G C T G A C G T C T C C T T C G G C T G
HN1_gDNA(5) A C A G C T C G C T C A A A T T C C A C T T T A G A T A - T C A A C T A G A T A - T C A A C T T A A A T - T C G G T C T A T T G C T G A C G T C T C C T T C G G C T G
HM2_gDNA(3) A C A G C T C G C T C A A A T T C C A C T T T A G A T A - T C A A C T A G A T A - T C A A C T T A A A T - T C G G T C T A T T G C T - - - - - - - - - - - - - - - - -
HM2_LA_gDNA_(2) - - - - - - - G C T A G C C T G C A T C T C T G G C T A T A C A G A T G G C T A T A C A G A G T A A A T - T C T T T C T G T C T G T A A A T T T A C C T C C G T A A G
HN1_gDNA(9) A C G G C G C G C T A G C C T G C A T C T C T G G C T A T A C A G A T G G C T A T A C A G A G T A A A T - T C T T T C T G T C T G T A A A T T T A C C T C C G T A A G



























3.5.3 Six differences between T6ODMa and T6ODMb at the amino acid level 
The nucleic acid differences between the characterised T6ODMa (Hagel and Facchini, 
2010a) and T6ODMb cloned and sequenced from HM2 gDNA and HN1 cDNA and gDNA are 











Table 15. Nucleic acid differences between T6ODMa and T6ODMb and their effect on amino acid 
sequence. For example G138A refers to position 138 in the multiple sequence alignment. T6ODMa has a G 
at this position while T6ODMb has an A. This results in a corresponding change in amino acid sequence of 
the protein-A to T. ‘=’ means the same amino acid is encoded by the corresponding codon in T6ODMb. The 
PSSM difference and SIFT scores are estimations of the impact of the substitutions on protein function. 
Mutations are predicted to have a severe effect on protein function if PSSM scores are >10 and the SIFT 
scores are <0.05. * Published T6ODMa has a T at this position which ensures an S amino acid is encoded 
rather than an A in T6ODMa from GSK HM2 & HN1.  
Most of the differences between the genes at the nucleotide level do not correspond to 
amino acid differences in the resulting proteins. There are 6 amino acid differences between 
T6ODMa and T6ODMb-A36T, I69V, F80S, E137A, I212K and I364M. The 
differences/substitutions in T6ODMb were not predicted to have impacts on protein function. 
The PARSESNP tool previously available at http://www.proweb.org/parsesnp/ was used to 
analyse the nucleotide polymorphisms (Taylor and Greene, 2003). Position-Specific Scoring 
Matrix (PSSM) scores, based on homology to related sequences, give an indication of the 
importance of certain amino acids. Substitutions can affect the structure of function of the 
resulting protein. PSSM scores of >10 are deleterious. The Sorting Intolerant from Tolerant 
(SIFT) programme similarly determines the severity of missense mutations but assigning a 
score between 0 and 1 to each change from the reference sequence. Here a SIFT score of 








G138A A36T   
A236G P68=   
A237G I69V   
A257G L75=   
T271C F80S -5.8 0.56 
G519A V128=   
A545C E137A   
T1531C V188=   
T1602A I212K   
*G1766T *A266L   
T1914C S292=   
G1992A S318=   
T2130G I364M   
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The differences do not occur in areas of the protein deemed important for substrate 
recognition, 2-oxoglutarate binding and coordinating Fe(II). Therefore, T6ODMb appears to 
be a functional 2-ODD expressed at least in HM2. This has obvious knock on effects for 
reverse genetics in that mutations in both T6ODMa and T6ODMb would have to be found to 
completely block metabolism at thebaine.  
3.5.4 At least two copies of T6ODM are closely linked 
While sequencing and assembly efforts were ongoing long range PCR with genomic DNA 
from HM2 was used in an attempt to amplify potential intergenic regions of 2-ODDs. 
LongAmp primers were designed to amplify out from the respective genes (Figure 30). Each 
primer combination possible was trialled in PCR with HM2 gDNA. It is reported that PCR 
products of up to 30 kb can be obtained using the LongAmp PCR kit. Successful PCR would 
indicate close proximity of a pair of 2-ODDs in the genome. Just one ~7 kb PCR product was 
obtained using primer pair T6ODM_F and DIOX2 (PODA)_R. However, when the PCR product 
was purified and sequenced from both ends it became clear that the result represents a link 
between two copies of T6ODM. It was not possible from the sequence information obtained 
to differentiate which copies of T6ODM were at either end of the PCR product.  
T6ODM    CODM    PODA/DIOX2 
 
 






3.5.5 Section summary 
As with CODM, the results indicate there are multiple copies of T6ODM in the genome. 
However, the nucleic acid and predicted amino acid sequences do differ between copies. 
Furthermore, long range PCR indicated that at least two copies of T6ODM are closely linked.  
3.6 TILLING for induced mutations in T6ODM 
3.6.1 Design of appropriate primers to screen the copy of T6ODM with proven 
activity against thebaine and codeine. 
Initial characterisation of T6ODM revealed that there are multiple copies in the genome 
(Table 14). Likewise, T6ODM-like contigs built from ESTs in our internal poppy EST database 
contained numerous conflicts between ESTs. Unlike with CODM, where there were just two 
polymorphic sites between copies, it would not be possible to screen all copies of T6ODM 
simultaneously. When this was attempted, the numerous polymorphisms created lots of 
different heteroduplexes after PCR. After treatment with the cleavage enzyme, the large 
number of bands on the TILLING gels would frustrate efforts to detect genuine mutations 
(Figure 31). On the other hand only two copies appear to be expressed (Table 11) which 
means that primer design could theoretically take advantage of the polymorphisms to 
selectively amplify a specific copy of T6ODM for screening.  
 
Figure 31. Initial efforts to TILL T6ODM. Differences between copies of T6ODM result in numerous 
common bands on the TILLING gel. 
T6ODMa is an 100% match at the nucleotide level to the previously characterised T6ODM 
(GenBank accession: GQ500139; Hagel and Facchini, 2010a). Because the function of this 
gene is known, it was prioritised for targeting by reverse genetics over the others. A 
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polymorphism at position 708 in the alignment between different copies of T6ODM (Table 
14), whereby T6ODMa has a ‘G’ and T6ODMb and others have either an ‘A’ or ‘C’, was 
exploited to design a primer (R27) for the targeted amplification of T6ODMa only in 
touchdown PCR. When used in conjunction with primer F14, exons 1 and 2 of T6ODMa would 
be amplified generating a 626 bp PCR product (Figure 32a). It was important to target exon 2 
because it encodes for a number of tryptophans, the codons of which are quite easily changed 
by EMS to stop codons.  





Figure 32. a) Region of T6ODMa screened for mutations using primer pair F14/R27. b) Pool plate 8 
T6ODMa screen and the rescreen of some of the mutations found to determine the individual in the pool 
carrying the T6ODMa mutation. 
Figure 32b shows the Fragment Analyser gel for pool plate 8 T6ODMa PCR products. A 
number of mutations were identified on this pool plate. The PCR product was cut into 
fragments, the sum of the sizes of which add up to 626 bp. The process was repeated for all 
twelve pool plates (Appendix C). Any potential mutations found were confirmed in the 
rescreen e.g. for wells A12, E10, F03 and G06 of pool plate 8 shown here. Unlike with CODM, 
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where multiple copies were amplified in PCR with the TILLING primers, only T6ODMa was 
amplified with primer pair F14/R27. For the rescreens then, the PCR needed to be spiked 
with wild type HM2 DNA to ensure heteroduplex formation potential homozygous mutants. 
In this way the individual in the pool of four carrying the mutation could be identified. 
3.6.2.1 Summary of T6ODM mutations detected in reverse genetic screen 
Table 16 provides a summary of the T6ODMa mutations found in the reverse genetic 
screen of 4146 M2 plants. Appendix C has the full record of the fragments detected in the 
initial screen and the follow up rescreen as well as the actual TILLING gel images. There were 
some PCR failures, but these were not repeated as satisfactory results were achieved in the 
initial screen. 
Just nine T6ODMa mutations were recovered. However, importantly two of these were 
nonsense mutations-Q141* and W145*. Three mutations were silent and one was in an 
intron leaving three individuals with two different missense mutations. A lower number of 
mutations was expected because of the shorter T6ODMa amplicon used. Overall the 
estimated mutation frequency (1 per 288 kb) is similar to that estimated from the recovery of 





Pool plate Well 
Screening Rescreening 





of mutant Population Fragment 1 (bp) Fragment 2 (bp) Fragment 1 (bp) Fragment 2 (bp) 
One 
- - - - - - - - - - - - - 
Two 
- - - - - - - - - - - - - 
Three 
- - - - - - - - - - - - - 
Four 
- - - - - - - - - - - - - 
Five 
- - - - - - - - - - - - - 
Six 
- - - - - - - - - - - - - 
Seven 
B11 316 611 161 450 102690 102691 102692 102693 D-10025 E11-H11 Q141* S-102693 B2 
Eight 
A12 58 612 103 509 103087 103088 103089 103090 D-10029 A12-D12 H162Y S-103090 B2 
C9 43 609 147 468 103160 103161 103162 103163 D-10030 A9-D9 A146T S-103161 B2 




F3 563 606 181 438 103257 103258 103259 103260 D-10031 E3-H3 G134G silent - C1 
G6 107 611 115 490 103397 103398 103399 103402 D-10032 A6-D6 
L156L silent - C1 
G8 167 609 156 473 103419 103420 103421 103422 D-10032 A8-D8 A146T S-103421 C1 
Nine 
- - - - - - - - - - - - - 
Ten 
D12 504 565 283 345 103991 103992 103997 103999 D-10036 E12-H12 Intron 1 - B3 
Eleven 
A12 219 609 151 468 104549 104550 104551 104553 D-10039 A12-D12 W145* S-104553 B3 
Twelve 
- - - - - - - - - - - - - 
Table 16. Summary of identified T6ODMa mutations in the HM2 EMS mutagenised population. Individuals in the pool of four carrying the mutation are shaded. The shaded 
mutations were prioritised for further work.
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3.6.2.2 A polymorphism in intron 1 of T6ODMa is present in a high thebaine forward 
screen line and commercial thebaine lines 
The same EcoTILLING strategy used previously (Figure 19) was employed to check 
whether there are any differences in the nucleotide sequence of T6ODM in high thebaine 
forward screen lines and WT HM2 and HN3 from which they were derived. These lines had 
undergone numerous rounds of selfing in the field in Tasmania. Capsules of these lines 
accumulate substantially more thebaine and oripavine than HM2 and HN3. The seed batches 
were sent to York for DNA extraction and analysis. DNA from the resulting seedlings was 
spiked with equal amounts of wild type DNA prior to PCR. Differences in sequence between 
wild type and mutant T6ODM would result in heteroduplexes and cleavage.  
Figure 33a shows the discovery of a T6ODM polymorphism in all lanes where successful 
amplification using template DNA of plants derived from S-114249 (MAS 2150 B C) occurred. 
This is a high thebaine forward screen line derived from HM2 mutagenesis. The same 
polymorphism was identified in 5 of the 8 HT6 plants tested in Figure 33b. No 
polymorphisms were detected in the other two thebaine forward screen lines derived from 
HM2 mutagenesis or the four noscapine-free thebaine/oripavine only forward screen lines 
derived from HN3 mutagenesis. Just 626 bp of one copy of T6ODM was screened for 
mutations (Figure 32) so these lines and the other two other high thebaine lines from HM2 
















a) D-10112 T6ODM EcoTILL 
 
b) D-10836 T6ODM EcoTILL  
 
 









GSK capsule data 
Grown in field in Tasmania 
(%DW) 
CNAP capsule data 





























16.1 1.7 4.0 78.2 47.9 3.8 5.0 39.3 2.9 - - 
S-125001 N/A - - - - - - 18.0 - 79.0 - - - 
S-125002 N/A - - - - - - 24.0 - 72.0 - - - 
S-125003 N/A - - - - - - 25.0 - 72.0 - - - 
S-125004 N/A - - - - - - 27.0 - 70.0 - - - 
HM2 WT N/A - - - - 85.8 0.3 5.2 3.4 4.3 N/A N/A 
Figure 33. Identification of a polymorphism in intron 1 of T6ODMa in a) a high thebaine forward screen 
line and b) a GSK commercial thebaine variety, HT6 (5 of 8 plants tested-lanes 14, 26, 38, 62 and 74; 
absent in lanes 2, 50 and 86). 
Sequencing T6ODMa of plants with the polymorphism revealed it is not in the coding 
sequence, but rather resides in intron 1 of T6ODM. It is unlikely that it was EMS induced as 
the polymorphism results in a change from T (HM2) to A (S-114249) at this position (Greene 
et al., 2003). Furthermore, the polymorphism (Tint) is present in all the commercial thebaine 
varieties from which DNA was available (HT1, HT4, HT5, HT6). It is probable that this allele 
was transferred to ancestors of S-114249 by a commercial T line in the field and may not 
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necessarily indicate a seed mix up at some point. At the time the polymorphism was 
discovered all HT1, HT4, HT5 and S-114249 individuals genotyped (3 of each) were 
homozygous for the polymorphism indicating that it is fixed. Subsequent work revealed that 
the polymorphism is not fixed both in HT5 and HT6 (Figure 34).  
 
 
Figure 34. Phenotypes of HT5 and HT6 commercial thebaine lines grown as controls during 
Tasmanian field trials. 
There are two distinct phenotypes in these lines-a morphine-thebaine-oripavine 
phenotype associated with the Tint polymorphism and a morphine-free thebaine-oripavine 
only phenotype with no detectable T6ODM polymorphisms. The latter has a complete block 
of metabolism at thebaine but the molecular basis of this phenotype is unknown. As 
knockouts of T6ODMa (W145* and Q141*) do not result in such complete blocks, presumably 
a regulator of T6ODM or a transporter of thebaine is affected. The Tint polymorphism could 
be used to assess future lines for homogeneity. 
Within an intron, a donor site (5’ end), a branch site (near the 3’ end) and an acceptor site 
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Tint homo T/O only 
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sequences, respectively. The branchpoint includes an adenine residue, which performs a 
nucleophilic attack on the donor site during splicing forming the lariat intermediate. In the 
second step the 3’OH of the released 5’ exon then performs a nucleophilic attack at the 
acceptor site, thus joining the exons and releasing the intron lariat. Netgene2 was used to 
predict whether the polymorphism would have an effect on splicing (Hebsgaard et al., 1996).  
Branch points, direct strand ----------------------------    
acceptor     branch 
pos 5'->3'  pos 5'->3'        strand    score     5'                    
3'        
   402          374             +       -2.25       TTAGCTAGTGAATCTTACTT 
 
Figure 35. Netgene2 analysis of intron 1 of T6ODMa. The T marked in bold (in commercial morphine 
and noscapine lines) is the base which is changed to A in commercial thebaine lines and the high T 
forward screen line S-114249. 
The analysis predicted the branch point in HM2 T6ODM to be the A in italics. The T in 
bold, which is changed to A in the GSK commercial thebaine lines and S-114249, is situated 
five bases upstream. It is possible that this substitution disrupts splicing of intron 1 during 
pre mRNA processing. Perhaps the wrong A is used in the nucleophilic attack on the donor 
site. Alternatively the change in sequence may affect recruitment of elements of the 
spliceosome, the large RNA-protein complex that catalyses splicing. Splicing factor 1 binds to 
the intron branch point sequence prior to displacement by the U2 small nuclear 
ribonucleoprotein (snRNP).  
A similar T to A mutation in the branch point consensus of the lecithin: cholesterol 
acyltransferase (LCAT) gene in humans is the cause of fish eye disease, a rare disorder 
characterised by low high-density lipoprotein (HDL) and dense corneal opacities (Li et al., 
1998). LCAT is involved in the metabolism of HDL. The authors claimed that the mutation 
affected the interaction of U2 snRNA to the branch point. Binding of U2 snRNA enables 
bulging of the A for splicing to begin. The result of this mutation was a disruption of splicing 
and an RT-PCR demonstration of intron 4 retention. The LCAT protein was not detected. It 
may be that secretion was affected by the altered protein or the translation product was 
rapidly degraded.  
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cDNA of high thebaine lines were tested for retention of intron 1 of T6ODMa but no 
evidence could be found. The intron seems to be spliced out, unlike in the example above. It 
may be that the polymorphism affects mRNA stability in some way or that the polymorphism 
is merely associated with a high thebaine phenotype. For this reason, the polymorphism was 
tracked in crosses (Chapter 5). It was later proved to be an effective tool in predicting 
thebaine content among siblings in which the polymorphism was segregating (Appendix I-
X051, S-186678). There are clear differences in thebaine yields of plants lacking the 
polymorphism (low thebaine), heterozygotes and homozygotes (highest thebaine).  
3.6.2.3 Selection of best candidates from TILLING screen for producing heritable 
phenotypic changes 
Q141* and W145* mutations should result in a truncated protein unable to catalyse O-
demethylation of thebaine and oripavine. Further to the two nonsense mutations, two A146T 
mutants were also identified. These had the potential to be interesting as the substitution lies 
in an area of T6ODMa thought to be important for substrate recognition (Hagel and Facchini, 
2010a; Runguphan et al., 2012). T6ODM and PODA have an A at this position, while CODM 
has a T. PSSM and SNAP analysis did not predict a deleterious effect for this missense 
mutation, but because of its potential role in substrate recognition it was brought forward 
together with the two nonsense mutations for further work.  
3.6.3 Section summary 
By exploiting a polymorphism between T6ODMa (the identified 2-ODD with 
demonstrated thebaine demethylation activity) and other copies, primers were designed to 
specifically amplify and use this gene for TILLING. Nonsense mutations were identified in the 
TILLING populations. Furthermore, a promising intron polymorphism was identified in lines 




3.7 Recovery of mutations in M2 siblings and assessment for phenotypic 
changes 
3.7.1 Recovery of mutations in M2 siblings 
Recovery of T6ODMa mutations in M2 siblings was achieved by both TILLING and AS-PCR 
(Appendix C). Both approaches provided similar results in that the recovery rate for each 
mutation was low i.e. just two Q141* mutants were recovered among 38 siblings and just one 
A146T mutant was recovered among 15 siblings (Table 17).  
M2 seed batch id T6ODMa 
polymorphism 
Seedling_id Zygosity M3 seed batch id 
sown 
S-104553 W145* Sd-833305 Homozygous S-123361 
S-104553 W145* Sd-833306 Heterozygous - 
S-104553 W145* Sd-833308 Heterozygous - 
S-104553 W145* Sd-833316 Heterozygous - 
S-102693 Q141* Sd-833291 Heterozygous S-123349 
S-102693 Q141* Sd-833298 Heterozygous - 
S-103421 A146T Sd-833331 Homozygous S-123374* 
S-103161 A146T Sd-833350 Heterozygous S-124115 
Table 17. Genotypes of M2 seedlings containing T6ODMa mutations. * indicates the M3 seed did not 
germinate.  
Zygosity was determined by sequencing (Figure 36). M3 seed was collected and sown.   
     
Sd-833305 example of W145* homozygote  Sd-833306 example of W145* heterozygote 
Figure 36. Sequencing chromatograms showing the difference between a W145* homozygote and 
heterozygote. The third base in the codon for tryptophan is changed to A by the mutation, causing a 
premature stop codon (TGA). In the heterozygote there are signals for equal magnitude for the wild type 





3.7.2 Analysis of M2 capsules-W145* mutant shows 5 fold increase in thebaine 
over HM2 
As mentioned above the W145* and Q141* T6ODMa mutations were segregating among 
their respective siblings. One W145* homozygote was recovered while two Q141* 
heterozygotes were identified and prioritised for selfing to produce M3 seed. M2 capsules 
were phenotyped (Figure 37). Although the numbers in each class are low, the results suggest 
that thebaine accumulation in the capsules is increased in T6ODMa W145* mutants. There is 
certainly a marked difference in thebaine content of the W145* homozygote (11 μg/mg dw 
(no SD as it was a single plant); 20% of total alkaloids) with that of siblings lacking the 
mutation (3.2±3.8 μg/mg dw; 7% of total alkaloids) and HM2 (1.4±1.5 μg/mg dw; 3% of 
total alkaloids). The three heterozygotes have an intermediate level of thebaine with a mean 
of 4.1±2.9 μg/mg dw (13% of total alkaloids). There is also a slight increase in the 
proportion of oripavine compared to HM2 (Appendix C). 
 
Figure 37. Thebaine content in the capsules of T6ODMa mutants and siblings with WT T6ODMa. 
3.7.3 Analysis of M3 capsules-Increased thebaine in W145* homozygotes 
Seed collected from the homozygous W145* M2 was brought forward to M3. All the 
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mutations were segregating in M3. Genotyping was completed using AS-PCR with 
visualisation of AS-PCR products on the Fragment Analyser.  
 
Figure 38. T6ODM M3 plants homozygous for T6ODM knockout mutations have higher thebaine and 
oripavine contents in their capsules than heterozygous and WT siblings and a commercial morphine line 
(HM6). However the relative amounts of these two alkaloids were lower than that in a current commercial 
thebaine line (HT5). The Q141* mutation was segregating among M3s. All W145* M3s were homozygous 
and displayed a partial block of metabolism at thebaine and oripavine. These are alkaloid profiles of 
single plants and not the mean for a line. Therefore error bars were not included. 
The alkaloid content of the capsules of the various mutant classes is displayed in Figure 
38. None of the mutants had thebaine and oripavine levels as high as the commercial 
thebaine line, HT5 (the molecular basis of which is unclear). However, there was 
substantially more thebaine in the capsules of two of the Q141* homozygotes (mean of all 
four was 4.0±3.8 μg/mg dw; 8% of total alkaloids) and all of the W145* homozygotes 
(5.7±3.6 μg/mg dw; 13% of total alkaloids) than commercial morphine lines HM2 
(previously analysed in 3.8.2) and HM6 (1.8±2.3 μg/mg dw; 5% of total alkaloids). The two 
A146T homozygotes identified in M3 had low total alkaloid levels and a small proportion of 
thebaine (1.9±0.6 μg/mg dw; 9% of total alkaloids). It was decided to only continue with the 
knockout mutations as these displayed the intended changes in phenotype. Similar to CODM 
 
136  
nonsense mutants, knockouts of T6ODMa resulted in plants where the predominant alkaloid 
was still morphine. The mutations led to partial blocks at thebaine and oripavine. Additional 
copies of T6ODM may continue to O-demethylate thebaine and oripavine at levels similar to 
wild type HM2 or its successor HM6.  
3.7.4 Section summary 
The T6ODMa nonsense mutations resulted in partial blocks of metabolism at thebaine 
and oripavine among homozygous M3 individuals.  
3.8 Discussion 
EMS mutagenesis is a well established approach to inducing genetic variation and it 
causes a high density of irreversible point mutations (Henikoff and Comai, 2003).  
Mutagenesis of seed from the morphine line HM2 provided large mutant populations for 
analysis. As well as leading to lines with interesting metabolite profiles identified by forward 
screens, a proportion of the M2 lines were used in reverse genetic screens. Based on the 
recovery of T6ODM and CODM mutations, the estimated mutation frequencies were 1 per 
288 kb and 1 per 395 kb, respectively. This compares favourably with estimated mutation 
frequencies based on results with other genes targeted previously (data not shown). With a 
genome size of 3724 Mbp, each M2 line could therefore contain in the region of 10,000 EMS 
induced mutations. Any line with a desired mutation would need to undergo numerous 
rounds of backcrosses to remove the undesired mutations. Mutant plants often had stunted 
growth, altered leaf shape, small capsules and flowered early. Some M2s even had albino 
sections, presumably resulting from mutations causing defects in chlorophyll production. 
Mutagenesis with EMS, then, provided a large population of plants with heritable changes in 
nucleotide sequence which could be detected in target genes by TILLING. 
To our knowledge, a reverse genetics approach has yet to be reported with mutagenised 
populations of opium poppy. Mutation detection was carried out using Advanced Analytical’s 
Fragment Analyser. Although this system has been sold by Advanced Analytical for a number 
of years, there is yet to be an example of its utilisation in TILLING in the literature.  
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CODMa and T6ODMa represent exact matches to the respective 2-ODD genes shown to be 
involved in O-demethylation steps in the final stages of morphine biosynthesis in 2010 (Hagel 
and Facchini, 2010a). Additional copies of both of these genes have been detected in gDNA of 
GSK commercial varieties. Copies of CODM have identical amino acid sequences and have just 
two polymorphic sites at the nucleotide level. In contrast there seems to be many more 
copies of T6ODM in the genome. Copies of T6ODM with minor amino acid differences to 
T6ODMa may have different activities or altered substrate preferences. Recombinant 
T6ODMa exhibited only trace to relatively minor activity with protopine alkaloids such as 
cryptopine, protopine and allocryptopine (Farrow and Facchini, 2013). However, these 
alkaloids accumulated in T6ODM VIGS silenced plants against expectations. VIGS would have 
silenced all copies of T6ODM including those with potential preferences for protopine 
alkaloids.  
Sequencing CODM-containing BACs confirmed the presence of multiple copies of CODM 
and suggested that at least some of the copies are physically linked. Other genes involved in 
morphine biosynthesis were not detected on the sequence contigs analysed and so genes 
involved in morphine biosynthesis are not likely to be clustered in a manner similar to that 
with noscapine (Winzer et al., 2012). Nevertheless, evidence of duplication of genes involved 
in the metabolism of an important plant secondary metabolite was not unexpected. Gene 
duplications drive the recruitment of genes for secondary metabolism. In contrast to primary 
metabolism in which the most stable and functional enzymes are maintained, enzymes of 
secondary metabolism may have emerged through gene duplication and subsequent 
mutation accumulation altering substrate specificities or reaction activation barriers (Weng 
et al., 2012). Gene copies are modified over evolutionary time to create new genes in the 
family with different specificities and expression patterns adapted to the needs of the plant 
(Ober, 2005). At least one copy may be allowed to accumulate mutations leading to greater 
mechanistic elasticity and neofunctionalisation before inactivating mutations are introduced. 
Duplicated genes are often in tandem repeats, forming clusters within the plant genome. 
Tandem repeats of CODM were not observed but the results did show at least two copies of 
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CODMc are within 150kb of each other. The inability to combine mutations in CODMa/c and 
CODMb through crosses further suggests close physical linkage of the CODM copies. The 
precise arrangement and organisation is subject of future work. Chromosome walking efforts 
may close the gaps and confirm the architecture of the region of the genome with CODM. It 
would be interesting to see whether there are any other genes involved in the biosynthesis or 
regulation of morphine biosynthesis.  
Various classes of transposable elements were present in the BACs sequenced. These 
complicate assembly of genomic sequence information, as sequence reads map with equal 
probability to multiple positions in the reference (Morrell et al., 2012). It is therefore 
understandable that most of the crop genomes sequenced to date have all been relatively 
small-pepper, tobacco and bread wheat being rare examples of genomes sequenced larger 
than opium poppy (3724 Mbp) and the average angiosperm genome (6000 Mbp). 
Transposable element induced null mutations are the most common cause of induced 
phenotypic changes and have been selected for many times in plant domestication. Insertions 
into repressors or enhancers can eliminate positive or negative regulatory functions e.g. 
insertion of Mutator elements into intron 1 of the knotted1 gene leads to ectopic expression 
of this gene in maize leaves (Greene et al., 1994). Transposition into the 5’ end of plant genes 
could also potentially introduce new regulatory information and alter gene expression. 
Transposable element activity is also thought to be involved in gene duplication and 
subfunctionalisation e.g. rearrangements at the r1 locus in maize caused by aberrant 
transposition of a CACTA element caused changes in tissue specificity of duplicated gene 
copies (Walker et al., 1995). Transposable elements are highly sensitive to various abiotic 
and biotic stresses and so insertion upstream of host genes can confer stress responsiveness 
e.g. insertion of mPing elements conferred salt or cold inducibility in the EG4 cultivar of rice 
(Naito et al., 2009). Aberrant transposition of Class II elements can lead to deletions, 
inversions and translocations (Lisch, 2013). Movement of genes to a new chromosomal 
context can alter their regulation. Capture of gene fragments during movement can also 
impact on the evolution of new genes and so as well as impacting on genetic variation, 
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transposable elements have important roles in plant evolution. Of course at the moment 
there is limited evidence for gene duplication and repetitive elements surrounding these 
genes and it is not clear if the transposable elements are enriched in this area compared to 
other areas of the poppy genome. However, it is intriguing to hypothesise that transposable 
elements could possibly play a role in duplication events and in the regulation of the various 
copies of T6ODM and CODM. 
Using RNA-seq over 50% of duplicated genes in soybean (which has undergone two 
separate polyploidy events 13 and 59mya) were shown to be differentially expressed and 
thus underwent expression subfunctionalisation (Roulin et al., 2013). Only a small fraction of 
duplicated genes were nonfunctionalised or neofunctionalised and overall the results 
suggested that polyploidy in soybean had impacts mainly at the regulatory level. At the 
beginning of this project only the publicly deposited sequences were available as targets for 
TILLING (GenBank accessions Q500141; GQ500139). During the validation of these targets a 
picture of multiple copies began to emerge, the completion of which goes beyond the scope of 
this thesis. Even though there are multiple copies of CODM and T6ODM in the genome, it is 
not clear which copies are most highly expressed and active in morphine biosynthesis. Also of 
the seven T6ODM copies sequenced there is only evidence of expression of two of these. 
Therefore, it was reasonable to proceed with targeting of these genes for reverse genetics 
with the focus being the characterised 2-ODDs, CODMa and T6ODMa (Hagel and Facchini, 
2010a). Disruptions in CODM would increase yields of codeine, while disruption in T6ODM 
activities would increase yields of its substrates thebaine and oripavine. Even a partial block 
of metabolism to morphine resulting from a mutation in one of the target genes could be 
useful in efforts to breed new varieties of poppy with altered metabolite profiles.  
Nonsense mutations were detected for both CODM and T6ODM in the reverse genetic 
screens which are highly likely to render the resulting proteins non-functional. These 
resulted in increases in codeine and thebaine/oripavine, respectively, as expected based on 
the substrate preferences of the enzymes (Figure 7). Despite identifying putative knockout 
mutations, complete blocks of the metabolism at the respective biosynthetic steps were not 
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observed and the increase in codeine and thebaine/oripavine, respectively, were relatively 
modest.  This can be explained by functional redundancy conferred by the additional non-
mutated copies of the gene. Virus induced gene silencing had resulted in much larger 
increases in the relative proportion of these compounds (Hagel and Facchini, 2010a). 
However, it is probable that the silencing construct used would have silenced more than one 
copy of the respective genes as it is now clear that there are a number of copies of each of 
these 2-ODD genes in the genome. More substantial blocks of metabolism at codeine or 
thebaine would require a plant with all copies of the relevant gene disrupted. This could be 
achieved without the use of genetic modification by crosses between individual mutants or 
by successive mutagenesis steps.  
Two nonsense mutations were found in CODM among the TILLING population. The 
crossing strategy failed when trying to produce plants homozygous for both the CODMa/c 
W261* and CODMb Q254* mutations. This suggested close linkage of the copies in the 
genome and much larger F2 populations would be required to identify recombinants. Given 
that two copies are contained on the same BAC (within about 150 kb) this approach could 
prove infeasible even if mutations in all copies known so far could be identified. As an 
alternative to crosses, seed from the CODMb Q254* mutant line was bulked up for further 
EMS mutagenesis in an effort to introduce mutations into additionaly copies of CODM. M2 
seedlings from this new mutant population would again be assessed in forward (Tasmanian 
field trials, section 5.6.3) and reverse genetic screens (to be completed).  
EMS induced CODM E193K and R158K mutations were detected in high codeine forward 
screen lines taken forward from the initial mutagenesis. Genealogy records indicate that 
codeine content may have increased when these induced mutations were brought to the 
homozygous state by selection. Use of these lines in crosses and comparison between 
homozygotes, heterozygotes and wild types will clarify whether this is the case. It is not clear 
if either, or both, mutation(s) contribute to the phenotype or if they are merely linked to a 
causative mutation. The E193K mutation may reside in CODMa (Hagel and Facchini, 2010a) 
and as such may represent the most expressed or active copy of CODM. The W261* and 
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E301K mutations identified in the reverse genetic screen may be in less active copies of 
CODM. Alternatively, there may be no difference between the copies and both the E193K and 
R158K mutations (or an as yet unidentified linked mutation) have the effect of reducing or 
altering CODM activity in the high codeine forward screen lines.  
Two nonsense mutations were also found in T6ODMa. For T6ODM so far only T6ODMa 
was screened due to its proven role in thebaine and oripavine O-demethylation and the 
inability to design primers to specifically amplify T6ODMb. Again these resulted in partial 
blocks of metabolism at thebaine indicating that there a multiple active copies of T6ODM in 
the genome that can demethylate thebaine and oripavine in plants homozygous for nonsense 
mutations in T6ODMa. Evidence for the presence of a second expressed copy of T6ODM was 
found in an in house EST library. A complete block at thebaine, like that observed with VIGS 
(Hagel and Facchini, 2010a; Wijekoon and Facchini, 2012), would require disruption of all 
active copies of T6ODM. An alternative strategy could be to use W145* material (homozygous 
seed has been bulked up) in another round of EMS mutagenesis in an effort to disrupt 
T6ODMb. It is also not clear what the molecular basis of the high thebaine phenotype in HT5 
is. Introduction of the nonsense mutations into already high thebaine lines may further 
impact on flux to morphine and increase yields of thebaine and oripavine.  
Because knockouts of T6ODMa provide only modest increases in thebaine, the Tint 
polymorphism detected in this gene in various high thebaine lines cannot in itself be the 
reason for the phenotype. Nevertheless the potential for the Tint polymorphism to affect 
splicing meant that this marker was included in those chosen to be followed in crosses set up 
between different chemotypes. Even if the polymorphism is not causative of the high 
thebaine phenotypes in commercial thebaine lines there is the potential that it is linked to a 
polymorphism that is. 
It is worth re-emphasising that only a small portion of T6ODMa had been screened for 
polymorphisms. With more genomic sequence information i.e. upstream and downstream 
sequence that may in future be gleaned from sequencing T6ODM-containing BACs, 
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differences between copies of T6ODM could be exploited to design primers for TILLING 
different portions of the gene.  
For future work, identifying and targeting of regulators of 2-ODD genes or transporters 
of metabolites may be better targets for reverse genetics. In particular, the mechanism by 
which thebaine is transported from the sieve elements to the laticifers should be studied 
further. If a transporter is involved then this would be an ideal target for reverse genetics as a 
disruption could cause a more extensive block at thebaine.
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Chapter 4- Plant-wide impacts of selected alleles  
4.1 Introduction 
To assess the impact of CODM and T6ODM mutations on the accumulation of alkaloids in 
the plant an experiment was set up whereby plants from five mutant lines and wild type HM2 
were sampled for alkaloids at different stages during their development. Also, a section of 
stem (approximately 1 inch in length) was taken immediately below the flower/capsule and 
used for RNA extraction. The latex that exuded was used for metabolite analysis. Likewise, 
the roots of the same plant were used for both RNA extraction and metabolite analysis. 
Because sampling involved sacrificing a plant, results for different growth stages are for 
siblings rather than a timecourse of a single plant. 
Stem and root material was collected from early seedlings (es), plants at the hook stage 
(bud turned upside down, stem and bud take on a characteristic ‘hook’ shape; some examples 
in Figure 1) prior to flowering (hk), flowering plants (flw) and maturing plants 10-14 days 
post flowering after petal fall (mat). Latex was collected from hk, flw and mat plants only as it 
was not present in the young seedlings.  
4.2 Phenotypes of the lines used in the experiment 
Five mutant lines were included in the experiment along with wild type morphine variety, 
HM2, from which the mutants were originally derived (Table 18). Three lines (W261*, Q254* 
and W145*) were chosen as they contain knockout mutations for CODM or T6ODM. Previous 
experiments have indicated that the W261* and Q254* CODM mutations result in modest 
increases in codeine content of mature capsules (Figure 26). Likewise the W145* T6ODM 
mutation results in an increase in thebaine and oripavine content of mature capsules (Figure 
38). The other two lines used in the experiment, E193K/R158K and HighT, came out of 
forward screens conducted by GSK in Tasmania (high codeine and high thebaine phenotypes, 
respectively). They have been repeatedly selfed over a number of years and their high 
codeine and high thebaine phenotypes are now stable. TILLING of DNA from these lines 
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identified CODM (Figure 20) and T6ODM (Figure 33) polymorphisms, which may cause or be 
linked to causes of their phenotypes.  
4.2.1 Evaluation of the alkaloid content of capsules of siblings grown to maturity 
Figure 39 shows the breakdown of the alkaloid content in capsules of the lines used in the 
study. Eight mature dried capsules were ground and analysed for each line. The results 
broadly agree with previous results obtained from these lines when plants were grown on 
soil, with the exception that codeine content of HM2 was higher than that seen before. Higher 
codeine content may possibly indicate a stressed plant. The reason the plants were grown on 
a 50:50 mix of silica sand and Terragreen as opposed to soil was to ensure that roots could be 
sampled without the damage that removing soil would entail. Washing the root system under 
a running tap was sufficient to remove the silica sand quickly and ensure the recovered root 
was flash frozen immediately before alkaloid and RNA extractions. The highest codeine was 
seen with the high codeine forward screen line with CODM mutant E193K/R158K 
polymorphisms. The W145* mutants displayed a partial block at T6ODM with levels of 
thebaine and oripavine are higher than in HM2. The HighT fwd line by contrast has a more 
substantial block at T6ODM whereby thebaine and oripavine are much more abundant at the 
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MUTS 437 G→ 
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Selfed 
MUB 1013 B→ (Tas 
10/11) 
Selfed 








   CODMb F271L 
T6ODMa intron 
polymorphism 
Table 18. Origins of seed batches (marked in bold) used to produce plants for the experiment to analyse the impact of CODM and T6ODM mutations in mutant lines. All five 
mutant lines came out of EMS mutagenesis of a GSK commercial morphine variety, HM2. The population ids refer to different EMS exposures and treatment dates of HM2 seed (Table 
1).“S” numbers refer to York assigned seed batch ids with the resulting plants (“Sd” numbers) grown in York. Plants grown in Tasmania are indicated (Tas & growing season) along 
with the plot number and plant id. The W261*, Q254* and W145* mutations were identified in reverse genetic screens in York. These were selfed until homozygous plants were 
identified in M2 or M3. The high codeine (E193K/R158K) and high thebaine (HighT) lines came out of a forward screen in Tasmania. In 2013, seed was shipped to York where CODM 




Figure 39. Mean amount  (% dw) of each of the 15 most abundant alkaloids in the dried capsules. The 
figures are an average of 8 biological replicates with each having 3 technical replicates.  These are siblings 
of the plants sacrificed and sampled for root and stem tissue and stem latex i.e. they were allowed to grow 
to maturity before dried capsules were harvested for analysis.  HM2 is the wild type morphine (3.41% dw) 
line from which the mutants were derived. The E193K and R158K mutations are in CODMa/c and CODMb, 
respectively. The W261* and Q254* nonsense mutations are in CODMa/c and CODMb, respectively. The 
W145* nonsense mutation and the Tint polymorphism are in T6ODMa. 
4.2.2 Evaluation of latex compositions of hk, flw and mat plants 
Previous work in the lab has shown that latex analysis of plants post flowering (mat; 2-3 days 
after petal fall) is a useful indicator of what the final phenotype will be in the capsules.  
 shows the latex alkaloid composition of each of the six lines at different development 
stages-hook stage, flowering and maturing plants. For each line, approximately 90% of the 
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Figure 40. Proportion of each of the major alkaloids of the latex during development (hk= hook stage, 
flw=flowering and mat=maturing stages) in HM2 and the mutant lines. The top ten most abundant 
identifiable alkaloids are shown. Metabolite figures are an average of 3 technical replicates for each 
sample. Columns are not stacked to 100% because of the presence of unknown alkaloids and trace levels 
of known alkaloids.  
In HM2, the proportion of codeine is higher after flowering. This appears to be at the 
expense of thebaine rather than morphine. This would indicate metabolism of thebaine to 
morphine through neopinone, codeinone and codeine. Typically, in mature capsules levels of 
each of codeine and thebaine are much reduced to around 3% of the total alkaloid content as 
the plant converts these alkaloids to the most abundant alkaloid morphine.  
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Surprisingly, in the high codeine forward screen line (E193K/R158K) the proportion of 
codeine was found to be higher than HM2 only in maturing plants. However, the proportion 
of thebaine is higher across all stages and this is at the expense of morphine. Therefore in at 
the hook and flowering stages the metabolic block may be at demethylation of thebaine to 
oripavine. In more mature plants, the block may be affecting demethylation of codeine to 
morphine, resulting in the final high codeine phenotypes. Alternatively, at the hook and 
flowering stage a partial block of the demethylation of  thebaine to neopinone could explain 
the higher levels of thebaine. As the capsule matures this block may be released and the block 
affecting the demethylation of codeine to morphine becomes observable in elevated codeine 
levels. 
Phenotypes reminiscent of HM2 are seen in the latex of W261* plants. Codeine levels are 
slightly increased at the expense of thebaine while morphine is still the predominant alkaloid 
in the latex. The latex profiles of the other CODM mutant line, Q254*, are broadly similar to 
that of HM2. However, this line has been shown previously (Figure 26) to have up to 3x more 
codeine in the mature capsules of plants grown on soil, which suggests that the CODMb may 
act at a later stage to convert any remaining codeine to morphine.  
The T6ODM W145* mutant displays the predicted phenotype clearly. A block at T6ODM 
should result in a larger proportion of thebaine and oripavine and this is observed in the 
latex samples of plants at the hook, flowering and maturing stages. The effect is perhaps most 
evident with increases in the proportion of oripavine, which would indicate a disruption in 
the conversion of oripavine to morphinone and on to morphine. Additional functional copies 
of T6ODM would allow flux through the pathway to morphine when T6ODMa is knocked out. 
However, lack of functional T6ODMa protein is enough to create a metabolic bottleneck 
resulting in the higher proportions of thebaine and oripavine in the latex of T6ODMa W145* 
mutant compared to HM2 and the CODM mutant lines.  
The most striking phenotypes were observed with the HighT forward screen line latex. In 
this line there is a clear change in phenotypes between plants at hook and flowering stages. 
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The time period between these stages is typically 3-4 days but in that time there is a 
pronounced change in alkaloid composition of the latex. At hook stage the latex is not too 
dissimilar to HM2. However, flowering appears to be a trigger for a large increase in the 
proportions of thebaine and oripavine at the expense of morphine. The fact that these plants 
produce morphine in the early stages suggests there is not a complete general block at 
T6ODM. However, this block appears to become stronger post flowering leading to increased 
levels of thebaine and oripavine. This line contains the T6ODMa intron polymorphism also 
present in GSK commercial thebaine varieties (Figure 33). This T6ODMa polymorphism 
cannot in itself be the cause of the block at T6ODM because a knockout in this gene (W145*) 
only provides a partial block at T6ODM. Unless the polymorphism affects splicing (no 
evidence found as yet) or mRNA stability and results in a general reduction in T6ODM protein 
synthesis, there must be another factor involved in determining the high thebaine phenotype. 
The fact that there is a marked change in phenotype between plants at the hook and 
flowering stages suggests that a regulator that becomes active at flowering may be involved.  
4.3 Morphinan gene expression 
4.3.1 CODM and T6ODM expression in HM2 stems is upregulated at flowering  
Figure 41 shows the fold difference changes in CODM and T6ODM gene expression as 
wild type HM2 plants develop. Relative transcript levels were determined using the 2-ΔΔCt 
method (Livak and Schmittgen, 2001) with beta actin serving as a normaliser and the mean 




Figure 41. Changes in morphinan gene expression in HM2 stems during development from early 
seedlings to maturing plants. The mean expression levels of the three es stem samples were used as 
calibrator.  
The results show that CODM and T6ODM gene expression in stems are similar in early 
seedling and hook stage plants. Expression is increased approximately twofold at flowering 
and this increase is maintained in maturing plants. 
The relative change in abundance of T6ODM transcripts is higher than that for CODM in 
all flowering and maturing plants although overall CODM transcripts are more abundant 
(lower Ct values). This change is most pronounced in flowering plants and could relate to the 
point at which thebaine in the latex is beginning to be metabolised to morphine.  
4.3.2 CODM and T6ODM expression in HM2 roots is also upregulated at 
flowering 
Figure 42 shows the fold difference changes in CODM and T6ODM gene expression in the 
roots as the same (Figure 41) wild type HM2 plants develop. Relative transcript levels were 
determined using the 2-ΔΔCt method (Livak and Schmittgen, 2001) with beta actin serving as a 
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Figure 42. Changes in morphinan gene expression in HM2 roots during development from early 
seedlings to maturing plants. The mean expression levels of the three es root samples were used as 
calibrator. 
 
CODM and T6ODM are expressed at lower levels in the roots compared to stems. The 
main site of BIA accumulation is the laticifers, which are associated with the phloem in the 
shoot. The latex analysed from these plants is simply the cytoplasm of laticifers. Latex does 
not exude from roots in the same way it does from shoots, although laticifers are present 
(Facchini and Bird, 1998). Laticifers are adjacent to other phloem cell types, known as sieve 
elements and companion cells, in aerial organs but are not necessarily proximal in roots 
(Liscombe and Facchini, 2008). Companion cells produce the enzymes required to synthesise 
alkaloids. These are translocated to sieve elements where alkaloids are produced. They are 
then transported to the laticifers for storage (Beaudoin and Facchini, 2014; Facchini et al., 
2007; Hagel et al., 2008b).  
However, CODM and T6ODM transcripts were detected in root material and alkaloids 
could be detected in dried and lyophilised roots. The transcript levels are comparatively low 
in early seedling and hook stage plants, but there appears to be a significant upregulation of 
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4.3.3 Expression in High T fwd line stems is also upregulated at flowering 
In the high thebaine forward screen line, CODM and T6ODM expression is increased at 
flowering and returns to similar levels to hook stage plants in maturing plants (Figure 43). 
 
Figure 43. Changes in morphinan gene expression in HighT fwd line stems during development from 
hk stage plants to maturing plants. The mean expression levels of the three hook stem samples were used 
as calibrator as early seedling plants were not sampled. 
Gene expression changes between hook and flowering stage plants correspond with a 
dramatic shift in the latex profiles with increases in the proportion of thebaine and oripavine 
and reductions in the proportions of codeine and morphine (Figure 40). Prior to flowering 
the plants are able to produce morphine but after flowering it appears that there is a block at 
thebaine that prevents the conversion of thebaine and oripavine to morphine that ordinarily 
occurs in HM2.  
The fold changes in CODM/T6ODM transcripts at flowering are much greater than that 
observed in HM2, which could reflect a recognition by the plant of significantly high 
proportions of thebaine in the latex at flowering and an attempt to metabolise thebaine to 
morphine. The high levels of CODM/T6ODM expression at flowering suggests that factors 
other than gene expression levels are responsible for the metabolic block. Upregulation, 
unlike with HM2, appears to be transient as maturing plants have similar levels of 
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4.4 Strategy for comparison of gene expression across mutant lines 
 The above results indicated that the most interesting development stage in terms of 
changes in gene expression and alkaloid profiles is flowering. For this reason it was decided 
to extract RNA from all the stems and roots of all flowering plants to compare morphinan 
gene expression. Flowering is the stage at which CODM and T6ODM are most highly 
expressed and so any differences in expression levels between the mutants were anticipated 
to be most evident at flowering.  
4.4.1 2-ODD expression was highest in the stems of flowering High T fwd mutants 
Figure 44 shows a comparison of morphinan gene expression in the stems of HM2 and 
the five mutant lines at the flowering stage. The mean HM2 flowering plants result for each 
target gene acted as calibrator and expression of each gene was calculated relative to beta 
actin.  
CODM/T6ODM/COR expression levels are similar in the three HM2 flowering stems 
sampled. The levels of codeineone reductase (COR) are similar to HM2 in most of the mutants 
(the HighT line being the exception). The differences between the lines, however, are most 
clearly seen with CODM and T6ODM expression levels. The high codeine forward line 
flowering plants (E193K/R158K) have 5 fold lower levels of CODM/T6ODM than HM2. The 
lower T6ODM transcript levels reflect the high thebaine content of the latex at this stage. 
Similar lower expression levels were observed for the CODM nonsense mutants, W261* and 
Q254*. As one copy of CODM is knocked out in these lines, a lower CODM transcript level may 
be been expected. However, any reduction in CODM transcript levels seems to be associated 







Figure 44. Morphinan gene expression and the corresponding latex alkaloid profiles of the stems of 
flowering plants. Metabolite figures are an average of 3 technical replicates for each sample. Columns are 
not stacked to 100% due the presence of unknown compounds. E193K is short for plants with both the 
CODMa/c E193K and CODMb R158K mutations.  
T6ODM transcript levels are reduced in the W145* mutant to approximately 60% of the 
level in HM2. This is reflected in the slightly higher proportions of thebaine and oripavine in 
the latex of W145* flowering plants. Although T6ODMa is knocked out in this line, additional 
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There is a large increase in CODM/T6ODM/COR gene expression in the HighT fwd line in 
response to the block at thebaine and oripavine described above. Although levels of T6ODM 
transcripts are high, the plants appear not to metabolise thebaine like they did prior to 
flowering and consequently thebaine and oripavine accumulate in the latex. This suggests a 
cause other than expression levels of CODM/T6ODM/COR for the block in the conversion of 
thebaine and oripavine in the HighT line. A potential candidate may be an as yet unidentified 
transporter of thebaine that acts to shuttle thebaine from the sieve elements to the laticifers. 
Alkaloid transport in opium poppy is not yet well understood-it could occur via symplastic 
transport via plasmodesmata (Facchini and De Luca, 2008) or apoplastic via as yet 
unidentified transporters. Thebaine is thought to be the major translocated intermediate 
between sieve elements and laticifers (Onoyovwe et al., 2013). 
4.4.2 Levels of protopine alkaloids are elevated in the roots of flowering mutant 
plants  
Figure 44 shows a comparison of morphinan gene expression in the roots of HM2 and the 
five mutant lines. The mean HM2 flw results for each target gene acted as calibrator and 
expression of each gene was calculated relative to beta actin.  
Gene expression levels in roots were highly variable, a phenomenon also observed 
previously (Facchini and Park, 2003). Even among the HM2 roots there were large 
differences in expression levels of CODM and T6ODM. Expression levels of these genes are 
down in the W145* mutants but this does not seem to be linked to any change in phenotype, 




Figure 45. Morphinan gene expression and the corresponding alkaloid profiles of the roots of flowering 
plants. Metabolite figures are an average of 3 technical replicates for each sample. Columns are not 
stacked to 100% due the presence of unknown compounds, the proportion of which is much higher than 
that in stem latex. E193K is short for plants with both the CODMa/c E193K and CODMb R158K mutations.  
There is generally a larger proportion of codeine and thebaine compared to stem latex of 
the same plants. In HM2 roots, codeine is the predominant alkaloid, while morphine is the 
most abundant alkaloid in the stem latex of the same plants. The proportions of unidentified 
alkaloids is much higher in the roots, in particular the roots of two plants W261* flw1 and 
Q254* flw3. Another interesting observation was the lack of sanguinarine in these roots. This 
was in contrast to a previous study that identified sanguinarine and dihydrosanguinarine as 
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2005) and the condiment “Marianne” cultivar (Facchini and De Luca, 1995; Frick et al., 2005). 
This may simply be due to differences between GSK’s HM2 variety and previously studied 
opium poppy varieties where sanguinarine is detected (Facchini et al., 1996b; Facchini and 
Park, 2003; Huang and Kutchan, 2000). HM2 is the result of many years of breeding for 
morphine and as such it may divert all its available resources to that end. Opium poppy cell 
cultures are known to accumulate sanguinarine in response to fungal elicitor treatment 
(Alcantara et al., 2005; Facchini et al., 1996a; Zulak et al., 2006). The absence of fungi in the 
silica sand/Terragreen mixture used to grow the plants in for this experiment may be a 
reason why sanguinarine was not found in roots (and stem latex). Sanguinarine has been 
shown to be toxic to fungi at low concentrations (Cline and Coscia, 1988) and its presence 
roots may offer protection against pathogens in the soil. 
Levels of cryptopine and protopine were higher among the mutants compared to HM2 
(each approximately 0.5% of total alkaloids in roots). This is in agreement with a previous 
study which silenced CODM and T6ODM in opium poppy using Virus Induced Gene Silencing 
(VIGS; Farrow and Facchini, 2013). VIGS resulted in increases in cryptopine and protopine in 
the latex due to newly discovered roles for these enzymes in the metabolism of protopine, 
benzophenanthridine and rhoeadine alkaloids. The proportions of cryptopine and protopine 
are as high as 3% in some of the CODM mutants and remain unchanged in the T6ODMa 
W145* mutant (Figure 46). The High T fwd line displays the highest levels of protopines in its 
roots. Expression of the morphinan genes in the roots of this line is down compared to HM2 
(Figure 45). This is in contrast to the situation in stems where expression levels are much 




Figure 46. Proportion of cryptopine and protopine alkaloids in the roots of flowering plants. The figures 
are an average of 3 technical replicates for each sample. E193K is short for plants with both the CODMa/c 
E193K and CODMb R158K mutations.  
4.5 Discussion 
The results indicate that flowering seems to be trigger for a change in gene expression 
and alkaloid composition of the latex. Even though plants sampled at the hook stage are only 
2-3 days younger than flowering plants, there is approximately a two fold increase in 
morphinan gene expression levels in flowering plants. Other examples where secondary 
metabolism has been shown to be coupled to a plant’s developmental stage include 
Hypericum, where the amounts of several compounds change across five phenological stages 
(Cirak et al., 2013), and Solanum lycopersicum (tomato), where the levels of carotenoids, 
polyphenols, volatiles and alkaloids change during fruit ripening (Tohge et al., 2014).  
Analysis of the latex of developing plants is a useful indicator of the composition. 
However, its limitation is that it is not quantitative. Therefore, even if absolute levels of a 
certain alkaloid, e.g. codeine or thebaine, increased in later stages of development, if levels of 
morphine also increased it may not evident from looking at percentages of each alkaloid 
present in latex. Nevertheless, a clear change in phenotype at flowering was observed with 
the high T forward screen line. Pre–flowering the morphine comprises approximately 50% of 
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increases in the proportion of thebaine and oripavine. It may be the case that further 
morphine production is halted at flowering and the relatively small amounts of morphine in 
mature capsules were made prior to this stage. Post-flowering flux into the morphinan 
pathway was blocked at thebine with the result that the major alkaloid components of both 
the latex (Figure 40) and capsules (Figure 33) are thebaine and oripavine (Figure 47). 
Figure 47. Summary showing the effects each of the known mutations have on flux through the morphinan 
pathway. In each case the red ‘x’ does not reflect a complete block because additional functional copies of 
CODM/T6ODM appear to operate in each of the mutants. The ‘x’ rather indicates a reduction in efficiency 
of the reactions indicated. After thebaine the pathway to morphine is bifurcated. The major route to 
morphine from thebaine is thought to occur via codeinone (Nielson et al., 1983). The minor route involves 
the intermediates oripavine and morphinone (Brochmann-Hanssen, 1984). Mutations in CODM therefore 
result in increases in the proportion of codeine (large black arrow) as a result of disrupting flux through 
the major pathway. Thebaine content (small black arrow) is also slightly higher than that found in HM2 as 
thebaine to oripavine reactions are also affected in these mutants. With the T6ODM W145* mutant 
thebaine and oripavine yields were increased at the expense of morphine due to disruption of thebaine 
and oripavine 6-O-demethylations. The HighT fwd has an intron polymorphism in T6ODMa or it may have 
other as yet undetected mutations in T6ODM, transporters of thebaine or regulators of morphinan gene 
activity.   
The CODMa/c W261* and CODMb Q254* lines display modest increases in codeine 
content of mature capsules when their CODM mutations are homozygous (Figure 47). 
Analysis of the alkaloid composition of the roots of these lines, however, has revealed the 
increased levels of cryptopine and protopine alkaloids. Likewise, higher levels of protopines 
were observed in the roots of plants from the CODM E193K/R158K line. This confirms results 
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from a recent study showing that CODM has activities outside of the morphinan pathway 
(Farrow and Facchini, 2013) with activities in the metabolism of protopine, 
benzophenanthridine and rhoeadine alkaloids. 
Levels of protopine alkaloids in T6ODMa W145* mutants were no different to that of wild 
type HM2. This was expected as recombinant T6ODMa showed no activity against protopines 
(Farrow and Facchini, 2013). T6ODM VIGS, however, did result in an increase in protopine 
and cryptopine content. It is likely therefore, that additional copies of T6ODM (b and/or c) 
with activities against protopine and cryptopine were co-silenced with T6ODMa in the VIGS 
experiments. Many of the amino acid differences between T6ODMa and T6ODMb (Table 9) 
also exist between CODM and T6ODMa i.e. T6ODMb is intermediate between CODM and 
T6ODMa. CODM has a clear activity against protopine and cryptopine and it may be that the 
T6ODMb is the copy of T6ODM which also metabolises these alkaloids. The highest levels of 
cryptopine and protopine were found in the High T forward line (2-5%) suggesting the same 
factor causing the metabolic block at thebaine and oripavine in stem latex is also leading to a 
reduction in protopine metabolism in roots. 
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Chapter 5- Use of detected CODM and T6ODM alleles in breeding 
for altered metabolite profiles 
5.1 Establishment of AS-PCR for the detection of mutations/polymorphisms 
Conventional plant breeding is based on phenotypic selection of superior genotypes 
within segregating progenies obtained from crosses. This approach is often complicated by 
reactions between genotypes and the environment. Marker assisted selection (MAS) avoids 
these problems by changing the selection criteria toward selection of genes rather than 
phenotypes (Francia et al., 2005). Molecular markers are unaffected by the environment and 
the conditions in which the plants are grown. Often quantitative trait loci (QTL) are used in 
MAS when the genes governing a desired trait are not known or mutations in the coding 
sequence which enhance a trait have not yet been identified. In this study, the markers are 
the single nucleotide polymorphisms (SNPs) detected in 2-ODD genes involved in morphine 
biosynthesis. These SNPs have been shown to alter flux to morphine in mutant lines. Crosses 
to combine CODM and T6ODM mutations may further increase yields of codeine, thebaine 
and oripavine and decisions on selection of seed for sowing could be made by marker 
analysis. This marker assisted gene (or QTL) pyramiding approach (MAGP) has been 
demonstrated successfully in a number of crops (Jiang et al., 2007; X. Li et al., 2010; 
Richardson et al., 2006; Wang et al., 2012). Alternatively, marker assisted recurrent selection 
(MARS) could be used to select genomic regions involved in the expression of complex traits 
and assemble the best performing genotype within a single, or across populations (Ribaut et 
al., 2010). Recurrent crosses could be initiated with HM6, HT5/HT6 and HN4, which are 
contemporary GSK morphine, thebaine and noscapine varieties, respectively. The mutations 
were derived from a previous morphine variety, HM2.  
SNPs can be detected using allele-specific PCR primers designed such that the 3' 
nucleotide of a primer corresponds to the site of the SNP (Ugozzoli and Wallace, 1991). Thus, 
the allele-specific primer matches perfectly with one allele and has a 3' mismatch with the 
nonspecific allele. Because mismatched 3' termini are extended by DNA polymerases with 
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much lower efficiency than correctly matched termini, the allele-specific primer should 
preferentially amplify the specific allele (Cha et al., 1992). 
Tracking of double mutants via AS-PCR would reduce the amount of expensive cleavage 
enzyme used if TILLING would be the sole genotyping strategy. Ensuring that different sized 
PCR products would be formed with the presence of various mutations would enable 
screening of each plant for multiple mutations simultaneously e.g. CODM and T6ODM 
mutations. This would save time and effort that would be spent TILLING the same DNA 
sample multiple times for different target genes.  
Primers used to track CODM and T6ODM mutations and polymorphisms in AS-PCR are 
listed in Appendix D. Successful PCR with mutant primers would indicate the presence of a 
mutation. The limitation of this approach is that it cannot distinguish between homozygotes 
and heterozygotes. AS-PCR was used to confirm the presence of mutations in F1s (mutations 
assumed to be heterozygous as it was present in just one of the gametes). For F2s and 
subsequent generations, AS-PCR was used as first step in genotyping to detect the presence 
of segregating mutations. TILLING the same DNA samples would then clarify whether 
detected mutations were in homozygous or heterozygous states. In heterozygotes a 
heteroduplex would form between amplified wild type and mutant alleles, which would be 
cut and detected with the Fragment Analyser. In contrast PCR products generated from 
homozygotes would be identical, would not be cut and only full length PCR products would 
be visible on the TILLING gel. Those F2 candidates with desirable genotypes would then have 
CODM and/or T6ODM sequenced to confirm zygosity in a third genotyping step prior to 
advancement to F3.  
5.2 Crossing strategy 
TILLING and ‘EcoTILLING’ CODM and T6ODM identified a number of alleles with the 
potential to disrupt O-demethylation of codeine, thebaine and oripavine. Phenotypic analysis 
of M2s, M3s and forward screen lines with CODM/T6ODM polymorphisms demonstrated that 
the effects of the polymorphisms in isolation are limited. Efforts to combine CODM 
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polymorphisms were already detailed in Chapter 3 (3.4.5). It is likely that double mutants 
were not recovered due to the close proximity of copies of CODM in the genome. BAC 
sequence information that suggests that copies of CODM might be closely linked was not 
available at the time the crosses were being set up. Therefore, attempts were made at the 
time to combine CODM polymorphisms, in particular to set up crosses to replace the CODMb 
R158K polymorphism in the high codeine forward screen lines with the CODMb Q254* 
mutation found by reverse genetics. In addition, attempts were made to combine CODM and 
T6ODM mutations/polymorphisms to create plants with partial blocks in both sides of the 
pathway to morphine from thebaine. As EMS introduced random mutations across the 
genome and it is estimated that each M2 carries as much as 10,000 induced mutations, the 
process of backcrosses to GSK elite lines was initiated with crosses of mutants to current 
commercial morphine (HM6), thebaine (HT5 & HT6) and noscapine (HN4) lines. Finally, lines 
with interesting metabolite profiles, but for which no CODM or T6ODM polymorphisms have 
been found, were included in the crossing scheme. These include high thebaine forward 
screen lines that arose from HM2 mutagenesis and noscapine-free thebaine/oripavine only 
lines that arose from HN3 mutagenesis.  
Figure 48 shows an overview of the 76 crosses carried out. More detail on each cross is 
provided in Appendix E. F1 seed was harvested from mature females and sown. 
 
164  
Figure 48. Overview of the parents used in each of the 76 crosses. Parents were drawn from forward 
screen, reverse screen lines and GSK commercial lines (blue). Those lines with known (dark) or predicted 
(light) codeine (green) and thebaine (purple) phenotypes are indicated alongside detected CODM and 
T6ODM mutations. Wk=week each seed batch was sown (if struckthrough the seed did not germinate). 




















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































CODM mutants  High codeine and Thebaine/ oripavine 
identified by   thebaine lines identified only lines identified Commercial   
reverse genetics-  by forward genetics-      by forward genetics- GSK lines 
mutagenized HM2  mutagenised HM2 mutagenised HN3 
 
Figure 49. Phenotypes of the lines used in the initial set of crosses. The proportions of each of the 
major alkaloids in the capsules of the parents actually used in the crosses detailed in Figure 46 are shown. 
Known mutations and polymorphisms in each line are detailed. 
  
Figure 49 provides an overview of the phenotypes of the parental lines used in the initial 
crosses (Appendix E, X001 to X056). Known mutations and polymorphisms in each line are 
indicated. CODMb Q254* TILLING mutants, in particular, had more codeine in their capsules 
than HM6. T6ODMa TILLING mutants are not included as they were discovered at a later date 
before being brought into the breeding programme. Their phenotypes are described in Figure 
38. Four of the high codeine forward screen lines were included as parents. These lines 
contained CODM E193 and R158K polymorphisms (Figure 20). S-114249 and S-114250 are 
high thebaine forward screen lines that came out of HM2 mutagenesis. CODM and T6ODM 
polymorphisms were detected in the former using TILLING (Figure 33). The four thebaine-
oripavine only lines (S-125001 to S-125004) came out of a forward screen of mutagenised 
HN3, a former noscapine line. The molecular basis of the phenotype remains unknown but 





5.3 Tracking of transferred mutant alleles in F1 individuals 
DNA was extracted from ten F1 individuals for each seed batch sown. For the first batch 
of F1s, two (96 well) DNA plates were screened by AS-PCR for the Q254*, E193K, R158K and 
Tint SNPs. PCR products were visualised on agarose gels (Appendix F). Successful 
amplification indicated the presence of SNPs contributed by parents (Table 19). Additional 
F1s, including those resulting from crosses involving T6ODMa TILLING mutants (Appendix E, 
X057 to X075), were later screened using a similar approach but with visualisation of AS-PCR 
products on the Fragment Analyser (Appendix F).  
In most cases alleles were successfully detected in the F1s. For example for X009 (Table 
19a) all three CODM SNPs were detected (+ for each SNP in each of the ten F1s tested), two 
contributed by the high codeine forward screen line and the other from the TILLING mutant. 
The aim of this cross was to replace the R158K mutation in the high codeine forward screen 
line with the CODMb knockout mutation to further impact on the capacity of the plant to O-
demethylate codeine.  The F1s possess both R158K and Q254* mutations and perhaps 
segregation of these in F2 would result in the recovery of E193K-Q254* mutants.  
X008, X001, X027, X030, X055 and X016 were carried out to begin the process of 
introducing detected CODM and T6ODM mutations to elite GSK germplasm i.e. morphine 
(HM6), thebaine (HT6) and noscapine (HN4) lines. The remaining crosses aimed to combine 
CODM, T6ODM and undetected mutations (in the high thebaine forward screen lines) to 
impact on both paths of the pathway to morphine from thebaine.  
The T6ODMa intron polymorphism observed in GSK high thebaine lines was not 
transferred to F1s in X043 (Table 19b). The polymorphism is present in most but not all HT6 
individuals (Table 19c and Figure 34). The HT6 individual used as a parent in X043 did not 






Seed batch id 
 Seedling id 
Known mutations 
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Seed batch id 
 Seedling id 
Known mutations 
F1 seed batch id 
Cross id 
F1 Seedling id 
T6ODMa 
















Sd-835300 - + + + 
Sd-835301 - + + + 
Sd-835302 - + + + 
Sd-835303 - + + + 
Sd-835304 - + + + 
Sd-835305 - + + + 
Sd-835306 - + + + 
Sd-835307 - + + + 
Sd-835308 - + + + 









Sd-835310 - N/A N/A + 
Sd-835311 - N/A N/A + 
Sd-835312 - N/A N/A + 
Sd-835313 - N/A N/A + 
Sd-835314 - N/A N/A + 
Sd-835315 - N/A N/A + 
Sd-835316 - N/A N/A + 
Sd-835317 - N/A N/A + 
Sd-835318 - N/A N/A + 








T6ODMa intron SNP 
S-124003 
X050 
Sd-835320 + + + N/A 
Sd-835321 + + + N/A 
Sd-835322 + + RF N/A 
Sd-835323 + + + N/A 
Sd-835324 + + + N/A 
Sd-835325 + + + N/A 
Sd-835326 + + + N/A 
Sd-835327 + + + N/A 
Sd-835328 + + + N/A 











Sd-835330 + + + N/A 
Sd-835331 + + + N/A 
Sd-835332 + + + N/A 
Sd-835333 + + + N/A 
Sd-835334 + - - N/A 
Sd-835335 + - - N/A 
Sd-835336 + + + N/A 
Sd-835337 + + + N/A 
Sd-835338 + + + N/A 




T6ODMa intron SNP 
S-114250 
Sd-833486 
High T Fwd 
S-123968 
X042 
Sd-835340 + N/A N/A N/A 
Sd-835341 + N/A N/A N/A 
Sd-835342 + N/A N/A N/A 
Sd-835343 + N/A N/A N/A 
Sd-835344 + N/A N/A N/A 
Sd-835345 + N/A N/A N/A 
Sd-835346 + N/A N/A N/A 
Sd-835347 + N/A N/A N/A 
Sd-835348 + N/A N/A N/A 
Sd-835349 + N/A N/A N/A 
Table 19a) Genotyping results for first batch of F1s. N/A indicates where DNA samples were not tested for 
this SNP because none of the parents had it. RF indicates reaction failure. Reactions were not repeated as 
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T6ODMa intron SNP 
S-114250 
Sd-833816 
High T Fwd 
S-123966 
X043 
Sd-835350 - N/A N/A N/A 
Sd-835351 - N/A N/A N/A 
Sd-835352 - N/A N/A N/A 
Sd-835353 - N/A N/A N/A 
Sd-835354 - N/A N/A N/A 
Sd-835355 - N/A N/A N/A 
Sd-835356 - N/A N/A N/A 
Sd-835357 - N/A N/A N/A 
Sd-835358 - N/A N/A N/A 
Sd-835359 - N/A N/A N/A 
S-114250 
Sd-833498 




T6ODMa intron SNP 
S-124001 
X014 
Sd-835360 + N/A N/A N/A 
Sd-835361 + N/A N/A N/A 
Sd-835362 + N/A N/A N/A 
Sd-835363 + N/A N/A N/A 
Sd-835364 + N/A N/A N/A 
Sd-835365 + N/A N/A N/A 
Sd-835366 + N/A N/A N/A 
Sd-835367 + N/A N/A N/A 
Sd-835368 + N/A N/A N/A 




T6ODMa intron SNP 
S-114250 
Sd-833824 
High T Fwd 
S-124066 
X044 
Sd-835370 + N/A N/A N/A 
Sd-835371 + N/A N/A N/A 
Sd-835372 + N/A N/A N/A 
Sd-835373 + N/A N/A N/A 
Sd-835374 + N/A N/A N/A 
Sd-835375 + N/A N/A N/A 
Sd-835376 + N/A N/A N/A 
Sd-835377 + N/A N/A N/A 
Sd-835378 + N/A N/A N/A 







T6ODMa intron SNP 
S-124009 
X015 
Sd-835380 + N/A N/A + 
Sd-835381 + N/A N/A + 
Sd-835382 + N/A N/A + 
Sd-835383 + N/A N/A + 
Sd-835384 + N/A N/A + 
Sd-835385 + N/A N/A + 
Sd-835386 + N/A N/A + 
Sd-835387 + N/A N/A + 
Sd-835388 + N/A N/A + 







T6ODMa intron SNP 
S-124015 
X054 
Sd-835390 + N/A N/A + 
Sd-835391 + N/A N/A + 
Sd-835392 + N/A N/A + 
Sd-835393 + N/A N/A + 
Sd-835394 + N/A N/A + 
Sd-835395 + N/A N/A + 
Sd-835396 + N/A N/A + 
Sd-835397 + N/A N/A + 
Sd-835398 + N/A N/A + 










Sd-835400 - + + N/A 
Sd-835401 - + + N/A 
Sd-835402 - + + N/A 
Sd-835403 - + + N/A 
Sd-835404 - + + N/A 
Sd-835405 - + + N/A 
Sd-835406 - + + N/A 
Sd-835407 - + + N/A 
Sd-835408 - + + N/A 










Sd-835410 - - - N/A 
Sd-835411 - - - N/A 
Sd-835412 - - - N/A 
Sd-835413 - + + N/A 
Sd-835414 - - - N/A 
Sd-835415 - - - N/A 
Sd-835416 - - - N/A 
Sd-835417 - - - N/A 
Sd-835418 - - - N/A 
Sd-835419 - - - N/A 
Table 19 b). Genotyping results for first batch of F1s. N/A indicates where DNA samples were not 
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Sd-835420 + + + N/A 
Sd-835421 + + + N/A 
Sd-835422 + + + N/A 
Sd-835423 + + + N/A 
Sd-835424 + + + N/A 
Sd-835425 + + + N/A 
Sd-835426 + + + N/A 
Sd-835427 + + + N/A 
Sd-835428 + + + N/A 











Sd-835430 + + + N/A 
Sd-835431 + + + N/A 
Sd-835432 + + + N/A 
Sd-835433 + + + N/A 
Sd-835434 + + + N/A 
Sd-835435 + + + N/A 
Sd-835436 + + + N/A 
Sd-835437 + + + N/A 
Sd-835438 + + + N/A 







T6ODMa intron SNP 
S-123972 
X016 
Sd-835440 + N/A N/A N/A 
Sd-835441 + N/A N/A N/A 
Sd-835442 + N/A N/A N/A 
Sd-835443 + N/A N/A N/A 
Sd-835444 + N/A N/A N/A 
Sd-835445 + N/A N/A N/A 
Sd-835446 + N/A N/A N/A 
Sd-835447 + N/A N/A N/A 
Sd-835448 + N/A N/A N/A 










Sd-835450 + N/A N/A N/A 
Sd-835451 + N/A N/A N/A 
Sd-835452 + N/A N/A N/A 
Sd-835453 + N/A N/A N/A 
Sd-835454 + N/A N/A N/A 
Sd-835455 + N/A N/A N/A 
Sd-835456 + N/A N/A N/A 
Sd-835457 + N/A N/A N/A 
Sd-835458 + N/A N/A N/A 
Sd-835459 RF N/A N/A N/A 
HT6 
T line 
T6ODMa intron SNP 
 
Sd-835550 + - - - 
Sd-835551 - - - - 
Sd-835552 - - - - 
Sd-835553 + - - - 
Sd-835554 + - - - 
Sd-835555 + N/A N/A N/A 
Sd-835556 + N/A N/A N/A 
Sd-835557 + N/A N/A N/A 
S-114139 
CODMb F271L 
T6ODMa intron SNP 
S-114139 
Sd-835566 + N/A N/A N/A 
Sd-835567 + N/A N/A N/A 
Sd-835568 + N/A N/A N/A 
Sd-835569 + N/A N/A N/A 
Sd-835570 + N/A N/A N/A 
Sd-835571 + N/A N/A N/A 
Sd-835572 - N/A N/A N/A 
Sd-835573 + N/A N/A N/A 
HN4 
N line  
Sd-835574 - N/A N/A N/A 
Sd-835575 - N/A N/A N/A 
Sd-835576 - N/A N/A N/A 
Sd-835577 - N/A N/A N/A 
Sd-835578 - N/A N/A N/A 
Sd-835579 + N/A N/A N/A 
Sd-835580 - N/A N/A N/A 
Sd-835581 - N/A N/A N/A 
HM6 
M line  
Sd-835582 - - - - 
Sd-835583 - - - - 
Sd-835584 - - - - 
Sd-835585 - - - - 
Sd-835586 - - - - 
Sd-835587 - N/A N/A N/A 
Sd-835588 - N/A N/A N/A 
Sd-835589 - N/A N/A N/A 
Table 19 c). Genotyping results for first batch of F1s, the high T forward screen line S-114139 and GSK 
commercial lines HT6, HN4 and HM6. N/A indicates where DNA samples were not tested for this SNP 
because neither of the parents had it. RF indicates reaction failure. Reactions were not repeated as there 
were sufficient siblings with the desired genotype (shaded) to take forward to F2.  
 For X027, just one of the ten F1s screened possessed the E193K and R158K markers 
inherited from the high codeine parent (likely heterozygous for these mutations; Table 19b). 
Nevertheless, this plant produced viable seed to progress this cross to F2.  
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All mutations were assumed to be in the heterozygous state and segregation in the F2 
would enable recovery of homozygotes. Figure 27 details the possible scenarios involved in 
the recovery of genotypes of interest in F2. If the genes involved are unlinked 1 in every 16 
F2s would be double mutants. If the genes are linked a greater number of F2s would be 
required to recover double mutants. It was decided to sow approximately 25 F2s for each 
cross that was taken forward due to limitations with greenhouse space. Figure 27 also 
explains how 6 in every 16 F2s would end up homozygous for one mutation and 
heterozygous for the other. In this case, one more selfing would lead to recovery of double 
mutants in F3s (1 in 4).  
5.4 F2s with desirable genotypes were identified using AS-PCR and 
sequencing 
Seed collected from F1s with confirmed genotypes was used to generate the F2 
individuals. DNA was extracted from F2s after four weeks and screened for the relevant 
CODM and T6ODM polymorphisms as before (visualisation with the Fragment Analyser). In 
the second step, the zygosity of each mutant was determined by TILLING the relevant gene in 
each plant. Finally, the genotypes of those individuals estimated to be homozygotes were 
confirmed by sequencing the portion of the gene with the mutation. As well as F2s, back-
cross 1 individuals (BC1) were genotyped. In these cases, the F1 was again crossed to a 
recurrent parent. Genotyping of BC1s would determine which individuals still possessed the 
CODM and T6ODM SNPs introduced by the original mutant parent (only half of the gametes 
transferred by the F1 would contain the SNPs). Appendix G details the genotyping of F2 and 
BC1 individuals. Genotypes confirmed by sequencing are marked in bold. If appropriate, 
these individual plants were allowed to self to produce F3 seed for further analysis.  
5.5 Selection of material for Tasmanian field trials 
Approximately 600 F2s and BC1s were genotyped in the first instance. At this time the 
crosses involving T6ODMa TILLING mutants were at the F1 stage and it was not possible to 
produce F3 seed (producing plants with stable genotypes and phenotypes) in time for the 
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2014/2015 growing season in Tasmania. However, F3 seed arising from the crosses detailed 
in Table 19 was shipped to Tasmania for field trials. The seed was collected from F2 
individuals with desirable genotypes (Appendix G; D-10858 to D-10865).  
Seed batches were sown alongside controls for morphine (HM6 and HM7), thebaine (HT5 
and HT6) and noscapine (HN1). Controls were randomly sown in duplicate within the same 
plot (Appendix H). HM2, the morphine line from which the mutant parents were originally 
derived, was sown in plots on an adjacent block in the same field. Each plot contained a row 
of approximately 20 plants. In a number of cases the F2s that produced the F3 seed had one 
mutation in the heterozygous state and so the resulting F3s would be segregating e.g. Q254* x 
HT1, Q254* x HN1, X008, X009, X042 and X051 (Table 20). For these lines DNA was 
requested from all individuals for genotyping. For the other lines, DNA would be extracted 
from a smaller number of individuals for QC genotyping to confirm expected genotypes 
(Table 20). Appendix H details the genotyping of field grown material carried out once DNA 
was shipped back to York.  
As the CODM E193K and R158K polymorphism were always inherited together in 
previous generations, only the R158K mutation was screened for. If a plant was homozygous 















Original Father Seed batch 
id 













CODMb Q254* Tint S-186628 Q254* segregating in high T background (Tint homozygous) C+T 
Q254*x HT1 
F3 
























CODMb Q254* CODM 
E193K/R158K 
S-186609 segregating CODM mutations C 
X009 
F3 
CODMb Q254* CODM 
E193K/R158K 












HN4 CODMb F271L 
Tint 
S-186619 homozygous for T6ODM Tint in N background T+N 
X016 
F3 
HN4 CODMb F271L 
Tint 
S-186620 homozygous for T6ODM Tint in N background T+N 
X016 
F3 
HN4 CODMb F271L 
Tint 
S-186621 homozygous for T6ODM Tint in N background T+N 
X016 
F3 
HN4 CODMb F271L 
Tint 
S-186622 homozygous for T6ODM Tint in N background T+N 
X016 
F3 
HN4 CODMb F271L 
Tint 




HN4 T/O only from 
HN3 mutagenesis 




















HN4 T/O only from 
HN3 mutagenesis 






T/O only from 
HN3 mutagenesis 





T/O only from 
HN3 mutagenesis 





T/O only from 
HN3 mutagenesis 




Tint High T fwd 
(no markers) 
S-186610  T6ODM Tint homozygous in high T forward screen line background T 
X042 
F3 
Tint High T fwd 
(no markers) 
 S-186611  T6ODM Tint homozygous in high T forward screen line background T 
X042 
F3 
Tint High T fwd 
(no markers) 
 S-186613  T6ODM Tint homozygous in high T forward screen line background T 
X042 
F3 
Tint High T fwd 
(no markers) 
 S-186716  T6ODM Tint homozygous in high T forward screen line background T 
X042 
F3 
Tint High T fwd 
(no markers) 
S-186719  T6ODM Tint segregating in high T forward screen line background T 
X042 
F3 
Tint High T fwd 
(no markers) 
S-186720  T6ODM Tint segregating in high T forward screen line background T 
X042 
F3 
Tint High T fwd 
(no markers) 
























S-186605  CODM E193K/R158K segregating in a background homozygous for the 
T6ODM Tint 
C+T 
Table 20. Material sent to Tasmania for field trials in 2014/2015 growing season. M=morphine, 




5.6 Towards a high codeine line 
Worldwide demand for codeine far exceeds the amount extracted from plants. As 
discussed in section 1.7.1 codeine is obtained from morphine through the process of O-
methylation, a time consuming and expensive process that produces toxic byproducts and 
waste that needs to disposed of safely. A plant with the morphinan pathway arrested at 
CODM would allow the direct recovery of codeine from the plant. It is not clear whether total 
alkaloid yield would be affected in such a plant but any reduction in yield and therefore 
commercial viability would be balanced by the current costs faced by the industry with the 
production of codeine from morphine crops.  
EMS-induced CODM mutations were introduced to the current commercial morphine 
variety HM6 to begin the process of removing other potentially deleterious mutations. As this 
is process is likely to take a longer time than permitted for this studentship, homozygous 
mutants were recovered in F2 to demonstrate the effects of the CODM mutations on codeine 
content in the capsules.  
5.6.1 X008-introducing the CODMb Q254* mutation to HM6 
Mother 




Seed batch id 
Seedling id 
Known mutations 
F1 seed batch id 
Cross id 
F1 seedling id F2 seed batch id 
F2 seedling id 
Genotype 













Table 21. X008 description and followup 
11 of the 34 F2s were genotyped as Q254* homozygotes (Appendix G, D-10858). Two 
were confirmed to have this genotype by sequencing, including Sd-837535 which, when 
selfed, produced S-186601 seed. This F3 seed was sown in Tasmania and it produced plants 
with on average 0.46% dw codeine (10.3% of total alkaloids) in the capsules (Figure 50). This 
is over double the amount of codeine observed in the commercial morphine varieties HM2 
(0.18% dw; 3.6% of total alkaloids) and HM6 (0.19% dw; 4.0% of total alkaloids). An F4 seed 
batch sown in the glasshouse in York (S-188301) also gave rise to Q254* homozygote plants 
with on average 0.39% dw codeine (11.1% of total alkaloids; Appendix I, X008). The increase 
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in codeine content suggests a partial block of metabolism at codeine, caused by the plants 
having one copy of CODM knocked out.  
 
Figure 50. Increased codeine in CODMb Q254* homozygotes. F3s homozygous for the mutation have 
twice as much codeine in the capsules as HM2 (the line in which the mutation was induced) and HM6 (a 
more recent commercial morphine line into which the mutation was introduced in X008).  
5.6.2 X001 & X027-introducing the CODMa/c E193K and CODMb R158K 
mutations to HM6 
Mother 




Seed batch id 
Seedling id 
Known mutations 
F1 seed batch id 
Cross id 
F1 seedling id F2 seed batch id 
F2 seedling id 
Genotype 




































Table 22. X001 & X027 description and followup 
4 of the 41 F2s derived from the X001 F2 S-122996 were genotyped as homozygous for 
the CODM E193K and R158K mutations (Appendix G, D-10861 & D-10865). Three of these 
produced F3 seed for Tasmanian field trials. Likewise, 3 of the 25 F2s derived from X027 F2 
S-122982 were homozygous for both mutations (Appendix G, D-10861).  
An important point to note is that the two polymorphisms were always inherited 
together i.e. if a plant was heterozygous for one it was also heterozygous for the other. 
Furthermore, X009 (Table 19), which attempted to replace the CODMb R158K mutations 
with the CODMb nonsense mutation (Q254*), failed to achieve the desired result in both F2 




















Codeine yields (± SD) of X008 F3s and controls 
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CODM are physically linked. Nevertheless, the greater contribution of the E193K/R158K 
mutations over the Q254* mutation to a high codeine phenotype was demonstrated among 
the F3s in which these mutations were segregating (Figure 51). The Q254* homozygotes had 
on average 0.61% dw codeine (11.1% of total alkaloids) while the E193K/R158K 
homozygotes had on average 1.01% dw codeine (17.0% of total alkaloids).   
 
 
Figure 51. X009 F3s demonstrating the contribution of the E193K/R158K polymorphisms to a codeine 
phenotype.  
Similar yields of codeine were observed in X001 and X027 F3s genotyped as 
E193K/R158K homozygotes (Figure 52 and Appendix I, X001 & X027). The largest number of 
E193K/R158K homozygote F3s genotyped and phenotyped came from S-186658. These had 
consistently high codeine, a 5-6 fold improvement over the yield of codeine from HM2 (the 
line in which the mutations were induced) and HM6 (the line into which the mutations were 
transferred).  Again, a complete block at codeine would require disruptions to all actively 
expressed copies of CODM. However, plants which possess these two CODM mutations clearly 
are associated with high codeine phenotypes. It may be useful to continue backcrossing these 
lines to HM6 to reduce the number of background mutations and ensure the resulting 
codeine line will have the same agronomic traits as HM6 but with a higher yield of codeine at 


















Figure 52. Increased yields of codeine in plants from X027 F3 seed batch S-186658. All F3s were 
homozygous for the CODM E193K/R158K mutations and showed significantly higher codeine (mean 
1.1%) than commercial morphine lines, HM2 (0.19%) and HM6 (0.18%).  
5.6.2.1 HM7 GSK line  
One of the controls grown alongside the F3 material in Tasmania was GSK variety, HM7, 
into which the CODMa/c E193K and CODMb R158K mutations were introduced (Appendix H; 
D-11114 B2-E2, D-11115 G12-H12, D-11116 A1-B1). Codeine content among the seven HM7 
plants phenotyped averaged at 0.81% dw (15% of total alkaloids).  
A larger trial of this line last year also demonstrated a higher proportion of codeine in this 
line compared to e.g. HM6. However, the total alkaloid content is approximately 60% of 
current commercial morphine lines and so it would not be commercially viable at present. 
The high codeine forward screen lines came from a heavily mutagenized M2 individual which 
underwent numerous rounds of selfing (Appendix B). The high codeine forward screen seed 
had a relatively poor germination rate and produced short plants which flowered early. They 
were clearly stressed plants with a high mutation burden. The creation of HM7, X001 and 
X027 represent the first backcrosses into elite material. Further backcrosses aided by 
tracking of the polymorphisms for high codeine will reduce the number of background 
mutations while maintaining the desirable trait. In the end the CODM mutations can be 
brought to homozygosity and the result should be a line with a high total alkaloid content, a 
large proportion of which would be codeine. The results from X027 demonstrate what can be 




















Codeine yields (± SD) of X027 F3s and controls 
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traits (developed in another arm of the project), which could be incorporated into the marker 
assisted breeding strategy. The end result would be a high codeine line with all the 
agronomic traits of the recurrent parent.  
 
Figure 53. Phenotypes of HM7 individuals grown in the field in Tasmania alongside F3s. HM7 is a 
candidate commercial codeine line. 
5.6.3 Further mutagenesis of bulked up Q254* material 
When crosses between CODM Q254* and W261* mutants failed to result in a double 
mutant with a more substantial block of metabolism at codeine and it became increasingly 
likely that copies of CODM may be linked, an alternative strategy for obtaining a CODM 
double mutant was required. Seed of the CODM mutant with the clearest change in 
phenotype, Q254*, was bulked up in the M4 generation. M5 seed was then subjected to 
another round of EMS mutagenesis (Table 2 & Figure 54) in an attempt to introduce 
mutations in other copies of CODM (or any other genes which when disrupted would result in 




















Figure 54. Strategy for introducing new mutations in CODMb Q254* material. M5 seed was 
mutagenised in April 2014. M1s were grown in the greenhouse in York over the summer before M2 seed 
was shipped to Tasmania for the 2014/2015 growing season. DNA has been collected from M2 individuals 
which could be used for a reverse genetic screen. 
M1 seedlings were grown in the glasshouse in York and selfed manually to ensure M2 
seed production. M2 seed was sown in Tasmania in a number of different blocks within the 
field trial site. A row (plot) of plants was generated with each seed batch and mature capsules 
from four of these siblings were assessed for their alkaloid content at GSK’s Port Fairy site. As 
with the original TILLING population, it was anticipated that any induced mutations would 
likely be in the heterozygous state at this stage. Therefore, some sibling variation was 
expected and the aim was to identify lines with increased codeine content that have the 
potential to be replicated in the M3 generation.  
As well as M2 seed from the B and C subpopulations, various controls (Table 23) were 
grown in each block (HM2, HM7, HT7) and among the blocks (non-EMS treated CODMb 
Q254* M5s). HM2 was the morphine line originally subjected to EMS mutagenesis resulting in 
CODM Q254*, E193K and R158K mutations. HM7 is a candidate codeine line in which the 
CODM E193K/R158K mutations were detected (section 5.6.2.1). HT7 has been bred by GSK 
for high thebaine and oripavine and little morphine and codeine are present in mature 
capsules. The three remaining controls are the Q254* M5 seed used for mutagenesis. The 
strategy was to identify M2 lines with codeine content approaching 1% or higher which could 




Seed batch id 
Block 
GSK plot id 
Mean codeine yield 




MD 1524 & MD 1574 
0.27 (n=7) Morphine line subject of original EMS mutagenesis. 
 
16 




MD 1578 & MD 1596 
0.61 (n=7) Candidate codeine line with EMS induced CODM E193K/R158K 
polymorphisms  
16 

























Table 23. Controls grown alongside the new mutagenised population in field trials in Tasmania. HM2 
was the morphine line originally subjected to EMS mutagenesis. The Q254*, E193K and R158K mutations 
were introduced in this way, polymorphisms which resulted in minor blocks of metabolism at codeine. 
HM7 is a candidate codeine line in which the CODM E193K/R158K polymorphisms are segregating. 
Individuals homozygous for the polymorphisms have high codeine levels. HT7 is a contemporary 
thebaine/oripavine line with little codeine. The three remaining controls represent Q254* M5 seed which 
was not subjected to EMS mutagenesis earlier in the year. Any M2 line with codeine content greater than 
0.6% would be an improvement on the Q254* M5 material and HM7. All of the yields quoted were 
determined in field trials that were also the source of the material in Table 24.  
Table 24 shows the top 25 M2s with regard to yields of codeine (that successfully 
produced M3 seed). Many are approaching or exceeding 1% codeine, which if replicated in 
the M3 generation, would be an improvement over the CODMb Q254* M5s before treatment 
with EMS and HM7, the candidate codeine line.  
Mutation detection efforts should focus on these 25 M2 lines in the first instance. Sowing 
the M3s would indicate whether the phenotypes are stable and if any de novo mutations are 
found then markers for the new mutation and Q254* could be used to begin backcrosses to 
elite material. These lines are the result of two rounds of EMS mutagenesis and the extremely 
low germination rates (Table 2) are testament to the burden of background mutations that 











GSK plot id 
Mean codeine 
yield (% dw) 
Individual capsules 
with highest codeine 
yield* (% dw) 
Resulting M3 















































































































































































































Table 24. Top 25 codeine yields (% dw) of M2s which successfully produced M3 seed. M2 seed was 
sown in plots (MD numbers) and four capsules were assessed for alkaloid content. The highest yields of 





5.7 Towards a high thebaine line 
5.7.1 X051-cross between high codeine and high thebaine forward screen lines 
Mother 
Seed batch id 
 Seedling id 
Known mutations 
Father 
Seed batch id 
 Seedling id 
Known mutations 
F1 seed batch id 
Cross id 
F1 Seedling id F2 seed batch id 
F2 Seedling id 
Genotype 





























1in4 F3s should be homo 
 for all 3 SNPs 
 
S-186605 
1in4 F3s should be homo 
 for all 3 SNPs 
 
Table 25. X051 description and followup. 
a)             b) 
 
Figure 55. a)Thebaine yields of X051 F3s (from seed batch S-186608) homozygous for both the CODM 
E193K and R158K mutations and the Tint polymorphism. b) Pathways to morphine from thebaine. The 
minor route is thought to proceed via oripavine and morphinone.  
Just 1 of the 37 F2s genotyped were homozygous for all three SNPs-CODMa/c E193K, 
CODMb R158K and T6ODMa Tint. Seed was collected from this individual and resulting F3s 
had significant increases in the yields of thebaine (mean 3.62% dw; 54.4% of total alkaloids). 
This is a not just an improvement over HM2, into which the mutations were induced, but also 
current commercial thebaine lines grown alongside the F3s in Tasmania (Figure 55a). 
Increased yields of thebaine may be attributed disruption of thebaine to oripavine reactions 

































T6ODM activity on thebaine, linked to the Tint polymorphism present in commercial 
thebaine lines and the high thebaine forward screen line used as a parent in this cross.  
The impact of segregating CODM E193K/R158K and T6ODMa Tint on F3 phenotypes is 
demonstrated in Appendix I (X051). The results show the usefulness of tracking these SNPs 
in crosses and the predictable impact on phenotypes. The CODM mutations, always inherited 
together, clearly increase codeine content- at the expense of morphine in X001 and X027 but 
at the expense of oripavine in X051. Likewise the impact of the Tint polymorphism (or the 
unknown T6ODM mutation it is linked to) has a clear effect on thebaine accumulation in 
capsules. Those without the polymorphism had on average 0.23% dw thebaine (4.7% of total 
alkaloids). Thebaine is increased in both heterozygotes (mean 1.29% dw; 25.0% of total 
alkaloids) and homozygotes (2.71% dw; 50.1% of total alkaloids).  
5.8 Towards a high oripavine line 
Oripavine is a much sought after alkaloid due to its use in the manufacture of semi-
synthetic drugs such as for naloxone and naltrexone, for which the market continues to grow. 
A number of crosses were attempted to boost yields of oripavine. Current commercial 
thebaine lines HT5 and HT6 had oripavine yields of 0.75% dw (14.8% of total alkaloids) and 
0.54% dw (11.0% of total alkaloids) when grown alongside the F3s in the 2014/2015 
growing season. The thebaine/oripavine only lines derived from HN3 mutagenesis (Figure 
49) may have mutations in a regulator of T6ODM or a transporter responsible for transport 
of thebaine between sieve elements and laticifers.  
5.8.1 X016-Attempt to introduce noscapine into a high thebaine forward line 
resulted in a high oripavine line 
Mother 
Seed batch id 




Seed batch id 










F2 Seedling id 
Genotype 

















8 of 36 F2s were Tint homo including 
Sd-837722 (2.6%N), 837723 (3.3%N), 837726 
(4.1%N), 837728 (2.9%N), 837734 (2.3%N) 
S-186619, 186620, 
186621, 
 186622, 186624 
Table 26. X016 description and followup. 
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X016 was set up initially in an attempt to introduce noscapine into the high thebaine 
forward screen line derived from HM2 mutagenesis. Seed from five of the F2s identified as 
being homozygous for the Tint polymorphism was shipped to Tasmania for field trials (Table 
20). All of these F2s had relatively small amount of noscapine in their capsules indicating that 
the noscapine gene cluster was likely in a hemizygous state. Therefore segregation of the 
noscapine gene cluster in the F3s in Tasmania was expected to result in plants with circa 50% 
noscapine/50% morphinans, similar phenotypes to F2s, or plants with no noscapine in their 
capsules. For four of the five F3 seed batches this was the case (Appendix I) but the capsules 
of plants derived from S-186622 had no noscapine or morphine and had on average 1.52% 
dw oripavine (Figure 56; 35.6% of total alkaloids) which is a 2-3 fold improvement on HT5 
and HT6 controls-oripavine yields of 0.75% dw (14.8% of total alkaloids) and 0.54% dw 
(11.0% of total alkaloids), respectively. These plants also lacked the Tint polymorphism so 
the block at thebaine and oripavine must be caused by additional mutation contributed by 
the high thebaine forward screen line that then segregates independently in the F2. The 
alkaloid profiles are similar to those of the thebaine/oripavine only lines derived from HN3 
mutagenesis (Figure 49). 
 



















5.8.2 X041-cross between two high thebaine forward screen lines 
Mother 
Seed batch id 
 Seedling id 
Known mutations 
Father 
Seed batch id 
 Seedling id 
Known 
mutations 
F1 seed batch 
id 
Cross id 
F1 Seedling id F2 seed batch id 
F2 Seedling id 
Genotype 

















11 of 12 F2s genotyped as Tint 
homo 









Table 27. X041 description and followup. 
 
  
Figure 57. High oripavine yields among X041 F3s. The Tint polymorphism was observed to segregated 
independently of the thebaine/oripavine phenotype. Absence of the Tint polymorphism was an indicator 
of a metabolic block towards morphine and a high yield of thebaine and oripavine. Plants homozygous for 
Tint were able to produce morphine suggesting only a partial block of metabolism at thebaine.  
The high thebaine forward screen lines derived from both HM2 and HN3 mutagenesis 
were crossed together in an effort to combine whatever mutations cause their phenotypes 
and further increase yields of thebaine and oripavine. Among the F3s there were a number of 
plants with more oripavine than thebaine in their capsules. The parental line derived from 
HN3 mutagenesis has approximately a 60-40% split in favour of thebaine. Some of the F3s, 
however, flipped this ratio in favour of oripavine with yields of over 2% dw in some cases 
(Figure 57). It is postulated that the T6ODM Tint polymorphism alone is not responsible for 





























X041 F3 S-186667 
Tint homo WT T6ODMa 
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could be an as yet undetected independently segregating mutation that contributes to the 
phenotype and when this was combined with the mutation causing the thebaine/oripavine 
only phenotype in the forward line derived from HN3 mutagenesis the result was high 
oripavine plants.  
5.9 Towards a morphine free noscapine line 
Mother 
Seed batch id 
 Seedling id 
Known mutations 
Father 
Seed batch id 
 Seedling id 
Known mutations 
F1 seed batch id 
Cross id 













Table 28. X029 description and followup. 
An important final objective was to attempt to create a noscapine/thebaine variety. GSK 
and its partners have found it possible to separate these alkaloids in the industrial extraction 
process. In the field trials control noscapine line HN4 had on average 1.64% morphine and 
2.16% noscapine in mature capsules with trace amounts of thebaine, codeine and oripavine. 
Currently one way to increase thebaine content of noscapine lines is to use a chemical spray 
containing the acylcyclohexanedione trinexapac-ethyl (Moddus). Introduction of mutations 
preventing flux from thebaine to morphine into noscapine lines should increase 
thebaine/oripavine levels and may possibly avoid the need for spraying with Moddus.  
A step towards this was taken with one of the F3s from X016 described previously 
(Appendix I, S-186620) with a phenotype of 0.25% oripavine, 1.06% thebaine, 1.55% 
morphine and 1.93% noscapine.  The noscapine cluster in this plant is restored to the 
homozygous state and it also contains the Tint polymorphism which may cause or be linked 
to the cause of the partial block of metabolism at thebaine.  
However, X029 provided an even better phenotype in field trials of F2 individuals. The 
parents in this case were HN4 and the thebaine/oripavine only line that came out of HN3 
mutagenesis. Among the X029 F2s grown in York (Figure 58) were individuals with the 
noscapine cluster restored to display a phenotype like HN4, some heterozygotes with a small 
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amount of noscapine and a third group comprising of only one morphine-free individual with 
0.99% oripavine, 1.85% thebaine and 1.93% noscapine. Seed from this plant should be sown 
to ensure that the phenotype is reproducible.  
 
Figure 58. Alkaloid profiles of X029 F2s sown in both the field in Tasmania and the glasshouse in 
York. No markers were available for this cross. However plants with circa half of their alkaloid content 
being noscapine are interpreted as being homozygous for the noscapine gene cluster.  
Two of the F2s in Tasmania had a thebaine/oripavine phenotype similar to one of the 
original parents. The noscapine cluster must be in a heterozygous state in these individuals 
and so approximately 25% of the F3s should have the desired noscapine/thebaine/oripavine 
profiles.  
5.10 Discussion  
Tracking mutations using AS-PCR and visualisation of products with the Fragment 
Analyser machine was an efficient and cost effective way of tracking mutations through the 
generations. Because different sized PCR products were generated for each SNP each gel 
could test 96 plants for the presence of 4-5 mutations. Once a mutation was found the be 
present, a TILLING assay was used to determine zygosity-PCR products would remain uncut 
if amplified from homozygotes, while PCR products would be cut into two expected 
fragments if amplified from heterozygotes. This strategy avoided the use of expensive 
labelled primers and overcame the challenges presented by multiple copies of the 2-ODD 
genes, which may have frustrated efforts to assign zygosity in e.g. KASP assays where an 




























Although a large number of crosses were carried out only a portion were brought through 
to field trials in Tasmania. The remaining crosses are still at the F1 or F2 stages and the seed 
could be a resource in future efforts to combine mutant alleles of CODM and/or T6ODM.  In 
particular, crosses involving T6ODM TILLING mutants should be considered for future trials. 
If possible they should be crossed with high thebaine lines for which no molecular markers 
are available. Introduction of a T6ODMa knockout mutation may contribute to an even more 
comprehensive block at thebaine/oripavine.  
Steps towards the creation of new high codeine varieties of opium poppy were taken. 
Introducing the CODMb Q254* TILLING mutation to the commercial morphine line, HM6, 
resulted in a doubling of codeine content in capsules of F3s (Figure 50). Likewise, introducing 
the EMS-induced CODM E193K/R158K mutations into HM6 resulted in a more substantial 
block at codeine with a five fold increase in F3s compared to HM6 (Figure 52). Due to the 
time limitations of this project these lines were brought to homozygosity to assess the 
impacts of these alleles in the F3. In the medium to long term, these lines should continue to 
be backcrossed to HM6 or another suitable recurrent parent and the alleles tracked by AS-
PCR. Each step would remove potentially debilitating background mutations and produce a 
crop with all the agronomic traits exhibited by HM6 but with a higher proportion of codeine. 
Furthermore, if other alleles of CODM are discovered these could be introduced through 
crosses and further impact on the disruption of codeine demethylation in the plant. Although 
some of the M2s in the new TILLING population (Figure 54, Table 24) displayed high yields of 
codeine, this population has yet to be screened for CODM mutations. This resource would 
likely be a source of new CODM (and T6ODM) alleles. In the meantime, the M3 seed of the 
highest codeine yielders should be sown to assess whether the high yields are stable and 
heritable. DNA from these M3s could be the starting point for a new reverse genetic screen.  
The usefulness of tracking the Tint polymorphism in crosses for high thebaine was 
demonstrated in X051 (Appendix I). The Tint polymorphism was segregating among plants 
resulting from seed batch S-186678. Three clear classes are visible in the chart-those with 
low thebaine (wild type T6ODM), moderate thebaine (heterozygotes) and high thebaine 
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(homozygotes). This cross also resulted in plants with the highest thebaine content with a 1.5 
fold increase in thebaine over current commercial thebaine lines HT5 and HT6 (Figure 55). 
This is presumably the result of the additional block at thebaine (in thebaine to oripavine 
conversions) contributed by the CODM E193K/R158K mutations. X051 led to lines with 
much potential. One possible way forward would be to set up crosses to elite commercial 
thebaine lines and to follow the segregation of the CODM E193K/R158K and T6ODM Tint 
polymorphisms by genotyping. As these mutations came from mutant lines they are likely to 
be associated with a high number of background mutations. Recurrent backcrosses will 
remove potentially deleterious mutations while retaining the CODM and T6ODM mutations 
which when brought to homozygosity at the end of the programme should result in the 
desired high thebaine phenotype. 
Increased yields of oripavine were also achieved in this project. F3s from X016 and X041 
displayed a 2-3 fold increase in oripavine content of capsules compared to current 
commercial thebaine lines HT5 and HT6. Although molecular markers for the high oripavine 
trait have not yet been identified these lines should be progressed to establish stable high 
oripavine lines. It is possible that as yet undiscovered transporters of thebaine/oripavine or 
regulators of T6ODM expression may be affected by EMS mutagenesis in these lines i.e. the 
T/O only parent derived from HN3 mutagenesis has a complete block of metabolism at 
T6ODM. Finally, seed from the noscapine-thebaine-oripavine only F2 grown in York should 
be sown to assess whether this trait is stable and heritable because it would be a useful 
addition to GSK’s portfolio, providing three sought after alkaloids without producing any 




Chapter 6- General Discussion 
EMS mutagenesis of opium poppy seed has proved a successful approach for the 
generation of alleles of key genes involved in the biosynthesis of important opiates. New lines 
of opium poppy with desirable alkaloid profiles have been created by means of forward and 
reverse genetics. The promising CODM alleles produce E193K, R158K and E301K 
subtitutions and truncations (nonsense mutations). Two nonsense mutations were also 
identified in T6ODM and an interesting polymorphism in intron 1 of T6ODM was found to be 
linked to a thebaine phenotype. However, the presence of multiple copies of CODM and 
T6ODM in the genome of opium poppy has meant that, although knockout mutations in both 
genes were recovered, complete metabolic blocks at specific alkaloids was not achievable. 
Despite this the mutant alleles could be used to fine tune metabolic phenotypes. The lack of 
genome sequence for opium poppy meant that the presence of multiple copies of 2-ODD 
genes was not known at the beginning of this project. It has now been demonstrated that the 
plant does indeed have multiple functional copies of CODM and T6ODM. Previous VIGS 
experiments, demonstrating the effect of silencing CODM and T6ODM, would have silenced all 
copies simultaneously (Hagel and Facchini, 2010a; Wijekoon and Facchini, 2012). A genome 
sequence or more sequence information around the site of these 2-ODD genes would have 
aided primer design for screening additional copies. A single polymorphism between 
T6ODMa and other copies of T6ODM was exploited to design a primer for the specific 
amplification of T6ODMa for TILLING (Table 8, Figure 32). It was not possible to do the same 
for T6ODMb. Sequence information upstream or downstream of the coding sequence would 
have revealed differences between the copies and enabled primer design for TILLING 
T6ODMb. To date, no genome sequence for opium poppy is available. This may be due to the 
fact that it remains quite a niche medicinal crop that has not attracted the interest of large 
consortia that typically are involved in genome sequencing. Also, opium poppy has a 
relatively large genome and although the cost of sequencing has come down in recent years 
the task of assembling the short reads into a genomic sequence is not trivial especially when 
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you consider the amount of repetitive DNA. The high frequency of repetitive sequences was 
demonstrated when BACs containing the noscapine gene cluster were sequenced and 
characterised (Winzer et al., 2012). Different sequencing methods needed to be deployed to 
achieve a good assembly of even a relatively small amount of genomic DNA (400kb). Of 
course it is technically feasible to sequence the entire genome but the challenge would more 
likely be accomplished with adoption of new sequencing technologies which generate read 
lengths of several thousand base pairs, such as MinION nanopore sequencing (Oxford 
Nanopore) and PacBio single molecule real time sequencing (Pacific Biosciences). Assembly 
of larger fragments into a functional genome sequence would then be a much less complex 
task and therefore the prospect of obtaining a genome sequence for opium poppy is much 
more feasible. Access to a genome sequence in conjunction with high density genetic maps 
will aid in the identification of genes involved in BIA biosynthesis and other important 
agronomic traits. A genome sequence will also allow for studies of the evolutionary 
relationships between other alkaloid producing plant species and give some insight into how 
the pathways evolved. 
As well as continuing to identify alleles of CODM and T6ODM for incorporation into the 
breeding programme, rational engineering of BIA metabolism in opium poppy will require a 
much deeper knowledge of how BIA synthesis is regulated in the plant at the transcriptional, 
cellular and biochemical levels. Obvious future targets would be transcription factors 
involved in initiating synthesis of key enzymes and metabolic components. Furthermore, 
there is still much to be learned about intra-and inter-cellular transport of pathway 
intermediates. If transporters are involved then regulation of their synthesis or activities 
would be one way to impact on BIA metabolism. Comparative transcriptomic profiling of 
morphine accumulating lines and, for example, the thebaine/oripavine only mutants or high 
thebaine mutants for which no T6ODM mutations have been found but transcript levels are 
reduced, may be a starting point in identifying putative regulators or transporters which may 
be affected in high thebaine lines.  
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Another way to employ marker assisted selection for the improvement of opium poppy 
crops is to identify resistance markers for downy mildew (Peronaspora). An outbreak of 
downy mildew was first reported in a commercial crop in Tasmania in 1996 (Scott et al., 
2004) and the 2014-2015 growing season in Tasmania featured many outbreaks throughout 
the state with many commonly used fungicides proving ineffective. A genetic study of downy 
mildew resistance indicated polygenic control (Dubey et al., 2008). Identification of these 
alleles and their incorporation into commercial crops should be prioritised.  
Overall TILLING has proved to be an effective strategy for detecting induced genetic 
variation. It is recognised as a useful tool when working with neglected or underutilised 
crops, so-called orphan crops, where access the genetic diversity is a problem for researchers 
(Jain and Gupta, 2013). EcoTILLING can be deployed to mine for alleles in other varieties but 
in the case of opium poppy access to genetic diversity in difficult to come by. Nevertheless, 
this study has demonstrated that utilisation of chemically induced variation is possible in 
poppy. The TILLING platform used allows for screening large sections of a target gene in a 
cost effective manner. TILLING using next generation sequencing platforms requires complex 
barcoding and is limited to read length of the machine used while high resolution melting 
platforms are limited to 300-400 bp TILLING ‘windows’.  
An alternative to TILLING would have been to use genetic modification to knockout the 
desired genes and achieve the required phenotypes. As discussed in section 1.8.1 genetically 
modified opium poppy crops are not currently used and in Tasmania, where half of the 
world’s opiate based medicines originate, there is a moratorium on the use of GM crops. 
During the lifetime of this project, the CRISPR/Cas9system, adapted from a bacterial immune 
system, has come to force as a simple, inexpensive and versatile tool for genome editing 
(Bortesi and Fischer, 2015). Two years ago five reports were published at the same time 
detailing the first applications of the CRISPR/Cas9-based genome editing in plants (Feng et 
al., 2013; Li et al., 2013; Nekrasov et al., 2013; Shan et al., 2013; Xie and Yang, 2013). Genome 
editing promises to accelerate plant breeding by helping to overcome problems with 
conventional breeding such as finding and exploiting natural genetic variation. Furthermore, 
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random mutagenesis programmes such as this one require large-scale screens to identify 
mutants with desirable properties and an extensive series of backcrosses to remove 
undesired mutations.  With genome editing it is possible to introduce specific and predictable 
modifications directly into elite material. With the sequence similarity observed between 
copies of CODM, a guide RNA for CODM might efficiently disrupt all copies. It remains to be 
seen whether new crops developed with this technology will be classified as GM and whether 
they will carry the same regulatory burdens (Hartung and Schiemann, 2014). Use of site-
specific nucleases means that the number of off-site mutations is much less than using 
chemical and physical mutants and means there is less of the perceived concern with GM 
technology that transgenes will integrate randomly in the genome and produce unintended 
consequences such as disrupting host metabolism or synthesis of toxic or allergenic 
compounds (Podevin et al., 2013). Although there have been several cases where the US 
Department of Agriculture ruled products of this technology do not have to be treated as GM 
organisms, the EU commission has not yet adopted a stance and this is frustrating efforts to 
adopt gene-editing throughout the 28 member states (Abbott, 2015). The technology has 
progressed rapidly in recent years, and if starting the project again now, genome editing 
would have to be considered as a realistic means to achieve the end goals. Likewise the cost 
of next generation sequencing has continued to come down and perhaps with a genome 
sequence of opium poppy, and prior knowledge of the number of copies of DIOX genes and 
their locations, different decisions could have been made and different points in the project 
i.e. more sequence information may have aided primer design for TILLING, the screens would 
have been limited to only those copies likely to be functional, crosses between plants with 
mutations in closely linked genes may not have been attempted (i.e. the W261* x Q254* 
cross) and the regulatory regions of DIOX genes could have been assessed for induced 
changes in nucleic acid sequence in those lines which have high thebaine/oripavine but for 
which no change in the coding sequence has yet been detected.  
The work has also demonstrated the expression levels of CODM and T6ODM at various 
stages of plant development. Flowering was shown to be an important time for changes in 
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gene expression and changes in alkaloid composition of the latex. The activities of these 
genes in pathways other than morphine biosynthesis were also confirmed. CODM mutant 
plants had increased levels of cryptopine and protopine alkaloids in their roots while the 
levels in the roots of T6ODMa knockout was similar to wild type HM2. The highest levels 
were observed in the HighT fwd screen mutant, presumably due to reduced activities of 
T6ODMb or other copies of T6ODM. The exact roles of each the different copies of T6ODM 
needs to be investigated. It is probable that gene duplication has resulted in a family of genes 
with roles in a variety of biosynthetic pathways-the morphinan but also in the pathways to 
protopines (Farrow and Facchini, 2013) and pacodine (Farrow and Facchini, 2015). T6ODMb, 
for example, looks to be intermediary between T6ODMa (98% sequence identity at the amino 
acid level) and CODM i.e. in those positions where amino acid differences exist between 
T6ODMa and T6ODMb, the amino acid of T6ODMb corresponds to the amino acid at the 
equivalent position in CODM. It remains to be seen what its substrate specificities are and 
how efficient it is in comparison to CODM and T6ODMa.  
Combining detected mutations in different copies of CODM by crossing failed due to close 
linkage. Evidence to support this conclusion was gained when the BAC sequences also 
suggested physical proximity of some copies. Therefore, alternative strategies for obtaining 
complete blocks a certain metabolic steps would be required. By embarking on another 
round of EMS mutagenesis of bulked up CODMb Q254* mutant seed an alternative strategy 
was initiated. Physical rather than chemical mutagens could be deployed if further BAC or 
genomic sequencing reveals close linkage of copies of CODM. Gamma radiation can produce 
small indels as well as point mutations (mostly transversions as opposed to transitions) as 
demonstrated by exposure of seeds of japonica rice to 500 Gy of gamma rays (Sato et al., 
2006). Fast neutrons are uncharged particles of high kinetic energy and are generated in 
nuclear reactors or in accelerators. Fast neutrons impart some of their high kinetic energy via 
collisions, largely with protons within the material. Fast neutron mutagenesis generally 
causes genomic deletions rather than point mutations. “Delete-a-gene” technology can be 
used to screen for deletions using primers flanking the target gene. Discovery can be aided by 
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adjusting the PCR extension time to promote the preferential amplification of shorter 
amplicons (Li et al., 2002; Li and Zhang, 2002). This method was improved upon in deletion-
based (de)-TILLING whereby much smaller deletions could be detected in a very large 
Medicago truncatula fast neutron generated mutant population (Rogers et al., 2009). This is a 
variation on TILLING where mutant populations are screened for deletions using two rounds 
of nested PCRs in which a third ‘poison’ primer (in the deleted region) is included. The poison 
primer amplifies a ‘suppressor’ product which, being smaller, is amplified from the wild type 
more efficiently. The amplicon cannot act as a template in the second round of PCR, however, 
and the mutant product is amplified efficiently. Fast neutron mutagenesis of opium poppy has 
been described before but the molecular basis of the observed phenotypes has not been 
elucidated (Fist et al., 2013). In order to carry out effective TILLING or (de)-TILLING studies 
additional sequence information is required to understand the genomic context of these 2-
ODD genes. With the advent of ever more affordable next generation sequencing platforms, 
the possibility of sequencing the genome of opium poppy must be a realistic prospect. In the 
meantime, the material generated in this project provides a good starting point for further 
marker assisted breeding to create bespoke varieties of opium poppy. For example, 
introducing the CODMa/c E193K and CODMb R158K mutations into a commercial morphine 
line increased codeine yields 6 fold. Introducing these CODM mutations to a high thebaine 
line had the effect of increasing thebaine yields still further. Finally, further work is required 
to identify the causative mutations involved in the high oripavine phenotypes observed in 
this project.  
A growing area of research is in the development of microbial based systems for the 
production of plant natural products. Common reasons cited for this approach include supply 
inefficiencies and variability in yields associated with the impact of climate and disease. The 
general objective of such work is to engineer microbes to complement or even replace plant 
based production systems. One such example is the supply of the antimalarial drug 
artemisinin. It can be isolated from the medicinal plant Artemisia annua (Sweet wormwood) 
which is cultivated in China, Vietnam and East Africa. Recently, synthetic biology researchers 
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have generated a strain of yeast that contains the required plant genes to reconstitute the 
pathway to a precursor of artemisinin, artemisinic acid. Since 2013, French company Sanofi 
have been using this technology for the commercial production of artemisinin at a facility in 
Italy. The production costs are in the region of $350-400 per kg which is comparable to the 
cost of plant biomass based extraction (Schaefer, 2015). This approach is seen as a steady and 
less volatile supply source of the drug and could supplement plant based production systems 
which still have major role with the advent of new high yielding varieties developed with 
molecular breeding techniques (Graham et al., 2010; Townsend et al., 2013). As mentioned in 
section 1.6.4 there has been a push recently to move BIA biosynthesis from opium poppy into 
yeast based production systems. Yields of, for example, thebaine from yeast based systems 
are still relatively small and inefficient-a yield of 6.4 μg/l thebaine was reported from strains 
of yeast with an impressive construction of 24 heterologous expression cassettes, 21 new 
enzyme activities and overexpression/inactivation of native enzymes (Galanie et al., 2015). 
The authors recognise that several orders of magnitude greater yields will be required if 
commercial production of morphinans in yeast based systems is to be feasible. It was claimed 
that a target of 5 g/l would need to be reached. A 5 ml culture would therefore produce 25 mg 
thebaine and potentially reduce the need for the cultivation of 0.2m2 of opium poppy. 
However thebaine yields of 70 kg per hectare (10000 m2) are achievable in Tasmania which 
equates to 1400 mg per 0.2 m2.  Therefore the 5 g/l target may still be an underestimation 
(50x) of the yield that would be required to become competitive with the existing poppy 
industry. However, the potential of the approach may well be in the formation of derivatives, 
both known and new to nature. Experimenting with various tailoring enzymes on a plant-
derived scaffold may in future produce novel alkaloids with medicinal uses. It may also be 
useful for the production of compounds that are extracted from other plants with less 
established agricultural practices, those more susceptible to changes in climate and disease 




Appendix A- Creation of DNA pool plates for TILLING 
Numbers refer to the Sd numbers of plants from which DNA was placed in each pool i.e. well 
A1 of pool plate 1 contained DNA from Sd-100001, Sd-100002, Sd-100003 and Sd-100004. 
 
Pool Plate 1 




row A 1 2 3 4 5 6 7 8 9 10 11 12 
A 100001 100009 100017 100025 100033 100041 100049 100057 100065 100073 100177 100185 
B 100002 100010 101203 100026 100034 100042 100050 100058 100066 100074 100178 100186 
C 100003 100011 100019 100027 100035 100043 100051 100059 100067 100075 100179 100187 
D 100004 101202 100020 100028 100036 100044 100052 100060 100068 100076 100180 100188 
row B 1 2 3 4 5 6 7 8 9 10 11 12 
E 100005 100013 100021 100029 100037 100045 100053 100061 100069 100077 100181 100189 
F 100006 100014 100022 100030 100038 100046 100054 100062 101213 100078 100182 100190 
G 100007 100015 100023 100031 101204 100047 100055 100063 100071 100079 100183 100191 




row C 1 2 3 4 5 6 7 8 9 10 11 12 
A 100081 100089 100097 100105 100113 100121 101211 100137 100145 100153 100161 100169 
B 100082 101206 101209 100106 100114 100122 100130 100138 100146 100154 101214 100170 
C 100083 100091 100099 100107 100115 100123 100131 100139 100147 100155 100163 100171 
D 101205 100092 100100 100108 100116 100124 100132 100140 101212 100156 100164 100172 
row D 1 2 3 4 5 6 7 8 9 10 11 12 
E 100085 101207 1000101 100109 100117 100125 100133 100141 100149 100157 100165 100173 
F 100086 100094 100102 100110 100118 100126 100134 100142 100150 100158 100166 100174 
G 100087 100095 100103 101210 100119 100127 100135 100143 100151 100159 100167 100175 




row E 1 2 3 4 5 6 7 8 9 10 11 12 
A 100193 100281 100289 100297 100305 100313 100321 101230 100337 100345 100353 100361 
B 100194 100282 101227 100298 100306 100314 100322 101330 100338 100346 100354 100362 
C 100195 100283 100291 100299 101228 100315 100323 101331 100339 100347 100355 101231 
D 100196 100284 100292 100300 100308 100316 100324 101332 100340 100348 100356 100364 
row F 1 2 3 4 5 6 7 8 9 10 11 12 
E 100197 100285 100293 100301 101229 100317 100325 100333 100341 100349 100357 100365 
F 101215 100286 100294 100302 100310 100318 100326 100334 100342 100350 100358 100366 
G 100199 100287 100295 100303 100311 100319 100327 100335 100343 100351 100359 100367 




row G 1 2 3 4 5 6 7 8 9 10 11 12 
A 100201 100209 100217 100225 100233 100241 100249 100257 100265 100273 100369 100377 
B 100202 101216 100218 100226 101220 100242 100250 100258 100266 100274 100370 100378 
C 100203 100211 100219 101217 100235 100243 100251 100259 100267 100275 100371 100379 
D 100204 100212 100220 100228 100236 100244 100252 100260 100268 100276 100372 100380 
row H 1 2 3 4 5 6 7 8 9 10 11 12 
E 100205 100213 100221 100229 101221 100245 100253 100261 100269 101232 100373 100381 
F 100206 100214 100222 101218 100238 100246 101223 100262 100270 100278 100374 100382 
G 100207 100215 100223 100231 100239 100027 100255 100263 100271 10079 100375 100383 







Pool Plate 2 
           
Source Plate  
D-10005 
row A 1 2 3 4 5 6 7 8 9 10 11 12 
A 100401 100409 100417 100425 100433 100441 100449 100457 100465 100473 100481 100489 
B 100402 100410 100418 100426 100434 100442 100450 101236 100466 100474 100482 100490 
C 100403 101224 100419 100427 100435 100443 100451 100459 100467 100475 100483 100491 
D 100404 100412 101233 100428 100431 100444 100452 100460 100468 100476 100484 100492 
row B 1 2 3 4 5 6 7 8 9 10 11 12 
E 100405 100413 100421 100429 100437 100445 100453 101237 100469 100477 100485 100493 
F 100406 100414 100423 100430 100438 100446 100454 100462 100470 100478 100486 100494 
G 100407 100415 100423 100431 100434 100447 100455 100463 101238 100479 100487 100495 
H 100408 101226 100424 101234 100440 100448 100456 100464 100472 100480 100488 100496 
Source Plate  
D-10006 
row C 1 2 3 4 5 6 7 8 9 10 11 12 
A 100497 100505 100513 100521 100529 100537 100545 100553 100561 100569 100577 100585 
B 100498 100506 100514 100522 100530 100538 101164 100554 100562 100570 100578 100586 
C 100494 100507 100515 100523 100531 100539 100547 100555 100563 100571 100579 100587 
D 100500 100508 100516 101162 100532 100540 100548 100556 100564 100572 100580 100588 
row D 1 2 3 4 5 6 7 8 9 10 11 12 
E 100501 100509 101161 100525 100533 100541 100549 100557 100565 100573 100582 100589 
F 100502 100510 100518 100526 100534 100542 100550 100558 100566 100574 100581 100590 
G 100503 100511 100519 100527 100535 100543 100551 100559 100567 100575 100583 100591 
H 101240 100512 100520 100528 100536 100544 100552 100560 100568 100576 100584 100592 
Source Plate  
D-10007 
row E 1 2 3 4 5 3 7 8 9 10 11 12 
A 100593 100601 100609 100617 100625 100633 100641 100649 100657 100664 101177 100680 
B 100594 100602 100610 100618 100626 100634 100642 100650 100658 100665 100673 101181 
C 100595 100603 100611 100619 100627 100635 100643 100651 100659 100666 101178 101182 
D 100596 100604 100612 100620 100628 100636 101169 100652 100660 100667 100675 101185 
row F 1 2 3 4 5 6 7 8 9 10 11 12 
E 100597 100605 100613 100621 100629 100637 100645 100653 100661 100668 101179 101186 
F 100598 100606 100614 100622 100630 100638 100646 101172 101174 100669 100677 101187 
G 100599 100607 100615 100623 100631 100639 100647 100655 100663 100670 100678 101188 
H 100600 100608 100616 100624 100632 100640 101171 100656 100662 100671 101180 101189 
Source Plate  
D-10008 
row G 1 2 3 4 5 6 7 8 9 3 11 12 
A 100385 100393 100761 100769 100777 100785 100793 100681 100689 100697 100705 100713 
B 100386 100394 100762 101165 100778 100786 100794 100682 100690 100698 101190 100714 
C 100387 100395 100763 100771 100779 100787 100795 100683 100691 100699 100707 100715 
D 100388 100396 100764 100772 100780 100788 100796 100684 100692 100700 100708 100716 
row H 1 2 3 4 5 6 7 8 9 10 11 12 
E 100389 100397 100765 100773 100781 100789 100797 100685 100693 100701 100709 100717 
F 100390 100398 100766 100774 100782 100790 100798 100686 100694 100702 100710 100718 
G 100391 100399 100767 100775 100783 100791 100799 100687 100695 100703 100711 100719 













Pool Plate 3 
           
Source Plate  
D-10009 
row A 1 2 3 4 5 6 7 8 9 10 11 12 
A 100721 100729 100737 100745 100753 100841 100849 100857 100865 100873 100801 100809 
B 100722 100730 100738 100746 100754 100842 100850 100858 100866 100874 100802 100810 
C 100723 100731 100739 100747 100755 100843 100851 100859 100867 100875 100803 100811 
D 100724 100732 100740 100748 100756 100844 100852 100860 100868 101184 100804 100812 
row B 1 2 3 4 5 6 7 8 9 10 11 12 
E 100725 100733 100741 100749 100757 100845 100853 100861 100869 100877 100805 100813 
F 100726 100734 100742 100750 100758 100846 100854 100862 100870 100878 100806 100814 
G 100727 100735 100743 100751 100759 100847 100855 100863 100871 100879 100807 100815 
H 100728 100736 101166 101168 101170 101173 100856 100864 100872 100880 10088 101191 
Source Plate  
D-10010 
row C 1 2 3 4 5 6 7 8 9 10 11 12 
A 100881 100889 100897 100905 101154 100921 100929 100937 100945 100953 100961 100969 
B 100882 100890 100898 100906 100914 100922 100930 100938 100946 100954 100962 101197 
C 100883 100891 100899 100907 100915 100923 100931 100939 100947 100955 100963 100971 
D 100884 100892 100900 100908 100916 100924 100932 100940 100948 100956 100964 100972 
row D 1 2 3 4 5 6 7 8 9 10 11 12 
E 100885 100893 100901 100909 100917 100925 100933 101195 100949 100957 100965 100973 
F 100886 100894 100902 100910 100918 100926 100934 100942 100950 100958 100966 100974 
G 100887 100895 100903 100911 100919 100927 100935 100943 100951 100959 100967 100975 
H 100888 100896 101193 100912 100920 100928 100936 100944 100952 100960 101196 100976 
Source Plate  
D-10011 
row E 1 2 3 4 5 6 7 8 9 10 11 12 
A 100817 100825 100833 101121 101009 101017 101025 101033 101131 101089 101135 101138 
B 100818 100826 100834 101002 101010 101018 101026 101130 101082 101133 101098 101106 
C 100819 100827 100835 101003 101011 101019 101027 101035 101083 101091 101099 101107 
D 100820 100828 100836 101004 101012 101020 101028 101036 101084 101092 101100 101108 
row F 1 2 3 4 5 6 7 8 9 10 11 12 
E 100821 100829 100837 101005 101013 101021 101029 101037 101085 101093 101101 101109 
F 100822 100830 100838 101006 101014 101022 101030 101038 101086 101094 101136 101110 
G 101198 100831 100839 101007 101015 101023 101031 101039 101087 101134 101103 101111 
H 100824 100832 101200 101008 101016 101024 101128 101040 101132 101096 101137 101112 
Source Plate  
D-10012 
row G 1 2 3 4 5 6 7 8 9 10 11 12 
A 100977 100985 100993 101041 101049 101057 101065 101073 101140 101149 101158   
B 100978 100986 100994 101042 101050 101058 101066 101074 101141 101150 101159   
C 100979 100987 100995 101043 101051 101059 101067 101075 101142 101151 101114   
D 100980 100988 101122 101044 101052 101060 101068 101076 101143 101152 101116   
row H 1 2 3 4 5 6 7 8 9 10 11 12 
E 100981 100989 100997 101045 101053 101061 101069 101077 101145 101153 101118   
F 100982 101199 100998 101046 101054 101062 101070 101078 101146 101154 
 
  
G 100983 100991 100999 101123 101055 101063 101071 101079 101147 101155 
 
  









Pool Plate 4 
           
Source Plate 
D-100013 
row A 1 2 3 4 5 6 7 8 9 10 11 12 
A 101297 101265 101273 101262 101289 101297 101306 101314 101322 101330 101338 101348 
B 101249 101266 101274 101281 101290 101298 101307 101315 101323 101331 101339 101349 
C 101241 101267 101275 101282 101291 101299 101308 101316 101324 101332 101341 101350 
D 101256 101268 101276 101283 101292 101300 101309 101317 101325 101333 101342 101351 
row B 1 2 3 4 5 6 7 8 9 10 11 12 
E 101258 101269 101277 101284 101293 101301 101310 101318 101326 101334 101343 101352 
F 101259 101270 101278 101285 101294 101302 101311 101319 101327 101335 101344 101353 
G 101261 101271 101279 101286 101295 101303 101312 101320 101328 101336 101345 101357 
H 101263 101272 101280 101287 101296 101304 101313 101321 101329 101337 101346 101358 
Source Plate 
D-10014 
row C 1 2 3 4 5 6 7 8 9 10 11 12 
A 101359 101367 101375 101383 101394 101405 101419 101428 101439 101448 101456 101464 
B 101360 101368 101376 101384 101396 101410 101420 101429 101440 101449 101457 101465 
C 101361 101369 101377 101386 101397 101411 101421 101430 101441 101450 101458 101466 
D 101362 101370 101378 101387 101398 101413 101422 101431 101442 101451 101459 101467 
row D 1 2 3 4 5 6 7 8 9 10 11 12 
E 101363 101371 101379 101388 101399 101414 101424 101432 101443 101452 11460 101468 
F 101364 101372 101380 101389 101400 101415 101425 101434 101444 101453 101461 101469 
G 101365 101373 101381 101390 101401 101417 101426 101437 101446 101454 101462 101470 
H 101366 101374 101382 101392 101403 101418 101427 101438 101447 101455 101463 101471 
Source Plate 
D-10015 
row E 1 2 3 4 5 6 7 8 9 10 11 12 
A 101472 101480 101488 101496 101508 101522 101542 101560 101694 101712 101729 101738 
B 101473 101481 101489 101498 101509 101526 101543 101683 101695 101714 101730 101739 
C 101474 101482 101490 101499 101510 101528 101549 101684 101696 101720 101731 101740 
D 101475 101483 101491 101500 101512 101531 101550 101685 101699 101721 101732 101741 
row F 1 2 3 4 5 6 7 8 9 10 11 12 
E 101476 101484 101493 101501 101514 101534 101551 101686 101701 101722 101733 101742 
F 101477 101485 101494 101502 101515 101535 101552 101687 101704 101723 101734 101743 
G 101478 101486 101495 101503 101519 101536 101554 101688 101706 101726 101735 101744 
H 101479 101487 101497 101506 101520 101541 101557 101691 101711 101728 101736 101745 
Source Plate 
D-10016 
row G 1 2 3 4 5 6 7 8 9 10 11 12 
A 101564 101576 101586 101594 101604 101613 101621 101630 101638 101646 101656 101664 
B 101566 101577 101587 101596 101605 101614 101623 101631 101639 101649 101657 101665 
C 101567 101578 101588 101597 101606 101615 101624 101632 101640 101650 101658 101666 
D 101569 101580 101589 101598 101607 101616 101625 101633 101641 101651 101659 101667 
row H 1 2 3 4 5 6 7 8 9 10 11 12 
E 101570 101582 101590 101599 101608 101617 101626 101634 101642 101652 101660 101668 
F 101573 101583 101591 101600 101610 101618 101627 101635 101643 101653 101661 101669 
G 101574 101584 101592 101602 101611 101619 101628 101636 101644 101654 101662 101670 









Pool Plate 5 




row A 1 2 3 4 5 6 7 8 9 10 11 12 
A 101747 101755 101763 101772 101780 101788 101796 101804 101815 101822 101831 101840 
B 101748 101756 101764 101773 101781 101789 101797 101805 101814 101823 101832 101961 
C 101749 101757 101765 101774 101782 101790 101798 101806 101816 101825 101833 101962 
D 101750 101758 101766 10775 101783 101791 101799 101807 101817 101826 101834 101964 
row B 1 2 3 4 5 6 7 8 9 10 11 12 
E 101751 101759 101767 101776 101784 101792 101800 101808 101808 101827 101835 101963 
F 101752 101760 101768 101777 101785 101793 101801 101810 101810 101828 101837 101965 
G 101753 101761 101769 101778 101786 101794 101802 101812 101812 101829 101838 101966 




row C 1 2 3 4 5 6 7 8 9 10 11 12 
A 101672 101841 101852 101861 101871 101885 101894 101902 101910 101918 101926 101934 
B 101673 101842 101853 101862 101872 101886 101895 101903 101911 101919 101927 101935 
C 101675 101843 101854 101864 101874 101888 101896 101904 101912 101920 101928 101936 
D 101676 101845 101855 101865 101875 101889 101897 101905 101913 101921 101929 101937 
row D 1 2 3 4 5 6 7 8 9 10 11 12 
E 101677 101847 101856 101866 101878 101890 101898 101906 101914 101922 101930 101938 
F 101678 101848 101857 101868 101880 101891 101899 101907 101915 101923 101931 101939 
G 101679 101849 101858 101870 101881 101892 101900 101908 101916 101924 101932 101940 




row E 1 2 3 4 5 3 7 8 9 10 11 12 
A 101968 101977 101985 101985 101993 102001 102009 102018 102029 102041 102059 102067 
B 101969 101978 101986 101986 101994 102002 102010 102019 102031 102042 102060 102068 
C 101970 101979 101987 101987 101995 102003 102011 102020 102032 102043 102061 102069 
D 101972 101980 101988 101988 101996 102004 102012 102021 102033 102044 10206 102070 
row F 1 2 3 4 5 6 7 8 9 10 11 12 
E 101973 101981 101989 101989 101997 102005 102013 102022 102034 102046 102063 102071 
F 101974 101982 101990 101990 101998 102006 102014 102023 102038 102047 102064 102072 
G 101975 101983 101991 101991 101999 102007 102015 102024 102939 102049 102065 102073 




row G 1 2 3 4 5 6 7 8 9 3 11 12 
A 101942 101950 101959 102087 102095 102104 102112 102120 102288 102296 102305 102313 
B 101943 101951 101960 102088 102096 102105 102113 102281 102289 102297 102306 10314 
C 101944 101952 102081 102089 102097 102106 102114 102282 102290 102298 102307 102315 
D 101945 101954 102082 102090 102098 102107 102115 102282 102291 102300 102308 102316 
row H 1 2 3 4 5 6 7 8 9 10 11 12 
E 101946 101955 102084 102091 102100 102108 102116 102284 102292 102301 102309 102317 
F 101947 101956 102083 102092 102101 102109 102117 102285 102293 102302 102310 102318 
G 101948 101957 102085 102093 102102 102110 102118 102286 102294 102303 102311 102319 









Pool Plate 6 
           
Source Plate 
D-10021 
row A 1 2 3 4 5 6 7 8 9 10 11 12 
A 102075 102163 102171 102179 102188 102198 102209 102218 102227 102236 102245 102253 
B 102076 102164 102172 102180 102189 1021990 102210 102219 102228 102237 102246 102254 
C 102077 102165 102173 102181 102190 102200 102211 102220 102229 102238 102247 102255 
D 102078 102166 102174 102182 102191 102203 102212 102221 102230 102239 102248 102256 
row B 1 2 3 4 5 6 7 8 9 10 11 12 
E 102079 102167 102175 102183 102192 102204 102213 102223 102231 102241 102249 102257 
F 102080 102168 102176 102184 102195 102205 102214 102224 102232 102242 102250 102258 
G 102161 102169 102177 102186 102196 102206 102216 102225 102234 102243 102251 102259 
H 102162 102170 102178 102187 102197 102207 102217 102226 102235 102244 102252 102260 
Source Plate 
D-10022 
row C 1 2 3 4 5 6 7 8 9 10 11 12 
A 102321 102329 102337 102346 102354 102364 102372 102383 102393 102404 102413 102423 
B 102322 102330 102338 102347 102355 102365 102373 102385 102394 102405 102415 102425 
C 102323 102331 102340 102348 102356 102366 102374 102386 102396 102406 102417 102426 
D 102324 102332 102341 102349 102357 102367 102377 102387 102397 102407 102418 102427 
row D 1 2 3 4 5 6 7 8 9 10 11 12 
E 102325 102333 102342 102350 102359 102368 102378 102388 103398 102409 102419 102428 
F 102326 102334 102343 102351 102360 102369 102379 102389 102399 102410 102420 102429 
G 102327 102335 102344 102352 102361 102370 102380 102390 102401 102411 102421 102430 
H 102328 102336 102345 102353 102362 102371 102381 102391 102402 102412 102422 102431 
Source Plate 
D-10023 
row E 1 2 3 4 5 6 7 8 9 10 11 12 
A 102261 102270 102432 102440 102448 102456 102467 
    
  
B 102262 102273 102433 102441 102449 102457 102468 
    
  
C 102263 102274 102434 102442 102450 102458 102471 
    
  
D 102264 102276 102435 102443 102451 102460 102473 
    
  
row F 1 2 3 4 5 6 7 8 9 10 11 12 
E 102265 102277 102436 102444 102452 102462 102474 
    
  
F 102266 102278 102437 102445 102453 102463 102475 
    
  
G 102268 102279 102438 102446 102454 102464 102476 
    
  
H 102269 102280 102439 102447 102455 102466 102477 




row G 1 2 3 4 5 6 7 8 9 10 11 12 
A 102482 102490 102499 102507 102515 102563 102571 102579 102587 102596 102644 102652 
B 102483 102491 102500 102508 102508 102564 102572 102580 102588 102597 102645 102653 
C 102484 102492 102501 102509 102509 102565 102573 102581 102589 102598 102646 102654 
D 102485 102493 102502 102510 102510 102566 102574 102582 102590 102599 102647 102655 
row H 1 2 3 4 5 6 7 8 9 10 11 12 
E 102486 102494 102503 102511 102511 102567 102575 102583 102591 102600 102648 192656 
F 102487 102495 102504 102512 102512 102568 102576 102584 102592 102641 102649 102657 
G 102488 102496 102505 102513 102513 102569 102577 102585 102593 102642 102650 102658 









Pool Plate 7 




row A 1 2 3 4 5 6 7 8 9 10 11 12 
A 102521 102531 102539 102548 102556 102605 102613 102621 102629 102637 102686 102694 
B 102522 102532 102540 102549 102557 102606 102614 102622 102630 102638 102687 102695 
C 102524 102533 102541 102550 102558 102607 102615 102623 102631 102639 102688 102696 
D 102525 102534 102542 102551 102559 102608 102616 102624 102632 102640 102689 102697 
row B 1 2 3 4 5 6 7 8 9 10 11 12 
E 102526 102535 102543 102552 102560 102609 102617 102625 102633 102681 102690 102698 
F 102527 102536 102544 102553 102601 102610 102618 102626 102634 102682 102691 102699 
G 102529 102537 102545 102554 102603 102611 102619 102627 102635 102683 102692 102700 




row C 1 2 3 4 5 6 7 8 9 10 11 12 
A 102660 102668 102676 102726 102735 102744 102754 102832 102843 102852 102860 102869 
B 102661 102669 102677 102727 102736 102746 102755 102833 102844 102853 102861 102870 
C 102662 102670 102678 102728 102738 102747 102756 102835 102845 102854 102852 102912 
D 102663 102671 102679 102729 102739 102748 102757 102836 102844 102863 102864 102914 
row D 1 2 3 4 5 6 7 8 9 10 11 12 
E 102664 102672 102680 102730 102740 102749 102758 102837 102847 102856 102865 102915 
F 102665 102673 102721 102731 102741 102750 102759 102840 102848 102857 102866 102916 
G 102666 102674 102723 102733 102742 102751 102760 102841 102849 102858 102867 102917 




row E 1 2 3 4 5 6 7 8 9 10 11 12 
A 102702 102710 102718 102786 102777 102786 102799 102877 102885 102893 102901 102910 
B 102703 102711 102719 102769 102778 102788 102800 102878 102886 102894 102902 102951 
C 102704 102712 102720 102771 102779 102789 102871 102879 102887 102895 102903 102952 
D 102705 102713 102761 102772 102780 102790 102872 102880 102888 102896 102904 102953 
row F 1 2 3 4 5 6 7 8 9 10 11 12 
E 102706 102714 102762 102773 102781 102791 102873 102881 102889 102897 102905 102954 
F 102707 102715 102763 102774 102782 102792 102874 102882 102890 102898 102906 102955 
G 102708 102716 102765 102775 102783 102797 102875 102883 102891 102899 102908 102956 




row G 1 2 3 4 5 6 7 8 9 10 11 12 
A 102919 102927 102938 102992 103002 103011 103020 103193 103201 103209 103217 103225 
B 102920 102928 102941 102994 103003 103012 103021 103194 103202 103210 103218 103226 
C 102921 102929 102943 102996 103004 103014 103022 103195 103203 103211 103219 103227 
D 102922 102930 102944 102997 103005 103015 103024 103196 103204 103212 103220 103228 
row H 1 2 3 4 5 6 7 8 9 10 11 12 
E 102923 102933 102945 102998 103006 103016 103027 103197 103205 103213 103221 103229 
F 102924 102935 102946 102999 103007 103017 103028 103198 103206 103214 103222 103230 
G 102925 102936 102950 103000 103009 103018 103030 103199 103207 103215 103323 103232 









Pool Plate 8 




row A 1 2 3 4 5 6 7 8 9 10 11 12 
A 102958 102966 102974 102982 102990 103038 103047 103055 103063 103071 103079 103087 
B 102959 102967 102975 102983 103031 103039 103048 103056 103064 103072 103080 103088 
C 102960 102968 102976 102984 103032 103041 103049 103057 103065 103073 103081 103089 
D 102961 102969 102977 102985 103033 103042 103050 103058 103066 103074 103082 103090 
row B 1 2 3 4 5 6 7 8 9 10 11 12 
E 102962 102970 102978 102986 103034 103043 103051 103059 103067 103075 103083 103091 
F 102963 102971 102979 102987 103035 103044 103052 103060 103068 103076 103084 103092 
G 102964 102972 102980 102988 103036 103045 103053 103061 103069 103077 103085 103093 




row C 1 2 3 4 5 3 7 8 9 10 11 12 
A 103095 103103 103111 103119 103128 103136 103144 103152 103160 103168 103176 103184 
B 103096 103104 103112 103120 103129 103137 103145 103153 103161 103169 103177 103185 
C 103097 103105 103113 103121 103130 103138 103146 103154 103162 103170 103178 103186 
D 103098 103106 103114 103122 103131 103139 103147 103155 103163 103171 103179 103187 
row D 1 2 3 4 5 6 7 8 9 10 11 12 
E 103099 103107 103115 103123 103132 103140 103148 103156 103164 103172 103180 103188 
F 103100 103108 103116 103124 103133 103141 103149 103157 103165 103173 103181 103189 
G 103101 103109 103117 103125 103134 103142 103150 103158 103166 103174 103182 103190 




row E 1 2 3 4 5 6 7 8 9 3 11 12 
A 103234 103244 103252 103261 103270 103279 103289 103298 103307 103317 103328 103337 
B 103235 103245 103253 103262 103271 103282 103290 103299 103309 103318 103330 103338 
C 103236 103246 103255 103264 103272 103283 103291 103300 103310 103319 103331 103339 
D 103239 103247 103256 103265 103273 103284 103292 103301 103311 103320 103332 103340 
row F 1 2 3 4 5 6 7 8 9 10 11 12 
E 103240 103248 103257 103266 103274 103285 103293 103302 103312 103321 103333 103341 
F 103241 103249 103258 103267 103276 103286 103295 103303 103314 103322 103334 103342 
G 103242 103250 103259 103268 103277 103287 103296 103304 103315 103324 103335 103343 




row G 1 2 3 4 5 6 7 8 9 10 11 12 
A 103348 103357 103366 103378 103389 103397 103409 103419 103428 103438 103447 103456 
B 103349 103358 103367 103379 103390 103398 103411 103420 103429 103439 103448 103458 
C 103350 103359 103369 103381 103391 103399 103412 103421 103432 103440 103449 103459 
D 103351 103360 103370 103382 103392 103402 103413 103422 103433 103442 103451 103460 
row H 1 2 3 4 5 6 7 8 9 10 11 12 
E 103352 103361 103371 103383 103393 103405 103415 103423 103434 103443 103452 103461 
F 103353 103362 103373 103385 103394 103406 103416 103424 103435 103444 103453 103462 
G 103354 103364 103375 103386 103395 103407 103417 103426 103436 103445 103454 103464 









Pool Plate 9 




row A 1 2 3 4 5 6 7 8 9 10 11 12 
A 103466 103477 103489 103497 103507 103517 103529 103540 103551 103560 103632 103642 
B 103467 103479 103490 103498 103508 103518 103530 103546 103552 103561 103634 103644 
C 103468 103480 103491 103499 103509 103519 103532 103547 103553 103562 103636 103645 
D 103469 103482 103492 103500 103510 103520 103534 103548 103555 103563 103637 103646 
row B 1 2 3 4 5 6 7 8 9 10 11 12 
E 103471 103483 103493 103501 103512 103523 103535 103549 103554 103564 103638 103647 
F 103472 103484 103494 103504 103514 103514 103536 103550 103556 103565 103639 103648 
G 103474 103485 103495 103505 103515 103525 103537 103629 103557 103566 103340 103626 




row C 1 2 3 4 5 6 7 8 9 10 11 12 
A 103567 103575 103583 103593 103601 103618 
     
  
B 103568 103576 103584 103594 103602 103619 
     
  
C 103569 103577 103585 103595 103603 103620 
     
  
D 103570 103578 103586 103596 103604 103621 
     
  
row D 1 2 3 4 5 6 7 8 9 10 11 12 
E 103571 103579 103588 103597 103609 103622 
     
  
F 103572 103580 103590 103598 103611 103623 
     
  
G 103573 103582 103592 103599 103612 103625 
     
  
















Pool Plate 10 
           
Source Plate 
D-10035 
row A 1 2 3 4 5 6 7 8 9 10 11 12 
A 103647 103661 103682 103773 103790 103743 103691 103706 103725 103649 103674 103783 
B 103652 103666 103683 103777 103791 103744 103694 103708 103727 103650 103675 103787 
C 103655 103667 103684 103779 103792 103749 103695 103709 103729 103654 103685 103788 
D 103656 103668 103688 103780 103796 103751 103699 103710 103730 103662 103687 103795 
row B 1 2 3 4 5 6 7 8 9 10 11 12 
E 103657 103669 103689 103781 103797 103752 103702 103712 103803 103664 103774 103798 
F 103658 103679 103690 103784 103732 103753 103703 103714 103807 103665 103775 103800 
G 103659 103680 103771 103785 103759 103759 103704 103718 103808 103670 103776 103731 
H 103660 103681 103772 103789 103764 103764 103705 103719 103809 103672 103782 103733 
Source Plate 
D-10036 
row C 1 2 3 4 5 6 7 8 9 10 11 12 
A 103842 103853 103862 103882 103891 103901 103910 104021 104040 104056 103971 103986 
B 103843 103854 103866 103883 103892 103902 103911 104024 104043 104057 103974 103988 
C 103845 103855 103867 103884 103893 103903 103912 104026 104044 104059 103975 103989 
D 103846 103856 103868 103885 103894 103904 103914 104028 104045 103961 103976 103990 
row D 1 2 3 4 5 6 7 8 9 10 11 12 
E 103848 103857 103870 103887 103895 103905 103915 104029 104047 103962 103980 103991 
F 103849 103859 103871 103888 103898 103907 103916 104032 104048 103963 103981 103992 
G 103851 103860 103875 103889 103899 103908 103919 104037 104052 103964 103982 103997 
H 103852 103861 103881 103890 103900 103909 103920 104039 104055 103970 103985 103999 
Source Plate 
D-10037 
row E 1 2 3 4 5 6 7 8 9 10 11 12 
A 103740 103692 103722 103928 103938 103949 103958 104075 104083 104004 104106 104165 
B 103742 103697 103723 103929 103941 103950 103959 104076 104086 104011 104107 104166 
C 103748 103698 103921 103930 103942 103951 103960 104077 104087 104012 104108 104167 
D 103754 103701 103922 103932 103943 103952 104062 104078 104090 104013 104111 104170 
row F 1 2 3 4 5 6 7 8 9 10 11 12 
E 103756 103707 103923 103934 103944 103953 104065 104079 104091 104014 104112 104175 
F 103760 103713 103925 103935 103945 103954 104070 104080 104094 104016 104114 104180 
G 103767 103716 103926 103936 103946 103956 104072 104081 104095 104017 104161 104187 
H 103768 103720 103927 103937 103947 103957 104074 104082 104097 104019 104162 104188 
Source Plate 
D-10038 
row G 1 2 3 4 5 6 7 8 9 10 11 12 
A 104121 104135 104149 104201 104221 104238 104408 104418 104432 104324 104348 104359 
B 104124 104136 104150 104202 104227 104239 104409 104420 104436 104325 104349 104281 
C 104125 104137 104152 104206 104230 104240 104411 104421 104447 104326 104351 104282 
D 104127 104139 104153 104207 104231 104401 104412 104422 104440 104330 104353 104283 
row H 1 2 3 4 5 6 7 8 9 10 11 12 
E 104130 104140 104154 104210 104232 104402 104413 104424 104331 104341 104354 104285 
F 104132 104141 104159 104215 104234 104403 104414 104426 104340 104343 104355 104286 
G 104133 104142 103958 104216 104235 104405 104415 104428 104321 104344 104356 104287 









Pool Plate 11   





row A 1 2 3 4 5 6 7 8 9 10 11 12 
A 104191 104269 104367 104382 104391 104400 104574 104586 104598 104529 104538 104549 
B 104192 104270 104368 104383 104392 104562 104576 104589 104600 104530 104539 104550 
C 104193 104271 104371 104384 104393 104563 104577 104590 104521 104531 104540 104551 
D 104194 104274 104373 104386 104395 104565 104578 104592 104522 104532 104543 104553 
row B 1 2 3 4 5 6 7 8 9 10 11 12 
E 104197 104277 104374 104387 104396 104569 104579 104594 104525 104533 104544 104554 
F 104250 104361 104379 104388 104397 104570 104581 104595 104526 104535 104545 104555 
G 104253 104363 104380 104389 104398 104571 104583 104596 104527 104536 104546 104556 





row C 1 2 3 4 5 6 7 8 9 10 11 12 
A 104289 104301 104315 104486 104496 104504 104517 104687 104701 104713 104609 104622 
B 104291 104307 104316 104487 104497 104507 104518 104688 104702 104714 104613 104623 
C 104292 104308 104317 104488 104498 104511 104519 104689 104703 104716 104614 104625 
D 104294 104310 104318 104489 104499 104512 104520 104690 104704 104717 104615 104626 
row D 1 2 3 4 5 6 7 8 9 10 11 12 
E 104295 104311 104319 104490 104500 104513 104681 104693 104705 104719 104616 104633 
F 104297 104312 104320 104491 104501 104514 104682 104698 104708 104720 104617 104634 
G 104298 104313 104482 104494 104502 104515 104684 104699 104711 104605 104618 104635 





row E 1 2 3 4 5 6 7 8 9 10 11 12 
A 104558 104729 104743 104754 104647 104658 104669 104845 104854 104866 104877 104811 
B 104560 104730 104744 104755 104649 104659 104671 104846 104855 104868 104878 104812 
C 104721 104733 104745 104756 104650 104660 104673 104847 104857 104869 104879 104813 
D 104722 104734 104748 104758 104651 104662 104674 104849 104858 104870 104880 104814 
row F 1 2 3 4 5 6 7 8 9 10 11 12 
E 104723 104737 104749 104641 104652 104665 104676 104850 104861 104871 104802 104815 
F 104725 104738 104750 104642 104654 104666 104680 104851 104862 104872 104803 104816 
G 104726 104739 104752 104643 104655 104667 104643 104852 104864 104873 104805 104817 





row G 1 2 3 4 5 6 7 8 9 3 11 12 
A 104639 104888 104902 104910 104761 104774 104786 105203 105212 105162 105172 105182 
B 104640 104889 104903 104911 104762 104775 104787 105204 105213 105163 105173 105183 
C 104881 104891 104904 104914 104764 104776 104788 105205 105214 105164 105174 105184 
D 104882 104892 104905 104916 104765 104779 104790 105206 105216 105166 105175 105185 
row H 1 2 3 4 5 6 7 8 9 10 11 12 
E 104883 104893 104906 104917 104766 104780 104791 105207 105217 105167 105177 105186 
F 104884 104895 104907 104918 104767 104782 104794 105208 105218 105168 105178 105187 
G 104886 104899 104908 104919 104770 104783 104795 105209 105219 105170 105179 105188 









Pool Plate 12 
           
Source Plate 
D-10043 
row A 1 2 3 4 5 6 7 8 9 10 11 12 
A 104819 104833 104924 104937 104948 104958 104967 104979 104988 104996 105006 105018 
B 104823 104834 104927 104938 104949 104959 104970 104980 104989 104997 105007 105019 
C 104824 104836 104928 104939 104950 104960 104971 104981 104990 104998 105009 105020 
D 104825 104837 104930 104943 104951 104961 104973 104982 104991 104999 105010 105021 
row B 1 2 3 4 5 6 7 8 9 10 11 12 
E 104828 104839 104932 104944 104952 104962 104974 104983 104992 105000 105011 105022 
F 104829 104840 104933 104945 104954 104963 104975 104984 104993 105002 105012 105025 
G 104830 104921 104935 104946 104955 104964 104976 104985 104994 105003 105014 105026 
H 104831 104923 104936 104947 104957 104965 104977 104987 104995 105004 105017 105028 
Source Plate 
D-10044 
row C 1 2 3 4 5 6 7 8 9 10 11 12 
A 105190 105200 105049 105057 105065 105075 105125 105134 105143 105154 105032 105081 
B 105191 105042 105050 105058 105066 105076 105126 105135 105145 105155 105033 105082 
C 105192 105043 105051 105059 105068 105077 105127 105137 105146 105156 105034 105083 
D 105195 105044 105052 105060 105069 105079 105129 105138 105147 105157 105035 105084 
row D 1 2 3 4 5 6 7 8 9 10 11 12 
E 105195 105045 105053 105061 105070 105080 105130 105139 105148 105159 105036 105085 
F 105196 105046 105054 105062 105071 105121 105131 105140 105149 105160 105037 105086 
G 105197 105047 105055 105063 105073 105122 105132 105141 105150 105030 105038 105089 
H 105198 105048 105056 105064 105074 105124 105133 105142 105151 105031 105039 105091 
Source Plate 
D-10045 
row E 1 2 3 4 5 6 7 8 9 10 11 12 
A 105094 105093 105115 
        
  
B 105095 105105 105116 
        
  
C 105096 105107 105118 
        
  
D 105097 105108 105119 
        
  
row F 1 2 3 4 5 6 7 8 9 10 11 12 
E 105098 105109 105120 
        
  
F 105100 105110 
         
  
G 105102 105113 
         
  
H 105103 105114 
         
  
 
row G 1 2 3 4 5 6 7 8 9 10 11 12 
A 
           
  
B 
           
  
C 
           
  
D 
           
  
row H 1 2 3 4 5 6 7 8 9 10 11 12 
E 
           
  
F 
           
  
G 
           
  
H                         
 
208  













Frag 1 (bp) Frag 2 (bp) Frag 1 (bp) Frag 2 (bp) 
A8 315 - 881 - 100057 100058 100059 100060 D-10001 A8-D8 Intron 2 - - - 
B1 326 - - - 100005 100006 100007 100008 D-10001 E1-H1 - - - - 
B6 321 - - - 100045 100046 100047 100048 D-10001 E6-H6 - - - - 
C2 355 - - - 100089 101206 100091 100092 D-10002 A2-D2 - - - - 
C4 390 914 386 911 100105 100106 100107 100108 D-10002 A4-D4 Intron 3 - - - 
E1 450 - - - 100193 100194 100195 100196 D-10003 A1-D1 - - - - 
E9 325 - - - 100337 100338 100339 100340 D-10003 A9-D9 - - - - 
F2 416 - - - 100285 100286 100287 100288 D-10003 E2-H2 - - - - 
F3 323 - - - 100293 100294 100295 100296 D-10003 E3-H3 - - - - 
F4 322 - - - 100301 100302 100303 100304 D-10003 E4-H4 - - - - 
F5 321 - - - 101229 100310 100311 100312 D-10003 E5-H5 - - - - 
F6 323 - - - 100317 100318 100319 100320 D-10003 E5-H6 - - - - 
Two 
A7 173 - - - 100457 101236 100459 100460 D-10005 A7-D7 - - - - 
B4 778 - 795 - 100429 100430 100431 101234 D-10005 E4-H4 Y177Y silent - - - 
C10 456 841 462 849 100569 100570 100571 100572 D-10006 A10-D10 Intron 2 - - - 
C11 426 - - - 100577 100578 100579 100580 D-10006 A11-D11 - - - - 
H3 185 - - - 100765 100766 100767 100768 D-10008 E3-H3 - - - - 
Three 
A12 392 - - - 100809 100810 100811 100812 D-10009 A12-D12 - - - - 






E10 912 - 406 896 101712 101714 101720 101721 D-10015 A10-D10 Intron 2 - - - 
F3 364 966 349 940 101493 101494 101495 101497 D-10015 E3-H3 T283I CODMb S-101497 B2 
F9 355 974 - - 101701 101704 101706 101711 D-10015 E9-H9 - - - - 
H1 475 - - - 101570 101573 101574 101575 D-10016 E1-H1 - - - - 
H3 470 - - - 101590 101591 101592 101593 D-10016 E3-H3 - - - - 
H6 328 - - - 101617 101618 101619 101620 D-10016 E6-H6 - - - - 
H7 446 849 442 844 101626 101627 101628 101629 D-10016 E7-H7 Intron 2 - - - 
Five 
F2 802 - 528 786 101981 101982 101983 101984 D-10019 E2-H2 S176F CODMb S-101983 B2 





101946 101947 101948 101949 D-10020 E1-H1 
Intron 2, a 
Intron 3,b - - - 
H11 135 - - - 102309 102310 102311 102312 D-10020 E11-H11 - - - - 
Six 
C7 326 - - - 102372 102373 102374 102377 D-10022 A7-D7 - - - - 
D7 327 - - - 102378 102379 102380 102381 D-10022 E7-H7 - - - - 
F3 172 - - - 102436 102437 102438 102439 D-10023 E3-H3 - - - - 
G7 530 788 536 784 102571 102572 102573 102574 D-10024 A7-D7 W261* CODMa S-102574 B2 
G8 323 - - - 102579 102580 102581 102582 D-10024 A8-D8 - - - - 
H2 357 - - - 102494 102495 102496 102498 D-10024 E2-H2 - - - - 
H3 785 - 535 783 102503 102504 102505 102506 D-10024 E3-H3 Y177Y silent - - - 
Seven 
A6 323 - - - 102605 102606 102607 102608 D-10025 A6-D6 - - - - 
B8 314 - - - 102625 102626 102627 102628 D-10025 E8-H8 - - - - 
G11 495 813 500 807 103225 103226 103227 103228 D-10028 A11-D11 F271L CODMb S-103228 C1 







B8 336 - 426 878 103059 103060 103061 103062 D-10029 E8-H8 Intron 2 - - - 
B12 401 - - - 103091 103092 103093 103094 D-10029 E12-H12 - - - - 







E6 372 955 336 957 103279 103282 103283 103284 D-10031 A6-D6 T283I CODMa S-103284 C1 





103248a 103249 103250b 103251 D-10031 E2-H2 
 
Intron 3,b - - - 
F9 337   386 935 103312 103314 103315 103316 D-10031 E9-H9 Intron 3 - - - 
G2 523 847 505 813 103357 103358 103359 103360 D-10032 A2-D2 Intron 2 - - - 
G3 385 984 373 933 103366 103367 103369 103370 D-10032 A3-D3 Intron 3 - - - 
G4 554 814 528 769 103378 103379 103381 103382 D-10032 A4-D4 S176S silent - - - 
G8 467 904 452 863 103419 103420 103421 103422 D-10032 A8-D8 Intron 2 - - - 
G12 556 823 533 785 103456 103458 103459 103460 D-10032 A12-D12 I262V CODMb S-103458 C1 





103361 103362 103364 103365 D-10032 E2-H2 
Intron 2, a 
Not found, b - - - 









A1 444 - 422 900 103466 103467 103468 103469 D-10033 A1-D1 Intron 3 - - - 
A6 336 - - - 103517 103518 103519 103520 D-10033 A6-D6 - - - - 
A7 537 817 520 786 103529 103530 103532 103534 D-10033 A7-D7 P266S CODMb S-103534 C1 
A9 338 - - - 103551 103552 103553 103555 D-10033 A9-D9 - - - - 
B4 336 - - - 103501 103504 103505 103506 D-10033 E4-H4 - - - - 





103535 103536 103537 103538 D-10033 E7-H7 
Not found, a 
Not found, b - - - 
B12 192 1166 506 816 103647 103648 103626 103627 D-10033 E12-H12 Intron 2 - - - 
C1 337, 435 1150 - - 103567 103568 103569 103570 D-10034 A1-D1 - - - - 
C3 450 902 436 873 103583 103584 103585 103586 D-10034 A3-D3 Intron 2 - - - 
C4 338 - - - 103593 103594 103595 103596 D-10034 A4-D4 - - - - 
C6 424 934 400 875 103618 103619 103620 103621 D-10034 A6-D6 Intron 3 - - - 
D1 328,450,482 1009 - - 103571 103572 103573 103574 D-10034 E1-H1 - - - - 
D6 334 1019 - - 103622 103623 103625 103539 D-10034 E6-H6 - - - - 
Ten 
A3 414 - - - 103682 103683 103684 103688 D-10035 A3-D3 - - - - 
B4 467 876 454 840 103781 103784 103785 103789 D-10035 E4-H4 Intron 2 - - - 
C2 166 - - - 103853 103854 103855 103856 D-10036 A2-D2 - - - - 
C5 222 - 422 859 103891 103892 103893 103894 D-10036 A5-D5 Intron 3 - - - 
D1 129 163 - - 103848 103849 103850 103851 D-10036 E1-H1 - - - - 
D9 383 - - - 104047 104048 104052 104055 D-10036 E9-H9 - - - - 
F3 828 - 506 780 103923 103925 103926 103927 D-10037 E3-H3 Not found - - - 
F4 425 935 417 881 103934 103935 103936 103937 D-10037 E4-H4 Intron 3 - - - 
F5 195 - - - 103944 103945 103946 103947 D-10037 E5-H5 - - - - 
G11 644 731 622 705 104359 104281 104282 104283 D-10038 A11-D11 L232F CODMb  S-104281 B3 
H1 170 - - - 104130 104132 104133 104134 D-10038 E1-H1 - - - - 
H5 186 386 - - 104232 104234 104235 104237 D-10038 E5-H5 - - - - 




A1 483 849 472 821 104191 104192 104193 104194 D-10039 A1-D1 Intron 2 - - - 
A2 372 - - - 104269 104270 104271 104274 D-10039 A2-D2 - - - - 
A5 330 - - - 104391 104392 104393 104395 D-10039 A5-D5 - - - - 
A10 573 787 548 754 104529 104530 104531 104532 D-10039 A10-D10 Q254* CODMb S-104530 B3 
A12 370 971 362 939 104549 104550 104551 104553 D-10039 A12-D12 Intron 2 - - - 
B8 328 889 - - 104594 104595 104596 104597 D-10039 E8-H8 - - - - 
B12 434 919 421 884 104554 104555 104556 104557 D-10039 E12-H12 Intron 2 - - - 
C2 327 - - - 104301 104307 104308 104310 D-10040 A2-D2 - - - - 
C6 223 334 - - 104504 104507 104511 104512 D-10040 A6-D6 - - - - 
D5 355 - - - 104500 104501 104502 104503 D-10040 E5-H5 - - - - 
D8 336 - - - 104693 104698 104699 104700 D-10040 E8-H8 - - - - 
F2 393 971 378 930 104737 104738 104739 104741 D-10041 E2-H2 Intron 3 - - - 
F6 404 - 346 952 104665 104666 104667 104668 D-10041 E6-H6 G285G silent - - - 
F9 336 - - - 104861 104862 104864 104865 D-10041 E9-H9 - - - - 
G2 333 - 414 888 104888 104889 104891 104892 D-10042 A2-D2 Not found - - - 
H5 342,456 599 - - 104766 104767 104770 104773 D-10042 E5-H5 - - - - 
Twelve 
A6 329 - - - 104958 104959 104960 104961 D-10043 A6-D6 - - - - 
B3 515 - - - 104932 104933 104935 104936 D-10043 E3-H3 - - - - 
B6 265 - - - 104962 104963 104964 104965 D-10043 E6-H6 - - - - 
B9 334,393 - - - 104992 104993 104994 104995 D-10043 E9-H9 - - - - 
C5 467 895 451 863 105065 105066 105068 105069 D-10044 A5-D5 Intron 2 - - - 
C8 673 - - - 105134 105135 105137 105138 D-10044 A8-D8 - - - - 




TILLING Gel images 
For each gel image lanes 1-12 = wells A1-A12, lanes 13-24=wells B1-B12 etc. 
Pool plate 1 
 


































































































Location of CODM mutations in nucleotide and amino acid sequences 
M   E   T   P   I   L   I   K   L   G   N   G   L   S   I   P   S   V      18     
atg gag aca cca ata ctt atc aag cta ggc aat ggt ttg tca ata cca agt gtt    54 
Q   E   L   A   K   L   T   L   A   E   I   P   S   R   Y   T   C   T      36 
cag gaa ttg gct aaa ctc acg ctt gca gaa att cca tct cga tac aca tgc acc   108 
G   E   S   P   L   N   N   I   G   A   S   V   T   D   D   E   T   V      54 
ggt gaa agc ccg ttg aat aat att ggt gcg tct gta aca gat gat gaa aca gtt   162 
P   V   I   D   L   Q   N   L   L   S   P   E   P   V   V   G   K   L      72 
cct gtc atc gat ttg caa aat tta cta tct cca gaa ccc gta gtt gga aag tta   216 
 
219  
                IPB002283A (4.5e-13) IC 2.46 
E   L   D   K   L   H   S   A   C   K   E   W   G   F   F   Q   | L        89 
gaa ttg gat aag ctt cat tct gct tgc aaa gaa tgg ggt ttc ttt cag | ctg     267 
                                                                    
IPB002283B (4.7e-05) IC 1.94 
V   N   H   G   V   D   A   L   L   M   D   N   I   K   S   E   I  K      107 
gtt aac cat gga gtc gac gct tta ctg atg gac aat ata aaa tca gaa att aaa   321 
G   F   F   N   L   P   M   N   E   K   T   K   Y   G   Q   Q   D   G     125 
ggt ttc ttt aac ctt cca atg aat gag aaa act aaa tac gga cag caa gat gga   375 
D   F   E   G   F   G   Q   P   Y   I   E   S   E   D   Q   R   L   D     143 
gat ttt gaa gga ttt gga caa ccc tat att gaa tcg gag gac caa aga ctt gat   429 
 
W   T   E   V   F   S   M   L   S   L   P   L   H   L   R   K   P   H     161 
tgg act gaa gtg ttt agc atg tta agt ctt cct ctc cat tta agg aag cct cat   483 
L   F   P   E   L   P   L   P   F   R  |   E   T   L   E   S   Y   L      178 
ttg ttt cca gaa ctc cct ctg cct ttc ag | g gag aca ctg gaa tcc tac cta    534 
                                                            tS176F  
                                                            tS176F  
 S   K   M   K   K   L   S   T   V   V   F   E   M   L   E   K   S   L    196 
tca aaa atg aaa aaa cta tca acg gtt gtc ttt gag atg ttg gaa aaa tct cta   588 
Q   L   V   E   I   K   G   M   T   D   L   F   E   D   G   L   Q   T     214 
caa tta gtt gag att aaa ggt atg aca gac tta ttt gaa gat ggg ttg caa aca   642 
M   R   M   N   Y   Y   P   P   C   P   R   P   E   L   V   L   G   L     232 
atg agg atg aac tat tat cct cct tgt cct cga cca gag ctt gta ctt ggt ctt   696 
                                                               tL232F 
IPB002283F (5.8e-06) IC 2.81 
T   S   H   
S   D   F   S   G   L   T   I   L   L   Q   L   N   E   V      250 
acg tca cac tcg gat ttt agc ggt ttg aca att ctc ctt caa ctt aat gaa gtt   750 
E   G   L   Q   I   R   K   E   E   R   W   I   S   I   K   P   L   P     268 
gaa gga tta caa ata aga aaa gaa gag agg tgg att tca atc aaa cct cta cct   804 
            tQ254*                          gI262V          tP266S  





        IPB002283G (1.6e-16) IC 2.76 
D   A   F   I   V   N   V   G   D   I   L   E   |I   M   T   N   G        285 
gat gcg ttc ata gtg aat gtt gga gac att ttg gag | ata atg act aat ggg     855 
          gF271L                                           tT283I  
                           tT283I  
                                       IPB002283H (6.0e-08) IC 2.25 
I   Y   R   S   V   E   H   R   A   V   V   N   S  T   K   E   R   L      303 
att tac cgt agc gtc gag cac cgg gca gta gta aac tca aca aag gag agg ctc   909 
                                                            aE301K  
S   I   A   T   F   H   D   S   K   L   E   S   E   I   G   P   I   S     321 
tca atc gcg aca ttt cat gac tct aaa cta gag tca gaa ata ggc cca att tcg   963 
S   L   V   T   P   E   T   P   A   L   F   K   R   G   R   Y   E   D     339 
agc ttg gtc aca cca gag aca cct gct ttg ttc aaa aga ggt agg tat gag gat  1017 
I   L   K   E   N   L   S   R   K   L   D   G   K   S   F   L   D   Y     357 
att ttg aag gaa aat ctt tca agg aag ctt gat gga aaa tca ttt ctc gac tac  1071 
M   R   M   *                                                             361 


































































Alkaloids in capsules of M3 CODM mutants 


































Proportion of each of the major alkaloids  
in capsules of M3 CODM mutants 
Morphine Oripavine Codeine Thebaine Cod-Theb Dimer
 
222  
Genotyping of F1s resulting from crosses between M3 CODM mutants 






Genotyping F2s resulting from W261* x Q254* crosses 
                        W261* screen  Q254* screen 
Plate 1  
Plate 2  
 
224  
Detection of E193K and R158K CODM polymorphisms in remaining two high 
codeine forward screen lines S-114247 and S-114248 
Plate D-10112 contained DNA from the remaining two (of five) high codeine forward 
screen lines plus DNA from two high thebaine forward screen lines (S-114249 and S-
114250), wild type HM2 DNA and three positive controls i.e. one example of each a plant 
from the other three high codeine forward screen lines where the E193K and R158K 
polymorphisms were first identified. The products generated after E193K and R158K AS-PCR 
on the entire plate are displayed. The final 6 samples of row 1 and the first 14 on row 2 from 
plants generated with S-114248. The end of row 3 and the first 3 of row 4 are samples from 
plants generated with S-114247. Both these high codeine lines, then possess the same CODM 
polymorphisms detected in S-122066, S-122067 and S-122068. The final 3 samples in row 4 
are the positive controls. No AS-PCR products were generated with samples from the high 
thebaine forward screen lines (S-114249 and S-114250) and HM2 wild type indicating the 








Genealogies of high codeine forward screen lines 
Phenotypes expressed as percentage dry weight of morphine (M), codeine (C), oripavine (O) and thebaine (T). 
MAS 2235 D 
        
S-114247 
          
           
popn season old ID seed ID 
 
plot no M C O T 
 
    
OP row HM2 3.1117 
    
C1M2 07_08 25c S-103234 OP row MUT 437 2.9664 0.2557 0.0150 0.2019 
 
    
SP caps MUTS 437 G 4.4067 0.5943 0.0060 0.0769 
 




   
 
      
          
C1M3 08_09 
  
OP row HM3 3.67 
    
    
OP row RMUU 314 3.7286 0.6138 0.0011 0.2387 
 
    
SP caps RMUUS 314 E 4.2614 0.6006 0.0136 0.0813 
 




    
 
      
          
C1M4 09_10 
  
OP row HM1 2.918 0.332 0.027 0.121 
 
    
OP row MUV 107 2.352 1.391 0.051 1.105 
 
    
SP caps MUVS 107 A 2.315 2.316 0.024 1.209 
 




      
           
           
C1M5 2010 Seed from MUVS 107 A sent to Tom Davies to grow over Australian winter. Seed harvested and returned labelled  UKMUVS 107 A 
  
     
Seed sown into 5 replicated rows in TAS 
   
           






   
      
          
          
      
M+pM C O T M 
C1M6 10_11 
  
OP row HT4 1.361 0.541 0.23 1.862 1.163 
   
REP 2/5  OP row HM4 2.569 0.144 0.015 0.105 2.352 
   
ex ukmuvs 107a OP row MUWT 1926 2.264 1.221 0.030 0.915 2.053 
   
(C1M5 2010) SP caps MUWTS 1926 C 2.607 2.200 0.065 2.086 2.345 





   
      
          
          
          
C1M7 11_12 
    
M C O T 
 
   
REP 2/2 OP row HM5 3.205 0.134 0.016 0.116 
 
   
ex MUWTS 1926 C OP row HT5 1.233 0.222 0.654 2.413 
 
   
(C1M6 10-11) OP row MA 2235 2.868 1.369 0.035 0.981 
 
    






MAS 2237 C 
        
S-114248 
          
           
popn season old ID seed ID 
 
plot no M C O T 
 
    
OP row HM2 3.1117 
    
C1M2 07_08 25c S-103234 OP row MUT 437 2.9664 0.2557 0.0150 0.2019 
 
    
SP caps MUTS 437 G 4.4067 0.5943 0.0060 0.0769 
 




   
 
      
          
C1M3 08_09 
  
OP row HM3 3.67 
    
    
OP row RMUU 314 3.7286 0.6138 0.0011 0.2387 
 
    
SP caps RMUUS 314 E 4.2614 0.6006 0.0136 0.0813 
 




    
 
      
          
C1M4 09_10 
  
OP row HM1 2.918 0.332 0.027 0.121 
 
    
OP row MUV 107 2.352 1.391 0.051 1.105 
 
    
SP caps MUVS 107 A 2.315 2.316 0.024 1.209 
 




      
           
           
C1M5 2010 Seed from MUVS 107 A sent to Tom Davies to grow over Australian winter. Seed harvested and returned labelled  UKMUVS 107 A 
  
     
Seed sown into 5 replicated rows in TAS 
   
           






   
      
          
          
      
M+pM C O T M 
C1M6 10_11 
  
OP row HT4 1.361 0.541 0.23 1.862 1.163 
   
REP 3/5  OP row HM4 2.569 0.144 0.015 0.105 2.352 
   
ex ukmuvs 107a OP row MUWT 1945 1.755 1.485 0.027 1.307 1.577 
   
(C1M5 2010) SP caps MUWTS 1945 D 1.967 2.274 0.066 1.669 1.742 
           




    
 
      
          
           
C1M7 11_12 
    
M C O T 
 
   
REP 2/2 OP row HM5 3.205 0.134 0.016 0.116 
 
   
ex MUWTS 1945 D OP row HT5 1.233 0.222 0.654 2.413 
 
   
(C1M6 10-11) OP row MA 2237 2.800 1.409 0.027 1.035 
 
    






MAS 1833 B 
        
S-122067 
          
popn season old ID seed ID 
 
plot no M C O T 
 
    
OP row HM2 3.1117 
    
C1M2 07_08 25c 
S-






    










   
 
      
     




OP row HM3 3.67 
    
    






    














      
          
          
C1M4 2009 Seed from RMUUS 314 E sent to Tom Davies to grow over Australian winter. Seed harvested and returned labelled UK MUUS 21 
 




      
      
M C O T 
 
C1M5 09_10 ex uk muus 21 
 





OP row TMUW 125 2.201 1.711 0.068 1.327 
 
    
SP caps TMUWS 125 A 3.276 1.792 0.027 0.486 
 




      
 
   
 
      
     
M+pM C O T M 
C1M6 10_11 ex tmuws 125a 
 




OP row HT4 1.361 0.541 0.23 1.862 1.163 
    
OP row MUX 1836 2.411 1.193 0.052 1.135 2.267 
    
SP caps MUXS 1836 B 3.918 1.266 0.061 0.296 3.744 
           
           
    
 
      
      
M C O T 
Total 
alk 
C1M7 11_12 ex muxs 1836 B 
 




OP row HT5 1.233 0.222 0.654 2.413 4.521 
    
OP row MA 1833 2.498 0.973 0.070 1.613 5.155 
    
SP caps MAS 1833 B 3.212 1.444 0.115 2.558 7.329 
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MAS 1835 D 
S-122068 
          
           
popn season old ID seed ID 
 
plot no M C O T 
 
    
OP row HM2 3.1117 
    
C1M2 07_08 25c 
S-






    










   
 
      
          
C1M3 08_09 
  
OP row HM3 3.67 
    
    






    










    
 
      
          
C1M4 09_10 
  
OP row HM1 2.918 0.332 0.027 0.121 
 
    
OP row MUV 107 2.352 1.391 0.051 1.105 
 
    
SP caps MUVS 107 A 2.315 2.316 0.024 1.209 
 




      
           
           
C1M5 2010 Seed from MUVS 107 A sent to Tom Davies to grow over Australian winter. Seed harvested and returned labelled UKMUVS 107 A 
 








Seed sown into 5 replicated rows in 
TAS 
   
 
         
 
REP 2/5  
  
M+pM C O T M 
C1M6 10_11 ex ukmuvs 107a 
 




OP row HT4 1.361 0.541 0.23 1.862 1.163 
    
OP row MUWT 1926 2.264 1.221 0.030 0.915 2.053 
    
SP caps MUWTS 1926 C 2.607 2.200 0.065 2.086 2.345 





   
      
          
          
           
C1M7 11_12 
ex muwts 1926 
C 
   






OP row HM5 3.205 0.134 0.016 0.116 3.472 
    
OP row HT5 1.233 0.222 0.654 2.413 4.521 
    
OP row MA 1835 2.806 1.477 0.046 1.558 5.886 
    
SP caps MAS 1835 D 2.661 1.944 0.037 1.230 5.872 
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MAS 1983 C 
S-122066 
          
popn season old ID seed ID 
 
plot no M C O T 
 
    
OP row HM2 3.1117 
    
C1M2 07_08 25c 
S-




    








   
 
      
          
C1M3 08_09 
  
OP row HM3 3.67 
    
    




    








    
 
      
          
C1M4 09_10 
  
OP row HM1 2.918 0.332 0.027 0.121 
 
    
OP row MUV 107 2.352 1.391 0.051 1.105 
 
    
SP caps MUVS 107 A 2.315 2.316 0.024 1.209 
 




      
           
           
C1M5 2010 Seed from MUVS 107 A sent to Tom Davies to grow over Australian winter. Seed harvested and returned labelled  UKMUVS 107 A 
 






   
Seed sown into 5 replicated rows in 
TAS 
   
          
          
 
          
     
M+pM C O T M 
C1M6 10_11 REP 4/5  
 
OP row HM4 2.569 0.144 0.015 0.105 2.352 
  
ex ukmuvs 107a 
 




OP row MUWT 1964 2.356 0.709 0.017 0.429 2.073 
    
SP caps MUWTS 1964 C 2.266 2.001 0.059 0.696 2.154 
           






   
      
          
          
           
C1M7 11_12 
    




ex muwts 1964 
C 
 




OP row HT5 1.001 0.189 0.709 2.473 4.372 
    
OP row MA 1983 3.005 1.691 0.040 1.316 6.052 
    
SP caps MAS 1983 C 3.766 2.089 0.076 1.379 7.309 
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Appendix C- T6ODMa mutation screen 
Pool plate Well 
Screening Rescreening 





of mutant Population Fragment 1 (bp) Fragment 2 (bp) Fragment 1 (bp) Fragment 2 (bp) 
One 
C9 80 615 - - 100145 100146 100147 101212 D-10002  A9-D9 - - - 
Two 
- - - - - - - - - - - - - 
Three 
- - - - - - - - - - - - - 
Four 
B1 612 - - - 101258 101259 101261 101263 D-10013 E1-H1 - - - 
B12 615 - - - 101352 101353 101357 101358 D-10013 E12-H12 - - - 
D11 253 - - - 101460 101461 101462 101463 D-10014 E11-H11 - - - 
D12 276 - - - 101468 101469 101470 101471 D-10014 E12-H12 - - - 
E2 219 611 - - 101480 101481 101482 101483 D-10015 A2-D2 - - - 
F3 253 - - - 101493 101494 101495 101497 D-10015 E3-H3 - - - 
Five 
B4 612 - - - 101776 101777 101778 101779 D-10017 E4-H4 - - - 
Six 
F7 132 - - - 102474 102475 102476 102477 D-10023 E7-H7 - - - 
Seven 
B11 316 611 161 450 102690 102691 102692 102693 D-10025 E11-H11 Q141* S-102693 B2 
Eight 
A12 58 612 103 509 103087 103088 103089 103090 D-10029 A12-D12 H162Y S-103090 B2 
C9 43 609 147 468 103160 103161 103162 103163 D-10030 A9-D9 A146T S-103161 B2 




F3 563 606 181 438 103257 103258 103259 103260 D-10031 E3-H3 G134G silent - C1 
G6 107 611 115 490 103397 103398 103399 103402 D-10032 A6-D6 
L156L silent - C1 
G8 167 609 156 473 103419 103420 103421 103422 D-10032 A8-D8 A146T S-103421 C1 
Nine 
- - - - - - - - - - - - - 
Ten 
D12 504 565 283 345 103991 103992 103997 103999 D-10036 E12-H12 Intron 1 - B3 
F12 498 - - - 104175 104180 104187 104188 D-10037 E12-H12 - - - 
Eleven 
A12 219 609 151 468 104549 104550 104551 104553 D-10039 A12-D12 W145* S-104553 B3 
H12 54 617 - - 105186 105187 105188 105189 D-10042 E12-H12 - - - 
Twelve - - - - - - - - - - - - - 
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TILLING gel images 
For each gel image lanes 1-12 = wells A1-A12, lanes 13-24=wells B1-B12 etc. 
 
Pool plate 1 




























161 bp and 450 bp fragments in fourth individual (Sd-102693) 
PP8_A12_H162Y 
 
103 bp and 509 bp fragments in fourth individual (Sd-103090) 
PP8_C9_A146T 
 









156 bp and 473 bp fragments in third individual (Sd-103421) 
PP11_A12_W145* 
 
151 bp and 468 bp fragments in fourth individual (Sd-104553) 
Location of T6ODM mutations in nucleotide and amino acid sequences 
M   E   K   A   K   L   M   K   L   G   N   G   M   E   I   P   S   V     18 
 atg gag aaa gca aaa ctt atg aag cta ggt aat ggt atg gaa ata cca agt gtt   54 
  
  
Q   E   L   A   K   L   T   L   A   E   I   P   S   R   Y   V   C   A      36 
caa gaa ttg gct aaa ctc acg ctt gcc gaa att cca tct cga tac gta tgc gcc    108 
  
  
N   E   N   L   L   L   P   M   G   A   S   V   I   N   D   H   E   T      54 
aat gaa aac ctt ttg ttg cct atg ggt gca tct gtc ata aat gat cat gaa acc    162 
  
  
I   P   V   I   D   I   E   N   L   L   S   P   E   P   I   I   G   K      72 
att cct gtc atc gat ata gaa aat tta tta tct cca gaa cca ata atc gga aag    216 
  
                    IPB002283A (4.2e-13) IC 2.46 
L   E   L   D   R   L   H   F   A   C   K   E   W   G   F   F   Q   | V    90 
tta gaa tta gat agg ctt cat ttt gct tgc aaa gaa tgg ggt ttt ttt cag | gt   269 
  
  
  V   N   H   G   V   D   A   S   L   V   D   S   V   K   S   E   I        107 
a gtg aac cat gga gtc gac gct tca ttg gtg gat agt gta aaa tca gaa att      321 
  
IPB002283B (4.2e-05) IC 1.94 
Q   G   F   F   N   L   S   M   D   E   K   T   K   Y   E   Q   E   D      125 
caa ggt ttc ttt aac ctt tct atg gat gag aaa act aaa tat gaa cag gaa gat    375 
  
  
G   D   V   E   G   F   G   Q   G   F   I   E   S   E   D   Q   T   L      143 
gga gat gtg gaa gga ttt gga caa ggc ttt att gaa tca gag gac caa aca ctt    429 
               tQ141* 
  
  
D   W   A   D   I   F   M   M   F   T   L   P   L   H   L   R   K   P      161 
gat tgg gca gat ata ttt atg atg ttc act ctt cca ctc cat tta agg aag cct    483 
        aA146T  





H   L   F   S   K   L   P   V   P   L   R  |   E   T   I   E   S   Y       178 




S   S   E   M   K   K   L   S   M   V   L   F   N   K   M   E   K   A      196 
tca tca gaa atg aaa aag tta tcc atg gtt ctc ttt aat aag atg gaa aaa gct    588 
  
  
L   Q   V   Q   A   A   E   I   K   G   M   S   E   V   F   I   D   G      214 
cta caa gta caa gca gcc gag att aag ggt atg tca gag gtg ttt ata gat ggg    642 
  
  
T   Q   A   M   R   M   N   Y   Y   P   P   C   P   Q   P   N   L   A      232 
aca caa gca atg agg atg aac tat tat ccc cct tgt cct caa cca aat ctc gcc    696 
  
                        IPB002283F (9.2e-06) IC 2.81 
I   G   L   T   S   H   S   D   F   G   G   L   T   I   L   L   Q   I      250 
atc ggt ctt acg tcg cac tcg gat ttt ggc ggt ttg aca atc ctc ctt caa atc    750 
  
  
N   E   V   E   G   L   Q   I   K   R   E   G   T   W   I   S   V   K      268 
aac gaa gtg gaa gga tta cag ata aaa aga gag ggg aca tgg att tca gtc aaa    804 
  
                    IPB002283G (3.0e-15) IC 2.76 
P   L   P   N   A   F   V   V   N   V   G   D   I   L   E   | I   M        285 
cct cta cct aat gcg ttc gta gtg aat gtt gga gat att ttg gag | ata atg      855 
  
                                                                IPB002283H (2.4e-09) IC 2.25 
T   N   G   I   Y   H   S   V   D   H   R   A   V   V   N   S   T   N      303 
act aat gga att tac cat agt gtc gat cac cgg gca gta gta aac tca aca aat    909 
  
  
E   R   L   S   I   A   T   F   H   D   P   S   L   E   S   V   I   G      321 
gag agg ctc tca atc gca aca ttt cat gac cct agt cta gag tcg gta ata ggc    963 
  
  
P   I   S   S   L   I   T   P   E   T   P   A   L   F   K   S   G   S      339 
cca ata tca agc ttg att act cca gag aca cct gct ttg ttt aaa agt gga tct    1017 
  
  
T   Y   G   D   L   V   E   E   C   K   T   R   K   L   D   G   K   S      357 
aca tat ggg gat ctt gtg gag gaa tgt aaa aca agg aag ctc gat gga aaa tca    1071 
  
  
F   L   D   S   M   R   I   *                                              365 
ttt ctt gac tcc atg agg att tga                                            1095 
Recovery of T6ODMa mutations in M2 individuals 
D-10834_T6ODMa_Mutation_Recovery 
 
W145* mutations observed in wells D1, E1, F2 and G1 (lanes 37, 49, 62 and 73 respectively). 






Alkaloid content of the capsules of T6ODMa M2 mutants and siblings 
 
Absolute alkaloid content in the capsules of T6ODMa mutants and siblings with WT T6ODMa. 
 



















































Phenotypes of T6ODMa M2 mutants and siblings 
Morphine Oripavine Codeine Thebaine Cod-Theb dimer

































Proportion of each of the major alkaloids in the capsules of 
M2 T6ODMa mutants and siblings without mutations 
Morphine Oripavine Codeine Thebaine Cod-Theb dimer
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Genealogies of high thebaine forward screen lines derived from HM2 
Phenotypes expressed as percentage dry weight of morphine (M), codeine (C), oripavine (O) and thebaine (T). 
MAS 2787 D 
        
           
popn season seed ID 
  
plot no M C O T 
 
    
OP row HM5 3.429 0.172 0.009 0.051 
 
B6M2 11_12 S-109141 
 
OP row HT5 1.153 0.202 0.679 2.606 
 
    
OP row MA 2787 3.438 0.285 0.001 0.508 
 
    
SP cap MAS 2787 4 3.561 1.053 0.356 3.243 
 
            
MAS 2150 B C 
        
           
popn season seed ID 
  
plot no M C O T 
 
    
OP row HM1 3.75 0.21 0.04 0.16 
 
B4M2 09_10 S-107166 
 
OP row MUA 2642 1.167 0.295 0.576 2.136 
 
    
SP caps MUAS 2642 A 1.168 0.249 0.919 3.321 
 




      
B4M3 10_11 
  
OP row HT4 0.926 0.187 0.520 2.029 0.926 
   
REP 1/2 OP row HM4 2.889 0.139 0.022 0.098 2.735 
   
ex MUAS 2642a OP row MUB 1013 0.832 0.231 0.305 2.194 0.683 
   
(B4M2 09-10) SP caps MUBS 1013 B 0.785 0.150 0.597 1.536 0.777 
           





   
      
          
B4M4 11_12 
         
   
REP 2/2 OP row HM5 3.587 0.107 0.023 0.081 3.799 
   
ex MUBS 1013 B OP row HT5 1.188 0.150 0.864 2.248 4.450 
   
(B4M3 10-11) OP row MA 2150 0.970 0.127 0.799 2.042 3.938 
    
SP caps MAS 2150 B C 0.845 0.353 1.056 3.182 5.437 









        
           
popn season seed ID 
  
plot no M C O T 
 
    
OP row HM1 3.65 0.15 0.03 0.14 
 
B4M2 09_10 S-106367 
 
OP row MUA 1723 3.136 0.294 0.122 1.335 
 
    
SP caps MUAS 1723 A 1.344 0.240 0.145 3.576 
 





      
          
          
           
 
M+pM C O T M 
B4M3 10_11 
  
OP row HT4 0.789 0.192 0.417 1.877 0.735 
   
Single Row OP row HM4 2.432 0.145 0.035 0.186 2.248 
   




SP caps MUBS 1336 D 0.424 0.616 0.078 4.374 0.391 




      
B4M4 11_12 
    
M C O T 
 
   
JIFFY (low seed) OP row HM5 4.112 0.152 0.017 0.089 
 
   
ex MUBS 1336 D OP row HT5 1.163 0.161 0.799 2.244 
 
   
(B4M3 10-11) OP row MA OP 1956- 4 0.537 0.228 0.002 6.218 
 
    
SP caps MAS 1956-4 0.873 0.214 0.091 4.229 
 
           
 
240  
























Oligo 1 :                                                       Pos.    Len.     Tm       
GC%   Self Any   Self End 
Wildtype Forward Primer 5': TCAACGGTTGTCTTTGAGATGTTTG           992     25     64.49     
40.00     7.00     0.00 
Mutant Forward Primer 5': TCAACGGTTGTCTTTGAGATGTTTA             992     25     62.03     
36.00     7.00     2.00 
Common Reverse Primer 5': AAGTACAAGCTCTGGTCGAG                  1129     20     54.76     
50.00     4.00     3.00 

























Oligo 3 :                                                       Pos.    Len.     Tm       GC%   Self Any   
Self End 
Wildtype Reverse Primer 5': AGGTAGAGGTTTGATTGAAATAC             1243     23     53.54     34.78     5.00     
2.00 
Mutant Reverse Primer 5': AGGTAGAGGTTTGATTGAAATAT               1243     23     53.14     30.44     5.00     
4.00 
Common Forward Primer 5': TTGCATTTGATCCCTAATTT                  917     20     54.84     30.00     4.00     
3.00 

























Oligo 4 :                                                       Pos.    Len.     Tm       GC%   Self Any   
Self End 
Wildtype Forward Primer 5': GCAGTAGTAAACTCAACAAATG              1428     22     52.08     36.36     4.00     
3.00 
Mutant Forward Primer 5': GCAGTAGTAAACTCAACAAATA                1428     22     49.46     31.82     4.00     
2.00 
Common Reverse Primer 5': CTCTCAGTCATCCACGAAAT                  1762     20     55.19     45.00     3.00     
2.00 
























Oligo 3 :                                                       Pos.    Len.     Tm       GC%   Self Any   
Self End 
Wildtype Forward Primer 5': TTAAGTCTTCCTCTCCATTTACG             589     23     56.83     39.13     5.00     
2.00 
Mutant Forward Primer 5': TTAAGTCTTCCTCTCCATTTACA               589     23     55.02     34.78     5.00     
2.00 
Common Reverse Primer 5': TTAGGGATCAAATGCAACTT                  933     20     54.90     35.00     4.00     
3.00 


























Primer Id         Primer Sequence    Tm       Primer Length   Product 
Size    Warnings 
Q254*_R_REF_1     GAAATCCACCTCTCTTCTTTTCTTATTCG    61.925    29 
Q254*_R_ALT_1     GATTGAAATCCACCTCTCTTCTTTTCTTATTAA 62.420    33 
Q254*_R_ALT_1_REVERSE    TGTCAGATGGAAAATATACTGAAGTTGCA    62.003    29       339 
T6ODMa 
Intron 1 polymorphism in GSK thebaine lines (Tint)_WASP 



























Oligo 3 :                                                   Pos.    Len.     Tm       GC%   Self Any   
Self End 
Wildtype Reverse Primer 5': TATATGTAAAGTAAGATTCACCA         392     23     49.01     26.09     4.00     
0.00 
Mutant Reverse Primer 5': TATATGTAAAGTAAGATTCACCT           392     23     47.51     26.09     4.00     
2.00 
Common Forward Primer 5': CAGAACCAATAATCGGAAAG              229     20     54.91     40.00     5.00     
0.00 





































Oligo 5 :                                                   Pos.    Len.     Tm       GC%   Self Any   
Self End 
Wildtype Forward Primer 5': GCTTTATTGAATCAGAGGAAC       536     21     53.32     38.10     5.00     
1.00 
Mutant Forward Primer 5': GCTTTATTGAATCAGAGGAAT         536     21     52.88     33.33     5.00     
2.00 
Common Reverse Primer 5': AGCATGAGGTGAGGTGTACT         1027     20     54.68     50.00     4.00     
2.00 


























|                   |                    |      |Primer|Product               | 
| Primer ID         | Primer Sequence    |  Tm  | Len. | Len. | Warnings      | 
|-----------------------------------------------------------------------------| 
| W145*_L_ALT_2     | TTTATTGAATCAGAGGAC | 67.0 |  33  |      |               | 
|                   | CAAACACTTGAGTGA    |      |      |      |               | 
|-----------------------------------------------------------------------------| 
| W145*_L_ALT_2_REV | ATGTTCACATACAACATG | 65.7 |  36  | 325  |               | 

























|                   |                    |      |Primer|Product               | 
| Primer ID         | Primer Sequence    |  Tm  | Len. | Len. | Warnings      | 
|-----------------------------------------------------------------------------| 
| A146T_R_ALT_1     | ATGGAGTGGAAGAGTGAA | 67.2 |  36  |      |               | 
|                   | CATCATAAATATATCCGT |      |      |      |               | 
|-----------------------------------------------------------------------------| 
| A146T_R_ALT_1_REV | AATCGGAAAGTTAGAATT | 67.0 |  36  | 368  |               | 




Appendix E- Record of crosses carried out 
Cross 
Mother plant Father plant Date of 
emasc-
ulation 











833543 HM6 Sd-833401 S-114248 11-Sep-13 12-Sep-13 S-123957 HM6 x CODM E193K/R158K 
X002 
Sd-
833557 HM6 Sd-833411 S-114248 11-Sep-13 12-Sep-13 S-123954 HM6 x CODM E193K/R158K 
X003 
Sd-
833509 S-122112 Sd-833401 S-114248 9-Sep-13 12-Sep-13 S-124007 




833595 HN4 Sd-833411 S-114248 11-Sep-13 12-Sep-13 S-123974 HN4 x CODM E193K/R158K 
X005 
Sd-
833452 S-122067 Sd-833868 S-125004 9-Sep-13 12-Sep-13 S-124004 
CODM E193K/R158K x T/O 
only from HN3 mut 
X006 
Sd-
833421 S-122066 Sd-833868 S-125004 9-Sep-13 12-Sep-13 S-123959 
CODM E193K/R158K x T/O 
only from HN3 mut 
X007 
Sd-
833598 HN4 Sd-833517 S-122112 11-Sep-13 14-Sep-13 S-123973 HN4 x CODMb Q254* 
X008 
Sd-
833541 HM6 Sd-833508 S-122112 12-Sep-13 14-Sep-13 S-123958 HM6 x CODMb Q254* 
X009 
Sd-
833514 S-122112 Sd-833385 S-114247 11-Sep-13 14-Sep-13 S-124006 




833617 S-125001 Sd-833418 S-114248 12-Sep-13 14-Sep-13 S-123988 




833596 HN4 Sd-833402 S-114248 11-Sep-13 14-Sep-13 S-123975 HN4 x CODM E193K/R158K 
X012 
Sd-
833386 S-114247 Sd-833542 HM6 11-Sep-13 14-Sep-13 S-123984 CODM E193K/R158K x HM6 
X013 
Sd-
833569 HT6 Sd-833464 S-114249 14-Sep-13 16-Sep-13 S-123970 




833498 S-114250 Sd-833464 S-114249 14-Sep-13 16-Sep-13 S-124001 




833503 S-122112 Sd-833464 S-114249 14-Sep-13 16-Sep-13 S-124009 




833580 HN4 Sd-833464 S-114249 14-Sep-13 16-Sep-13 S-123972 




833488 S-114250 Sd-833545 HM6 14-Sep-13 16-Sep-13 S-123997 High T x HM6 
X018 
Sd-
833483 S-114250 Sd-833850 S-125003 16-Sep-13 18-Sep-13 S-123998 




833619 S-125001 Sd-833697 S-114139 16-Sep-13 18-Sep-13 S-123989 




833620 S-114248 Sd-833566 HT6 16-Sep-13 18-Sep-13 S-124038 CODM E193K/R158K x HT6 
X021 
Sd-
833789 HN4 Sd-833827 S-114250 16-Sep-13 18-Sep-13 S-124071 HN4 x High T 
X022 
Sd-
833825 S-114250 Sd-833649 S-122067 16-Sep-13 18-Sep-13 S-124018 High T x CODM E193K/R158K 
X023 
Sd-
833585 HN4 Sd-833873 S-125004 16-Sep-13 18-Sep-13 S-123976 HN4 x T/O only from HN3 mut 
X024 
Sd-
833520 S-122152 Sd-833380 S-114247 16-Sep-13 18-Sep-13 S-123965 




833481 S-114250 Sd-833532 S-122152 17-Sep-13 19-Sep-13 S-124002 High T x CODMa/c W261* 
X026 
Sd-
833538 S-122152 Sd-833553 HM6 17-Sep-13 19-Sep-13 S-123963 CODMa/c W261* x HM6 
X027 
Sd-
833559 HM6 Sd-833434 S-122066 16-Sep-13 19-Sep-13 S-123955 HM6 x CODM E193K/R158K 
X028 
Sd-
833815 S-114250 Sd-833806 S-122066 17-Sep-13 19-Sep-13 S-124021 High T x CODM E193K/R158K 
X029 
Sd-
833583 HN4 Sd-833842 S-125002 16-Sep-13 19-Sep-13 S-123977 HN4 x T/O only from HN3 mut 
X030 
Sd-
833578 HT6 Sd-833390 S-114247 16-Sep-13 19-Sep-13 S-123971 HT6 x CODM E193K/R158K 
X031 
Sd-
833555 HM6 Sd-833853 S-125003 18-Sep-13 20-Sep-13 S-123956 HM6 x T/O only from HN3 mut 
X032 
Sd-
833536 S-122152 Sd-833599 HN4 18-Sep-13 20-Sep-13 S-123962 CODMa/c W261* x HN4 
X033 
Sd-
833714 S-125001 Sd-833818 S-114250 18-Sep-13 20-Sep-13 S-124073 




833755 S-122152 Sd-833895 S-114247 18-Sep-13 20-Sep-13 S-124025 








Mother plant Father plant Date of 
emasc-
ulation 












833720 S-122122 Sd-833489 S-114250 23-Sep-13 25-Sep-13 S-124057 CODMb Q254* x High T 
X036 
Sd-
833725 S-122122 Sd-833851 S-125003 23-Sep-13 25-Sep-13 S-124052 




833737 S-122122 Sd-833564 HT6 23-Sep-13 25-Sep-13 S-124043 CODMb Q254* x HT6 
X038 
Sd-
833681 S-114139 Sd-833759 S-122152 23-Sep-13 25-Sep-13 S-124067 




833778 HT6 Sd-833533 S-122152 23-Sep-13 25-Sep-13 S-124075 HT6 x CODMa/c W261* 
X040 
Sd-
833770 HT6 Sd-833619 S-125001 23-Sep-13 25-Sep-13 S-124076 HT6 x T/O only from HN3 mut 
X041 
Sd-
833680 S-114139 Sd-833604 S-125001 23-Sep-13 25-Sep-13 S-124064 
CODMb/T6ODMa mutant x T/O 
only from HN3 mut 
X042 
Sd-
833560 HT6 Sd-833486 S-114250 23-Sep-13 25-Sep-13 S-123968 HT6 x High T 
X043 
Sd-
833577 HT6 Sd-833816 S-114250 23-Sep-13 25-Sep-13 S-123966 HT6 x High T 
X044 
Sd-
833690 S-114139 Sd-833824 S-114250 23-Sep-13 25-Sep-13 S-124066 




833702 S-125001 Sd-833728 S-122122 25-Sep-13 27-Sep-13 S-124074 




833839 S-125002 Sd-833746 S-122152 25-Sep-13 27-Sep-13 S-124077 




833753 S-122152 Sd-833719 S-125001 25-Sep-13 27-Sep-13 S-124037 
CODMa/c W261* x T/O only 
from HN3 mut 
X048 
Sd-
833750 S-122152 Sd-833773 HT6 25-Sep-13 27-Sep-13 S-124031 CODMa/c W261* x HT6 
X049 
Sd-
833962 HM6 Sd-833695 S-114139 1-Oct-13 3-Oct-13 S-124069 HM6 x CODMb/T6ODMa 
X050 
Sd-
833459 S-122067 Sd-833684 S-114139 1-Oct-13 3-Oct-13 S-124003 




834053 S-114139 Sd-834078 S-114156 7-Oct-13 9-Oct-13 S-124013 




833966 S-122152 Sd-834039 S-114118 7-Oct-13 9-Oct-13 S-124040 CODMa/c W261* x High T 
X053 
Sd-
833989 S-122122 Sd-833950 HM6 7-Oct-13 9-Oct-13 S-124014 CODM Q254* x HM6 
X054 
Sd-
833985 S-122122 Sd-834043 S-114139 7-Oct-13 9-Oct-13 S-124015 




833942 HT6 Sd-833628 S-114248 7-Oct-13 9-Oct-13 S-124068 HT6 x CODM E193K/R158K 
X056 
Sd-
833920 HN4 Sd-833751 S-122152 7-Oct-13 9-Oct-13 S-124061 HN4 x CODMa/c W261* 
X057 
Sd-
835248 S-114118 Sd-835193 S-123361 14-Jan-14 16-Jan-14 S-122954 




835269 S-122122 Sd-835198 S-123361 14-Jan-14 16-Jan-14 S-122968 




835262 S-122122 Sd-835207 S-123349 14-Jan-14 16-Jan-14 S-122966 




835205 S-123349 Sd-835280 S-114248 14-Jan-14 16-Jan-14 S-122944 




835261 S-122122 Sd-835187 S-123361 16-Jan-14 18-Jan-14 S-122969 




835266 S-122122 Sd-835210 S-123349 16-Jan-14 18-Jan-14 S-122970 




835250 S-114118 Sd-835189 S-123361 16-Jan-14 18-Jan-14 S-122952 




835292 S-114248 Sd-835193 S-123361 18-Jan-14 20-Jan-14 S-122956 
CODM E193K/R158K x 
T6ODMa W145* (homo) 
X065 
Sd-
835221 HT5 Sd-835184 S-123361 18-Jan-14 20-Jan-14 S-122962 HT5 x T6ODMa W145* (homo) 
X066 
Sd-
835279 S-122122 Sd-835192 S-123361 18-Jan-14 20-Jan-14 S-122967 




835230 HT5 Sd-835182 S-123361 20-Jan-14 22-Jan-14 S-122963 HT5 x T6ODMa W145* (homo) 
X068 
Sd-
835233 HT5 Sd-835212 S-123349 20-Jan-14 22-Jan-14 S-122694 HT5 x T6ODMa Q141* (wt) 
X069 
Sd-








Mother plant Father plant Date of 
emasc-
ulation 












835288 S-114248 Sd-835182 S-123361 20-Jan-14 22-Jan-14 No seed 
CODM E193K/R158K x 
T6ODMa W145* (homo) 
X071 
Sd-
835583 HM6 Sd-835195 S-123361 20-Jan-14 22-Jan-14 S-122979 HM6 x T6ODMa W145* (homo) 
X072 
Sd-
835247 S-114118 Sd-835218 S-123349 20-Jan-14 23-Jan-14 S-122953 




835284 S-114248 Sd-835218 S-123349 20-Jan-14 23-Jan-14 S-122957 
CODM E193K/R158K x 
T6ODMa Q141* (wt) 
X074 
Sd-
835253 S-114118 Sd-835201 S-123349 25-Jan-14 27-Jan-14 S-122955 




835694 HT6 Sd-835673 S-124115 04-Mar-14 06-Mar-14 No seed HT6 x T6ODMa A146T (het) 
X076 
Sd-
835701 HT6 Sd-835682 S-124115 04-Mar-14 06-Mar-14 N/A HT6 x T6ODMa A146T (wt) 
Crosses involving F1s, BC1s and F2s 
X077 
Sd-
835585 HM6 Sd-835304 S-124006 18-Jan-14 20-Jan-14 S-122980 HM6 x X009 
X078 
Sd-
835587 HM6 Sd-835413 S-123955 20-Jan-14 22-Jan-14 S-122978 HM6 x X027  
X079 
Sd-
835580 HN4 Sd-835445 S-123972 20-Jan-14 22-Jan-14 S-122972 HN4 x X016  
X080 
Sd-
835568 S-114139 Sd-835330 S-124013 20-Jan-14 22-Jan-14 S-122973 High T Fwd x X051  
X081 
Sd-
835552 HT6 Sd-835427 S-123971 22-Jan-14 24-Jan-14 S-122977 HT6 x X030 
X082 
Sd-
831987 HT5 Sd-837839 S-122977 28-May-14 29-May-14 TBD HT5 x X081 E193K/R158K (wt) 
X083 
Sd-
831956 HM6 Sd-837806 S-122978 28-May-14 29-May-14 TBD HM6 x X078 E193K/R158K (wt) 
X084 
Sd-
831930 HN4 Sd-837759 S-122972 28-May-14 29-May-14 TBD HN4 x X079 Tint (wt) 
X085 
Sd-
831981 HT5 Sd-831873 S-122962 04-Jun-14 05-Jun-14 S-186688 HT5 x X065 
 
Crosses struckthrough indicate instances where the parent intended to be the transmitter 
of a CODM/T6ODM mutation was subsequently genotyped as wild type. This happened when 
the mutations were still segregating in the line sown to provide the parent in a cross. The 







Appendix F- Genotyping of F1 individuals to confirm presence of alleles 
contributed by mutants 
First batch of F1s-agarose gel visualisation 
All samples of both D-10842 and D-10843 DNA plates were screened for the T6ODM Tint 
polymorphism. Only those samples relevant for the CODM E193K, R158K and Q254* 
polymorphisms were screened for these markers. Presence of an appropriately sized PCR 
product indicated possession the marker.  
Tint  164 bp 
E193K 138 bp 
R158K 345 bp 
Q254*  339 bp 
 




        E193K         R158K         Q254* 
Second batch of F1s-visualisation on Fragment Analyser 













F1s were screened for the Q254* (339 bp), R158K (345 bp), W261* (327 bp), Q141* (492 
bp), W145* (325 bp), A146T (368 bp) and Tint (164 bp) SNPs where appropriate. AS-PCR 
products generated with each DNA sample are displayed on the TILLING gel below. Well A1 = 
lane 1, well B1 = lane 2 etc. Both these samples contain the CODMa/c W261* SNP (327 bp 




D-10863                         
 
1 2 3 4 5 6 7 8 9 10 11 12 
A 
W261* W261*                     
                  Q254*   Q254* 
      W145* W145* Q141*       W145*     
      Tint   Tint             
B 
W261*                       
                  Q254*   Q254* 
      W145* W145* Q141*       W145*   Q141* 
      Tint   Tint             
C 
                        
                  Q254*   Q254* 
    
 
W145* W145*         W145*   Q141* 
      Tint                 
D 
W261*   
 
                  
    
 
          Q254* Q254*   Q254* 
    W145*   W145* Q141*     W145* W145*   Q141* 
    Tint     Tint             
E 
W261*   
 
                  
    
 
          Q254* Q254*   Q254* 
    W145* W145* W145* Q141*     W145* W145*     
    Tint     
 
            
F 
W261*                       
                Q254*     Q254* 
    W145* W145* W145*       W145*     Q141* 
    Tint     Tint             
G 
W261*   
 
                  
    
 
          Q254*   Q254* Q254* 




    W145*   Q141* Q141* 
    
 
  Tint Tint             
H 
                        
                Q254* R158K het Q254* Q254* 
    W145* W145* Q141*       W145* W145*     

















DNA plate D-10864 contained DNA from approximately ten plants of the following F1 seed 
batches: 
S-122955 X074 (A1-B2) 
S-122997 X075 (E5-E7) 
 
The plate also contained DNA from M4 T6ODMa TILLING mutants S-124986 (A146T), S-
124789 (W145*) and S-122951 (Q141*).  
 
For X074 F1s well A1 (lane 1) contained the Q141* mutation but B1 (lane 2) did not. The SNP 
was expected to be present in half of the F1s because the Q141* parent in the cross was a 
heterozygote (Appendix E). None of the F1s from the X075 cross carried the A146T SNP 
(lanes 37-53) so work with this cross was terminated at this stage.  
 




D-10864                         
 
1 2 3 4 5 6 7 8 9 10 11 12 
A 
Q141*             W145* W145* W145* Q141* Q141* 
                        
          Tint Tint           
                        
B 
  Q141*           W145* W145* W145* Q141* Q141* 
                        
          Tint Tint           
                        
C 
              W145* W145* W145* Q141* Q141* 
                        
          Tint Tint           
                        
D 
Q141*             W145* W145* W145* Q141*   
                        
          Tint Tint           
                        
E 
Q141*             W145* W145* W145* Q141* Q141* 
                        
        Tint Tint Tint           
                        
F 
            W145* W145* W145* Q141* Q141* Q141* 
                        
        Tint Tint             
                        
G 
Q141*           W145* W145* W145* Q141* Q141* Q141* 
                        
        Tint Tint         
 
  
                        
H 
            W145* W145* W145*   Q141* Q141* 
                        
        Tint Tint             
                        
 
251  
F2 seed collection 
Mother 
Seed batch id 
 Seedling id 
Known mutations 
Father 
Seed batch id 
 Seedling id 
Known mutations 
F1 seed batch id 
Cross id 











































































Seed batch id 
 Seedling id 
Known mutations 
Father 
Seed batch id 
 Seedling id 
Known mutations 
F1 seed batch id 
Cross id 



















































Appendix G- Genotyping of F2, F3 and BC1 individuals grown in York 
F2s and BC1s were screened for the Q254* (339 bp), R158K (345 bp), W261* (327 bp), Q141* (492 bp), W145* 
(325 bp), A146T (368 bp) and Tint (164 bp) SNPs where appropriate. CODMb heterozygotes indicated by 
predicted fragment sizes after treatment with cleavage enzyme i.e. R158K (919 bp+203 bp), F271L (843 bp+278 
bp) and Q254* (789 bp+332 bp). Likewise, T6ODMa heterozygotes were indicated Tint (359 bp+267 bp), Q141* 
(450 bp+161 bp) and W145* (468 bp+151 bp). 
D-10858 
X009 F2  S-122981 A1-A4 
X008 F2  S-122988 B4-B7  
X015 F2  S-122991 C7-B10 
X041 F2  S-122994 C10-F11 
X008 F2  S-122988 G11-G12 
 
D-10858 Mutation screen  
 
D-10858 CODMb TILL 
 




D-10858                         
 
1 2 3 4 5 6 7 8 9 10 11 12 
A 
E193K E193K wt E193K E193K Q254* het Q254* homo Q254* homo Q254* homo Q254* het Q254* het   Q254* wt 
R158K homo Q254* homo R158K Q254* homo F271L het F271L het F271L het F271L het F271L het F271L het     
Q254* wt F271L het Q254* F271L het                 
              Tint het Tint homo Tint het Tint homo   
B 
E193K E193K E193K wt Q254* homo Q254* homo Q254* homo Q254* het Q254* het Q254* het Q254* het     
R158K het R158K Q254* homo F271L het F271L het F271L het F271L het F271L het F271L het F271L het     
Q254* het Q254* F271L het         Tint het Tint het     F271L het 
                  Tint het     
C 
E193K wt E193K E193K Q254* homo Q254* het Q254* het F271L het F271L het Q254* homo       
Q254* homo R158K R158K F271L het F271L het F271L het Q254* het Q254* het F271L het       
F271L het Q254* Q254*                   
            Tint homo Tint homo Tint het Tint homo Tint homo   
D 
E193K E193K E193K Q254* het Q254* het Q254* rxn fail   Q254* het Q254* het       
R158K R158K R158K F271L het F271L het     F271L het F271L het       
Q254* Q254* Q254*       F271L het 
 
      F271L het 
            Tint homo Tint het Tint homo Tint homo Tint homo   
E 
E193K E193K E193K Q254* het Q254* homo Q254* homo Q254* het         Q254* het 
R158K R158K R158K F271L het F271L het F271L het F271L het F271L het F271L het     F271L het 
Q254* Q254* Q254*                   
            Tint het Tint homo Tint homo Tint homo Tint homo   
F 
E193K E193K E193K wt Q254* het Q254* het Q254* het Q254* het Q254* het Q254* het     Q254* het 
R158K R158K Q254* homo F271L het     F271L het F271L het F271L het     F271L het 
Q254* Q254* F271L het   F271L het F271L het             
            Tint homo Tint homo Tint het Tint homo Tint homo   
G 
E193K E193K E193K Q254* het Q254* het Q254* het   Q254* het Q254* homo   Q254* homo Q254* homo 
R158K R158K R158K F271L het F271L het F271L het F271L het F271L het F271L het   F271L het   
Q254* Q254* Q254*                   
            Tint het Tint het/homo? Tint WT Tint homo     
H 
  E193K E193K   Q254* het Q254* homo Q254* het       Q254* wt   
  R158K R158K   F271L het F271L het F271L het   F271L het   F271L het   
  Q254* Q254*                   
            Tint het Tint het Tint homo Tint homo     
 




X051 F2   S-122983 A1-A4 
X051 BC1   S-122973 B4-A7 
X042 F2   S-122989 B7-D8  
X014 F2   S-122990 E8-D11 
X051 F2   S-122983 E11-H12 
 
D-10859 Mutation screen 
 
 
D-10859 CODMb TILL  
 





D-10859                         
 
1 2 3 4 5 6 7 8 9 10 11 12 
A 
E193K E193K E193K homo E193K               E193K 
R158K het R158K het R158K homo R158K homo               R158K het 
F271L het F271L het     F271L het F271L het           F271L het 
Tint het Tint het Tint homo   Tint homo Tint homo Tint het Tint het Tint het Tint het   Tint ? rxn failed 
B 
E193K E193K E193K E193K het               E193K 
R158K het R158K het R158K homo? R158K het               R158K homo 
F271L het F271L het F271L het F271L het F271L het F271L het           F271L het? 
Tint homo   Tint het Tint homo Tint homo Tint het Tint het Tint homo Tint homo Tint het   Tint het 
C 
  E193K E193K E193K het               E193K 
  R158K het R158K het R158K het               R158K het 
F271L het F271L het F271L het F271L het F271L het F271L het           F271L het 
Tint homo Tint het Tint homo Tint homo Tint het Tint homo Tint homo Tint homo Tint het Tint homo Tint het Tint het 
D 
  E193K                   E193K 
  R158K het                   R158K 
F271L het F271L het F271L het F271L het F271L het F271L het           F271L het 
  Tint het Tint het Tint het Tint homo Tint homo Tint het Tint homo Tint homo   Tint het Tint het 
E 
  E193K E193K               E193K E193K 
  R158K het R158K het               R158K het? R158K 
F271L het F271L het F271L het F271L het F271L het F271L het         F271L het F271L het 
Tint homo       Tint het Tint homo Tint homo   Tint het   Tint het   
F 
  E193K E193K               
 
  
  R158K homo? R158K het                   
F271L het F271L het F271L het F271L het F271L het           F271L het F271L het 
Tint het Tint homo Tint homo Tint het Tint homo Tint het Tint het Tint homo Tint het Tint het Tint het   
G 
E193K E193K       E193K het             
  R158K het       R158K het           R158K homo? 
F271L het F271L het F271L het F271L het F271L het F271L het         F271L het F271L het 
Tint het Tint het Tint het   Tint homo Tint homo Tint het Tint het Tint het   Tint het   
H 
  E193K   E193K         E193K?   E193K   
R158K het R158K het   R158K het   R158K het     R158K? R158K? R158K homo? R158K het 
F271L het F271L het F271L het F271L het F271L het F271L het         F271L het F271L het 












X016 F2   S-122995 A1-A4 
X016 BC1  S-122972 B4-B7 
X015 F2  S-122991 C7-H7 
X016 F2  S-122995 A8-C9 
X016 BC1  S-122972 D9-D10 
Q254* x HT1 F2 S-124776 E10-C11 
X051 BC1  S-122973 D11-B12 
X009 F2  S-122981 C12-H12 
 
D-10860  Mutation screen 
 
D-10860 CODMb TILL  
 




D-10860                         
 
1 2 3 4 5 6 7 8 9 10 11 12 
A 
                        
                    Q254* het   
                    F271L het   
Tint het Tint het Tint homo Tint homo       Tint het Tint het   Tint TILL rxn fail   
B 
                      E193K 
                    Q254* het R158K het 
                    F271L het F271L het 
Tint het Tint het Tint het         Tint homo Tint het   Tint het Tint TILL rxn fail 
C 
                      E193K het 
                    Q254* homo Q254* het 
                    F271L het R158K het 
  Tint homo Tint homo         Tint het     Tint homo F271L no het signal 
D 
                    E193K het E193K wt 
            Q254*?       R158K het Q254* homo 
            F271L het       F271L het F271L het 
Tint het Tint het Tint het       Tint homo       Tint homo   
E 
                        
                  Q254* het   R158K homo? 
                  F271L het   F271L het 
Tint het Tint homo             Tint het Tint homo   Q254* homo? 
F 
                      E193K 
                  Q254* het   R158K het 
                  F271L het   Q254* het 
  Tint homo Tint het             Tint het   F271L het 
G 
                        
                  Q254* het   Q254* homo 
                  F271L het 
 
F271L het 
  Tint het Tint het         Tint het   Tint het     
H 
                        
            Q254*?     Q254* het     
            F271L het     F271L het     






X027 F2   S-122982 A1-A4 
X027 BC1  S-122978 B4-A7 
X030 F2  S-122987 B7-B10 
X030 BC1  S-122977 C10-H12  
 
D-10861 Mutation Screen 
 



















D-10861                         
 
1 2 3 4 5 6 7 8 9 10 11 12 
A 
E193K homo E193K E193K E193K homo   E193K         E193K   
R158K homo R158K het R158K rxn fail R158K homo   R158K         R158K   
F271L het F271L het   F271L het                 
              Tint Tint Tint Tint Tint 
B 
E193K E193K     E193K   E193K E193K E193K     E193K 
R158K het R158K het     R158K   R158K het R158K R158K het     R158K 
F271L het F271L het         F271L het   F271L het   Tint   
            Tint   Tint       
C 
E193K     E193K E193K E193K   E193K E193K       
R158K het     R158K R158K R158K   R158K R158K homo       
F271L het               F271L het       
            Tint   Tint het Tint   Tint 
D 
    E193K homo E193K E193K   E193K E193K   E193K E193K E193K 
    R158K homo R158K R158K   R158K R158K het   R158K R158K R158K 
    F271L het         F271L het         
              Tint     Tint   
E 
  E193K   E193K E193K E193K E193K   E193K E193K   E193K 
  R158K het   R158K R158K R158K R158K het   R158K R158K   R158K 
  F271L het         F271L het           
            Tint Tint     Tint Tint 
F 
E193K E193K   E193K     E193K   E193K     E193K 
R158K het R158K rxn fail R158K het R158K     R158K   R158K het     R158K 
F271L het   F271L het           F271L het       
              Tint Tint Tint Tint Tint 
G 
E193K homo E193K   E193K     E193K   E193K E193K     
R158K homo R158K homo   R158K     R158K het   R158K het R158K     
F271L het F271L het         F271L het   F271L het       
            Tint Tint Tint Tint   Tint 
H 
E193K E193K E193K   E193K     E193K     E193K E193K 
R158K het R158K het R158K het   R158K     R158K     R158K   
F271L het F271L het F271L het                   






X001 F2  S-122996 A1-A4 
Q254* x W261* F3 S-124758 B4-F6 
Q254* x HN1 F2 S-124770 G6-G9 
Q254* x HT1 F2 S-124776 H9-H12 
 
D-10862 Mutation screen 
 
 





D-10862                         
 
1 2 3 4 5 6 7 8 9 10 11 12 
A 
E193K E193K E193K homo E193K W261*?               
R158K het R158K het R158K homo R158K het Q254* het   Q254* het   Q254* het Q254* het Q254* het Q254* homo 
F271L het F271L het F271L het F271L het F271L het F271L het F271L het F271L het F271L het F271L het F271L het F271L het 
                  Tint Tint Tint het 
B 
E193K E193K   W261* W261*?               
R158K het R158K het     Q254* het Q254* homo       Q254* het Q254* het Q254* het 
F271L het F271L het F271L het F271L het F271L het F271L het F271L het F271L het F271L het F271L het F271L het F271L het 
                  Tint Tint   
C 
  E193K   W261* W261*? W261*?             
  R158K het     Q254* het Q254* het Q254* het Q254* het   Q254* het   Q254* het 
F271L het F271L het F271L het F271L het F271L het F271L het F271L het F271L het F271L het F271L het F271L het F271L het 
                  Tint homo     
D 
E193K E193K   W261*                 
R158K het R158K het     Q254* het     Q254* het Q254* homo Q254* homo Q254* het Q254* het 
F271L het F271L het F271L het F271L het F271L het F271L het F271L het F271L het F271L het F271L het F271L het F271L het 
                  Tint het Tint Tint het 
E 
    E193K   W261* het               
    R158K het Q254* homo Q254* het Q254* homo Q254* het   Q254* het Q254* het Q254* homo Q254* het 
F271L het F271L het F271L het F271L het F271L het F271L het F271L het F271L het F271L het F271L het F271L het F271L het 
                  Tint het Tint homo Tint 
F 
E193K E193K   W261* het   W261* het             
R158K het R158K het   Q254* het Q254* homo Q254* het Q254* het Q254* het Rxn failure Q254* het   Q254* het 
F271L het F271L het Rxn failure F271L het F271L het F271L het F271L het F271L het   F271L het F271L het F271L het 
                      Tint 
G 
E193K homo E193K   W261* W261*               
R158K homo R158K het     Q254* het Q254* het Q254* homo Q254* het Q254* het Q254* het Q254* het Q254* het 
F271L het F271L het F271L het F271L het F271L het F271L het F271L het F271L het F271L het F271L het F271L het F271L het 
                  Tint   Tint 
H 
E193K E193K E193K W261* W261*               
R158K het R158K het R158K het   Q254* het Q254* het Q254* het Q254* het Q254* het Q254* het Q254* het Q254* het 
F271L het F271L het F271L het F271L het F271L het F271L het F271L het F271L het F271L het F271L het F271L het F271L het 






Q141* M4  S-122951 A1-F1 
Q254* x W261* F3 S-124758 G1-H7 
X042 F2  S-122998 A8-H10 
X001 F2  S-122996 A11-H12 
 
D-10865 Mutation screen 
 
 
D-10865                         
 
1 2 3 4 5 6 7 8 9 10 11 12 
A 
                    E193K E193K 
                    R158K 
R158K 
het 
              Tint Tint Tint     
                        
B 
                    E193K E193K 
                    R158K 
R158K 
het 
              Tint Tint Tint     
                        
C 
                    E193K   
                    R158K   
              Tint Tint wt 
Tint 
homo     
                        
D 
                    E193K   
                    
R158K 
homo   
              Tint Tint Tint     
                        
E 
                    E193K   
                    
R158K 
homo   
              Tint het Tint Tint     
                        
F 
                    E193K   
                    
R158K 
het   
              Tint Tint Tint     
                        
G 
                      E193K 
                      
R158K 
het 
              Tint Tint het Tint 
 
  
                        
H 
                    E193K E193K 
                    R158K R158K 
              Tint wt   Tint     





X027 BC1self  S-186656 A1-G3 
X051 BC1self  S-186602 H3-B4 
X009 F3  S-186609 C4-C7 
X059 F2  S-186709 D7 
X071 F2  S-186702 E7-B8 
HM6     C8-A10 
HT5     B10-H11 
X031 F2  S-186693 A12-H12 
 



































D-10868                         
 
1 2 3 4 5 6 7 8 9 10 11 12 
A 
        Q254* wt or homo Q254* wt or homo Q254* wt or homo           
R158K wt  R158K het PCR fail R158K het R158K wt or homo R158K wt or homo R158K wt or homo           
        F271L F271L             
              W145* WT         
B 
  F271L     Q254* het Q254* wt or homo PCR fail           
PCR fail R158K  homo R158K pos het R158K het R158K het R158K wt or homo             
    seq rxn failed     F271L             
              W145* het         
C 
  F271L   Q254* wt or homo Q254* wt or homo Q254* wt or homo Q254* wt or homo           
PCR fail R158K  homo R158K het R158K wt or homo R158K wt or homo R158K wt or homo R158K wt or homo           
        F271L               
                        
D 
      Q254* wt or homo Q254* wt or homo Q254* wt or homo Q254* homo           
R158K het R158K  homo R158K het R158K wt or homo R158K wt or homo R158K wt or homo Q141* WT           
          F271L             
                        
E 
F271L      Q254* wt or homo Q254* wt or homo Q254* het             
R158K wt or homo R158K wt R158K wt or homo R158K wt or homo R158K wt or homo R158K het             
      F271L   F271L             
            W145* homo           
F 
F271L      Q254* wt or homo Q254* het Q254* het             
R158K wt or homo R158K het R158K het R158K wt or homo R158K het R158K het             
        F271L F271L             
            W145* WT           
G 
F271L      PCR fail Q254* het Q254* het             
R158K wt or homo R158K het R158K het   R158K het R158K het             
        F271L F271L             
            W145* het           
H 
      PCR fail Q254* het Q254* het             
R158K het R158K het R158K wt   R158K het R158K het             
        F271L F271L             




X041 F3  S-186742 A1-B1 
X051 BC1 self  S-186603 C1-C4 
X016 BC1 self  S-186625 D4-D7 
X016 BC1 self  S-186626 E7-E10 
X059 F2  S-186710 F10-C11 
Q254* x HT1 F3 S-186633 D11-H11 













D-10869                         
 
1 2 3 4 5 6 7 8 9 10 11 12 
A 
                        
F271L het R158K het R158K het R158K het             Q254* het   
                    Q141* homo   
Tint Tint Tint Tint Tint het Tint homo Tint het wt Tint het wt     
B 
                      W261* het 
F271L TBD R158K het R158K het R158K homo             Q254* het   
                    wt   
Tint Tint Tint Tint wt wt wt wt Tint het Tint het     
C 
                        
R158K het R158K het   R158K het             wt   
                    Q141* het   
Tint Tint Tint Tint Tint homo Tint het Tint het Tint het wt Tint homo     
D 
                      W261* het 
                    wt   
                        
Tint Tint Tint Tint het Tint het Tint het wt Tint het Tint het Tint homo     
E 
                      W261* het 
R158K het   R158K het               Q254* homo   
                        
Tint Tint Tint wt wt Tint het wt Tint homo Tint het wt Tint   
F 
                      W261* het 
R158K het R158K het R158K het             wt Q254* het   
                  Q141* het     
Tint Tint Tint Tint het Tint het wt Tint het Tint het wt   Tint   
G 
                        
R158K het   R158K het             Q254* homo Q254* het   
                  Q141* homo     
Tint Tint   Tint homo wt Tint homo Tint het Tint het Tint het   Tint   
H 
                        
                  Q254* het wt   
                  Q141* homo     





Q254* x HT1 F3 S-186680  A1-A4 
X071 F3  S-186703 B4-B7 
X029 F2  S-186686 C7-B10 
Q254* x HN1 F3 S-186635 C10-E12 
 
D-10870 Mutation screen 
 
 
D-10870 T6ODMa TILL 
  
 




D-10870                         
 
1 2 3 4 5 6 7 8 9 10 11 12 
A 
                        
                    wt Q254* het 
                        
  Tint Tint Tint wt W145* het W145* homo           
B 
                        
                    wt Q254* het 
                        
Tint Tint   wt wt wt W145* het           
C 
                        
                  wt wt Q254* homo 
                        
Tint Tint Tint wt wt W145* het             
D 
                        
                  wt Q254* homo wt 
                        
Tint Tint Tint W145* het wt wt             
E 
                        
                  Q254* het wt wt 
                        
Tint Tint Tint wt wt W145* het             
F 
                        
                  Q254* het Q254* het   
                        
Tint   Tint wt W145* het W145* het             
G 
                        
                  Q254* het Q254* het   
                        
Tint Tint Tint W145* het W145* het W145* het             
H 
                        
                  wt wt   
                        
Tint Tint Tint W145* het W145* het W145* het             
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D-10871   &   D-10872 
Q254* x HN1 F3 S-186634 A1-A4  X001 F3 S-186724 A1 
X008 F3  S-186676 B4-A7  X001 F3 S-186725 B1-G2 
X065 F2  S-186696 B7-B10 X074 F2 S-186704 H2-G4 
X069 F2  S-186698 C10-G12 
 
D-10871 Mutation screen  
  
D-10872 Mutation screen 
 
D-10871(Cols1-7)+D-10872 (Cols11-12) CODMb TILL 
  




D-10871 1 2 3 4 5 6 7 8 9 10 11 12 
A 
                        
Q254* homo Q254* het Q254* homo Q254* het Q254* het Q254* het wt           
                    Q141* Q141* 
              Tint Tint   Tint Tint 
B 
                        
Q254* homo Q254* het wt wt wt Q254* het             
                    Q141* homo Q141* homo 
              Tint Tint       
C 
                        
wt wt Q254* het Q254* het Q254* het Q254* het             
                  pos Q141*     
            Tint Tint Tint   Tint Tint 
D 
                        
Q254* het Q254* homo Q254* het Q254* het Q254* pos het Q254* het             
                      Q141* homo 
            Tint Tint Tint Q141* het     
E 
                        
wt wt Q254* het Q254* homo Q254* het wt             
                    Q141* het   
            Tint   Tint Tint   Tint 
F 
                        
Q254* het Q254* het Q254* het wt Q254* homo wt             
                    Q141* Q141* 
                Tint Q141* homo Tint   
G 
                        
Q254* WT wt wt wt wt Q254* homo             
                  pos Q141* Q141* Q141* 
              Tint Tint       
H 
                        
Q254* homo Q254* homo wt wt Q254* het Q254* homo             
                        
            W145* het   W145* het Tint Tint   
 
D-10872 1 2 3 4 5 6 7 8 9 10 11 12 
A 
                        
R158K het R158K het  Q141* het  Q141* het                 
                        
B 
                        
wt R158K het Q141* homo Q141* het                 
                        
C 
                        
wt wt Q141* homo Q141* het                 
                        
D 
                        
R158K het wt Q141* homo                   
                        
E 
                        
wt R158K het Q141*                   
                        
F 
                        
wt wt   Q141*                 
G 
                        
wt R158K TBD   Q141*                 
                        
H 
                        
wt   Q141*                   
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Appendix H- Genotyping of material grown in Tasmania 
Field plots each seed batch was sown in 
Seed batch id Plot  
S-186660 MD 801 
HT6 MD 802 
S-186608 MD 803 
S-186658 MD 804 
HM6 MD 805 
S-186610 MD 806 
S-186609 MD 807 
S-186720 MD 808 
S-186729       MD 809 
S-186620 MD 810 
S-186622 MD 811 
HT5 MD 812 
S-186728 MD 813 
S-186667 MD 814 
S-186716 MD 815 
S-186742 MD 816 
S-186661 MD 817 
S-186609 MD 818 
HM7 MD 819 
S-186617 MD 820 
S-186611 MD 821 
S-186601 MD 822 
S-186660 MD 823 
S-186613 MD 824 
HM6 MD 825 
S-186671 MD 826 
S-186608 MD 827 
S-186728 MD 828 
S-186619 MD 829 
S-186622 MD 830 
HT6 MD 831 
S-186611 MD 832 
S-186609 MD 833 
S-186659 MD 834 
S-186610 MD 835 
S-186613 MD 836 
S-186640 MD 837 
S-186719 MD 838 
HM6 MD 839 
S-186608 MD 840 
S-186617 MD 841 
S-186667 MD 842 
S-186671 MD 843 
S-186620 MD 844 
HT5 MD 845 
S-186716 MD 846 
S-186605 MD 847 
S-186729       MD 848 
S-186742 MD 849 
S-186601 MD 850 
S-186608 MD 851 
S-186659 MD 852 
HM7 MD 853 
S-186662 MD 854 
S-186637 MD 855 
S-186661 MD 856 
S-186609 MD 857 
S-186619 MD 858 
S-186678 MD 859 
S-186621 MD 860 
S-186605 MD 861 
S-186658 MD 862 
S-186716 MD 863 
S-186624 MD 864 
S-186637 MD 865 
S-186740 MD 866 
S-186613 MD 867 
S-186678 MD 868 
T 32 MD 869 
S-186607 MD 870 
 
 
Seed batch id Plot 
S-186682 MD 871 
S-186685 MD 872 
S-186716 MD 873 
S-186628 MD 874 
S-186720 MD 875 
S-186632 MD 876 
S-186717 MD 877 
S-186640 MD 878 
S-186613 MD 879 
HN1 MD 880 
S-186628 MD 881 
S-186607 MD 882 
S-186624 MD 883 
S-186719 MD 884 
S-186685 MD 885 
S-186665 MD 886 
S-186682 MD 887 
S-186717 MD 888 
HN1 MD 889 
S-186662 MD 890 
S-186632 MD 891 




Genotyping of six DNA plates representing field grown material 
Plants were screened for the Q254* (339 bp), R158K (345 bp), and Tint (164 bp) SNPs where appropriate. CODMb 
heterozygotes indicated by predicted fragment sizes after treatment with cleavage enzyme i.e. R158K (919 
bp+203 bp), F271L (843 bp+278 bp) and Q254* (789 bp+332 bp). Likewise, T6ODMa heterozygotes were 
indicated Tint (359 bp+267 bp).  
 
D-11113 Mutation Screen  
 
D-11114 Mutation Screen 
D-11115 Mutation Screen 
  
 




D-11117 Mutation Screen 
  




TILLING plate layouts (to determine zygosity in individuals where SNPs were segregating) 
T6ODMa TILL Plate 1 
           
 
1 2 3 4 5 6 7 8 9 10 11 12 
A 




Tint     
B 




Tint     
C 




Tint     
D 




Tint     
E 




Tint Tint   
F 
      Tint Tint Tint   R158K R158K 
R158K 
Tint Tint   
G 






Tint Tint   
H 




Tint       
 
7 8 10 11 12 2 3 3 4 5 12 
 
 
D-11113 D-11115 D-11116 
  
T6ODMa TILL Plate 2 
           
 









































































Tint Tint         
 

















T6ODMa TILL Plate 3 
 
1 2 3 4 5 6 7 8 9 10 11 12 
A 




Tint Q254*           
B 




Tint             
C 




Tint             
D 




Tint             
E 




Tint             
F 




Tint             
G 




Tint             
H 
  Tint Tint 
Q254* 
Tint                 
 
9 10 11 12 1 2 3 
     
 
D-11118 D-11119 
      
CODMb TILL Plate 1 
           
 
1 2 3 4 5 6 7 8 9 10 11 12 
A   R158K   Q254* Q254*     Q254* Q254* Q254*   Q254* 
B   R158K   R158K   Q254*   Q254* Q254* Q254*     
C R158K R158K   Q254*   Q254*   Q254* Q254* Q254*     
D R158K R158K R158K Q254*   Q254* Q254* Q254* Q254*     Q254* 
E R158K     Q254*   Q254* R158K Q254* Q254*     Q254* 
F R158K   R158K Q254* Q254*   Q254* Q254* Q254*   Q254* Q254* 
G R158K   R158K R158K Q254*   R158K Q254* Q254*   R158K R158K 
H R158K     Q254* R158K   Q254* Q254* Q254*   R158K   
 
6 7 8 1 2+5 6 9+11 12 1 2 5 6 
 
D-11113 D-11114 D-11115 
CODMb TILL Plate 2 
           
 




Tint Tint     
R158K 
Tint Tint   
Q254* 










Tint   
Q254* 










Tint     Tint 
R158K 
Tint   
Q254* 
















Tint   
Q254* 
Tint   
Q254* 











Tint   
Q254* 















Tint   
Q254* 


















Tint     Tint 
R158K 
Tint   
Q254* 




Tint   
 
8 9 10 2 6 7 8 6 7 4 5 6 
 

























T6ODMa TILL Plate1 
 
T6ODMa TILL Plate2 
  
 
T6ODMa TILL Plate3 
  
 







Mutations identified with AS-PCR 
          
D-11113 1 2 3 4 5 6 7 8 9 10 11 12 
A 
R158K R158K R158K 
R158K 
Tint R158K Tint 
Q254* het 
R158K het WT T6ODMa Tint Tint WT Tint homo 
B 
R158K R158K R158K 
R158K 
Tint R158K Tint 
Q254* het 
R158K het Tint homo Tint Tint Tint homo Tint homo 
C 
R158K   R158K 
R158K 
Tint   R158K homo R158K homo Tint homo Tint Tint Tint homo Tint homo 
D 
R158K R158K R158K 
R158K 




R158K het R158K homo   R158K Tint homo Tint homo 
E 
R158K R158K Tint R158K   R158K homo Tint homo     R158K Tint homo Tint homo 
F 
R158K R158K   R158K   R158K homo WT T6ODMa R158K homo   R158K Tint homo Tint homo 
G 
R158K R158K Tint R158K Tint 
Q254* het 
R158K het Tint homo R158K homo   R158K Tint homo Tint homo 
H 
R158K R158K     Tint R158K zy_nd Tint homo   Tint Tint homo Tint homo   
             
 
S-186660 X027 F3     
 
pred  all E193K/R158K homo 
     
 
HT6 control       
        
 
S-186608 X051 F3     
 
pred all E193/R158K/Tint homo 
    
 
S-186658 X027 F3     
 
pred all E193K/R158K homo 
     
 
HM6 control       
        
 
S-186610 X042 F3     
 
pred all Tint homo 
     
 
S-186609 X009 F3     
 
Q254* and E193K/R158K mutations to segregate  
   
 
S-186720 X042 F3     
 
Tint segregating 
     
 
S-186729 X001 F3     
 
pred all E193K/R158K homo 
     
 
S-186620 X016 F3     
 
pred all Tint homo 
     
 
S-186622 X016 F3     
 
pred all Tint homo 
     
 
HT5 control       
        
 
S-186728 X001 F3     
 
pred  all E193K/R158K homo 
     
 
S-186667 X041 F3     
 
pred all Tint homo 
     
 
S-186716 X042 F3     
 
pred all Tint homo 
     
 
S-186742 X041 F3     
 
pred all Tint homo 
     
 
S-186661 X041 F3     
 
pred all Tint homo 
     
 
S-186609 X009 F3     
 
Q254* and E193K/R158K mutations to segregate  
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Mutations identified with AS-PCR 
          





Q254* het R158K Q254* Tint   
R158K 
Tint   Tint R158K Tint Q254* homo 
B 
R158K homo R158K Tint R158K   
R158K het 
Q254* het R158K   Tint R158K Tint Q254* homo 
C 
Q254* homo R158K Tint R158K   Q254* homo R158K   Tint R158K Tint Q254* homo 
D 
R158K het 
Q254* het R158K Tint R158K   Q254* homo Tint   
R158K het 
Q254* het R158K Tint Q254* homo 
E 
Q254* homo R158K Tint R158K   
R158K het 
Q254* het Tint Tint R158K homo R158K Tint Q254* homo 
F 
R158K het 
Q254* het R158K Q254* Tint Q254* homo 
R158K 
Tint Tint Tint 
R158K het 
Q254* het R158K Tint Q254* homo 
G 




Tint Tint Tint R158K homo R158K Tint Q254* homo 
H 
Q254* zy_nd R158K Q254* Tint R158K homo 
R158K 
Tint     R158K Q254* Q254 het Q254* homo 
             
 
S-186609 X009 F3   
 
Q254* and E193K/R158K mutations to segregate  
    
 
HM7 control       
        
 
S-186617 X001 F3     
 
pred E193K/R158K homo 
     
 
S-186611 X042 F3     
 
pred Tint homo 
      
 
S-186601 X008 F3     
 
pred Q254* homo 
     
 
S-186660 X027 F3     
 
pred E193K/R158K homo 
     
 
S-186613 X042 F3     
 
pred Tint homo 
      
 
HM6 control       
        
 
S-186671 X009 F3     
 
Q254* and E193K/R158K mutations to segregate  
    
 
S-186608 X051 F3     
 
pred E193K/R158K and Tint homo 
     
 
S-186728 X001 F3     
 
pred E193K/R158K homo 
     
 
S-186619 X016 F2     
 
pred Tint homo 
      
 
S-186622 X016 F2     
 
pred Tint homo 
      
 
HT6 control       
        
 
S-186611 X042 F3     
 
pred Tint homo 
      
 
S-186609 X009 F3     
 
Q254* and E193K/R158K mutations to segregate 
    
 
S-186659 X027 F3     
 
pred E193K/R158K homo 
     
 
S-186610 X042 F3     
 
pred Tint homo 
      
 
S-186613 X042 F3     
 
pred Tint homo 
      
 
S-186640 Q254* x HN1 F3     
 
pred Q254* mutation segregating 









Mutations identified by AS-PCR 
          
D-11115 1 2 3 4 5 6 7 8 9 10 11 12 
A 
Q254* homo Q254* homo Tint het 
R158K 
Tint   
R158K het 




Tint R158K Q254* 
B 
Q254* homo Q254* homo Tint het 
R158K 








Q254* homo Q254* zy_nd WT T6ODMa 
R158K 








Q254* homo Tint het Tint homo 
R158K 
Tint   
R158K het 




















Q254* homo Tint homo   R158K 
R158K het 






Tint Q254* R158K 
G 






Tint Q254* R158K 
H 




Tint R158K Q254* R158K 
             
 
S-186640 Q254* x HN1 F3     
 
pred Q254* mutation segregating 
    
 
S-186719 X042 F3     
 
pred Tint segregating 
     
 
HM6 control       
        
 
S-186608 X051 F3     
 
pred homo for E193K/R158K and Tint 
    
 
S-186617 X001 F3     
 
pred E193K/R158K homo 
     
 
S-186667 X041 F3     
 
pred Tint homo 
     
 
S-186671 X009 F3     
 
Q254* and E193K/R158K mutations to segregate 
   
 
S-186620 X016 F3     
 
pred Tint homo 
     
 
HT5 control       
        
 
S-186716 X042 F3     
 
pred Tint homo 
     
 
S-186605 X051 F3     
 
pred E193K/R158K segregating, Tint homo 
    
 
S-186729 X001 F3     
 
pred E193K/R158K homo 
     
 
S-186742 X041 F3     
 
pred all Tint homo_check seq of F2 plant 
    
 
S-186601 X008 F3     
 
pred all Q254* homo 
     
 
S-186608 X051 F3     
 
pred homo for E193K/R158K and Tint 
    
 
S-186659 X027 F3     
 
pred E193K/R158K homo 
     
 
HM7 control       
         
 
280  
Mutations detected with AS-PCR 
          
D-11116 1 2 3 4 5 6 7 8 9 10 11 12 
A 








Tint R158K R158K Tint Q254* 
B 








Tint R158K R158K Tint Q254* 
C 








Tint R158K R158K Tint Q254* 
D 










































Tint R158K R158K Tint Tint homo 
G 






















Tint R158K R158K Tint Q254*   
             
 
HM7 control       
        
 
S-186637 Q254* x HN1     
 
pred Q254* homo 
     
 
S-186661 X041 F3     
 
pred Tint homo_check F2 seq 
     
 
S-186609 X009 F3     
 
Q254* and E193K/R158K mutations to segregate 
    
 
S-186619 X016 F3     
 
pred Tint homo 
      
 
S-186678 X051 F3     
 
pred Tint segregating, E193K/R158K homo 
    
 
S-186621 X016 F3     
 
pred Tint homo 
      
 
S-186605 X051 F3     
 
pred E193K/R158K segregating, Tint homo 
    
 
S-186658 X027 F3     
 
pred E193K/R158K homo 
     
 
S-186716 X042 F3     
 
pred Tint homo 
      
 
S-186624 X016 F3     
 
pred Tint homo 
      
 
S-186637 Q254* x HN1     
 
pred Q254* homo 
     
 
S-186740 X041 F3     
 
pred Tint homo 







Mutations detected with AS-PCR                       






WT T6ODMa Tint   Tint 
Q254* homo 
Tint Tint homo 
Q254* 
Tint pos het 
Q254* 






Tint homo Tint   Tint 
Q254* homo 










Tint homo       
Q254* het 










Tint homo     Tint 
Q254* het 









































Tint het Tint   
Q254* het 























Tint het Tint het WT T6ODMa 
             
 
S-186613 X042 F3       
 
pred all Tint homo 
      
 
S-186678 X051 F3       
 
pred Tint segregating, E193K/R158K homo 
     
 
HT5 control       
 
  
      
 
S-186607 X014 F3       
 
pred all Tint homo 
      
 
S-186682 X023 F3       
 
no markers 
      
 
S-186685 X029 F3       
 
no markers 
      
 
S-186716 X042 F3       
 
pred all Tint homo 
      
 
S-186628 Q254* x HT1 F3     
 
pred Q254* segregating, Tint homo 
     
 
S-186720 X042 F3       
 
pred Tint segregating 
      
 
S-186632 Q254* x HT1 F3     
 
pred Q254* homo, Tint segregating 
     
 
S-186717 X042 F3       
 
pred Tint segregating 










Mutations detected with AS-PCR                       
D-11118 1 2 3 4 5 6 7 8 9 10 11 12 
A 




Tint Tint WT T6ODMa   Tint homo WT T6ODMa Tint homo 
B 




Tint Tint Tint homo   Tint het Tint homo   
C 




Tint Tint WT T6ODMa   Tint homo Tint homo   
D 
Q254* Q254* Q254*   
Q254* het 
Tint Tint Tint homo TILL rxn fail   Tint homo Tint het   
E 
Q254* Q254* Q254*   
Q254* het 
Tint Tint TILL rxn fail     Tint het Tint het   
F 
Q254* Q254* Q254*   
Q254* het 




Q254* Q254* Q254*   
WT CODMb 








Tint Tint WT T6ODMa   WT T6ODMa Tint homo Tint het 
Q254* 
Tint het 
             
 
S-186717 X042 F3       
 
pred Tint segregating 
      
 
S-186640 Q254* x HN1 F3     
 
pred Q254* segregating 
     
 
S-186613 X042 F3       
 
pred Tint homo 
      
 
HN1 control       
 
  
      
 
S-186628 Q254* x HT1 F3     
 
pred Q254* segregating, Tint homo 
     
 
S-186607 X014 F3       
 
pred Tint homo 
      
 
S-186624 X016 F3       
 
pred Tint homo 
      
 
S-186719 X042 F3       
 
pred Tint segregating 
      
 
S-186685 X029 F3       
 
no markers 
      
 
S-186665 X041 F3       
 
pred Tint homo 
      
 
S-186682 X023 F3       
 
no markers 
      
 
S-186717 X042 F3       
 
pred Tint segregating 
      
 
HN1 control       
 
  
      
 
S-186632 Q254* x HT1 F3     
 
pred Q254* homo, Tint segregating 






Mutations detected with AS-PCR 
          
D-11119 





pos Tint homo 
Q254* 






























Tint het                     
H 
WT T6ODMa WT T6ODMa                     
             
 
S-186632 Q254* x HT1 F3     
 
pred Q254* homo, Tint segregating 
     
 
S-186664 X041 F3     
 
pred Tint homo 











F3s sown in Tasmania. Average 0.46% codeine 
 
 

































All 8 genotyped had the R158K marker-assumed homozygotes-higher codeine than HM6 
 














Morphine Oripavine Codeine Thebaine













Morphine Oripavine Codeine Thebaine




5 of the 6 genotyped had the R158K marker-must be segregating hence lower codeine 

































Morphine Oripavine Codeine Thebaine




All genotyped had the R158K marker-assumed homozygotes-high codeine (mean 0.81%) 
 
 
1 of the F3s genotyped did not possess the R158K marker (low codeine). Codeine varies from 



















Morphine Oripavine Codeine Thebaine









































































































































































Morphine Oripavine Codeine Thebaine
WT 





Tint fixed, CODM E193K/R158K segregating. Codeine is increased in CODM E193K/R158K 




CODM E193K/R158K mutations fixed, Tint polymorphism segregating. The phenotypes 
demonstrate the usefulness of the Tint marker in predicting thebaine content. Those without 
the polymorphism had on average 0.23% thebaine. Thebaine is increased in both 






































































































































































































































































Morphine Oripavine Codeine Thebaine






























































































































































































































































































All three SNPs fixed. Phenotypes resemble the third groups of individuals derived from S-
186605 and S-186678.  
X016 
In the F2s the noscapine gene cluster was in a hemizygous state and plants had small 
amounts of noscapine in their capsules. Segregation of the noscapine gene cluster in these 
F3s in Tasmania was expected to result in plants with circa 50% noscapine/50% 
morphinans, similar phenotypes to F2s, or plants with no noscapine in their capsules. For 
four of the five F3 seed batches this was the case (see below). Although not all the F3s grown 
were phenotyped it is clear in each case which individual plants (those on the right of each 
figure) have the noscapine gene cluster in the homozygous state i.e. noscapine comprises 
















Morphine Oripavine Codeine Thebaine






























































Appendix J- Sequences of largest contigs containing CODM sequence 
In each of the three contigs CODM coding sequence (including the three introns) is 
highlighted in green and the locations of the two polymorphic sites between different copies 
of CODM are highlighted in bold/underlined. CODM in each contig reads in an antisense 
manner.  
















































































































































































































































































































































































































































































































































































































































































































































































































































































































































Attempt to amplify CODMa/c and CODMb from CODM-containing BACs
 
301  
Appendix K- Oligonucleotide primers used in the study 
CODM primers used 
BAC library probe design & sequencing 
CODM_F4 TATCCTCCTTGTCCTCGACC  
CODM_R3 TGTTCACACTTTCTCACATCC  
  
CODM_F5 GGTTTGTCAATACCAAGTGTTC  
CODM_R4 TTGTCCATCAGTAAAGCGTC  
  
CODM_F6 TACGGACAGCAAGATGGAG  






































QPCR (Wijekoon and Facchini, 2012) 
CODM_fwd TTGTGCTTAAATTTCGTGGATGAC 
CODM_rev TGATTACATCACTTGACCCAAACAG 








T6ODM primers used 




































QPCR (Wijekoon and Facchini, 2012) 
T6ODM_fwd TTGAGGCACAAATGAGAAAATTGA 
T6ODM_rev CACAACGCACTTTCGAGAAATTAC 
Table 30. T6ODM primers used in the study 
Other primers used 

























Table 31. Miscellaneous primers used in the study
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Table of Abbreviations 
2-ODD 2-oxoglutarate/Fe(II) dependent dioxygenase  
BAC Bacterial artificial chromosome  
BBE Berberine bridge enzyme  
BIAs Benzylisoquinolines alkaloids 
bp/kb/Mb Base pair/ kilo base pairs (1,000bp)/ mega base pairs 
(1,000,000bp) 
CODM Codeine-O-demethylase 
COR Codeinone reductase  
DIOX Dioxygenase 
DNA/gDNA/cDNA/dsDNA Deoxyribonucleic acid/ genomic DNA/ complementary DNA/ 
double stranded DNA 
DW Dry weight 
EMS Ethylmethane sulfonate  
EST Expressed sequence tag 
FAD Flavin adenine dinucleotide 
FNM Fast neutron mutagenesis  
LTR Long Terminal Repeat (Retrotransposons) 
MAS Marker assisted selection  
NADPH Nicotinamide adenine dinucleotide phosphate 
ORF Open reading frame 
PARSESNP Project Aligned Related Sequences and Evaluate SNPs 
PODA Protopine O-dealkylase  
PCR/AS-PCR/RT-QPCR Polymerase chain reaction/ Allele specific PCR/ Real time 
quantitative PCR 
PDA Personal Digital Assistant 
QTL Quantitative trait loci  
RFU Relative Fluorescence Units 
RNA/mRNA Ribonucleic acid/ messenger RNA 
rpm revolutions per minute 
RT Room temperature 
SIFT Sorting intolerant from tolerant 
SNAP Screening for non-acceptable polymorphisms 
SNP Single nucleotide polymorphism 
STORR (S)- to (R)-reticuline fusion protein 
T6ODM Thebaine-6-O-demethylase 
TE Tris-EDTA (Ethylenediaminetetraacetic acid) 
TILLING Targeting Induced Local Lesions in Genomes 
Tint T6ODMa intron (polymorphism) 
UPLC Ultra Performance Liquid Chromatography  
VIGS Virus Induced Gene Silencing 







Abbott, A., 2015. Europe’s genetically edited plants stuck in legal limbo. Nature 528, 319–320. 
doi:10.1038/528319a 
Alcantara, J., Bird, D.A., Franceschi, V.R., Facchini, P.J., 2005. Sanguinarine biosynthesis is 
associated with the endoplasmic reticulum in cultured opium poppy cells after 
elicitor treatment. Plant Physiol. 138, 173. 
Allen, R.S., Millgate, A.G., Chitty, J.A., Thisleton, J., Miller, J.A.C., Fist, A.J., Gerlach, W.L., Larkin, 
P.J., 2004. RNAi-mediated replacement of morphine with the nonnarcotic alkaloid 
reticuline in opium poppy. Nat. Biotechnol. 22, 1559–1566. 
American Society of Health-System Pharmacists, 2015. Codeine Monograph for Professionals 
- Drugs.com [WWW Document]. URL 
http://www.drugs.com/monograph/codeine.html (accessed 2.9.15). 
Aragon-Poce, F., Martınez-Fernández, E., Marquez-Espinos, C., Perez, A., Mora, R., Torres, L.M., 
2002. History of opium, in: International Congress Series. Elsevier, pp. 19–21. 
Askitopoulou, H., Ramoutsaki, I.A., Konsolaki, E., 2002. Archaeological evidence on the use of 
opium in the Minoan world, in: International Congress Series. Elsevier, pp. 23–29. 
Barken, I., Geller, J., Rogosnitzky, M., 2008. Noscapine Inhibits Human Prostate Cancer 
Progression and Metastasis in a Mouse Model. Anticancer Res. 28, 3701–3704. 
Beaudoin, G.A., Facchini, P.J., 2014. Benzylisoquinoline alkaloid biosynthesis in opium poppy. 
Planta 1–14. 
Beaudoin, G.A.W., Facchini, P.J., 2013. Isolation and characterization of a cDNA encoding (S)-
cis-N-methylstylopine 14-hydroxylase from opium poppy, a key enzyme in 
sanguinarine biosynthesis. Biochem. Biophys. Res. Commun. 431, 597–603. 
doi:10.1016/j.bbrc.2012.12.129 
Belny, M., Hérouart, D., Thomasset, B., David, H., Jacquin-Dubreuil, A., David, A., 1997. 
Transformation of Papaver somniferum cell suspension cultures with sam1 from A. 
thaliana results in cell lines of different S-adenosyl-L-methionine synthetase activity. 
Physiol. Plant. 99, 233–240. doi:10.1111/j.1399-3054.1997.tb05407.x 
Bennett, M.D., Smith, J.B., 1976. Nuclear DNA Amounts in Angiosperms. Philos. Trans. R. Soc. 
Lond. B Biol. Sci. 274, 227–274. doi:10.1098/rstb.1976.0044 
Berenyi, S., Csutoras, C., Sipos, A., 2009. Recent Developments in the Chemistry of Thebaine 
and its Transformation Products as Pharmacological Targets. Curr. Med. Chem. 16, 
3215–3242. doi:10.2174/092986709788803295 
Bessi, I., Bazzicalupi, C., Richter, C., Jonker, H.R.A., Saxena, K., Sissi, C., Chioccioli, M., Bianco, S., 
Bilia, A.R., Schwalbe, H., Gratteri, P., 2012. Spectroscopic, Molecular Modeling, and 
NMR-Spectroscopic Investigation of the Binding Mode of the Natural Alkaloids 
Berberine and Sanguinarine to Human Telomeric G-Quadruplex DNA. ACS Chem. Biol. 
7, 1109–1119. doi:10.1021/cb300096g 
Bhandari, M.M., 1990. Out-crossing in opium poppy Papaver somniferum L. Euphytica 48, 
167–169. 
Bielecka, M., Kaminski, F., Adams, I., Poulson, H., Sloan, R., Li, Y., Larson, T.R., Winzer, T., 
Graham, I.A., 2014. Targeted mutation of Δ12 and Δ15 desaturase genes in hemp 
produce major alterations in seed fatty acid composition including a high oleic hemp 
oil. Plant Biotechnol. J. 12, 613–623. doi:10.1111/pbi.12167 
Bird, D.A., Franceschi, V.R., Facchini, P.J., 2003. A tale of three cell types: alkaloid biosynthesis 
is localized to sieve elements in opium poppy. Plant Cell Online 15, 2626. 
Bortesi, L., Fischer, R., 2015. The CRISPR/Cas9 system for plant genome editing and beyond. 
Biotechnol. Adv. 33, 41–52. doi:10.1016/j.biotechadv.2014.12.006 
Botticella, E., Sestili, F., Hernandez-Lopez, A., Phillips, A., Lafiandra, D., 2011. High resolution 
melting analysis for the detection of EMS induced mutations in wheat SbeIIa genes. 




Boycheva, S., Daviet, L., Wolfender, J.-L., Fitzpatrick, T.B., 2014. The rise of operon-like gene 
clusters in plants. Trends Plant Sci. 19, 447–459. doi:10.1016/j.tplants.2014.01.013 
Brochmann-Hanssen, E., 1984. A Second Pathway for the Terminal Steps in the Biosynthesis 
of Morphine. Planta Med. 50, 343–345. doi:10.1055/s-2007-969727 
Bromberg, Y., Rost, B., 2007. SNAP: predict effect of non-synonymous polymorphisms on 
function. Nucleic Acids Res. 35, 3823–3835. doi:10.1093/nar/gkm238 
Brownstein, M.J., 1993. A brief history of opiates, opioid peptides, and opioid receptors. Proc. 
Natl. Acad. Sci. U. S. A. 90, 5391–5393. 
Chang, S., Puryear, J., Cairney, J., 1993. A simple and efficient method for isolating RNA from 
pine trees. Plant Mol. Biol. Report. 11, 113–116. doi:10.1007/BF02670468 
Cha, R.S., Zarbl, H., Keohavong, P., Thilly, W.G., 1992. Mismatch amplification mutation assay 
(MAMA): application to the c-H-ras gene. Genome Res. 2, 14–20. 
doi:10.1101/gr.2.1.14 
Chaterjee, A., Shukla, S., Mishra, P., Rastogi, A., Singh, S.P., 2010. Prospects of in vitro 
production of thebaine in opium poppy (Papaver somniferum L.). Ind. Crops Prod. 32, 
668–670. doi:10.1016/j.indcrop.2010.04.007 
Chauhan, S.P., Patra, N.K., 1993. Mutagenic Effects of Combined and Single Doses of Gamma 
Rays and EMS in Opium Poppy*. Plant Breed. 110, 342–345. doi:10.1111/j.1439-
0523.1993.tb00600.x 
Cheng, A.-X., Han, X.-J., Wu, Y.-F., Lou, H.-X., 2014. The Function and Catalysis of 2-
Oxoglutarate-Dependent Oxygenases Involved in Plant Flavonoid Biosynthesis. Int. J. 
Mol. Sci. 15, 1080–1095. doi:10.3390/ijms15011080 
Chen, X., Facchini, P.J., 2014. Short-chain dehydrogenase/reductase catalyzing the final step of 
noscapine biosynthesis is localized to laticifers in opium poppy. Plant J. 77, 173–184. 
Chitty, J.A., Allen, R.S., Larkin, P.J., Fist, A.J., 2003. Genetic transformation in commercial 
Tasmanian cultivars of opium poppy, Papaver somniferum, and movement of 
transgenicpollen in the field. Funct. Plant Biol. 30, 1045–1058. 
Cirak, C., Radusiene, J., Camas, N., Caliskan, O., Odabas, M.S., 2013. Changes in the contents of 
main secondary metabolites in two Turkish Hypericum species during plant 
development. Pharm. Biol. 51, 391–399. doi:10.3109/13880209.2012.733012 
Clifton, I.J., McDonough, M.A., Ehrismann, D., Kershaw, N.J., Granatino, N., Schofield, C.J., 2006. 
Structural studies on 2-oxoglutarate oxygenases and related double-stranded β-helix 
fold proteins. J. Inorg. Biochem. 100, 644–669. doi:10.1016/j.jinorgbio.2006.01.024 
Cline, S.D., Coscia, C.J., 1988. Stimulation of Sanguinarine Production by Combined Fungal 
Elicitation and Hormonal Deprivation in Cell Suspension Cultures of Papaver 
bracteatum. Plant Physiol. 86, 161–165. doi:10.1104/pp.86.1.161 
Colbert, T., Till, B.J., Tompa, R., Reynolds, S., Steine, M.N., Yeung, A.T., McCallum, C.M., Comai, 
L., Henikoff, S., 2001. High-Throughput Screening for Induced Point Mutations. Plant 
Physiol. 126, 480–484. 
Comai, L., Henikoff, S., 2006. TILLING: practical single-nucleotide mutation discovery. Plant J. 
45, 684–694. doi:10.1111/j.1365-313X.2006.02670.x 
Cooper, J.L., Till, B.J., Laport, R.G., Darlow, M.C., Kleffner, J.M., Jamai, A., El-Mellouki, T., Liu, S., 
Ritchie, R., Nielsen, N., Bilyeu, K.D., Meksem, K., Comai, L., Henikoff, S., 2008. TILLING 
to detect induced mutations in soybean. BMC Plant Biol. 8, 9. doi:10.1186/1471-
2229-8-9 
Cotterill, P., 2010. METHOD OF ALTERING THE ALKALOID COMPOSITION IN POPPY PLANTS. 
Dean, G.J., 2011. Modifying poppy growth and alkaloid yield with plant growth regulators 
(cmaster). University of Tasmania. 
DeLoache, W.C., Russ, Z.N., Narcross, L., Gonzales, A.M., Martin, V.J.J., Dueber, J.E., 2015. An 
enzyme-coupled biosensor enables (S)-reticuline production in yeast from glucose. 
Nat. Chem. Biol. doi:10.1038/nchembio.1816 
Desgagne-Penix, I., Hagel, J.M., Facchini, P.J., 2009. Mutagenesis as a Functional Genomics 
Platform for Pharmaceutical Alkaloid Biosynthetic Gene Discovery in Opium Poppy. 
Desgagné-Penix, I., Khan, M.F., Schriemer, D.C., Cram, D., Nowak, J., Facchini, P.J., 2010. 
Integration of deep transcriptome and proteome analyses reveals the components of 




Díaz Chávez, M.L., Rolf, M., Gesell, A., Kutchan, T.M., 2011. Characterization of two 
methylenedioxy bridge-forming cytochrome P450-dependent enzymes of alkaloid 
formation in the Mexican prickly poppy Argemone mexicana. Arch. Biochem. 
Biophys., P450 Catalysis Mechanisms 507, 186–193. doi:10.1016/j.abb.2010.11.016 
Dicker, n.d. The Poppy Industry in Tasmania [WWW Document]. URL 
http://www.launc.tased.edu.au/online/sciences/agsci/alkalo/popindus.htm 
(accessed 2.19.15). 
Dinsmore, W.W., 2005. Available and future treatments for erectile dysfunction. Clin. 
Cornerstone, Erectile Dysfunction 7, 37–44. doi:10.1016/S1098-3597(05)80047-X 
Dong, C., Vincent, K., Sharp, P., 2009. Simultaneous mutation detection of three homoeologous 
genes in wheat by High Resolution Melting analysis and Mutation Surveyor®. BMC 
Plant Biol. 9, 143. doi:10.1186/1471-2229-9-143 
Drenkard, E., Richter, B.G., Rozen, S., Stutius, L.M., Angell, N.A., Mindrinos, M., Cho, R.J., Oefner, 
P.J., Davis, R.W., Ausubel, F.M., 2000. A Simple Procedure for the Analysis of Single 
Nucleotide Polymorphisms Facilitates Map-Based Cloning in Arabidopsis. Plant 
Physiol. 124, 1483–1492. doi:10.1104/pp.124.4.1483 
Dubey, M.K., Dhawan, O.P., Khanuja, S.P.S., 2008. Downy mildew resistance in opium poppy: 
resistance sources, inheritance pattern, genetic variability and strategies for crop 
improvement. Euphytica 165, 177–188. doi:10.1007/s10681-008-9804-4 
Escobar, N.M., Haupt, S., Thow, G., Boevink, P., Chapman, S., Oparka, K., 2003. High-
Throughput Viral Expression of cDNA–Green Fluorescent Protein Fusions Reveals 
Novel Subcellular Addresses and Identifies Unique Proteins That Interact with 
Plasmodesmata. Plant Cell 15, 1507–1523. doi:10.1105/tpc.013284 
Facchini, P., Hagel, J., Liscombe, D., Loukanina, N., MacLeod, B., Samanani, N., Zulak, K., 2007. 
Opium poppy: blueprint for an alkaloid factory. Phytochem. Rev. 6, 97–124. 
doi:10.1007/s11101-006-9042-0 
Facchini, P.J., Bird, D.A., 1998. Developmental regulation of benzylisoquinoline alkaloid 
biosynthesis in opium poppy plants and tissue cultures. Vitro Cell. Dev. Biol. - Plant 
34, 69–79. doi:10.1007/BF02823126 
Facchini, P.J., De Luca, V., 2008. Opium poppy and Madagascar periwinkle: model non-model 
systems to investigate alkaloid biosynthesis in plants. Plant J. 54, 763–784. 
Facchini, P.J., De Luca, V., 1995. Phloem-specific expression of tyrosine/dopa decarboxylase 
genes and the biosynthesis of isoquinoline alkaloids in opium poppy. Plant Cell Online 
7, 1811. 
Facchini, P.J., Johnson, A.G., Poupart, J., De Luca, V., 1996a. Uncoupled defense gene expression 
and antimicrobial alkaloid accumulation in elicited opium poppy cell cultures. Plant 
Physiol. 111, 687. 
Facchini, P.J., Loukanina, N., Blanche, V., 2008. Genetic transformation via somatic 
embryogenesis to establish herbicide-resistant opium poppy. Plant Cell Rep. 27, 719–
727. doi:10.1007/s00299-007-0483-8 
Facchini, P.J., Park, S.U., 2003. Developmental and inducible accumulation of gene transcripts 
involved in alkaloid biosynthesis in opium poppy. Phytochemistry 64, 177–186. 
Facchini, P.J., Penzes, C., Johnson, A.G., Bull, D., 1996b. Molecular characterization of berberine 
bridge enzyme genes from opium poppy. Plant Physiol. 112, 1669. 
FAO-IAEA, 2015. Mutation Enhanced Technologies for Agriculture (META) [WWW 
Document]. URL http://mvgs.iaea.org/Default.aspx (accessed 5.26.15). 
Farrow, S.C., Facchini, P.J., 2015. Papaverine 7-O-demethylase, a novel 2-oxoglutarate/Fe2+-
dependent dioxygenase from opium poppy. FEBS Lett. 589, 2701–2706. 
doi:10.1016/j.febslet.2015.07.042 
Farrow, S.C., Facchini, P.J., 2013. Dioxygenases catalyze O-demethylation and O, O-
demethylenation with widespread roles in benzylisoquinoline alkaloid metabolism in 
opium poppy. J. Biol. Chem. 288, 28997–29012. 
Farrow, S.C., Hagel, J.M., Beaudoin, G.A.W., Burns, D.C., Facchini, P.J., 2015. Stereochemical 
inversion of (S)-reticuline by a cytochrome P450 fusion in opium poppy. Nat. Chem. 




Feng, Z., Zhang, B., Ding, W., Liu, X., Yang, D.-L., Wei, P., Cao, F., Zhu, S., Zhang, F., Mao, Y., Zhu, 
J.-K., 2013. Efficient genome editing in plants using a CRISPR/Cas system. Cell Res. 23, 
1229–1232. doi:10.1038/cr.2013.114 
Field, B., Fiston-Lavier, A.-S., Kemen, A., Geisler, K., Quesneville, H., Osbourn, A.E., 2011. 
Formation of plant metabolic gene clusters within dynamic chromosomal regions. 
Proc. Natl. Acad. Sci. 108, 16116–16121. doi:10.1073/pnas.1109273108 
Fisinger, U., Grobe, N., Zenk, M.H., 2007. Thebaine synthase: a new enzyme in the morphine 
pathway in Papaver somniferum. Nat. Prod. Commun. 2, 249–253. 
Fist, A., Byme, C., Gerlach, W., Sayer, C., Bailey, T., 2005. Production of reticuline. 
US20050257295 A1. 
Fist, A.J., 2001. The Tasmanian Poppy Industry: A Case Study of the Application of Science and 
Technology. 
Fist, A.J., Byrne, C.J., Gerlach, W.L., 2000. Papaver somniferum strain with high concentration 
of thebaine and oripavine. US6067749 A. 
Fist, A.J., Miller, J.A.C., Gregory, D., 2013. Papaver somniferum with high concentration of 
codeine. US8541647 B2. 
Fist, A.J., Miller, J.A.C., Gregory, D., 2010. Papaver somniferum with high concentration of 
codeine. US20100234600 A1. 
Flem-Bonhomme, V.L., Laurain-Mattar, D., Fliniaux, M.A., 2004. Hairy root induction of 
Papaver somniferum var. album, a difficult-to-transform plant, by A. rhizogenes LBA 
9402. Planta 218, 890–893. doi:10.1007/s00425-003-1196-z 
Floria, F.G., Ghiorghita, G.I., 1980. The influence of the treatment with alkylating agents on 
Papaver somniferum L., in M1. Rev. Roum. Biol. Biol. Veg. 25, 151–155. 
Fossati, E., Ekins, A., Narcross, L., Zhu, Y., Falgueyret, J.-P., Beaudoin, G.A., Facchini, P.J., Martin, 
V.J., 2014. Reconstitution of a 10-gene pathway for synthesis of the plant alkaloid 
dihydrosanguinarine in Saccharomyces cerevisiae. Nat. Commun. 5. 
Fossati, E., Narcross, L., Ekins, A., Falgueyret, J.-P., Martin, V.J.J., 2015. Synthesis of Morphinan 
Alkaloids in Saccharomyces cerevisiae. PLoS ONE 10, e0124459. 
doi:10.1371/journal.pone.0124459 
Francia, E., Tacconi, G., Crosatti, C., Barabaschi, D., Bulgarelli, D., Dall’Aglio, E., Valè, G., 2005. 
Marker assisted selection in crop plants. Plant Cell Tissue Organ Cult. 82, 317–342. 
doi:10.1007/s11240-005-2387-z 
Frenzel, T., Zenk, M.H., 1990. S-adenosyl-l-methionine: 3′-hydroxy-N-methyl-(S)-coclaurine-
4′-O-methyl transferase, a regio- and stereoselective enzyme of the (S)-reticuline 
pathway. Phytochemistry 29, 3505–3511. doi:10.1016/0031-9422(90)85265-H 
Frick, S., Chitty, J.A., Kramell, R., Schmidt, J., Allen, R.S., Larkin, P.J., Kutchan, T.M., 2004. 
Transformation of opium poppy (Papaver somniferumL.) with antisense berberine 
bridge enzyme gene (anti-bbe) via somatic embryogenesis results in an altered ratio 
of alkaloids in latex but not in roots. Transgenic Res. 13, 607–613. 
Frick, S., Kramell, R., Schmidt, J., Fist, A.J., Kutchan, T.M., 2005. Comparative Qualitative and 
Quantitative Determination of Alkaloids in Narcotic and Condiment Papaver 
somniferum Cultivars. J. Nat. Prod. 68, 666–673. doi:10.1021/np0496643 
Gady, A.L., Hermans, F.W., Van de Wal, M.H., van Loo, E.N., Visser, R.G., Bachem, C.W., 2009. 
Implementation of two high through-put techniques in a novel application: detecting 
point mutations in large EMS mutated plant populations. Plant Methods 5, 13. 
doi:10.1186/1746-4811-5-13 
Galanie, S., Thodey, K., Trenchard, I.J., Interrante, M.F., Smolke, C.D., 2015. Complete 
biosynthesis of opioids in yeast. Science 349, 1095–1100. 
doi:10.1126/science.aac9373 
Gates, M., Tschudi, G., 1952. The Synthesis of Morphine. J. Am. Chem. Soc. 74, 1109–1110. 
Gebhardt, Y., Witte, S., Forkmann, G., Lukačin, R., Matern, U., Martens, S., 2005. Molecular 
evolution of flavonoid dioxygenases in the family Apiaceae. Phytochemistry, 





Gesell, A., Rolf, M., Ziegler, J., Díaz Chávez, M.L., Huang, F.-C., Kutchan, T.M., 2009. CYP719B1 Is 
Salutaridine Synthase, the C-C Phenol-coupling Enzyme of Morphine Biosynthesis in 
Opium Poppy. J. Biol. Chem. 284, 24432 –24442. doi:10.1074/jbc.M109.033373 
Glenn, W.S., Runguphan, W., O’Connor, S.E., 2013. Recent progress in the metabolic 
engineering of alkaloids in plant systems. Curr. Opin. Biotechnol. 24, 354–365. 
doi:10.1016/j.copbio.2012.08.003 
GMO Review Submission No. 158 - GSK Australia - Department of Primary Industries, Parks, 
Water and Environment [WWW Document], 2013. URL 
http://dpipwe.tas.gov.au/Pages/document.aspx?path=/Documents/GMO-Review-
Submission-158-GSK-Submission.pdf (accessed 2.10.15). 
Gorres, K.L., Raines, R.T., 2010. Prolyl 4-hydroxylase. Crit. Rev. Biochem. Mol. Biol. 45, 106–
124. doi:10.3109/10409231003627991 
Gözler, B., Lantz, M.S., Shamma, M., 1983. The Pavine and Isopavine Alkaloids. J. Nat. Prod. 46, 
293–309. doi:10.1021/np50027a001 
Graham, I.A., Besser, K., Blumer, S., Branigan, C.A., Czechowski, T., Elias, L., Guterman, I., 
Harvey, D., Isaac, P.G., Khan, A.M., Larson, T.R., Li, Y., Pawson, T., Penfield, T., Rae, A.M., 
Rathbone, D.A., Reid, S., Ross, J., Smallwood, M.F., Segura, V., Townsend, T., Vyas, D., 
Winzer, T., Bowles, D., 2010. The Genetic Map of Artemisia annua L. Identifies Loci 
Affecting Yield of the Antimalarial Drug Artemisinin. Science 327, 328–331. 
doi:10.1126/science.1182612 
Greene, B., Walko, R., Hake, S., 1994. Mutator insertions in an intron of the maize knotted1 
gene result in dominant suppressible mutations. Genetics 138, 1275–1285. 
Greene, E.A., Codomo, C.A., Taylor, N.E., Henikoff, J.G., Till, B.J., Reynolds, S.H., Enns, L.C., 
Burtner, C., Johnson, J.E., Odden, A.R., Comai, L., Henikoff, S., 2003. Spectrum of 
Chemically Induced Mutations From a Large-Scale Reverse-Genetic Screen in 
Arabidopsis. Genetics 164, 731 –740. 
Grothe, T., Lenz, R., Kutchan, T.M., 2001. Molecular Characterization of the Salutaridinol 7-O-
Acetyltransferase Involved in Morphine Biosynthesis in Opium Poppy Papaver 
somniferum. J. Biol. Chem. 276, 30717–30723. doi:10.1074/jbc.M102688200 
Hagel, J.M., Beaudoin, G.A., Fossati, E., Ekins, A., Martin, V.J., Facchini, P.J., 2012. 
Characterization of a flavoprotein oxidase from opium poppy catalyzing the final 
steps in sanguinarine and papaverine biosynthesis. J. Biol. Chem. 287, 42972–42983. 
Hagel, J.M., Facchini, P.J., 2013. Benzylisoquinoline alkaloid metabolism – a century of 
discovery and a brave new world. Plant Cell Physiol. doi:10.1093/pcp/pct020 
Hagel, J.M., Facchini, P.J., 2010a. Dioxygenases catalyze the O-demethylation steps of 
morphine biosynthesis in opium poppy. Nat. Chem. Biol. 6, 273–275. 
Hagel, J.M., Facchini, P.J., 2010b. Biochemistry and occurrence of O-demethylation in plant 
metabolism. Front. Physiol. 1. 
Hagel, J.M., Weljie, A.M., Vogel, H.J., Facchini, P.J., 2008a. Quantitative 1H nuclear magnetic 
resonance metabolite profiling as a functional genomics platform to investigate 
alkaloid biosynthesis in opium poppy. Plant Physiol. 147, 1805. 
Hagel, J.M., Yeung, E.C., Facchini, P.J., 2008b. Got milk? The secret life of laticifers. Trends 
Plant Sci. 13, 631–639. 
Hansen, B.G., Kerwin, R.E., Ober, J.A., Lambrix, V.M., Mitchell-Olds, T., Gershenzon, J., Halkier, 
B.A., Kliebenstein, D.J., 2008. A Novel 2-Oxoacid-Dependent Dioxygenase Involved in 
the Formation of the Goiterogenic 2-Hydroxybut-3-enyl Glucosinolate and Generalist 
Insect Resistance in Arabidopsis. Plant Physiol. 148, 2096–2108. 
doi:10.1104/pp.108.129981 
Hartmann, T., 1999. Chemical ecology of pyrrolizidine alkaloids. Planta 207, 483–495. 
doi:10.1007/s004250050508 
Hartmann, T., Ober, D., 2000. Biosynthesis and Metabolism of Pyrrolizidine Alkaloids in 
Plants and Specialized Insect Herbivores, in: Leeper, F., Vederas, J. (Eds.), 
Biosynthesis, Topics in Current Chemistry. Springer Berlin / Heidelberg, pp. 207–243. 
Hartung, F., Schiemann, J., 2014. Precise plant breeding using new genome editing 





Hashimoto, T., Yamada, Y., 1986. Hyoscyamine 6β-Hydroxylase, a 2-Oxoglutarate-Dependent 
Dioxygenase, in Alkaloid-Producing Root Cultures. Plant Physiol. 81, 619–625. 
doi:10.1104/pp.81.2.619 
Hawkins, K.M., Smolke, C.D., 2008. Production of benzylisoquinoline alkaloids in 
Saccharomyces cerevisiae. Nat. Chem. Biol. 4, 564–573. doi:10.1038/nchembio.105 
Hebsgaard, S.M., Korning, P.G., Tolstrup, N., Engelbrecht, J., Rouzé, P., Brunak, S., 1996. Splice 
site prediction in Arabidopsis thaliana pre-mRNA by combining local and global 
sequence information. Nucleic Acids Res. 24, 3439–3452. 
Henikoff, S., Comai, L., 2003. Single-Nucleotide Mutations for Plant Functional Genomics. 
Annu. Rev. Plant Biol. 54, 375–401. doi:10.1146/annurev.arplant.54.031902.135009 
Huang, F.C., Kutchan, T.M., 2000. Distribution of morphinan and benzo [c] phenanthridine 
alkaloid gene transcript accumulation in Papaver somniferum. Phytochemistry 53, 
555–564. 
Ikezawa, N., Iwasa, K., Sato, F., 2007. Molecular cloning and characterization of 
methylenedioxy bridge-forming enzymes involved in stylopine biosynthesis in 
Eschscholzia californica. FEBS J. 274, 1019–1035. doi:10.1111/j.1742-
4658.2007.05652.x 
Ikezawa, N., Tanaka, M., Nagayoshi, M., Shinkyo, R., Sakaki, T., Inouye, K., Sato, F., 2003. 
Molecular Cloning and Characterization of CYP719, a Methylenedioxy Bridge-forming 
Enzyme That Belongs to a Novel P450 Family, from cultured Coptis japonica Cells. J. 
Biol. Chem. 278, 38557–38565. doi:10.1074/jbc.M302470200 
INCB, 2015. Narcotic Drugs Report 2014-Estimated World Requirements for 2015. 
INCB, 2010. INCB Annual Report 2010. 
Itkin, M., Heinig, U., Tzfadia, O., Bhide, A.J., Shinde, B., Cardenas, P.D., Bocobza, S.E., Unger, T., 
Malitsky, S., Finkers, R., Tikunov, Y., Bovy, A., Chikate, Y., Singh, P., Rogachev, I., 
Beekwilder, J., Giri, A.P., Aharoni, A., 2013. Biosynthesis of Antinutritional Alkaloids in 
Solanaceous Crops Is Mediated by Clustered Genes. Science 341, 175–179. 
doi:10.1126/science.1240230 
Jain, S.M., Gupta, S.D., 2013. Biotechnology of Neglected and Underutilized Crops. Springer 
Science & Business Media. 
Jiang, G.-L., Dong, Y., Shi, J., Ward, R.W., 2007. QTL analysis of resistance to Fusarium head 
blight in the novel wheat germplasm CJ 9306. II. Resistance to deoxynivalenol 
accumulation and grain yield loss. Theor. Appl. Genet. 115, 1043–1052. 
doi:10.1007/s00122-007-0630-1 
Jonczyk, R., Schmidt, H., Osterrieder, A., Fiesselmann, A., Schullehner, K., Haslbeck, M., Sicker, 
D., Hofmann, D., Yalpani, N., Simmons, C., Frey, M., Gierl, A., 2008. Elucidation of the 
Final Reactions of DIMBOA-Glucoside Biosynthesis in Maize: Characterization of Bx6 
and Bx7. Plant Physiol. 146, 1053–1063. doi:10.1104/pp.107.111237 
Jones, M.O., Piron-Prunier, F., Marcel, F., Piednoir-Barbeau, E., Alsadon, A.A., Wahb-Allah, M.A., 
Al-Doss, A.A., Bowler, C., Bramley, P.M., Fraser, P.D., Bendahmane, A., 2012. 
Characterisation of alleles of tomato light signalling genes generated by TILLING. 
Phytochemistry 79, 78–86. doi:10.1016/j.phytochem.2012.04.005 
Kai, K., Mizutani, M., Kawamura, N., Yamamoto, R., Tamai, M., Yamaguchi, H., Sakata, K., 
Shimizu, B., 2008. Scopoletin is biosynthesized via ortho-hydroxylation of feruloyl 
CoA by a 2-oxoglutarate-dependent dioxygenase in Arabidopsis thaliana. Plant J. 55, 
989–999. doi:10.1111/j.1365-313X.2008.03568.x 
Kassell, N.F., Helm, G., Simmons, N., Phillips, C.D., Cail, W.S., 1992. Treatment of cerebral 
vasospasm with intra-arterial papaverine. J. Neurosurg. 77, 848–852. 
doi:10.3171/jns.1992.77.6.0848 
Kato, N., Dubouzet, E., Kokabu, Y., Yoshida, S., Taniguchi, Y., Dubouzet, J.G., Yazaki, K., Sato, F., 
2007. Identification of a WRKY Protein as a Transcriptional Regulator of 
Benzylisoquinoline Alkaloid Biosynthesis in Coptis japonica. Plant Cell Physiol. 48, 8–
18. doi:10.1093/pcp/pcl041 
Kaul, B.L., Tandon, V., Choudhary, D.K., 1979. Cytogenetic studies inPapaver somniferum L. 





Kawai, Y., Ono, E., Mizutani, M., 2014. Evolution and diversity of the 2–oxoglutarate-
dependent dioxygenase superfamily in plants. Plant J. 78, 328–343. 
doi:10.1111/tpj.12479 
Khan, R., Khan, M.M.A., Singh, M., Nasir, S., Naeem, M., Siddiqui, M.H., Mohammad, F., 2007. 
Gibberellic acid and triacontanol can ameliorate the opium yield and morphine 
production in opium poppy (Papaver somniferum L.). Acta Agric. Scand. Sect. B — Soil 
Plant Sci. 57, 307–312. doi:10.1080/09064710600982811 
Kliebenstein, D.J., Lambrix, V.M., Reichelt, M., Gershenzon, J., Mitchell-Olds, T., 2001. Gene 
Duplication in the Diversification of Secondary Metabolism: Tandem 2-Oxoglutarate–
Dependent Dioxygenases Control Glucosinolate Biosynthesis in Arabidopsis. Plant 
Cell Online 13, 681–693. doi:10.1105/tpc.13.3.681 
Kohany, O., Gentles, A.J., Hankus, L., Jurka, J., 2006. Annotation, submission and screening of 
repetitive elements in Repbase: RepbaseSubmitter and Censor. BMC Bioinformatics 7, 
474. doi:10.1186/1471-2105-7-474 
Kramlinger, V.M., Rojas, M.A., Kanamori, T., Guengerich, F.P., 2015. Cytochrome P450 3A 
enzymes catalyze the O6-demethylation of thebaine, a key step in endogenous 
mammalian morphine biosynthesis. J. Biol. Chem. jbc.M115.665331. 
doi:10.1074/jbc.M115.665331 
Krist, S., Stuebiger, G., Unterweger, H., Bandion, F., Buchbauer, G., 2005. Analysis of Volatile 
Compounds and Triglycerides of Seed Oils Extracted from Different Poppy Varieties 
(Papaver somniferum L.). J. Agric. Food Chem. 53, 8310–8316. 
doi:10.1021/jf0580869 
Krokida, A., Delis, C., Geisler, K., Garagounis, C., Tsikou, D., Peña-Rodríguez, L.M., Katsarou, D., 
Field, B., Osbourn, A.E., Papadopoulou, K.K., 2013. A metabolic gene cluster in Lotus 
japonicus discloses novel enzyme functions and products in triterpene biosynthesis. 
New Phytol. 200, 675–690. doi:10.1111/nph.12414 
Krug, E., Proksch, P., 1993. Influence of dietary alkaloids on survival and growth of 
Spodoptera littoralis. Biochem. Syst. Ecol. 21, 749–756. doi:10.1016/0305-
1978(93)90087-8 
Kumar, B., Patra, N.K., 2010. Gene frequency-based estimation of natural outcrossing in 
opium poppy (Papaver somniferum L.). Mol. Breed. 26, 619–626. 
Kurowska, M., Daszkowska-Golec, A., Gruszka, D., Marzec, M., Szurman, M., Szarejko, I., 
Maluszynski, M., 2011. TILLING - a shortcut in functional genomics. J. Appl. Genet. 52, 
371–390. doi:10.1007/s13353-011-0061-1 
Kutchan, T., 1995. Alkaloid Biosynthesis-]The Basis for Metabolic Engineering of Medicinal 
Plants. Plant Cell 7, 1059–1070. 
Lam, K.C., Ibrahim, R.K., Behdad, B., Dayanandan, S., 2007. Structure, function, and evolution 
of plant               O               -methyltransferases. Genome 50, 1001–1013. 
doi:10.1139/G07-077 
Lavania, U., Srivastava, S., 1999. Quantitative delineation of karyotype variation in Papaver as 
a measure of phylogenetic differentiation and origin. Curr. Sci. 77, 429–435. 
Lee, E.-J., Facchini, P., 2010. Norcoclaurine Synthase Is a Member of the Pathogenesis-Related 
10/Bet V1 Protein Family. Plant Cell Online 22, 3489–3503. 
doi:10.1105/tpc.110.077958 
Le Signor, C., Savois, V., Aubert, G., Verdier, J., Nicolas, M., Pagny, G., Moussy, F., Sanchez, M., 
Baker, D., Clarke, J., Thompson, R., 2009. Optimizing TILLING populations for reverse 
genetics in Medicago truncatula. Plant Biotechnol. J. 7, 430–441. doi:10.1111/j.1467-
7652.2009.00410.x 
Li, J.-F., Norville, J.E., Aach, J., McCormack, M., Zhang, D., Bush, J., Church, G.M., Sheen, J., 2013. 
Multiplex and homologous recombination-mediated genome editing in Arabidopsis 
and Nicotiana benthamiana using guide RNA and Cas9. Nat. Biotechnol. 31, 688–691. 
doi:10.1038/nbt.2654 
Li, M., Kuivenhoven, J.A., Ayyobi, A.F., Pritchard, P.H., 1998. T→G or T→A mutation introduced 
in the branchpoint consensus sequence of intron 4 of lecithin:cholesterol 




Biophys. Acta BBA - Lipids Lipid Metab. 1391, 256–264. doi:10.1016/S0005-
2760(97)00198-7 
Linné, C. von, Salvius, L., 1753. Caroli Linnaei ... Species plantarum :exhibentes plantas rite 
cognitas, ad genera relatas, cum differentiis specificis, nominibus trivialibus, 
synonymis selectis, locis natalibus, secundum systema sexuale digestas... Impensis 
Laurentii Salvii, Holmiae : 
Lisch, D., 2013. How important are transposons for plant evolution? Nat. Rev. Genet. 14, 49–
61. doi:10.1038/nrg3374 
Liscombe, D.K., Facchini, P.J., 2008. Evolutionary and cellular webs in benzylisoquinoline 
alkaloid biosynthesis. Curr. Opin. Biotechnol., Food biotechnology / Plant 
biotechnology 19, 173–180. doi:10.1016/j.copbio.2008.02.012 
Liscombe, D.K., Facchini, P.J., 2007. Molecular cloning and characterization of 
tetrahydroprotoberberine cis-N-methyltransferase, an enzyme involved in alkaloid 
biosynthesis in opium poppy. J. Biol. Chem. 282, 14741. 
Liscombe, D.K., MacLeod, B.P., Loukanina, N., Nandi, O.I., Facchini, P.J., 2005. Evidence for the 
monophyletic evolution of benzylisoquinoline alkaloid biosynthesis in angiosperms. 
Phytochemistry 66, 1374–1393. 
Liu, H., Wang, J., Zhao, J., Lu, S., Wang, J., Jiang, W., Ma, Z., Zhou, L., 2009. Isoquinoline alkaloids 
from Macleaya cordata active against plant microbial pathogens. Nat. Prod. Commun. 
4, 1557–1560. 
Livak, K.J., Schmittgen, T.D., 2001. Analysis of Relative Gene Expression Data Using Real-Time 
Quantitative PCR and the 2−ΔΔCT Method. Methods 25, 402–408. 
doi:10.1006/meth.2001.1262 
Li, X., Han, Y., Teng, W., Zhang, S., Yu, K., Poysa, V., Anderson, T., Ding, J., Li, W., 2010. 
Pyramided QTL underlying tolerance to Phytophthora root rot in mega-environments 
from soybean cultivars “Conrad” and “Hefeng 25.” Theor. Appl. Genet. 121, 651–658. 
doi:10.1007/s00122-010-1337-2 
Li, X., Lassner, M., Zhang, Y., 2002. Deleteagene: A Fast Neutron Deletion Mutagenesis-Based 
Gene Knockout System for Plants. Comp. Funct. Genomics 3, 158–160. 
doi:10.1002/cfg.148 
Li, X., Zhang, Y., 2002. Reverse genetics by fast neutron mutagenesis in higher plants. Funct. 
Integr. Genomics 2, 254–258. doi:10.1007/s10142-002-0076-0 
Li, Y.-D., Chu, Z.-Z., Liu, X.-G., Jing, H.-C., Liu, Y.-G., Hao, D.-Y., 2010. A Cost-effective High-
resolution Melting Approach using the EvaGreen Dye for DNA Polymorphism 
Detection and Genotyping in Plants. J. Integr. Plant Biol. 52, 1036–1042. 
doi:10.1111/j.1744-7909.2010.01001.x 
Loenarz, C., Schofield, C.J., 2008. Expanding chemical biology of 2-oxoglutarate oxygenases. 
Nat. Chem. Biol. 4, 152–156. doi:10.1038/nchembio0308-152 
Luch, A., 2009. Molecular, Clinical and Environmental Toxicology: Volume 1: Molecular 
Toxicology. Springer Science & Business Media. 
Mahlberg, P., 1993. Laticifers: An historical perspective. Bot. Rev. 59, 1–23. 
doi:10.1007/BF02856611 
Mahmoudian, M., Rahimi-Moghaddam, P., 2009. The Anti-Cancer Activity of Noscapine: A 
Review. Recent Patents Anticancer Drug Discov. 4, 92–97. 
doi:10.2174/157489209787002524 
Marchler-Bauer, A., Lu, S., Anderson, J.B., Chitsaz, F., Derbyshire, M.K., DeWeese-Scott, C., 
Fong, J.H., Geer, L.Y., Geer, R.C., Gonzales, N.R., Gwadz, M., Hurwitz, D.I., Jackson, J.D., 
Ke, Z., Lanczycki, C.J., Lu, F., Marchler, G.H., Mullokandov, M., Omelchenko, M.V., 
Robertson, C.L., Song, J.S., Thanki, N., Yamashita, R.A., Zhang, D., Zhang, N., Zheng, C., 
Bryant, S.H., 2011. CDD: a Conserved Domain Database for the functional annotation 
of proteins. Nucleic Acids Res. 39, D225–D229. doi:10.1093/nar/gkq1189 
Martín, B., Ramiro, M., Martínez-Zapater, J.M., Alonso-Blanco, C., 2009. A high-density 
collection of EMS-induced mutations for TILLING in Landsberg erecta genetic 
background of Arabidopsis. BMC Plant Biol. 9, 147. doi:10.1186/1471-2229-9-147 
Matsumoto, S., Mizutani, M., Sakata, K., Shimizu, B.-I., 2012. Molecular cloning and functional 




involved in formation of umbelliferone and scopoletin in sweet potato, Ipomoea 
batatas (L.) Lam. Phytochemistry 74, 49–57. doi:10.1016/j.phytochem.2011.11.009 
McCallum, C.M., Comai, L., Greene, E.A., Henikoff, S., 2000. Targeted screening for induced 
mutations. Nat. Biotechnol. 18, 455–457. doi:10.1038/74542 
Meißner, C., 1819. Über Pflanzenalkalien: II. Über ein neues Pflanzenalkali (Alkaloid). J. Für 
Chem. Phys. 25, 379–381. 
Merck, G., 1848. Annalen der Chemie und Pharmacie: vereinigte Zeitschrift des Neuen 
Journals der Pharmacie für Ärzte, Apotheker und Chemiker u. des Magazins für 
Pharmacie und Experimentalkritik. Winter. 
Meza, T.J., Moen, M.N., Vågbø, C.B., Krokan, H.E., Klungland, A., Grini, P.E., Falnes, P.Ø., 2012. 
The DNA dioxygenase ALKBH2 protects Arabidopsis thaliana against methylation 
damage. Nucleic Acids Res. 40, 6620–6631. doi:10.1093/nar/gks327 
Millgate, A.G., Pogson, B.J., Wilson, I.W., Kutchan, T.M., Zenk, M.H., Gerlach, W.L., Fist, A.J., 
Larkin, P.J., 2004. Analgesia: Morphine-pathway block in top1 poppies. Nature 431, 
413–414. doi:10.1038/431413a 
Minami, H., Dubouzet, E., Iwasa, K., Sato, F., 2007. Functional Analysis of Norcoclaurine 
Synthase in Coptis japonica. J. Biol. Chem. 282, 6274–6282. 
doi:10.1074/jbc.M608933200 
Mishra, S., Triptahi, V., Singh, S., Phukan, U.J., Gupta, M.M., Shanker, K., Shukla, R.K., 2013. 
Wound Induced Tanscriptional Regulation of Benzylisoquinoline Pathway and 
Characterization of Wound Inducible PsWRKY Transcription Factor from Papaver 
somniferum. PLoS ONE 8, e52784. doi:10.1371/journal.pone.0052784 
Missirian, V., Comai, L., Filkov, V., 2011. Statistical Mutation Calling from Sequenced 
Overlapping DNA Pools in TILLING Experiments. BMC Bioinformatics 12, 287. 
doi:10.1186/1471-2105-12-287 
Montgomery, C.T., Cassels, B.K., Shamma, M., 1983. The Rhoeadine Alkaloids. J. Nat. Prod. 46, 
441–453. doi:10.1021/np50028a001 
Morimoto, S., Suemori, K., Moriwaki, J., Taura, F., Tanaka, H., Aso, M., Tanaka, M., Suemune, H., 
Shimohigashi, Y., Shoyama, Y., 2001. Morphine metabolism in the opium poppy and its 
possible physiological function - Biochemical characterization of the morphine 
metabolite, bismorphine. J. Biol. Chem. 276, 38179–38184. 
Morimoto, S., Suemori, K., Taura, F., Shoyama, Y., 2003. New dimeric morphine from opium 
poppy (Papaver somuniferum) and its physiological function. J. Nat. Prod. 66, 987–
989. doi:10.1021/np0205831 
Morrell, P.L., Buckler, E.S., Ross-Ibarra, J., 2012. Crop genomics: advances and applications. 
Nat. Rev. Genet. 13, 85–96. doi:10.1038/nrg3097 
Mosammaparast, N., Shi, Y., 2010. Reversal of Histone Methylation: Biochemical and 
Molecular Mechanisms of Histone Demethylases. Annu. Rev. Biochem. 79, 155–179. 
doi:10.1146/annurev.biochem.78.070907.103946 
Munsey, C., 2005. HEROIN® and ASPIRIN® The Connection! & The Collection!-Part I. 
Muth, J., Hartje, S., Twyman, R.M., Hofferbert, H.-R., Tacke, E., Prüfer, D., 2008. Precision 
breeding for novel starch variants in potato. Plant Biotechnol. J. 6, 576–584. 
doi:10.1111/j.1467-7652.2008.00340.x 
Naito, K., Zhang, F., Tsukiyama, T., Saito, H., Hancock, C.N., Richardson, A.O., Okumoto, Y., 
Tanisaka, T., Wessler, S.R., 2009. Unexpected consequences of a sudden and massive 
transposon amplification on rice gene expression. Nature 461, 1130–1134. 
doi:10.1038/nature08479 
Nakajima, N., Mori, H., Yamazaki, K., Imaseki, H., 1990. Molecular Cloning and Sequence of a 
Complementary DNA Encoding 1-Aminocyclopropane-l-carboxylate Synthase 
Induced by Tissue Wounding. Plant Cell Physiol. 31, 1021–1029. 
Nekrasov, V., Staskawicz, B., Weigel, D., Jones, J.D.G., Kamoun, S., 2013. Targeted mutagenesis 
in the model plant Nicotiana benthamiana using Cas9 RNA-guided endonuclease. Nat. 
Biotechnol. 31, 691–693. doi:10.1038/nbt.2655 
Nessler, C.L., Allen, R.D., Galewsky, S., 1985. Identification and Characterization of Latex-




Nessler, C.L., Mahlberg, P.G., 1979. Ultrastructure of laticifers in redifferentiated organs on 
callus from Papaver somniferum (Papaveraceae). Can. J. Bot. 57, 675–685. 
doi:10.1139/b79-086 
Nessler, C.L., Mahlberg, P.G., 1977. Ontogeny and Cytochemistry of Alkaloidal Vesicles in 
Laticifers of Papaver somniferum L. (Papaveraceae). Am. J. Bot. 64, 541–551. 
doi:10.2307/2442002 
Ng, P.C., Henikoff, S., 2003. SIFT: predicting amino acid changes that affect protein function. 
Nucleic Acids Res. 31, 3812–3814. doi:10.1093/nar/gkg509 
Nielson, B., Röe, J., Brochmann-Hanssen, E., 1983. Oripavine - a new opium alkaloid. Planta 
Med. 48, 205–206. 
Ober, D., 2005. Seeing double: gene duplication and diversification in plant secondary 
metabolism. Trends Plant Sci. 10, 444–449. doi:10.1016/j.tplants.2005.07.007 
Ober, D., Hartmann, T., 2000. Phylogenetic origin of a secondary pathway: the case of 
pyrrolizidine alkaloids. Plant Mol. Biol. 44, 445–450. 
Okabe, Y., Asamizu, E., Saito, T., Matsukura, C., Ariizumi, T., Brès, C., Rothan, C., Mizoguchi, T., 
Ezura, H., 2011. Tomato TILLING Technology: Development of a Reverse Genetics 
Tool for the Efficient Isolation of Mutants from Micro-Tom Mutant Libraries. Plant 
Cell Physiol. 52, 1994–2005. doi:10.1093/pcp/pcr134 
Onoyovwe, A., Hagel, J.M., Chen, X., Khan, M.F., Schriemer, D.C., Facchini, P.J., 2013. Morphine 
biosynthesis in opium poppy involves two cell types: sieve elements and laticifers. 
Plant Cell Online 25, 4110–4122. 
Paddon, C.J., Westfall, P.J., Pitera, D.J., Benjamin, K., Fisher, K., McPhee, D., Leavell, M.D., Tai, A., 
Main, A., Eng, D., Polichuk, D.R., Teoh, K.H., Reed, D.W., Treynor, T., Lenihan, J., Jiang, 
H., Fleck, M., Bajad, S., Dang, G., Dengrove, D., Diola, D., Dorin, G., Ellens, K.W., Fickes, S., 
Galazzo, J., Gaucher, S.P., Geistlinger, T., Henry, R., Hepp, M., Horning, T., Iqbal, T., 
Kizer, L., Lieu, B., Melis, D., Moss, N., Regentin, R., Secrest, S., Tsuruta, H., Vazquez, R., 
Westblade, L.F., Xu, L., Yu, M., Zhang, Y., Zhao, L., Lievense, J., Covello, P.S., Keasling, 
J.D., Reiling, K.K., Renninger, N.S., Newman, J.D., 2013. High-level semi-synthetic 
production of the potent antimalarial artemisinin. Nature 496, 528–532. 
doi:10.1038/nature12051 
Panicker, S., Wojnoa, H.L., Ziska, L.H., 2007. Quantitation of the Major Alkaloids in Opium from 
Papaver Setigerum DC. Microgram 13. 
Park, I.-K., Lee, H.-S., Lee, S.-G., Park, J.-D., Ahn, Y.-J., 2000. Antifeeding Activity of Isoquinoline 
Alkaloids Identified in Coptis japonica Roots Against Hyphantria cunea (Lepidoptera: 
Arctiidae) and Agelastica coerulea (Coleoptera: Galerucinae). J. Econ. Entomol. 93, 
331–335. doi:10.1603/0022-0493-93.2.331 
Park, S.U., Facchini, P., 2000a. Agrobacterium-mediated transformation of opium poppy, 
Papaver somniferum, via shoot organogenesis. J. Plant Physiol. 157, 207–214. 
Park, S.U., Facchini, P.J., 2000b. Agrobacterium rhizogenes-mediated transformation of opium 
poppy, Papaver somniferum L., and California poppy, Eschscholzia californica Cham., 
root cultures. J. Exp. Bot. 51, 1005. 
Pathak, S., Mishra, B., Misra, P., Misra, P., Joshi, V., Shukla, S., Trivedi, P., 2012. High frequency 
somatic embryogenesis, regeneration and correlation of alkaloid biosynthesis with 
gene expression in &lt;i&gt;Papaver somniferum&lt;/i&gt; Plant Growth Regul. 68, 
17–25. doi:10.1007/s10725-012-9689-z 
Patra, N.K., Ram, R.S., Chauhan, S.P., Singh, A.K., 1992. Quantitative studies on the mating 
system of opium poppy (Papaver somniferum L.). Theor. Appl. Genet. 84, 299–302. 
Pauli, H.H., Kutchan, T.M., 1998. Molecular cloning and functional heterologous expression of 
two alleles encoding (S)-N-methylcoclaurine 3′-hydroxylase (CYP80B1), a new 
methyl jasmonate-inducible cytochrome P-450-dependent mono-oxygenase of 
benzylisoquinoline alkaloid biosynthesis. Plant J. 13, 793–801. doi:10.1046/j.1365-
313X.1998.00085.x 
Phillips, A.L., 1998. Gibberellins in Arabidopsis. Plant Physiol. Biochem., Arabidopsis thaliana 




Podevin, N., Davies, H.V., Hartung, F., Nogué, F., Casacuberta, J.M., 2013. Site-directed 
nucleases: a paradigm shift in predictable, knowledge-based plant breeding. Trends 
Biotechnol. 31, 375–383. doi:10.1016/j.tibtech.2013.03.004 
Qian, J.-Q., 2002. Cardiovascular pharmacological effects of bisbenzylisoquinoline alkaloid 
derivatives. Acta Pharmacol Sin 23, 1086–1092. 
Qi, X., Bakht, S., Leggett, M., Maxwell, C., Melton, R., Osbourn, A., 2004. A gene cluster for 
secondary metabolism in oat: Implications for the evolution of metabolic diversity in 
plants. Proc. Natl. Acad. Sci. U. S. A. 101, 8233–8238. doi:10.1073/pnas.0401301101 
Raghavan, C., Naredo, M., Wang, H., Atienza, G., Liu, B., Qiu, F., McNally, K., Leung, H., 2007. 
Rapid method for detecting SNPs on agarose gels and its application in candidate 
gene mapping. Mol. Breed. 19, 87–101. doi:10.1007/s11032-006-9046-x 
Raymond, M.J., 2004. Isolation and characterization of latex-specific promoters from Papaver 
somniferum L. [WWW Document]. URL 
http://scholar.lib.vt.edu/theses/available/etd-08312004-174505/ (accessed 
7.12.15). 
Ribaut, J.-M., de Vicente, M., Delannay, X., 2010. Molecular breeding in developing countries: 
challenges and perspectives. Curr. Opin. Plant Biol. 13, 213–218. 
doi:10.1016/j.pbi.2009.12.011 
Richardson, K.L., Vales, M.I., Kling, J.G., Mundt, C.C., Hayes, P.M., 2006. Pyramiding and 
dissecting disease resistance QTL to barley stripe rust. Theor. Appl. Genet. 113, 485–
495. doi:10.1007/s00122-006-0314-2 
Ririe, K.M., Rasmussen, R.P., Wittwer, C.T., 1997. Product Differentiation by Analysis of DNA 
Melting Curves during the Polymerase Chain Reaction. Anal. Biochem. 245, 154–160. 
doi:10.1006/abio.1996.9916 
Robiquet, P., 1832. Nouvelles observations sur les principaux produits de l’opium. Ann. Chim. 
Phys. 51, 225–267. 
Robiquet, P., 1817. Observations sur le memoire de M. Sertuerner relatif à l’analyse de 
l’opium. Ann. Chim. Phys. 5, 275–278. 
Rogers, C., Wen, J., Chen, R., Oldroyd, G., 2009. Deletion-Based Reverse Genetics in Medicago 
truncatula. Plant Physiol. 151, 1077–1086. doi:10.1104/pp.109.142919 
Roulin, A., Auer, P.L., Libault, M., Schlueter, J., Farmer, A., May, G., Stacey, G., Doerge, R.W., 
Jackson, S.A., 2013. The fate of duplicated genes in a polyploid plant genome. Plant J. 
73, 143–153. doi:10.1111/tpj.12026 
Ruff, B.M., Bräse, S., O’Connor, S.E., 2012. Biocatalytic production of tetrahydroisoquinolines. 
Tetrahedron Lett. 53, 1071–1074. doi:10.1016/j.tetlet.2011.12.089 
Runguphan, W., Glenn, W.S., O’Connor, S.E., 2012. Redesign of a Dioxygenase in Morphine 
Biosynthesis. Chem. Biol. 19, 674–678. doi:10.1016/j.chembiol.2012.04.017 
Safi, M., 2014. Opium poppies to be legalised in Victoria as demand for painkillers soars 
[WWW Document]. the Guardian. URL 
http://www.theguardian.com/world/2014/mar/18/opium-poppies-to-be-legalised-
in-victoria-as-demand-for-painkillers-soars (accessed 4.16.15). 
Samanani, N., Alcantara, J., Bourgault, R., Zulak, K.G., Facchini, P.J., 2006. The role of phloem 
sieve elements and laticifers in the biosynthesis and accumulation of alkaloids in 
opium poppy†. Plant J. 47, 547–563. 
Samanani, N., Liscombe, D.K., Facchini, P.J., 2004. Molecular cloning and characterization of 
norcoclaurine synthase, an enzyme catalyzing the first committed step in 
benzylisoquinoline alkaloid biosynthesis. Plant J. 40, 302–313. doi:10.1111/j.1365-
313X.2004.02210.x 
Samanani, N., Park, S.U., Facchini, P.J., 2005. Cell Type–Specific Localization of Transcripts 
Encoding Nine Consecutive Enzymes Involved in Protoberberine Alkaloid 
Biosynthesis. Plant Cell Online 17, 915. 
Sariyar, G., 2002. Biodiversity in the alkaloids of Turkish Papaver species. Pure Appl. Chem. 
74, 557–574. 
Sato, F., Takeshita, N., Fitchen, J.H., Fujiwara, H., Yamada, Y., 1993. S-adenosyl-l-methionine: 




Phytochemistry, The International Journal of Plant Biochemistry 32, 659–664. 
doi:10.1016/S0031-9422(00)95151-3 
Sato, Y., Shirasawa, K., Takahashi, Y., Nishimura, M., Nishio, T., 2006. Mutant Selection from 
Progeny of Gamma-ray-irradiated Rice by DNA Heteroduplex Cleavage using Brassica 
Petiole Extract. Jpn. J. Breed. 56, 179–183. doi:10.1270/jsbbs.56.179 
Schaefer, B., 2015. Natural Products in the Chemical Industry. Springer. 
Schmeller, T., Latz-Brüning, B., Wink, M., 1997. Biochemical activities of berberine, palmatine 
and sanguinarine mediating chemical defence against microorganisms and 
herbivores. Phytochemistry 44, 257–266. doi:10.1016/S0031-9422(96)00545-6 
Schumacher, H.-M., Gundlach, H., Fiedler, F., Zenk, M.H., 1987. Elicitation of 
benzophenanthridine alkaloid synthesis in Eschscholtzia cell cultures. Plant Cell Rep. 
6, 410–413. doi:10.1007/BF00272770 
Scott, J.B., Hay, F.S., Wilson, C.R., 2004. Phylogenetic analysis of the downy mildew pathogen 
of oilseed poppy in Tasmania, and its detection by PCR. Mycol. Res. 108, 198–205. 
doi:10.1017/S095375620300916X 
Sellier, M.-J., Reeb, P., Marion-Poll, F., 2011. Consumption of Bitter Alkaloids in Drosophila 
melanogaster in Multiple-Choice Test Conditions. Chem. Senses 36, 323–334. 
doi:10.1093/chemse/bjq133 
Sertürner, F., 1806. . J. Pharm. Fuer Aerzte Apoth. 14, 47–93. 
Shan, Q., Wang, Y., Li, J., Zhang, Y., Chen, K., Liang, Z., Zhang, K., Liu, J., Xi, J.J., Qiu, J.-L., Gao, C., 
2013. Targeted genome modification of crop plants using a CRISPR-Cas system. Nat. 
Biotechnol. 31, 686–688. doi:10.1038/nbt.2650 
Sharma, J.R., Lal, R.K., Gupta, A.P., Misra, H.O., Pant, V., Singh, N.K., Pandey, V., 1999. 
Development of non-narcotic (opiumless and alkaloid-free) opium poppy, Papaver 
somniferum. Plant Breed. 118, 449–452. doi:10.1046/j.1439-0523.1999.00419.x 
Shields, V.D.C., Smith, K.P., Arnold, N.S., Gordon, I.M., Shaw, T.E., Waranch, D., 2008. The effect 
of varying alkaloid concentrations on the feeding behavior of gypsy moth larvae, 
Lymantria dispar (L.) (Lepidoptera: Lymantriidae). Arthropod-Plant Interact. 2, 101–
107. doi:10.1007/s11829-008-9035-6 
Shitan, N., Bazin, I., Dan, K., Obata, K., Kigawa, K., Ueda, K., Sato, F., Forestier, C., Yazaki, K., 
2003. Involvement of CjMDR1, a plant multidrug-resistance-type ATP-binding 
cassette protein, in alkaloid transport in Coptis japonica. Proc. Natl. Acad. Sci. 100, 
751–756. doi:10.1073/pnas.0134257100 
Sievers, F., Wilm, A., Dineen, D., Gibson, T.J., Karplus, K., Li, W., Lopez, R., McWilliam, H., 
Remmert, M., Söding, J., Thompson, J.D., Higgins, D.G., 2011. Fast, scalable generation 
of high‐quality protein multiple sequence alignments using Clustal Omega. Mol. Syst. 
Biol. 7, 539. doi:10.1038/msb.2011.75 
Simas, N.K., Ferrari, S.F., Pereira, S.N., Leitão, G.G., 2001. Chemical ecological characteristics of 
herbivory of Siparuna guianensis seeds by buffy-headed marmosets (Callithrix 
flaviceps) in the Atlantic Forest of southeastern Brazil. J. Chem. Ecol. 27, 93–107. 
Singh, S., Jain, L., Pandey, M.B., Singh, U.P., Pandey, V.B., 2009. Antifungal activity of the 
alkaloids from Eschscholtzia californica. Folia Microbiol. (Praha) 54, 204–206. 
doi:10.1007/s12223-009-0032-7 
Slade, A.J., McGuire, C., Loeffler, D., Mullenberg, J., Skinner, W., Fazio, G., Holm, A., Brandt, K.M., 
Steine, M.N., Goodstal, J.F., Knauf, V.C., 2012. Development of high amylose wheat 
through TILLING. BMC Plant Biol. 12, 69. doi:10.1186/1471-2229-12-69 
Solovyev, V., Kosarev, P., Seledsov, I., Vorobyev, D., 2006. Automatic annotation of eukaryotic 
genes, pseudogenes and promoters. Genome Biol. 7, S10. doi:10.1186/gb-2006-7-s1-
s10 
Stadler, R., Kutchan, T.M., Loeffler, S., Nagakura, N., Cassels, B., Zenk, M.H., 1987. Revision of 
the early steps of reticuline biosynthesis. Tetrahedron Lett. 28, 1251–1254. 
doi:10.1016/S0040-4039(00)95338-3 
Stadler, R., Kutchan, T.M., Zenk, M.H., 1989. (S)-norcoclaurine is the central intermediate in 





Stephenson, P., Baker, D., Girin, T., Perez, A., Amoah, S., King, G.J., Østergaard, L., 2010. A rich 
TILLING resource for studying gene function in Brassica rapa. BMC Plant Biol. 10, 62. 
doi:10.1186/1471-2229-10-62 
Straeten, D.V. der, Wiemeersch, L.V., Goodman, H.M., Montagu, M.V., 1990. Cloning and 
sequence of two different cDNAs encoding 1-aminocyclopropane-1-carboxylate 
synthase in tomato. Proc. Natl. Acad. Sci. 87, 4859–4863. 
doi:10.1073/pnas.87.12.4859 
Sue, M., Nakamura, C., Nomura, T., 2011. Dispersed Benzoxazinone Gene Cluster: Molecular 
Characterization and Chromosomal Localization of Glucosyltransferase and 
Glucosidase Genes in Wheat and Rye. Plant Physiol. 157, 985–997. 
doi:10.1104/pp.111.182378 
Suzuki, T., Eiguchi, M., Kumamaru, T., Satoh, H., Matsusaka, H., Moriguchi, K., Nagato, Y., 
Kurata, N., 2007. MNU-induced mutant pools and high performance TILLING enable 
finding of any gene mutation in rice. Mol. Genet. Genomics 279, 213–223. 
doi:10.1007/s00438-007-0293-2 
Takemura, T., Ikezawa, N., Iwasa, K., Sato, F., 2013. Molecular cloning and characterization of 
a cytochrome P450 in sanguinarine biosynthesis from Eschscholzia californica cells. 
Phytochemistry, Meinhart H. Zenk Memorial Issue 91, 100–108. 
doi:10.1016/j.phytochem.2012.02.013 
Takeshita, N., Fujiwara, H., Mimura, H., Fitchen, J.H., Yamada, Y., Sato, F., 1995. Molecular 
Cloning and Characterization of S-Adenosyl-L-Methionine:Scoulerine-9-O-
Methyltransferase from Cultured Cells of Coptis japonica. Plant Cell Physiol. 36, 29–
36. 
Takeuchi, T., Watanabe, Y., Takano-Shimizu, T., Kondo, S., 2006. Roles of jumonji and jumonji 
family genes in chromatin regulation and development. Dev. Dyn. 235, 2449–2459. 
doi:10.1002/dvdy.20851 
Tasmanian Government, 2012. Legislative Council Select Committee Inquiry: Tasmanian 
Poppy Industry. 
Taylor, N.E., Greene, E.A., 2003. PARSESNP: a tool for the analysis of nucleotide 
polymorphisms. Nucleic Acids Res. 31, 3808–3811. doi:10.1093/nar/gkg574 
Thodey, K., Galanie, S., Smolke, C.D., 2014. A microbial biomanufacturing platform for natural 
and semisynthetic opioids. Nat. Chem. Biol. 10, 837–844. doi:10.1038/nchembio.1613 
Tibi, S., 2003. Opium in ninth century Baghdad. Pharm. J. 271, 855–858. 
Till, B.J., Burtner, C., Comai, L., Henikoff, S., 2004. Mismatch cleavage by single‐strand specific 
nucleases. Nucleic Acids Res. 32, 2632–2641. doi:10.1093/nar/gkh599 
Till, B.J., Cooper, J., Tai, T.H., Colowit, P., Greene, E.A., Henikoff, S., Comai, L., 2007. Discovery of 
chemically induced mutations in rice by TILLING. BMC Plant Biol. 7, 19. 
doi:10.1186/1471-2229-7-19 
Till, B.J., Reynolds, S.H., Greene, E.A., Codomo, C.A., Enns, L.C., Johnson, J.E., Burtner, C., Odden, 
A.R., Young, K., Taylor, N.E., Henikoff, J.G., Comai, L., Henikoff, S., 2003. Large-Scale 
Discovery of Induced Point Mutations With High-Throughput TILLING. Genome Res. 
13, 524–530. doi:10.1101/gr.977903 
Till, B.J., Zerr, T., Comai, L., Henikoff, S., 2006. A protocol for TILLING and Ecotilling in plants 
and animals. Nat. Protoc. 1, 2465–2477. doi:10.1038/nprot.2006.329 
Tohge, T., Alseekh, S., Fernie, A.R., 2014. On the regulation and function of secondary 
metabolism during fruit development and ripening. J. Exp. Bot. ert443. 
doi:10.1093/jxb/ert443 
Townsend, T., Segura, V., Chigeza, G., Penfield, T., Rae, A., Harvey, D., Bowles, D., Graham, I.A., 
2013. The Use of Combining Ability Analysis to Identify Elite Parents for Artemisia 
annua F1 Hybrid Production. PLoS ONE 8, e61989. 
doi:10.1371/journal.pone.0061989 
Tsai, H., Howell, T., Nitcher, R., Missirian, V., Watson, B., Ngo, K.J., Lieberman, M., Fass, J., Uauy, 
C., Tran, R.K., Khan, A.A., Filkov, V., Tai, T.H., Dubcovsky, J., Comai, L., 2011. Discovery 





Uauy, C., Paraiso, F., Colasuonno, P., Tran, R.K., Tsai, H., Berardi, S., Comai, L., Dubcovsky, J., 
2009. A modified TILLING approach to detect induced mutations in tetraploid and 
hexaploid wheat. BMC Plant Biol. 9, 115. doi:10.1186/1471-2229-9-115 
Ugozzoli, L., Wallace, R.B., 1991. Allele-specific polymerase chain reaction. Methods 2, 42–48. 
doi:10.1016/S1046-2023(05)80124-0 
Untergasser, A., Nijveen, H., Rao, X., Bisseling, T., Geurts, R., Leunissen, J.A.M., 2007. 
Primer3Plus, an enhanced web interface to Primer3. Nucleic Acids Res. 35, W71–
W74. doi:10.1093/nar/gkm306 
Unterlinner, B., Lenz, R., Kutchan, T.M., 1999. Molecular cloning and functional expression of 
codeinone reductase: the penultimate enzyme in morphine biosynthesis in the opium 
poppy Papaver somniferum. Plant J. Cell Mol. Biol. 18, 465–475. 
Van Hout, M., Bergin, M., Foley, M., Rich, E., Rapca, A., Harris, R., Norman, I., 2014. A Scoping 
Review of Codeine Use, Misuse and Dependence, final report. 
van Ree, J.M., Gerrits, M.A.F.M., Vanderschuren, L.J.M.J., 1999. Opioids, Reward and Addiction: 
An Encounter of Biology, Psychology, and Medicine. Pharmacol. Rev. 51, 341–396. 
Vazquez-Flota, F., Carolis, E.D., Alarco, A.-M., Luca, V.D., 1997. Molecular cloning and 
characterization of desacetoxyvindoline-4-hydroxylase, a 2-oxoglutarate dependent-
dioxygenase involved in the biosynthesis of vindoline in Catharanthus roseus (L.) G. 
Don. Plant Mol. Biol. 34, 935–948. doi:10.1023/A:1005894001516 
Vialart, G., Hehn, A., Olry, A., Ito, K., Krieger, C., Larbat, R., Paris, C., Shimizu, B., Sugimoto, Y., 
Mizutani, M., Bourgaud, F., 2012. A 2-oxoglutarate-dependent dioxygenase from Ruta 
graveolens L. exhibits p-coumaroyl CoA 2′-hydroxylase activity (C2′H): a missing step 
in the synthesis of umbelliferone in plants. Plant J. 70, 460–470. doi:10.1111/j.1365-
313X.2011.04879.x 
Vree, T.B., van Dongen, R.T., Koopman-Kimenai, P.M., 2000. Codeine analgesia is due to 
codeine-6-glucuronide, not morphine. Int. J. Clin. Pract. 54, 395–398. 
Wakhlu, A.K., Bajwa, P.S., 1987. Cytological Analysis in Embryogenic Callus Cultures and 
Regenerated Plants of Papaver somniferum L. (Opium Poppy). Cytologia (Tokyo) 52, 
631–638. doi:10.1508/cytologia.52.631 
Walker, E.L., Robbins, T.P., Bureau, T.E., Kermicle, J., Dellaporta, S.L., 1995. Transposon-
mediated chromosomal rearrangements and gene duplications in the formation of the 
maize R-r complex. EMBO J. 14, 2350–2363. 
Wangkumhang, P., Chaichoompu, K., Ngamphiw, C., Ruangrit, U., Chanprasert, J., 
Assawamakin, A., Tongsima, S., 2007. WASP: a Web-based Allele-Specific PCR assay 
designing tool for detecting SNPs and mutations. BMC Genomics 8, 275. 
doi:10.1186/1471-2164-8-275 
Wang, X., Jiang, G.-L., Green, M., Scott, R.A., Hyten, D.L., Cregan, P.B., 2012. Quantitative trait 
locus analysis of saturated fatty acids in a population of recombinant inbred lines of 
soybean. Mol. Breed. 30, 1163–1179. doi:10.1007/s11032-012-9704-0 
Watts, S.M., Dodson, C.D., Reichman, O.J., 2011. The Roots of Defense: Plant Resistance and 
Tolerance to Belowground Herbivory. PLoS ONE 6, e18463. 
doi:10.1371/journal.pone.0018463 
Weid, M., Ziegler, J., Kutchan, T.M., 2004. The roles of latex and the vascular bundle in 
morphine biosynthesis in the opium poppy, Papaver somniferum. Proc. Natl. Acad. 
Sci. U. S. A. 101, 13957. 
Weiss, D., Baumert, A., Vogel, M., Roos, W., 2006. Sanguinarine reductase, a key enzyme of 
benzophenanthridine detoxification. Plant Cell Environ. 29, 291–302. 
doi:10.1111/j.1365-3040.2005.01421.x 
Wells, R., Trick, M., Fraser, F., Soumpourou, E., Clissold, L., Morgan, C., Pauquet, J., Bancroft, I., 
2013. Sequencing-based variant detection in the polyploid crop oilseed rape. BMC 
Plant Biol. 13, 111. doi:10.1186/1471-2229-13-111 
Weng, J.-K., Philippe, R.N., Noel, J.P., 2012. The rise of chemodiversity in plants. Science 336, 
1667–1670. 
Wenningmann, I., Dilger, J.P., 2001. The Kinetics of Inhibition of Nicotinic Acetylcholine 
Receptors by (+)-Tubocurarine and Pancuronium. Mol. Pharmacol. 60, 790–796. 




Wijekoon, C.P., Facchini, P.J., 2012. Systematic knockdown of morphine pathway enzymes in 
opium poppy using virus‐induced gene silencing. Plant J. 69, 1052–1063. 
doi:10.1111/j.1365-313X.2011.04855.x 
Williams, G., 2013. A Submission to the Review of the moratorium on genetically modified 
organisms (GMOs). 
Wilmouth, R.C., Turnbull, J.J., Welford, R.W.., Clifton, I.J., Prescott, A.G., Schofield, C.J., 2002. 
Structure and Mechanism of Anthocyanidin Synthase from Arabidopsis thaliana. 
Structure 10, 93–103. doi:10.1016/S0969-2126(01)00695-5 
Winzer, T., Gazda, V., He, Z., Kaminski, F., Kern, M., Larson, T.R., Li, Y., Meade, F., Teodor, R., 
Vaistij, F.E., Walker, C., Bowser, T.A., Graham, I.A., 2012. A Papaver somniferum 10-
Gene Cluster for Synthesis of the Anticancer Alkaloid Noscapine. Science 336, 1704–
1708. doi:10.1126/science.1220757 
Winzer, T., Kern, M., King, A.J., Larson, T.R., Teodor, R., Donninger, S., Li, Y., Dowle, A.A., 
Cartwright, J., Bates, R., Ashford, D., Thomas, J., Walker, C., Bowser, T.A., Graham, I.A., 
2015. Morphinan biosynthesis in opium poppy requires a P450-oxidoreductase 
fusion protein. Science aab1852. doi:10.1126/science.aab1852 
Xie, K., Yang, Y., 2013. RNA-Guided Genome Editing in Plants Using a CRISPR–Cas System. 
Mol. Plant 6, 1975–1983. doi:10.1093/mp/sst119 
Xu, Q., Lin, M., 1999. Benzylisoquinoline Alkaloids from Gnetum parvifolium. J. Nat. Prod. 62, 
1025–1027. doi:10.1021/np980472f 
Yamada, Y., Kokabu, Y., Chaki, K., Yoshimoto, T., Ohgaki, M., Yoshida, S., Kato, N., Koyama, T., 
Sato, F., 2011. Isoquinoline Alkaloid Biosynthesis is Regulated by a Unique bHLH-
Type Transcription Factor in Coptis japonica. Plant Cell Physiol. 52, 1131–1141. 
doi:10.1093/pcp/pcr062 
Yamaguchi, S., 2008. Gibberellin Metabolism and its Regulation. Annu. Rev. Plant Biol. 59, 
225–251. doi:10.1146/annurev.arplant.59.032607.092804 
Yazaki, K., 2006. ABC transporters involved in the transport of plant secondary metabolites. 
FEBS Lett. 580, 1183–1191. doi:10.1016/j.febslet.2005.12.009 
Yazaki, K., 2005. Transporters of secondary metabolites. Curr. Opin. Plant Biol. 8, 301–307. 
doi:10.1016/j.pbi.2005.03.011 
Yi, C., Yang, C.-G., He, C., 2009. A Non-Heme Iron-Mediated Chemical Demethylation in DNA 
and RNA. Acc. Chem. Res. 42, 519–529. doi:10.1021/ar800178j 
Zerr, T., Henikoff, S., 2005. Automated band mapping in electrophoretic gel images using 
background information. Nucleic Acids Res. 33, 2806–2812. doi:10.1093/nar/gki580 
Zhang, K., Halitschke, R., Yin, C., Liu, C.-J., Gan, S.-S., 2013. Salicylic acid 3-hydroxylase 
regulates Arabidopsis leaf longevity by mediating salicylic acid catabolism. Proc. Natl. 
Acad. Sci. 110, 14807–14812. doi:10.1073/pnas.1302702110 
Zhang, W., Hu, J.-F., Lv, W.-W., Zhao, Q.-C., Shi, G.-B., 2012. Antibacterial, Antifungal and 
Cytotoxic Isoquinoline Alkaloids from Litsea cubeba. Molecules 17, 12950–12960. 
doi:10.3390/molecules171112950 
Zhang, Z., Ren, J.-S., Clifton, I.J., Schofield, C.J., 2004. Crystal Structure and Mechanistic 
Implications of 1-Aminocyclopropane-1-Carboxylic Acid Oxidase—The Ethylene-
Forming Enzyme. Chem. Biol. 11, 1383–1394. doi:10.1016/j.chembiol.2004.08.012 
Zhou, L., Wang, L., Palais, R., Pryor, R., Wittwer, C.T., 2005. High-Resolution DNA Melting 
Analysis for Simultaneous Mutation Scanning and Genotyping in Solution. Clin. Chem. 
51, 1770–1777. doi:10.1373/clinchem.2005.054924 
Zhu, W., 2008. CYP2D6: a key enzyme in morphine synthesis in animals. Med. Sci. Monit. 14, 
SC15–SC18. 
Ziegler, J., Diaz-Chávez, M.L., Kramell, R., Ammer, C., Kutchan, T.M., 2005. Comparative 
macroarray analysis of morphine containing Papaver somniferum and eight 
morphine free Papaver species identifies an O-methyltransferase involved in 
benzylisoquinoline biosynthesis. Planta 222, 458–471. doi:10.1007/s00425-005-
1550-4 
Ziegler, J., Facchini, P.J., 2008. Alkaloid biosynthesis: metabolism and trafficking. Annu Rev 




Ziegler, J., Voigtländer, S., Schmidt, J., Kramell, R., Miersch, O., Ammer, C., Gesell, A., Kutchan, 
T.M., 2006. Comparative transcript and alkaloid profiling in Papaver species identifies 
a short chain dehydrogenase/reductase involved in morphine biosynthesis. Plant J. 
48, 177–192. doi:10.1111/j.1365-313X.2006.02860.x 
Zulak, K.G., Cornish, A., Daskalchuk, T.E., Deyholos, M.K., Goodenowe, D.B., Gordon, P.M.K., 
Klassen, D., Pelcher, L.E., Sensen, C.W., Facchini, P.J., 2006. Gene transcript and 
metabolite profiling of elicitor-induced opium poppy cell cultures reveals the 
coordinate regulation of primary and secondary metabolism. Planta 225, 1085–1106. 
doi:10.1007/s00425-006-0419-5 
 
